
<html lang="en"     class="pb-page"  data-request-id="80018669-6441-4753-8e78-576892d82a5f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-16;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.8b00260;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthetic Approaches to New Drugs Approved During 2016" /></meta><meta name="dc.Creator" content="Andrew&#xA;C.  Flick" /></meta><meta name="dc.Creator" content="Hong X.  Ding" /></meta><meta name="dc.Creator" content="Carolyn A.  Leverett" /></meta><meta name="dc.Creator" content="Sarah J.  Fink" /></meta><meta name="dc.Creator" content="Christopher J.  O’Donnell" /></meta><meta name="dc.Description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight into molecular recognition while serving..." /></meta><meta name="Description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight into molecular recognition while serving..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 5, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00260" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00260" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00260" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00260" /></link>
        
    
    

<title>Synthetic Approaches to New Drugs Approved During 2016 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00260" /></meta><meta property="og:title" content="Synthetic Approaches to New Drugs Approved During 2016" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0037.jpeg" /></meta><meta property="og:description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 19 new chemical entities that were approved for the first time in 2016." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00260"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00260">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00260&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00260&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00260&amp;href=/doi/10.1021/acs.jmedchem.8b00260" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 7004-7031</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00124" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01122" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthetic Approaches to New Drugs Approved During 2016</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Andrew C. Flick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew C. Flick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew%0AC.++Flick">Andrew C. Flick</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong X. Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong X. Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacodia (Beijing) Co., Ltd., Beijing, 100085, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong+X.++Ding">Hong X. Ding</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carolyn A. Leverett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carolyn A. Leverett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carolyn+A.++Leverett">Carolyn A. Leverett</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah J. Fink</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah J. Fink</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">BioDuro, 11011 Torreyana Road, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+J.++Fink">Sarah J. Fink</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Christopher J. O’Donnell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. O’Donnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 860-303-1138. E-mail: <a href="/cdn-cgi/l/email-protection#eb848f8485858e87878881d9d8ab8c868a8287c5888486"><span class="__cf_email__" data-cfemail="4c23282322222920202f267e7f0c2b212d2520622f2321">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++O%E2%80%99Donnell">Christopher J. O’Donnell</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00260&amp;href=/doi/10.1021%2Facs.jmedchem.8b00260" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 7004–7031</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 5, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 February 2018</li><li><span class="item_label"><b>Published</b> online</span>5 April 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 August 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00260" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00260</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7004%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndrew%250AC.%2BFlick%252C%2BHong%2BX.%2BDing%252C%2BCarolyn%2BA.%2BLeverett%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D16%26contentID%3Dacs.jmedchem.8b00260%26title%3DSynthetic%2BApproaches%2Bto%2BNew%2BDrugs%2BApproved%2BDuring%2B2016%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7031%26publicationDate%3DAugust%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00260"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">11107</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00260" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthetic Approaches to New Drugs Approved During 2016&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew\nC.&quot;,&quot;last_name&quot;:&quot;Flick&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;X. Ding&quot;},{&quot;first_name&quot;:&quot;Carolyn&quot;,&quot;last_name&quot;:&quot;A. Leverett&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;J. Fink&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. O’Donnell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;7004-7031&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00260&quot;},&quot;abstract&quot;:&quot;New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 19 new chemical entities that were approved for the first time in 2016.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00260&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00260" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00260&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00260" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00260&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00260" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00260&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00260&amp;href=/doi/10.1021/acs.jmedchem.8b00260" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00260" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00260" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00260%26sid%3Dliteratum%253Aachs%26pmid%3D29620889%26genre%3Darticle%26aulast%3DFlick%26date%3D2018%26atitle%3DSynthetic%2BApproaches%2Bto%2BNew%2BDrugs%2BApproved%2BDuring%2B2016%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D16%26spage%3D7004%26epage%3D7031%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291301" title="Salts">Salts</a>,</li><li><a href="/action/doSearch?ConceptID=291650" title="Alcohols">Alcohols</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/jmcmar.2018.61.issue-16/20180823/jmcmar.2018.61.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0037.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 19 new chemical entities that were approved for the first time in 2016.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32225" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32225" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">“<i>The most fruitful basis for the discovery of a new drug is to start with an old drug</i>.” – Sir James Whyte Black, winner of the 1988 Nobel Prize in medicine.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Inaugurated 15 years ago,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> this annual review presents synthetic methods for molecular entities that were approved for the first time by governing bodies within various countries during 2016. Because drugs can have structural homology across similar biological targets, it is widely believed that the knowledge of new chemical entities and approaches to their construction will enhance the ability to discover new drugs more efficiently. This review describes the most likely process-scale synthetic approaches to the 19 small molecule new chemical entities (NCEs) that were approved for the first time in 2016 by a governing body anywhere in the world (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and each section will only contain a limited introduction to the pharmacology of the drug as more detailed reviews on this topic are readily available.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> New indications for previously launched medications, new combinations or formulations of existing drugs, and drugs synthesized purely via bioprocesses or peptide synthesizers have been excluded from this review. Drugs presented in this review are divided into the following seven therapeutic categories: anti-infective, neuroscience, dermatologic, gastrointestinal, metabolic, oncology, and ophthalmology. Within each of these therapeutic areas, drug coverage follows alphabetical order by generic name. It is important to note that a drug’s process-scale synthetic approach is often not explicitly disclosed at the time of this review’s publication. However, the synthetic sequences presented in this review have all been published in the public domain and represent scalable routes that originate from commercially available starting materials (determined by explicit statement in the description or by experimental detail).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0001.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 19 NCEs approved in 2016.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  Anti-Infective Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  Beclabuvir (Ximency)</h3><div class="NLM_p">Beclabuvir is a non-nucleoside, nonstructural protein 5B (NS5B) polymerase inhibitor approved in Japan as part of a fixed-dose combination product for the treatment of hepatitis C virus (HCV). Upon administration and after intracellular uptake, the drug binds to the allosteric, noncatalytic “Thumb 1” site of NS5B resulting in a decreased rate of viral RNA synthesis and replication.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Beclabuvir is combined with asunaprevir and declatasvir (both approved in 2014) and was discovered and developed by Bristol-Myers Squibb.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">The syntheses of asunaprevir and declatasvir were described in an earlier review article.<a onclick="showRef(event, 'cit2m'); return false;" href="javascript:void(0);" class="ref cit2m">(2m)</a> The synthesis to produce 10–100 g of beclabuvir is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Condensation of indole-6-carboxylic acid (<b>1</b>) with cyclohexanone under basic conditions gave acid <b>2</b> in quantitative yield. Hydrogenation of the double bond in <b>2</b> using Pearlman’s catalyst was followed by esterification to give ester <b>3</b> in high yield.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Bromination of the indole at the 2-position was accomplished with pyridinium tribromide, and this was followed by saponification to provide acid <b>4</b>. Treatment of <b>4</b> with carbonyldiimidazole (CDI) followed by <i>N,N</i>-dimethylsulfamide and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) gave compound <b>5</b> in 74% yield. Suzuki coupling of <b>5</b> with commercial boronic acid <b>6</b> provided intermediate <b>7</b>, which converted to hemiaminal <b>8</b> upon continued heating in 61% yield. Compound <b>8</b> was then treated with methyl 2-(dimethoxyphosphoryl)acrylate (<b>9</b>) to affect a tandem conjugate addition and Horner–Wadsworth–Emmons (HWE) olefination to give ester <b>10</b>. Alternatively, the Suzuki coupling reaction of <b>5</b> with <b>6</b> could be stopped at intermediate <b>7</b>, which could be treated with <b>9</b> to promote the tandem conjugate addition/HWE to give <b>10</b>. Corey–Chaykovsky cyclopropanation of <b>10</b> using sodium hydride and trimethylsulfoxonium iodide followed by chiral separation provided cyclopropane <b>11</b> in good yield and >99% enantiomeric excess (ee). Saponification of the methyl ester of <b>11</b> followed by coupling with 3-methyl-3,8-diazabicyclo[3.2.1]octane dihydrochloride (<b>12</b>) gave beclabuvir (<b>I</b>) in high yield.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Beclabuvir (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.2.  Elbasvir/Grazoprevir (Zepatier)</h3><div class="NLM_p">Discovered and developed by Merck, the combination of elbasvir and grazoprevir was approved by the United States Food and Drug Administration (USFDA) for the treatment of adults with chronic hepatitis C virus (HCV) genotype 1 or 4 infection.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Interestingly, neither of these drugs is approved as a separate medication. In clinical trials, the two drugs were coadministered as separate tablets and administered as a fixed-dose combination tablet with the primary end point being the sustained virological response rate 12 weeks post-treatment (SVR<sub>12</sub>); patients exhibited a 95% SVR<sub>12</sub> rate overall.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Elbasvir inhibits HCV NS5A, which is necessary for viral RNA replication and virion assembly.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Grazoprevir inhibits HCV NS3/4A protease, which is essential for the proteolytic cleavage of the HCV encoded polyprotein and viral replication.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> For the purpose of this review, the synthesis of elbasvir and grazoprevir for HCV treatment will be discussed separately.</div><div class="NLM_p">Elbasvir possesses a particularly interesting molecular architecture consisting of two identical <i>N-</i>Moc-valine-linked pyrrolidinoimidazole subunits appended to a 2-arylindolyl hemiaminal spacer. A clever process-scale synthesis of elbasvir, as described by researchers at Merck in both a 2014 publication and a patent application, relies upon a stereochemical relay approach to set the challenging hemiaminal stereogenic center.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The synthetic route began with esterification of commercially available 2,5-dibromoacetic acid (<b>13</b>) with 3-bromophenol (<b>14</b>), a reaction that proceeded through the corresponding acyl halide of <b>13</b> en route to ester <b>15</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Next, a Fries rearrangement was employed to effect ester-to-ketone transposition. Exposure of <b>15</b> to a mixture of methanesulfonic acid and methanesulfonic anhydride at elevated temperatures gave rise to acetophenone <b>16</b>. Although the authors do not explicitly comment about the regiochemical considerations of this reaction, presumably the <i>meta</i>-aryl bromide provides sufficient steric hindrance to favor ketone formation at the position <i>para</i> to the bromide substituent. Ketone <b>16</b> was subsequently converted to the corresponding imine <b>17</b> upon condensation with ammonia in methanol. At this point, the stage was set for a critical stereochemical relay strategy for the construction of the hemiaminal geometry within elbasvir. This chirality-establishing sequence ultimately began with an asymmetric reduction of imine <b>17</b> in which ruthenium-catalyzed transfer hydrogenation conditions utilizing a metal–ligand complex, originally described by Wills,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> delivered branched amine <b>18</b> in excellent yield and enantioselectivity. This was followed by an intramolecular copper-mediated amination reaction to furnish indoline <b>19</b>. This indoline, which possessed a stereogenic center unlikely to epimerize under strongly acidic conditions, was treated with benzaldehyde in warm TFA and acetonitrile to facilitate smooth conversion to tetrahydrooxazinoindole <b>20</b> in excellent yield and a remarkable 99:1 diastereomeric ratio (dr). From dibromoarene <b>20</b>, Miyaura conditions were employed to convert both aryl bromides to the corresponding <i>bis</i>-pinacol borane (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), and this reaction was followed by a cross-coupling with pyrrolidino bromoimidazole <b>21</b> (whose preparation is described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Salt formation with <i>p</i>-nitrobenzoic acid furnished azacycle <b>22</b> in 82% overall yield from <b>20</b>. Coincidentally, this two-step sequence also resulted in oxidation of the indoline ring, establishing the 2,3-indolyl π-bond within <b>22</b>. Next, exposure to potassium carbonate followed by reaction with methanolic HCl removed both Boc groups, converted <b>22</b> to diamine <b>23</b>, which was immediately coupled with commercially available methyl carbamate (Moc)-substituted valine (<b>24</b>) under standard amide bond-forming conditions. Recrystallization in warm ethanol completed the assembly of elbasvir (<b>II</b>) in 80% yield from <b>23</b>.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Dibromoarene Fragment <b>20</b> for Elbasvir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Elbasvir (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Pyrrolidino Bromoimidazole Fragment <b>21</b> for Elbasvir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pyrrolidino bromoimidazole <b>21</b> was derived from oxidation of commercially available <i>S</i>-Boc-prolinol (<b>25</b>, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) followed by exposure to ammonia and glyoxal to secure the imidazole ring to give <b>26</b>. Perbromination of <b>26</b> and subsequent reduction completed the construction of key bromide coupling partner <b>21</b>.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Grazoprevir hydrate is one of several structurally related macrocycles developed for the treatment of patients with HCV. The structure of the drug presents considerable complexity given the numerous stereocenters both within and external to the macrocyclic array. Several different approaches to the construction of grazoprevir have been reported.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Interestingly, the original synthetic approach used by the discovery team proceeded through the use of a ring-closing olefin metathesis to produce the macrocyclic ring.<a onclick="showRef(event, 'cit10a cit10b'); return false;" href="javascript:void(0);" class="ref cit10a cit10b">(10a,b)</a> However, this route suffered from low yield in the key macrocycle forming step, necessitating development of an alternative strategy on scale, which hinges upon a macrolactamization disconnection. Toward this end, grazoprevir was retrosynthetically subdivided into three key fragments: chloroquinoxaline <b>29</b>, cyclopropanol <b>ent-32</b>, and amine <b>38</b>. The synthesis and union of these three fragments represents the most likely process-scale entry to this structurally complex drug given that the patent application exemplified the synthetic sequence on kilogram scale, which is described in <a class="ref internalNav" href="#sch5" aria-label="Schemes 5">Schemes 5</a><named-content content-type="anchor" rid="sch6" type="simple"></named-content><named-content content-type="anchor" rid="sch7" type="simple"></named-content>–<a class="ref internalNav" href="#sch8" aria-label="8">8</a>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Chloroquinoxaline Fragment <b>29</b> for Grazoprevir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Chiral Cyclopropanol Fragment <b>ent-32</b> for Grazoprevir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Grazoprevir Hydrate (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Aminovinylcyclopropane Fragment <b>38</b> for Grazoprevir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of chloroquinoxaline <b>29</b> started with the acid-mediated condensation of 4-methoxy-1,2-benzenediamine dihydrochloride salt (<b>27</b>) with oxalic acid followed by <i>bis</i>-chlorination to provide the corresponding dichloroquinoxaline (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).<a onclick="showRef(event, 'cit11a'); return false;" href="javascript:void(0);" class="ref cit11a">(11a)</a> Upon exposure to S<sub>N</sub>Ar conditions (DBU, DMA) in the presence of commercially available hydroxyproline <b>28</b>, chloroquinoxaline <b>29</b> was isolated in 68% yield. This three-step reaction sequence delivered the product with 95:5 selectivity for the desired regioisomer, which could be further purified by recrystallizing from MTBE/heptanes.</div><div class="NLM_p">The cyclopropanol <b>ent-32</b> was prepared using a strategy that relied on enzymatic resolution (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).<a onclick="showRef(event, 'cit11b'); return false;" href="javascript:void(0);" class="ref cit11b">(11b)</a> A diastereoselective cyclopropanation of a vinyl boronate resembling <b>30</b> was attempted, but low yields and difficult purification prompted the authors to consider a racemic cyclopropanation. On 34.3 kg scale, commercially available vinyl boronate <b>30</b> was subjected to trifluoroacetic acid-modified cyclopropanation conditions developed by Shi and co-workers (ICH<sub>2</sub>ZnO<sub>2</sub>CCF<sub>3</sub>), which gave higher conversion and a cleaner impurity profile than those of classic Simmons–Smith conditions (Zn(CH<sub>2</sub>I)<sub>2</sub>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The product was isolated as a solution in heptane (96% yield) and treated directly with 10 M sodium hydroxide and aqueous hydrogen peroxide to provide racemic cyclopropanol <b>rac-31</b>, which was carried forward crude as a solution in MTBE. Direct displacement of the chloride with lithium acetylide-ethylene diamine complex was optimized to generate terminal alkyne <b>rac-32</b>. Safety considerations surrounding the use of lithium acetylide-ethylene diamine on scale were closely examined due to the risk of uncontrolled release of acetylene gas. To minimize acetylene gas evolution, pretreatment of <b>rac-31</b> with 1.2 equiv of <i>n-</i>hexyllithium (HexLi) formed the alkoxide prior to addition of 1.1 equiv of lithium acetylide-ethylene diamine at 50 °C. This procedure was used successfully to synthesize <b>rac-32</b> on 16.1 kg scale from the bulk stream of <b>rac-31</b>. Next, acylation of crude <b>rac-32</b> in MTBE gave rise to ester <b>rac-33</b>, the key substrate for the enzymatic hydrolysis step. Optimized conditions employed Novozyme 435 in MTBE with 0.1 M aqueous potassium phosphate dibasic. Whereas all previous steps could be carried through without isolation or purification, chromatography was required to isolate <b>ent-32</b> (desired) from <b>ent-33</b> and all other impurities generated through the five-step process. At 40% conversion, <b>ent-32</b> could be isolated in 96% ee and 19% overall yield from <b>30</b>. An alternate gram-scale synthesis of this fragment has recently been reported by researchers at Merck using a route that avoids the use of lithium acetylide and enzymatic resolution.<a onclick="showRef(event, 'cit11c'); return false;" href="javascript:void(0);" class="ref cit11c">(11c)</a></div><div class="NLM_p">With chloroquinaxoline <b>29</b> and cyclopropanol <b>ent-32</b> in hand, assembly of the macrocycle commenced (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).<a onclick="showRef(event, 'cit11a cit11d'); return false;" href="javascript:void(0);" class="ref cit11a cit11d">(11a,d)</a><b>Ent-32</b> was reacted with CDI and DIPEA followed by slow addition of <span class="smallcaps smallerCapital">l</span>-<i>tert</i>-leucine (<b>34</b>) to give carbamate <b>35</b>, which was isolated as a solution in cyclopentyl methyl ether (CPME) and used without further purification. After extensive optimization, the Sonogashira cross-coupling product of alkyne <b>35</b> and chloroquinoxaline <b>29</b> was isolated in 98% HPLC purity following aqueous workup and carried forward without purification. The resulting alkyne was subjected to catalytic hydrogenation conditions to furnish the macrocyclization precursor <b>36</b>, which was also not isolated. Phenylsulfonic acid-mediated Boc removal followed by direct addition of excess DIPEA and slow addition of the mixture to a solution of HATU in acetonitrile resulted in intramolecular lactam formation with minimal dimerization byproducts (<2%). Macrocycle <b>37</b> was the first crystalline intermediate to be isolated in this sequence and was obtained in 65% yield in analytically pure form. Careful saponification utilizing LiOH was followed by amidation with amine <b>38</b> (the synthesis of which is described in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>) under conditions designed to minimize proline carboxylate epimerization (EDC, pyridine, MeCN) to give grazoprevir. Grazoprevir hydrate (<b>III</b>) was then generated by recrystallization from acetone and water at 50 °C, and the last three steps were completed in 44% overall yield.</div><div class="NLM_p last">Aminovinylcyclopropane <b>38</b> was generated in one step from the commercially available Boc-protected derivative (<b>39</b>, <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>) by treatment with TsOH.<a onclick="showRef(event, 'cit11a ref13'); return false;" href="javascript:void(0);" class="ref cit11a ref13">(11a,13)</a> Interestingly, this same stereogenic vinyl cyclopropane subunit has been incorporated into a number of other recently approved antiviral drugs. A description of its synthesis, originally developed by researchers at Bristol-Myers Squibb (BMS), has been summarized in our previous review for the synthesis of asunaprevir.<a onclick="showRef(event, 'cit2m'); return false;" href="javascript:void(0);" class="ref cit2m">(2m)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.3.  Narlaprevir (Arlansa)</h3><div class="NLM_p">Narlaprevir was approved as a treatment for genotype 1 HCV and serves as a class 2 HCV NS3 serine protease inhibitor. In clinical trials, it showed a rapid and steady decline in HCV-RNA levels in both previously treated and treatment-naı̈ve patients when used in combination with ritonavir and PEG-IFN-α.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(14)</a> This combination ultimately led to ≥50% of patients with undetectable HCV-RNA levels after a second period of treatment.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(14)</a> Narlaprevir also has demonstrated activity against HCV mutations resistant to other treatments such as boceprevir and telaprevir.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(15)</a> The unique activity of this drug can be attributed to a critical electrophilic α-keto-amide “warhead”, which covalently reacts with an HCV NS3 protease active-site serine residue involved in the HCV viral replication process.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(15,16)</a> Because of their essential roles in viral replication, HCV NS3 and NS5B proteases have recently become key targets for HCV drug development.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(16)</a> Strategically, the development of narlaprevir stems specifically from the pursuit of a single-diastereomer, second generation HCV protease inhibitor, which would provide in vitro potency and pharmacokinetic profile improvements over the structurally related antiviral drug boceprevir,<a onclick="showRef(event, 'cit2j'); return false;" href="javascript:void(0);" class="ref cit2j">(2j)</a> which exists as a mixture of diastereomers.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(16,17)</a> After the R-Pharm pharmaceutical group obtained the license to manufacture narlaprevir from Merck in 2012, further development of the drug was realized through collaborations with Schering-Plough and Texas Liver Institute.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(18)</a></div><div class="NLM_p">A kilogram-scale synthetic route to narlaprevir has been reported and proceeds strategically through the union of urea <b>45</b>, bicyclic amine intermediate <b>46</b>, and amine salt <b>48</b> (<a class="ref internalNav" href="#sch9" aria-label="Schemes 9">Schemes 9</a> and <a class="ref internalNav" href="#sch10" aria-label="10">10</a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Preparation of urea <b>45</b> begins with commercial cyclohexanecarboxylic acid methyl ester (<b>40</b>), which was treated with freshly prepared LDA and TMSCl in THF to provide silyl enol ether <b>41</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). This intermediate was immediately reacted with commercial 2-[(chloromethyl)thio]-2-methylpropane (<b>42</b>) under Lewis acid conditions (ZnBr<sub>2</sub>) to provide ester <b>43</b> in 58% yield over the two-step process.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(17,19)</a> A solution of crude <b>43</b> was subjected to saponification conditions (NaOH, H<sub>2</sub>O, MeOH) and sulfide oxidation with oxone in DCM/MeOH, leading to the target sulfone <b>44</b> in 65% yield. From <b>44</b>, a Curtius rearrangement delivered an isocyanate intermediate that could be trapped with <span class="smallcaps smallerCapital">l</span>-<i>tert</i>-leucine, forming the desired urea <b>45</b> in 53% over the two-step sequence.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(17,19)</a> Coupling <b>45</b> with commercially available bicyclic amine <b>46</b> under peptide coupling conditions (EDC, HOBt, NMM) led to the desired amide in 79% yield, which was then saponified with aqueous NaOH in 2-methyltetrahydrofuran (2-MeTHF) to provide acid intermediate <b>47</b> (84% yield). This intermediate was coupled with amine salt <b>48</b> (synthesis of <b>48</b> is described in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>) with EDC and HOBt, providing the penultimate intermediate to narlaprevir. Completion of the synthesis relied upon installation of the essential α-keto-amide functionality, which was accomplished by α-hydroxy amide oxidation using TEMPO-catalyzed conditions. A final recrystallization from acetone/water completed synthesis of narlaprevir (<b>IV</b>) in 83% yield.<a onclick="showRef(event, 'cit19a'); return false;" href="javascript:void(0);" class="ref cit19a">(19a)</a> It is worth noting that this overall route was used to generate >1 kg of narlaprevir and required no chromatographic separation steps.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(16,17,19)</a></div><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Narlaprevir (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Cyclohexane Amino Fragment <b>48</b> for Narlaprevir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Amine salt <b>48</b> was prepared by first subjecting commercially available pentanal (<b>49</b>) to Knoevenagel condensation conditions using malonic acid followed by conversion of the resulting acid to the corresponding <i>t</i>-butyl ester <b>50</b> by reaction with H<sub>2</sub>SO<sub>4</sub> and isobutylene (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>).<a onclick="showRef(event, 'cit19a'); return false;" href="javascript:void(0);" class="ref cit19a">(19a)</a> The key transformation for establishing the requisite stereocenter in intermediate <b>48</b> relied on an asymmetric conjugate addition of a <i>bis-</i>protected lithiated amine followed by enolate trap with an electrophilic source of oxygen. In practice, treatment of α-methyl-<i>N</i>-(phenylmethyl)-(α<i>S</i>)-benzenemethanamine (<b>51</b>) with <i>n</i>-hexyllithium resulted in stereoselective 1,4-addition to enone <b>50</b>. Subjection of lithium enolate intermediate <b>52</b> to (1<i>S</i>)-(+)-(10-camphorsulfonyl)oxaziridine (<b>53</b>) then furnished the α-hydroxyl group and delivered the <i>syn</i>-amino alcohol derivative <b>54</b> in 81% yield for the two-step protocol.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><i>tert</i>-Butyl ester removal was realized by exposure of <b>54</b> to TFA in warm toluene. Subsequent coupling of the resulting acid with cyclopropylamine (<b>55</b>) utilizing EDC and HOBt conditions provided cyclopropyl amide <b>56</b> in 71% yield from <b>54</b>. Finally, hydrogenolytic removal of the benzyl groups from the β-amine followed by subjection of the product to refluxing HCl provided amine salt <b>48</b> in 83% yield.<a onclick="showRef(event, 'cit19a'); return false;" href="javascript:void(0);" class="ref cit19a">(19a)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.4.  Nemonoxacin (Taigexyn)</h3><div class="NLM_p">Nemonoxacin is a novel nonfluorinated quinolone and broad-spectrum antibiotic for the treatment of drug-resistant bacterial infections, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and quinolone-resistant MRSA as well as quinolone-resistant <i>Streptococcus pneumonia</i>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The drug was originally discovered by Procter & Gamble Pharmaceuticals (P&GP).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> It was codeveloped by TaiGen Biotechnology for development in Asia and by Warner Chilcott for development in the United States and Europe and was first approved by the China Food and Drug Administration (CFDA).<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a></div><div class="NLM_p">Although several synthetic approaches to marketed quinolone antibiotics similar in structure to nemonoxacin have been reported,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> two dedicated synthetic routes to nemonoxacin have been reported.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The route depicted in <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>, which has been disclosed by workers at Warner Chilcott, not only describes a process route to the pharmaceutically active ingredient but also describes the preparation and examination of several salt forms under consideration for intravenous and/or oral dosing approaches.<a onclick="showRef(event, 'cit24d'); return false;" href="javascript:void(0);" class="ref cit24d">(24d)</a> Condensation of commercial 2,4-difluoroacetophenone (<b>57</b>) with ethylene glycol furnished ketal <b>58</b> in 86% yield. This was followed by fluorine-directed <i>o-</i>lithiation with <i>n</i>-butyllithium and trimethylborate quench. Acidification followed by oxidation of the boron species rendered hydroxyketone <b>59</b> in 79% yield from <b>58</b>. Next, phenol methylation with dimethyl sulfate followed by deprotonation and reaction with diethyl carbonate (<b>60</b>) gave rise to the keto-ester intermediate, which underwent condensation with dimethylformamide-dimethylacetal (DMF-DMA) in refluxing toluene to provide the corresponding vinylogous amide <b>61</b>. An addition–elimination reaction with cyclopropylamine (<b>55</b>) and subjection of this intermediate to acetimidate <b>62</b> in refluxing toluene presumably facilitated alkene isomerization with concomitant cyclization to produce the quinolinone derivative <b>63</b> in 82% yield over five steps. Acidic hydrolysis followed by treatment with diboron trioxide and acetic anhydride generated triacetoxyborate <b>64</b>, which served as a unique protecting group for the next step of the synthesis. Exposure of <b>64</b> to aminopiperidine <b>65</b> (whose synthesis is described in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>) under S<sub>N</sub>Ar conditions provided aniline derivative <b>66</b>. This was followed by base-mediated borate removal, acidic quench with concomitant Boc deprotection, and basification to furnish nemonoxacin (<b>V</b>) in 79% yield from <b>64</b>.<a onclick="showRef(event, 'cit24d'); return false;" href="javascript:void(0);" class="ref cit24d">(24d)</a></div><figure id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Nemonoxacin (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Aminopiperidine Fragment <b>65</b> for Nemonoxacin</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">For the preparation of aminopiperidine fragment <b>65</b> of nemonoxacin, commercial proline derivative <b>67</b> was converted to the corresponding ester <b>68</b> in 52% yield prior to treatment with Bredereck’s reagent to give enamine <b>69</b> (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>). Next, catalytic hydrogenation of <b>69</b> using a Pfaudler reactor and 5% Pd/C converted the vinylogous amide to the corresponding methyl group, delivering <b>70</b> in nearly quantitative yield and 93:7 diastereomeric excess in favor of the desired geometry. Further reduction of <b>70</b> using NaBH<sub>4</sub> followed by treatment with calcium chloride dihydrate gave the corresponding diol <b>71</b> in 66% yield. Mesylation of diol <b>71</b> followed by cyclization with benzylamine and hydrogenation to remove the <i>N-</i>benzyl group provided aminopiperidine <b>65</b>.<a onclick="showRef(event, 'cit24c'); return false;" href="javascript:void(0);" class="ref cit24c">(24c)</a> The yields of the last three steps were not reported.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">2.5.  Tenofovir Alafenamide Fumarate (Vemlidy)</h3><div class="NLM_p">Tenofovir alafenamide fumarate is an oral phosphonoamidate prodrug of the reverse transcriptase inhibitor tenofovir. It was approved by the USFDA for the treatment of chronic hepatitis B virus infection with compensated liver disease. Tenofovir alafenamide fumarate was discovered and developed by Gilead as a potentially safer form of the previously approved tenofovir disoproxil fumarate (Viread).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">A multikilogram synthesis of tenofovir alafenamide fumarate was described in a Gilead patent.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Additional process improvements on specific steps of the Gilead process have been reported on 100 g scale, and these will be noted throughout the description of the synthesis. The synthesis was initiated with the alkylation of adenine (<b>72</b>) with (<i>R</i>)-propylene carbonate (<b>73</b>) to give hydroxypropyl adenine <b>74</b> in 75% yield (<a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>). It should be noted that sodium hydroxide can be replaced by potassium bases with increased yields on 100 g scale.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Alkylation of <b>74</b> with diethyl <i>p</i>-toluenesulfonyloxymethylphosphonate (<b>75</b>) gave intermediate <b>76</b>, which was not isolated. Hydrolysis of the phosphonate esters with trimethylsilyl bromide followed by recrystallization from water gave phosphonic acid <b>77</b> in 50% yield. Interestingly, replacing Mg(O<i>t</i>-Bu)<sub>2</sub> with PhMgCl/<i>t</i>-BuOH led to improved yields for the alkylation step (<b>74</b> → <b>76</b>) on a 100 g scale.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Additionally, the authors note that conditions for hydrolyzing the phosphonate ester can be modified using HCl or HBr for improved yields on smaller scale.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Dicyclohexylcarbodiimide (DCC) coupling of <b>77</b> with phenol produced phosphonate <b>78</b> in 51% yield. This step was also reported to proceed in higher yield on smaller scale by changing the solvent to cyclopentylmethyl ether.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Monophosphonate ester <b>78</b> was treated with thionyl chloride followed by <span class="smallcaps smallerCapital">l</span>-alanine isopropyl ester (<b>79</b>) and triethylamine to give tenofovir alafenamide <b>rac-80</b> as a mixture of phosphonate diastereomers in 47% yield. The diastereomers were separated using simulated moving bed chromatography<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> to give the desired diastereomer <b>ent-80</b> in 47% yield and 99% diastereomeric purity. The diastereomers could also be separated using a crystallization-induced dynamic resolution of <b>rac-80</b>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Tenofovir alafenamide fumarate (<b>VI</b>) was prepared from <b>ent-80</b> and fumaric acid in 83% yield.</div><figure id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Tenofovir Alafenamide Fumarate (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">5.6.  Velpatasvir/Sofosbuvir (Epclusa)</h3><div class="NLM_p">In 2016, velpatasvir was approved in the US, Europe, and Canada as a once-daily oral treatment for chronic HCV genotypes 1–6 when used as a combination therapy with the recently approved HCV inhibitor sofosbuvir (SOVALDI).<a onclick="showRef(event, 'cit2l'); return false;" href="javascript:void(0);" class="ref cit2l">(2l)</a> Whereas velpatasvir functions as an HCV NS5A protein inhibitor, sofosbuvir serves as an inhibitor of HCV NS5B RNA polymerase, both of which play key roles in inhibiting HCV replication.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The combination, developed by Gilead, has been shown to provide very high rates of sustained virological responses (SVRs) in a variety of clinical trials<a onclick="showRef(event, 'cit31a ref32'); return false;" href="javascript:void(0);" class="ref cit31a ref32">(31a,32)</a> and exhibits full antiviral activity against resistance-associated variants developed by other HCV inhibitors with varying mechanisms of action.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The velpatasvir/sofosbuvir combination has been classified as pangenotypic,<a onclick="showRef(event, 'cit32a'); return false;" href="javascript:void(0);" class="ref cit32a">(32a)</a> demonstrating antiviral activity for all known HCV genotypes, and joins a class of direct-acting antivirals (DAAs) that can also be used for patients suffering from severe liver failure who were previously contraindicated for treatment with standard interferon- and ribavirin-based regimens.<a onclick="showRef(event, 'cit32a ref33'); return false;" href="javascript:void(0);" class="ref cit32a ref33">(32a,33)</a></div><div class="NLM_p">The synthetic strategy for the preparation of velpatasvir involves a series of bidirectional functionalizations that require the preparation and union of several structural subunits. Although several routes to velpatasvir intermediates have been recently published,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> including a potential alternate process route,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> the most likely process-scale route to the drug target has been described in a 2015 patent application authored by scientists at Gilead; this patent also describes several alternative routes to the drug’s key building blocks.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> It is important to note that no yields are reported throughout the patent, and only the route to pyrrolidine <b>91</b> was exemplified on multikilogram scale.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Synthesis of the central tetracyclic intermediate in the velpatasvir synthesis, tetralone <b>86</b>, began with commercial 2-bromo-5-iodo-benzenemethanol (<b>81</b>), which underwent iodide-metal exchange and subsequent quenching with acetamide <b>82</b> (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Mesylation of the resulting alcohol followed by treatment with LiBr furnished benzyl bromide <b>83</b>, which was then subjected to nucleophilic attack by commercial 7-hydroxytetralone (<b>84</b>) in the presence of K<sub>2</sub>CO<sub>3</sub>/MeCN to provide ether <b>85</b>. An innovative use of an intramolecular Pd-mediated C–H activation reaction catalyzed by Pd(OAc)<sub>2</sub>/PPh<sub>3</sub> secured the central tetracyclic core, which then underwent <i>bis</i>-α-keto-bromination with pyridinium tribromide in MeOH/DCM at room temperature to furnish tetralone <b>86</b>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of Tetralone Fragment <b>86</b> for Velpatasvir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of the ethereal pyrrolidine subunit <b>91</b> began with formylation of commercial glutamate <b>87</b> followed by an intramolecular cyclocondensation reaction facilitated by TFA to secure dihydropyrrole <b>88</b> (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> It should be noted that although TFA was used to affect the formation of enamine <b>88</b>, the reported route indicates no loss of Boc or <i>t</i>-Bu ester protecting groups in this transformation, and no further discussion was provided by the authors.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Reduction of the enamine (H<sub>2</sub>, Pd/C, HOAc) and ester (NaBH<sub>4</sub>, H<sub>2</sub>O/THF) moieties present in <b>88</b> yielded pyrrolidine <b>89</b> as a mixture of diastereomers. Global deprotection of this mixture using room temperature HCl in methanol generated the free amino acid, which was immediately subjected to mono reprotection with Boc anhydride to allow isolation of the Boc-protected amino acid intermediate <b>90</b>. Final steps of the synthesis of <b>91</b> included alkylation with methyl iodide and dicyclohexylamine salt formation, enabling isolation of the desired cis isomer after crystallization. Finally, subjection to NaOH in MTBE/H<sub>2</sub>O provided the desired ethereal pyrrolidine <b>91</b>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Preparation of Velpatasvir Ethereal Pyrrolidine <b>91</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Construction of the final building block, methylpyrrolidine <b>96</b>, began with a ring-opening reaction to convert <i>N</i>-Boc-pyrrolidinone <b>92</b> to ketone <b>93</b> followed by a one-pot Boc-deprotection/ring-closing reductive amination sequence (<a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> This step resulted in stereoselective hydride addition from the face opposite the ethyl ester,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> leading to the desired syn product, which was isolated as tosylate salt <b>94</b> after heating with <i>p</i>-toluenesulfonic acid monohydrate. Subsequent coupling with commercially available valine derivative <b>95</b> under standard peptide coupling conditions (HATU, DIPEA) and ester saponification with LiOH/MeOH furnished methyl pyrrolidine <b>96</b>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Methyl Pyrrolidine Fragment <b>96</b> for Velpatasvir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The final approach to the velpatasvir synthesis proceeded linearly, starting with the central tetralone core and building outward (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Alkylation of dibromide <b>86</b> first with acid <b>91</b> and second with acid <b>96</b> resulted in the transient <i>bis</i>-ketoester intermediate <b>97</b>, which was converted to <i>bis</i>-imidazole <b>98</b> using ammonium acetate followed by DDQ oxidation. Finally, introduction of fragment <b>99</b> relied upon Boc-deprotection with HCl/MeOH and subsequent neutralization of the resulting HCl salt to enable crystallization as the triphosphate salt. A second neutralizing step (aq NH<sub>4</sub>OH) and CDMT/NMM-mediated coupling of the free amine with commercially available phenylacetic acid derivative <b>99</b> provided velpatasvir (<b>VII</b>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Velpatasvir (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">2.7.  Zabofloxacin <span class="smallcaps smallerCapital">d</span>-Aspartate (Zabolante)</h3><div class="NLM_p">Zabofloxacin is a quinolone antibiotic originally developed by Dong Wha Pharmaceuticals and licensed to Pacific Beach Biosciences in 2007.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In March 2015, Korea’s Ministry of Food and Drug Safety (MFDS) approved zabofloxacin for the treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABE-COPD).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In 2016, zabofloxacin gained approval from the USFDA for the treatment of community-acquired pneumonia. ABE-COPD is caused by respiratory tract and pulmonary parenchyma that cause chronic pulmonary inflammation and obstruction in the respiratory tract, which leads to irreversible damage. In the nonclinical evaluation process, zabofloxacin showed strong antibiotic activity on respiratory germs (e.g., S<i>treptococcus pneumonia</i>, <i>S. Haemophilus</i>, <i>S. moraxella</i>) and was the most potent antibacterial agent against penicillin-resistant <i>S. pneumoniae</i> (PRSP) in the murine systemic infection model.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">The synthesis of zabofloxacin leverages the wide commercial availability of chloronaphthyridinone acid <b>106</b> to essentially reduce the task to the construction of functionalized diazaspirocyclic pyrrolidine <b>105</b> (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> As described in a series of patents from researchers at Dong Wha who have exemplified the synthesis on multikilogram scale, the route began with first converting the commercially available ketone <b>100</b> to the corresponding oxime followed by formylation to give oximyl alcohol <b>101</b>. Next, mesylation of the alcohol was followed by conversion of the nitrile to the corresponding amine <b>103</b>. An intramolecular ring closing step then occurred to secure the azetidine using aqueous sodium hydroxide. Salt formation with phthalic acid furnished <b>104</b> in good yield. Next, Boc-protection of the azetidine followed by hydrogenative Cbz removal and treatment with succinic acid resulted in the formation of amine salt <b>105</b>, and this was followed by a substitution reaction with <b>106</b> to deliver the Boc-protected zabofloxacin structure <b>107</b>. Lastly, removal of Boc via TFA followed by basification and subjection to <span class="smallcaps smallerCapital">d</span>-aspartate in warm ethanol furnished zabofloxacin <span class="smallcaps smallerCapital">d</span>-aspartate (<b>VIII</b>) in 56% yield for the three-step sequence.</div><figure id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Zabofloxacin <span class="smallcaps smallerCapital">d</span>-Aspartate (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">3.  CNS Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47772" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47772" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">3.1.  Brivaracetam (Briviact)</h3><div class="NLM_p">Brivaracetam, a novel oral antiepileptic drug with a high affinity for synaptic vesicle protein 2A (SV2A), was approved in Europe and the US as an adjunctive therapy for the treatment of partial onset seizures with or without secondary generalization in patients aged 16 or older.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Brivaracetam is very closely related to levetiracetam, an antiepileptic treatment whose immediate release formulation has been available in the United States as a generic drug since 2008, but whose extended release formulation is under patent protection until 2028. The two drugs, which were both developed by UCB Pharma, are structurally similar with brivaracetam having an <i>n</i>-propyl group at the C-4 position of the pyrrolidinone ring and levetiracetam having a hydrogen at this same position. A systematic investigation of the various substitutions of levetiracetam resulted in the identification of more potent and selective SV2A ligands and ultimately culminated in the discovery of brivaracetam, which has greater affinity for SV2A, improved selectivity, more rapid brain penetration, and faster onset of action against seizures than levetiracetam.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a></div><div class="NLM_p">Regarding the large-scale synthetic approach to brivaracetam, stereocontrolled installation of the 4-<i>n</i>-propyl group stands as the central challenge in the assembly of the molecule. Several routes have been published that require chiral separation.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Two enantioselective routes have been reported, one employing an enzymatic resolution<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and the other utilizing (<i>R</i>)-(−)-epichlorohydrin as a chiral starting material.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The route detailed in <a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>, which involves an enzymatic resolution, is the only kilogram-scale route disclosed in the literature to date and reportedly permits the production of brivaracetam within the required commercial quality specifications. However, the authors note that the development of this route for commercial purposes has been stopped.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Commercial dimethyl <i>n</i>-propylmalonate <b>108</b> was first alkylated with <i>tert</i>-butyl-2-bromoacetate. The resulting product underwent Krapcho decarboxylation to afford racemic succinate derivative <b>109</b> in 94% yield over the two steps.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Optimized conditions for the key enzymatic resolution employed protease C from <i>Bacillus subtilis</i> type 2 at 30 °C for 18 h to resolve ester <b>109</b> and provide the acid enantiomer <b>110</b>. This biocatalytic process allowed for residual unreacted diester <b>109</b> to be washed away with cyclohexane at pH 9 (adjusted with 0.5 M NaOH), and the desired acid <b>110</b> could be isolated upon lowering the pH (∼1) and extracting with isopropyl acetate (42% yield, 97% ee). The transformation of acid <b>110</b> into propyllactone <b>111</b> proceeded in nearly quantitative yield by a three-step sequence: activation of the acid with ethyl chloroformate, reduction to the alcohol with sodium borohydride, and cyclization upon acidic workup with TFA. Exposure of <b>111</b> to HBr in acetic acid followed by esterification of the resulting acid-generated bromoester <b>112</b>. Finally, TBAI-catalyzed alkylation of <b>112</b> with commercial (<i>S</i>)-2-aminobutanamide (<b>113</b>) in refluxing isopropyl acetate introduced the <i>n</i>-butylamide moiety while facilitating lactamization. Addition of MTBE followed by filtration and recrystallization from isopropyl acetate afforded brivaracetam (<b>IX</b>) in 32% yield and 96% ee.</div><figure id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Brivaracetam (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">3.2.  Opicapone (Ongentys)</h3><div class="NLM_p">Opicapone is a selective and reversible catechol <i>O</i>-methyltransferase (COMT) inhibitor that was developed by the Portuguese pharmaceutical firm Bial and sold to Neurocrine Biosciences.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The drug was approved by the USFDA as adjunctive treatment to levodopa (<span class="smallcaps smallerCapital">l</span>-Dopa)/dopa-decarboxylase inhibitor (DDCI) therapy in adults with Parkinson’s disease (PD) and end-of-dose motor fluctuations that cannot be stabilized on those combinations.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In 14- to 15-week double-blind multinational trials and in one-year open-label extension studies in this patient population, opicapone was an effective and generally well-tolerated adjunctive therapy to <span class="smallcaps smallerCapital">l</span>-Dopa plus a DDCI and other PD therapies.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> During the double-blind phase, adjunctive opicapone (50 mg once daily) provided significantly greater improvements in motor fluctuations than placebo, and no new unexpected safety concerns were identified after treatment with opicapone over a 1.4 year period.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Furthermore, no serious cases of hepatotoxicity were reported in clinical trials, which represents a significant safety profile improvement over existing standard-of-care COMT inhibitors enticapone, tolcapone, and nebicapone.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a></div><div class="NLM_p">Although several synthetic approaches to opicapone or opicapone subunits have been disclosed,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> a synthetic approach described by Bial was exemplified on a scale capable of producing 14.4 kg of the active pharmaceutical ingredient (API).<a onclick="showRef(event, 'cit50e'); return false;" href="javascript:void(0);" class="ref cit50e">(50e)</a> Commercial 2,4-pentanedione (<b>114</b>) was condensed with cyanoacetamide in warm methanol to give rise to cyanopyridone <b>115</b> in excellent yield (<a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>). Chlorination with sulfuryl chloride in chilled acetonitrile followed by treatment with phosphorus oxychloride resulted in dichloropyridine <b>117</b>. Next, treatment with hydroxylamine in aqueous methanol converted nitrile <b>117</b> to the corresponding <i>N</i>-hydroxyamidine <b>118</b>, and this was followed by exposure to pyridine and acid chloride <b>119</b> (whose preparation is described in <a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>). These operations facilitated a cyclization reaction, which furnished the key oxadiazole <b>120</b> in good yield. Subjection of <b>120</b> to urea hydrogen peroxide (UHP) in dichloromethane to establish the pyridine <i>N</i>-oxide functionality within opicapone preceded methyl ether cleavage through the use of aluminum trichloride in warm pyridine to furnish opicapone (<b>X</b>) in 53% yield for the two-step sequence.</div><figure id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Opicapone (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of Acid Chloride Fragment <b>119</b> for Opicapone</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The preparation of acid chloride <b>119</b> involved the nitration of commercially available benzoic acid <b>121</b> followed by thionyl chloride-mediated conversion of the resulting nitrobenzoic acid <b>122</b> to acid chloride <b>119</b> (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>). Interestingly, although the nitration step is low-yielding and involves nitric acid, the authors report an operationally simple isolation method that has been exemplified on multiple kilogram scale. No yield was reported for the conversion of <b>122</b> to <b>119</b>.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">3.3.  Pimavanserin Tartrate (Nuplazid)</h3><div class="NLM_p">Pimavanserin, developed by San Diego-based Acadia Pharmaceuticals, is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The USFDA approved this once-daily drug to treat the delusions and hallucinations associated with psychosis as a function of Parkinson’s disease.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Pimavanserin has a unique mechanism of action relative to other antipsychotics, behaving as a selective inverse agonist of the serotonin 5-HT2A receptor while exhibiting 40-fold selectivity over the 5-HT2C receptor and having no significant affinity or activity with the 5-HT2B or dopamine receptors.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><div class="NLM_p">Three patent applications filed by Acadia described the process-scale synthetic approach to pimavanserin.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The kilogram-scale synthesis (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>) began with the alkylation of commercially available 4-hydroxybenzaldehyde (<b>123</b>) with isobutyl bromide (<b>124</b>) under basic conditions. Condensation of the resultant benzaldehyde <b>125</b> with hydroxylamine furnished the corresponding oxime <b>126</b> in 63% yield from <b>123</b>. Hydrogenation of <b>126</b> catalyzed by Pd/C under acidic conditions produced benzylamine <b>127</b>, which was isolated as the acetate salt in 41% yield. This compound underwent sodium hydroxide workup followed by reaction with HCl gas and phosgene to deliver isocyanate <b>128</b>. Nucleophilic attack of this isocyanate by benzylamine <b>129</b> (prepared from reductive amination of commercially available <i>N</i>-methylpiperid-4-one <b>130</b> with 4-fluorobenzylamine <b>131</b>, <a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>) followed by salt formation using tartaric acid in aqueous isopropyl acetate, and THF completed the synthesis of pimavanserin tartrate (<b>XI</b>) in 50% yield over the two-step protocol and a 10.6% overall yield from <b>123</b>.<a onclick="showRef(event, 'cit54c'); return false;" href="javascript:void(0);" class="ref cit54c">(54c)</a></div><figure id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0023.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Pimavanserin Tartrate (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0024.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Benzylamine Fragment <b>129</b> for Pimavanserin</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">3.4.  Pitolisant Hydrochloride (Wakix)</h3><div class="NLM_p">Pitolisant hydrochloride, a first-in-class inverse agonist of the histamine H<sub>3</sub> receptor, was approved in the EU for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy with or without cataplexy.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The drug, which was developed by Bioprojet and has orphan drug designation in the EU and US, enhances wakefulness by increasing histaminergic neuron activity. With once daily oral administration in the morning, patients taking pitolisant exhibited significantly reduced EDS versus placebo but not versus modafinil.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Plasma levels of the drug are reduced at the end of the day such that its waking effect is minimized at night (plasma <i>t</i><sub>1/2</sub> 10–12 h). Several articles have been published detailing the discovery of pitolisant.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">The most likely scale preparation of pitolisant hydrochloride consists of only four synthetic steps starting with the mesylation of commercial 3-(4-chlorophenyl)propan-1-ol (<b>132</b>, <a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Displacement of the mesylate with the sodium salt of commercial 3-(piperidin-1-yl)propan-1-ol (<b>133)</b> in warm DMA assembled the parent drug in 97% yield over two steps.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Salt formation was affected by pH adjustment to 3–4 using HCl gas in EtOAc. Recrystallization from ethyl acetate and isopropanol provided pitolisant hydrochloride (<b>XII</b>) on kilogram scale in 78% overall yield across the short four-step protocol.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><figure id="sch24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0025.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Pitolisant Hydrochloride (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">4.  Dermatologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87573" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87573" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">4.1.  Crisaborole (Eucrisa)</h3><div class="NLM_p">Crisaborole is a phosphodiesterase-4 (PDE4) inhibitor that was approved by the USFDA for the treatment of mild to moderate atopic dermatitis (AD) in patients aged two years and older.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The drug, which was developed by Anacor Pharmaceuticals and later acquired and marketed by Pfizer, is delivered as a 2% ointment, which is applied topically.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The unique employment of boron within the chemical structure of the drug is designed to enable selective engagement of PDE4 (an enzyme involved in the conversion of cAMP into AMP, which signals for downstream inflammatory events), effective penetration of the drug through human skin, and rapid clearance to limit systemic circulation.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> During in vitro experiments, the drug demonstrated significantly reduced cytokine production from peripheral blood mononuclear cells in a pattern similar to other PDE4 inhibitors and distinct from corticosteroids.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In phase 1 and 2 clinical studies, crisaborole ointment was generally well tolerated and improved AD disease severity scores, pruritus, and all other AD signs and symptoms.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Several disclosures describing synthetic approaches to ethereal boron-containing anti-inflammatory compounds have been published by Anacor.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(63)</a> A scalable synthetic route to crisaborole is described in <a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a> and closely follows an approach to the drug reported in the public literature by researchers at Anacor.<a onclick="showRef(event, 'cit200e'); return false;" href="javascript:void(0);" class="ref cit200e">(63e)</a> Commercially available bromobenzaldehyde <b>134</b> was protected as the corresponding acetal upon subjection to warm ethylene glycol in the presence of catalytic <i>p</i>-toluenesulfonic acid. This was followed by nucleophilic aromatic substitution involving 4-fluorobenzonitrile and subsequent acetal deprotection to furnish diaryl ether <b>136</b>. Although multiple approaches to crisaborole have been reported from this intermediate diaryl ether <b>136</b>,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(63)</a> the published literature approach involves the following sequence: reduction of the aldehyde with sodium borohydride followed by THP protection to furnish bromobenzene <b>137</b>, which then underwent lithium-halogen exchange prior to quenching with triisopropyl borate and acidification to arrive at crisaborole (<b>XIII</b>).<a onclick="showRef(event, 'cit200e'); return false;" href="javascript:void(0);" class="ref cit200e">(63e)</a> Alternatively, patents from Anacor describe a general approach employing a Miyaura coupling of <b>136</b>, enabling the installation of the corresponding pincacol borane, which could then be exposed to reduction conditions using sodium borohydride followed by boric acid wash, aqueous workup, and lyophilization to furnish <b>XIII</b>.<a onclick="showRef(event, 'cit200e'); return false;" href="javascript:void(0);" class="ref cit200e">(63e)</a></div><figure id="sch25" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0026.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Crisaborole (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">5.  Gastrointestinal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06231" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06231" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45">5.1.  Obeticholic Acid (Caliva)</h3><div class="NLM_p">Obeticholic acid is a potent and selective farnesoid X receptor agonist that promotes the flow of bile in the liver.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(64)</a> The drug was approved by the USFDA for the treatment of the rare chronic liver disease primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA or as a single agent therapy in adults unable to tolerate UDCA.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(65)</a> Obeticholic acid was discovered at the Università de Perugia and developed by Intercept Pharmaceuticals. Obeticholic acid has also been granted orphan drug designation for the treatment of primary sclerosing cholangitis and primary biliary cirrhosis and has received breakthrough therapy designation for the treatment of patients with nonalcohol steatohepatitis (NASH) with liver fibrosis.</div><div class="NLM_p">The synthesis of obeticholic acid was initiated from commercial 3α-hydroxy-7-keto-5β-cholan-24-oic acid (<b>138</b>) and is described in <a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(66)</a> Fischer esterification of <b>138</b> provided methyl ester <b>139</b>, which was treated with trimethylsilyl chloride and triethylamine to protect the secondary alcohol. Reaction of the protected alcohol with lithium diisopropylamine and trimethylsilyl chloride gave silyl enol ether <b>140</b>. Aldol condensation with acetaldehyde and boron trifluoride etherate followed by saponification of the methyl ester produced enone <b>141</b>. Hydrogenation of the olefin followed by heating to reflux to epimerize the resulting ethyl group produced the α-ethyl ketone <b>142</b> in 62% yield from compound <b>138</b>. Reduction of the ketone in <b>142</b> with sodium borohydride and subsequent crystallization from phosphoric acid and water gave obeticholic acid (<b>XIV</b>) in 90% yield.</div><figure id="sch26" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0027.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Obeticholic Acid (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">6.  Metabolic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06733" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06733" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48">6.1.  Migalastat Hydrochloride (Galafold)</h3><div class="NLM_p">Migalastat, which is marketed by Amicus Therapeutics, received approval in the EU for the treatment of Fabry disease in adults and adolescents aged 16 or older.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(67)</a> Fabry disease is caused by mutations of the enzyme α-galactosidase A (α-GAL A) that cause protein misfolding and prevents efficient metabolism of the glycosphingolipid globotriaosylceramide (GL3).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(68)</a> Accumulation of GL3 in lysosomes, blood vessels, and various tissues ultimately leads to significant heart, kidney, and dermatological problems.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(68)</a> Migalastat functions as a molecular chaperone to α-GAL A, engaging the enzyme and enabling it to adopt the proper conformation allowing for efficient breakdown of GL3.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(67)</a> Because the standard of care prior to 2016 for treating Fabry disease was enzyme replacement therapy (ERT), migalastat’s approval in the EU represents an important advance for patients suffering from this disorder.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(67)</a></div><div class="NLM_p">Several unique synthetic approaches to migalastat, which is also known as <span class="smallcaps smallerCapital">d</span>-1-deoxygalactonojirimycin (DGJ), have been reported in the literature.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(69)</a> Although the most likely commercial-scale preparation of this drug proceeds through a microbial fermentation process disclosed in a 2015 patent,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(70)</a> a kilogram-scale synthesis of the drug outlined in <a class="ref internalNav" href="#sch27" aria-label="Scheme 27">Scheme 27</a> has been described in a 2008 patent application filed by Amicus. This route closely resembles a procedure disclosed in 1999 by Uriel and Santoyo-Gonzalez<a onclick="showRef(event, 'cit68i ref70'); return false;" href="javascript:void(0);" class="ref cit68i ref70">(69i,71)</a> that presented handling and safety concerns.<a onclick="showRef(event, 'cit68i'); return false;" href="javascript:void(0);" class="ref cit68i">(69i)</a> Commercial <span class="smallcaps smallerCapital">d</span>-galactose (<b>143</b>) was treated with five equivalents of pivaloyl imidazole (<b>144</b>),<a onclick="showRef(event, 'cit68i'); return false;" href="javascript:void(0);" class="ref cit68i">(69i)</a> followed by triflation, treatment with Hünig’s base, and exposure to sodium nitrite to furnish the tetrapivaloyl altofuranose triflate <b>145</b> after recrystallization from heptane. Next, stereospecific azide displacement of the triflate successfully delivered azidofuranose <b>146</b> in 65–70% yield. This reaction generated over 3 kg of the desired alkyl azide after recrystallization from ethanol and water. Lastly, palladium-catalyzed hydrogenolysis in the presence of sodium methoxide, a methanolic acidification step, and then a subsequent acidification step using HCl in THF furnished migalastat hydrochloride (<b>XV</b>) in 70–75% yield over the three-step sequence from <b>146</b>.</div><figure id="sch27" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0028.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Migalastat Hydrochloride (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">7.  Oncology Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51">7.1.  Olmutinib (Olita)</h3><div class="NLM_p">Olmutinib, codeveloped by Boehringer Ingelheim and Hanmi Pharmaceutical Co., was approved by the Korean Ministry of Food and Drug Safety (MFDS) for treatment of locally advanced or metastatic EGFR T790 M mutation-positive non-small cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(72)</a> Olmutinib serves as a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), which is being used as an oral therapy for patients who have previously been treated with an alternate EGFR TKI.<a onclick="showRef(event, 'cit71a'); return false;" href="javascript:void(0);" class="ref cit71a">(72a)</a> First- and second-generation EGFR TKIs, which bind reversibly and irreversibly to the TK domain, respectively, are both generally effective at onset of treatment but result in development of resistance within the first year of treatment.<a onclick="showRef(event, 'cit71b ref72'); return false;" href="javascript:void(0);" class="ref cit71b ref72">(72b,73)</a> Third-generation EGFR TKIs such as olmutinib have demonstrated the ability to covalently bind to the kinase domain of EGFR while sparing wild-type EGFR, leading to irreversible inhibition of both EGFR mutations and the T790 M mutation, which is linked to EGFR TKI resistance.<a onclick="showRef(event, 'cit71b ref73'); return false;" href="javascript:void(0);" class="ref cit71b ref73">(72b,74)</a></div><div class="NLM_p">Synthetically, olmutinib can be accessed in two steps beginning with 2,4-dichloro-thieno[3,2-<i>d</i>]pyrimidine (<b>147</b>, <a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>), which is commercially available and can be prepared in two steps from urea and 3-aminothiophene 2-carboxylate.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(75)</a> Nucleophilic addition of <i>N</i>-(3-hydroxyphenyl)-2-propenamide (<b>148</b>) to <b>147</b> proceeded with complete regioselectivity via treatment with K<sub>2</sub>CO<sub>3</sub> in warm DMSO, smoothly providing the desired diaryl ether <b>149</b> in 87% yield after crystallization from isopropanol and water.<a onclick="showRef(event, 'cit74b ref75'); return false;" href="javascript:void(0);" class="ref cit74b ref75">(75b,76)</a> From <b>149</b>, substitution with commercially available piperazinyl aniline <b>150</b> under acidic heating conditions (DMA, IPA, TFA, 90 °C) provided olmutinib in 82% yield. After recrystallization, olmutinib (<b>XVI</b>) was obtained in 60% overall yield and 99.1% purity.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(76)</a></div><figure id="sch28" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0029.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Synthesis of Olmutinib (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53">7.2.  Rucaparib Camsylate (Rubraca)</h3><div class="NLM_p">Rucaparib was approved in the US as an oral treatment for advanced ovarian cancer.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(77)</a> Development of rucaparib began with collaborations between Cancer Research UK and Agouron Pharmaceuticals (later acquired by Pfizer). Global development rights for rucaparib were ultimately granted to Clovis Oncology via a licensing agreement from Pfizer.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(77)</a> To qualify for treatment with rucaparib monotherapy, patients must demonstrate deleterious breast cancer (<i>BRCA</i>) mutation (germline and/or somatic)-associated advanced ovarian cancer and also must have previously been treated with two or more chemotherapy regimens.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(78)</a> Rucaparib functions as a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor, which plays an important role in DNA repair.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(78,79)</a> This newly approved drug displays nanomolar potency against PARP-1, -2, and -3 enzymes,<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(80)</a> which translates into improved efficacy over alternative therapies such as olaparib or niraparib.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(81)</a> Furthermore, rucaparib is also known to cause vasodilation, which is thought to induce tumor perfusion and increased accumulation of the drug in cancer cells.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(82)</a> Although rucaparib shows higher cytotoxicity in cancer cells with mutation of <i>BRCA1/2</i> genes and other DNA repair genes,<a onclick="showRef(event, 'ref76 ref82'); return false;" href="javascript:void(0);" class="ref ref76 ref82">(77,83)</a> reduced tumor growth was observed in mouse xenograft models of human cancers with and without <i>BRCA</i> mutations.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(77)</a> Rucaparib is also being pursued as a treatment for breast cancer<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(84)</a> and has displayed promising initial results in trials for pancreatic cancer.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(85)</a></div><div class="NLM_p">Synthesis of rucaparib camsylate begins from commercially available phthalimide acetal <b>151</b> (<a class="ref internalNav" href="#sch29" aria-label="Scheme 29">Scheme 29</a>).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(86)</a> Unveiling of the aldehyde via treatment with aqueous HCl and precipitation from toluene provided aldehyde <b>152</b> in 62% yield. To avoid polymerization, <b>152</b> was immediately subjected to 6-fluoro-1<i>H</i>-indole-4-carboxylic acid methyl ester (<b>153</b>) under reductive conditions in the presence of acid to give rise to tryptamine derivative <b>154</b>. After considerable research, optimal conditions for this transformation (triethylsilane in DCM/TFA)<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(87)</a> were found that were successful on up to 15.7 kg scale, enabling clean separation of the aldehyde reduction byproduct following crystallization.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(86)</a> Conversion of the phthalimide within <b>154</b> to the corresponding amine using aqueous methylamine at room temperature was accompanied by an intramolecular cyclization reaction to secure the intermediate lactam as a solid in 89% isolated yield. This was followed by a high-yielding bromination reaction (83%) at the indole C-2 position employing pyridinium tribromide, providing access to indoloazepinone <b>155</b>. After screening various catalysts for the coupling of bromide <b>155</b> and commercial boronic acid <b>156</b>, Pd(dppf)Cl<sub>2</sub>·DCM was found to reliably deliver the desired coupling product with reasonable rates of reaction. Thus, after development of an extensively optimized reaction protocol,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(86)</a> Suzuki coupling of <b>155</b> and 4-formylphenylboronic acid (<b>156)</b> with Pd(dppf)Cl<sub>2</sub>·DCM and Na<sub>2</sub>CO<sub>3</sub> in DMA at 90 °C generated the desired 2-arylated indole <b>157</b> in high yield (92%) after trituration and reslurry with methanol. Conversion of aldehyde <b>157</b> to amine <b>158</b> necessitated a two-pot procedure designed to limit the formation of dimerization and aldehyde reduction products that generally arise under conventional one-pot reductive amination conditions and have traditionally been problematic on scale. Toward this end, subjection of aldehyde <b>157</b> to a methylamine solution in EtOH/MeOH/THF and wash of the resulting reaction solids with methanol led to efficient isolation of pure imine intermediate, which could be immediately reduced with NaBH<sub>4</sub> in THF/MeOH, providing hydrochloride salt <b>158</b> upon acidic workup in 76% over two steps. The two remaining steps for conversion to the drug involve a salt-swap, first breaking the HCl salt with NaOH in MeOH, then treatment with (<i>S</i>)-camphorsulfonic acid/IPA/H<sub>2</sub>O at 70 °C. Filtration and washing of the cake with water generated rucaparib camsylate (<b>XVII</b>) in 95% yield.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(86)</a></div><figure id="sch29" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0030.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Rucaparib Camsylate (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55">7.3.  Venetoclax (Venclexta)</h3><div class="NLM_p">Venetoclax, codeveloped by AbbVie (previously Abbott Laboratories) and Genentech/Roche, was approved in the US for treatment of patients with chronic lymphocytic leukemia (CLL). To meet qualifications for venetoclax treatment, patients must have received prior therapy and possess the 17p deletion genetic mutation, as determined by USFDA testing.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(88)</a> Venetoclax functions as a selective inhibitor of B cell lymphoma subtype 2 (BCL-2), which is often overexpressed on malignant cells and thus leads to impairment of the apoptotic pathway.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(89)</a> Along these lines, the orally dosed small molecule drug restores the ability of malignant cells to undergo apoptosis as its mechanism of action.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(90)</a> Although other BCL-2 inhibitors are known, development of similar agents such as navitoclox have been pursued and halted due to undesired inhibition of BCL-X<sub>L</sub>, leading to significant thrombocytopenia and demonstrating the need for more selective inhibitors.<a onclick="showRef(event, 'cit88b'); return false;" href="javascript:void(0);" class="ref cit88b">(89b)</a> Venetoclax is also currently being considered for approval in Europe and Canada for similar indications and is in various stages of development for the treatment of non-Hodgkin lymphomas (NHL), acute myeloid leukemia (AML), multiple myeloma (MM), and several other disorders, either as a combination therapy or a stand-alone treatment.<a onclick="showRef(event, 'cit88a'); return false;" href="javascript:void(0);" class="ref cit88a">(89a)</a></div><div class="NLM_p">The manufacturing route to venetoclax takes place by coupling of three key structural subunits: azaindole <b>162</b>, sulfonamide <b>165</b>, and piperazine <b>172</b>.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(91)</a> The first of these subunits was generated in two steps from commercially available 4-bromo-2-fluoro-1-iodo-benzene (<b>159</b>, <a class="ref internalNav" href="#sch30" aria-label="Scheme 30">Scheme 30</a>). Grignard formation of iodide <b>159</b> (<i>i</i>-PrMgCl) followed by quenching with Boc<sub>2</sub>O provided the desired <i>tert</i>-butyl ester <b>160</b> without the need for chromatographic purification. Aromatic substitution of crude <b>160</b> with azaindole <b>161</b> provided access to <b>162</b> in 86% yield after recrystallization from EtOAc/heptane. Separately, as shown in <a class="ref internalNav" href="#sch31" aria-label="Scheme 31">Scheme 31</a>, sulfonamide <b>165</b> was formed in 91% yield and 99.9% purity via aromatic substitution of commercially available <b>163</b> with amine <b>164</b> at 80 °C (DIPEA, MeCN).<a onclick="showRef(event, 'cit90a'); return false;" href="javascript:void(0);" class="ref cit90a">(91a)</a></div><figure id="sch30" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0031.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Azaindole Fragment <b>162</b> for Venetoclax</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch31" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0032.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Synthesis of Sulfonamide Fragment <b>165</b> for Venetoclax</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Synthesis of the third venetoclax subunit, piperazine amine hydrochloride salt <b>172</b>, began with commercial cyclohexanone <b>166</b> (<a class="ref internalNav" href="#sch32" aria-label="Scheme 32">Scheme 32</a>).<a onclick="showRef(event, 'cit90a'); return false;" href="javascript:void(0);" class="ref cit90a">(91a)</a> Vilsmeier–Haack formylation of the sterically more accessible enol tautomer of <b>166</b> delivered vinyl chloride <b>167</b> in quantitative yield. Coupling of this chloride with commercial aryl boronate <b>168</b> gave rise to transient enal <b>169</b> in 87% assay yield, which was not isolated. Crude <b>169</b> was then carried into a reductive amination reaction with commercial <i>N</i>-Boc piperazine (<b>170</b>). Precipitation and recrystallization from acetonitrile ultimately furnished piperazinyl alkene <b>171</b> in 74% yield from <b>167</b>. Finally, subunit <b>172</b> was obtained via Boc removal with concentrated HCl in IPA at 65 °C and subsequent filtration, conditions that provided a 95% yield of high purity intermediate <b>172</b> (>99.5%).<a onclick="showRef(event, 'cit90a'); return false;" href="javascript:void(0);" class="ref cit90a">(91a)</a></div><figure id="sch32" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0033.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Piperazine Hydrochloride Amine Fragment <b>172</b> for Venetoclax</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The final approach to venetoclax involved a palladium-catalyzed coupling of amine <b>172</b> with aryl bromide <b>162</b>, ester hydrolysis, and coupling of the resulting carboxylic acid with sulfonamide <b>165</b> (<a class="ref internalNav" href="#sch33" aria-label="Scheme 33">Scheme 33</a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(91)</a> In practice, Buchwald–Hartwig amination of <b>162</b> with <b>172</b> proceeded smoothly and relied upon workup with cysteine to enable cleansing of residual palladium from the reaction mixture. This reaction gave rise to advanced intermediate <b>173</b> in 89% yield after crystallization from cyclohexane. Treatment of <b>173</b> with <i>t</i>-BuOK/H<sub>2</sub>O/2-MeTHF at 55 °C provided the corresponding free acid, which was immediately activated with EDC/DMAP/Et<sub>3</sub>N to promote coupling with sulfonamide <b>165</b> at room temperature. The final drug target could be accessed by crystallization from EtOAc and washing with 1:1 DCM/EtOAc, yielding venetoclax (<b>XVIII</b>) in free base form<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(91,92)</a> in 71% over the two final steps.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(90,91)</a> This synthetic route was capable of fashioning the drug target in 52% overall yield based on the longest linear sequence (7 steps).<a onclick="showRef(event, 'cit90b'); return false;" href="javascript:void(0);" class="ref cit90b">(91b)</a></div><figure id="sch33" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0034.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Venetoclax (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60">8.  Ophthalmologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64044" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64044" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61">8.1.  Lifitegrast (Xiidra)</h3><div class="NLM_p">Lifitegrast, initially designed and developed by SARcode Bioscience (which was acquired by Shire in 2013),<a onclick="showRef(event, 'cit93a'); return false;" href="javascript:void(0);" class="ref cit93a">(93a)</a> is a novel tetrahydroisoquinoline derivative that is marketed as a 5% ophthalmic solution.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(93)</a> The drug was approved by the USFDA for the treatment of dry eye disease.<a onclick="showRef(event, 'cit93a'); return false;" href="javascript:void(0);" class="ref cit93a">(93a)</a> As a small molecule integrin antagonist, lifitegrast reduces inflammation through binding inhibition of the proteins lymphocyte function-associated antigen 1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1), influencing T-cell activation and cytokine (protein) release. Lifitegrast represents the first LFA-1/ICAM-1 interaction inhibitor approved globally, making it a first-in-class therapy for the treatment of dry eye disease by this mechanism.<a onclick="showRef(event, 'ref92 ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref92 ref93 ref94">(93−95)</a></div><div class="NLM_p">The most likely synthetic approach capable of delivering lifitegrast on scale is described in <a class="ref internalNav" href="#sch34" aria-label="Scheme 34">Scheme 34</a> beginning with commercial 3-bromo-<span class="smallcaps smallerCapital">l</span>-phenylalanine (<b>174</b>) as the starting material.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(96)</a> After Boc protection, reaction with sodium methanesulfinate in the presence of copper iodide, K<sub>2</sub>CO<sub>3</sub>, and <span class="smallcaps smallerCapital">l</span>-proline gave rise to sulfonate <b>176</b>. Esterification of <b>176</b> with benzyl alcohol followed by removal of the Boc group within <b>177</b> yielded the corresponding HCl salt of the aminoester <b>178</b>. Amide bond coupling with acid <b>179</b> (prepared as shown in <a class="ref internalNav" href="#sch35" aria-label="Scheme 35">Scheme 35</a>) furnished amide <b>180</b>, which was then subjected to 4 N HCl in dioxane resulting in trityl removal and arrival at HCl salt <b>181</b> in 88% yield over two steps. Tetrahydroisoquinoline <b>181</b> was then coupled with commercial benzofuranyl acid <b>182</b> to give rise to lifitegrast benzyl ester in 90% yield. Finally, saponification delivered lifitegrast (<b>XIX</b>) in 88% yield.<a onclick="showRef(event, 'cit95c'); return false;" href="javascript:void(0);" class="ref cit95c">(96c)</a></div><figure id="sch34" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0035.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Lifitegrast (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch35" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0036.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Tetrahydroisoquinoline-6-carboxylic Acid Fragment <b>179</b> for Lifitegrast</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Tetrahydroisoquinoline-6-carboxylic acid <b>179</b> was prepared starting from commercial 3,5-dichlorobenzaldehyde <b>183</b> (<a class="ref internalNav" href="#sch35" aria-label="Scheme 35">Scheme 35</a>). Reductive amination with 1-chloro-2-aminoethane <b>184</b> gave chloroethyl amine <b>185</b>, which underwent an efficient intramolecular Friedel–Crafts reaction using AlCl<sub>3</sub> to generate the corresponding tetrahydroisoquinoline <b>186</b> in 91% yield. <i>N-</i>Tritylation of <b>186</b> proceeded in 89% yield, and this was followed by a directed <i>o</i>-metalation reaction and carbon dioxide quench to furnish the requisite acid <b>179</b> in 75% yield.</div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">9.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, the pharmaceutical industry collectively enjoyed a productive 2016, a year that saw the introduction of these 19 new and important small molecule medicines to the marketplace. Innovative synthetic chemistry, particularly new methods for bond construction and the assembly of complex molecular architectures that can be effectively applied not only in the discovery setting but on process scale as well, will continue to permit access to challenging and/or novel chemical space. As the discipline continues to advance, the discovery of new synthetic methodologies and expansion of the limits of known bond-making technologies to new substrates through deeper mechanistic understanding will play an increasingly important role in the discovery and development of new medicines. This review continues to highlight the application of such technology and innovation toward the production of important treatments for disease and will hopefully provide inspiration to researchers worldwide in the continued discovery of new drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00260" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02877" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02877" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. O’Donnell</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#234c474c4d4d464f4f4049111063444e424a4f0d404c4e"><span class="__cf_email__" data-cfemail="076863686969626b6b646d353447606a666e6b2964686a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew
C. Flick</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong X. Ding</span> - <span class="hlFld-Affiliation affiliation">Pharmacodia
(Beijing) Co., Ltd., Beijing, 100085, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolyn A. Leverett</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah J. Fink</span> - <span class="hlFld-Affiliation affiliation">BioDuro, 11011 Torreyana Road, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Andrew
C. Flick</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=BIO-d89e2838-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrew C. Flick</b> earned a B.A. in Chemistry from Lake Forest College and then joined Abbott Laboratories’ Diagnostics Group in Abbott Park, Illinois. He then moved to Array BioPharma in Longmont as a Research Associate in their Process Chemistry Group. In 2003, he joined Professor Albert Padwa’s laboratory at Emory University where he successfully demonstrated a Michael addition-nitrone dipolar cycloaddition approach for the total synthesis of the marine natural alkaloid cylindricine C. After obtaining his Ph.D. in 2008, he joined the Medicine Design group at Pfizer in Groton, CT where he has been involved in numerous discovery projects within the Neurosciences, Rare Diseases, and Inflammation & Immunology therapeutic areas. Andy has authored over 30 peer-reviewed publications and patents.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Hong X. Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=BIO-d89e2843-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hongxia (Sheryl) Ding</b> obtained a B.S. in Pharmaceutics in 2001 and a Ph.D. in Medicinal Chemistry in 2006 from Zhejiang University in Hangzhou, China. Hongxia is the cofounder and Chief Executive Officer of PHARMACODIA, a company founded in 2013, which is an online platform (<a href="http://www.pharmacodia.com" class="extLink">http://www.pharmacodia.com</a>) providing big data and information service in the pharmaceutical R&D field. In 2010–2013, Hongxia joined Shenogen Pharma Group, a China-based Biotech company. As senior director of the R&D department, Hongxia is responsible for the CMC development of a novel ER-α36 targeted phase II candidates drug named Icaritin (SNG162) and the discovery and development of second-generation small molecules based on the structure optimization of SNG162. Before Shenogen, Hongxia worked at BioDuro since 2006 as senior group leader and senior research scientist.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Carolyn A. Leverett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=BIO-d89e2851-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Carolyn Leverett</b> began her career at Pfizer in 2012, focusing on the development of microtubule inhibitor-based payloads for use as antibody–drug conjugates. She currently works in the Applied Synthesis Technologies group, where she is involved in the discovery of biocatalytic routes to support various chemistry therapeutic areas. Carolyn is a native of North Carolina and obtained her B.S. in chemistry from North Carolina State University. She completed her doctoral studies with Professor Albert Padwa at Emory University in Atlanta, GA working on total synthesis of several piperidine-based natural products and the alkaloid minfiensine. Prior to joining Pfizer, she was a postdoctoral fellow working with Professor Daniel Romo at Texas A&M University exploring new applications of nucleophile-catalyzed aldol lactonization reactions.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Sarah J. Fink</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=BIO-d89e2856-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sarah Fink</b> is a Senior Manager for Integrated Programs at BioDuro and is based in the Boston area. She obtained a B.A. in Chemistry and English literature from Williams College followed by a Ph.D. in Organic Chemistry from the University of Cambridge with Professor Ian Paterson. Her thesis work focused on the total synthesis of aplyronine C. After a fellowship for young international scientists at Shanghai Institute of Materia Medica, Sarah joined BioDuro in Shanghai in 2014, where she was a scientist and chemistry group leader for integrated drug discovery projects in multiple therapeutic areas. She relocated to Boston in early 2017; in her current role, she provides medicinal chemistry and scientific project management support for collaborations with pharma and biotech.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Christopher J. O’Donnell</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=BIO-d89e2861-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. O’Donnell</b> obtained a B.S. in Chemistry from the University of Illinois in Urbana/Champaign and a Ph.D. in Organic Chemistry from the University of Wisconsin, Madison. After postdoctoral research at the University of California-Irvine, he joined the Neuroscience Medicinal Chemistry group at Pfizer. As a scientist, project leader, and manager, he has led teams to the nomination of over 10 clinical candidates and he is the inventor of the Phase 2 AMPA PAM PF-04958242 for schizophrenia. Chris moved to the Oncology Medicinal Chemistry group to build the Antibody Drug Conjugate chemistry group, and his team nominated 14 conjugates for clinical development. In 2017, Chris built the Applied Synthesis Technology group at Pfizer. Chris is an author/inventor of 70 peer-reviewed journal articles and patents.</p></figure></div><div class="ack" id="ACK-d89e2866-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44557" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Dr. Matthew Perry for helpful and insightful discussions regarding crisaborole. The authors also thank Dr. Emma McIntuff and Dr. John Ragan for helpful discussions and suggestions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">Ad</td><td class="NLM_def"><p class="first last">adamantyl</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>N</i>-<i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">Bu, <i>n</i>-Bu</td><td class="NLM_def"><p class="first last">butyl, <i>n-</i>butyl</p></td></tr><tr><td class="NLM_term">cat</td><td class="NLM_def"><p class="first last">catalytic</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last">benzyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CDMT</td><td class="NLM_def"><p class="first last">2-chloro-4,6-dimethoxy-1,3,5-triazine</p></td></tr><tr><td class="NLM_term">CPME</td><td class="NLM_def"><p class="first last">cyclopentyl methyl ether</p></td></tr><tr><td class="NLM_term">CSA</td><td class="NLM_def"><p class="first last">camphorsulfonic Acid</p></td></tr><tr><td class="NLM_term">Cy</td><td class="NLM_def"><p class="first last">cyclohexyl</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">1,3-dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DDQ</td><td class="NLM_def"><p class="first last">2,3-dichloro-5,6-dicyano-1,4-benzoquinone</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N,N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMF-DMA</td><td class="NLM_def"><p class="first last">dimethylformamide–dimethylacetal</p></td></tr><tr><td class="NLM_term">DMPU</td><td class="NLM_def"><p class="first last">1,3-dimethyl-3,4,5,6-tetrahydro-2(1<i>H</i>)-pyrimidinone</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DPPA</td><td class="NLM_def"><p class="first last">diphenyl phosphoryl azide</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-ferrocenediyl-bis(diphenylphosphine)</p></td></tr><tr><td class="NLM_term">dr</td><td class="NLM_def"><p class="first last">diastereomeric ratio</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropal)-<i>N</i>-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">ee</td><td class="NLM_def"><p class="first last">enantiomeric excess</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>N</i>-[(dimethylamino)-1<i>H</i>-1,2,3-triazolo-[4,5-<i>b</i>]pyridin-1-ylmethylene]-<i>N</i>-methyl methanaminium hexafluorophosphate <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">Hex, <i>n</i>-Hex</td><td class="NLM_def"><p class="first last">hexyl</p></td></tr><tr><td class="NLM_term">HMDS</td><td class="NLM_def"><p class="first last">hexamethyldisilazane</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole hydrate</p></td></tr><tr><td class="NLM_term">HWE</td><td class="NLM_def"><p class="first last">Horner–Wadsworth–Emmons</p></td></tr><tr><td class="NLM_term"><i>i-</i>Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">IPAc</td><td class="NLM_def"><p class="first last">isopropyl acetate</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">methyl ethyl ketone</p></td></tr><tr><td class="NLM_term">Moc</td><td class="NLM_def"><p class="first last">methoxycarbonyl</p></td></tr><tr><td class="NLM_term">Ms</td><td class="NLM_def"><p class="first last">methylsulfonyl, mesyl</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl morpholine</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">Pin</td><td class="NLM_def"><p class="first last">pinacolato</p></td></tr><tr><td class="NLM_term">Piv</td><td class="NLM_def"><p class="first last">pivaloyl</p></td></tr><tr><td class="NLM_term"><i>p</i>-TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">Py</td><td class="NLM_def"><p class="first last">pyridine</p></td></tr><tr><td class="NLM_term">rac</td><td class="NLM_def"><p class="first last">racemic</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">TBAB</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl ammonium bromide</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBAH</td><td class="NLM_def"><p class="first last">tetrabutylammonium hydroxide</p></td></tr><tr><td class="NLM_term">TBAI</td><td class="NLM_def"><p class="first last">tetrabutylammonium iodide</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>,<i>N</i>-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term"><i>t</i>-Bu</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TES</td><td class="NLM_def"><p class="first last">triethylsilane</p></td></tr><tr><td class="NLM_term">TEMPO</td><td class="NLM_def"><p class="first last">2,2,6,6-tetramethylpiperidine 1-oxyl</p></td></tr><tr><td class="NLM_term">Tf</td><td class="NLM_def"><p class="first last">triflic, trifluoromethanesulfonyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid anhydride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">TMEDA</td><td class="NLM_def"><p class="first last"><i>N,N,N</i>′<i>,N</i>′-tetramethylethylenediamine</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">trimethylsilyl</p></td></tr><tr><td class="NLM_term">tol</td><td class="NLM_def"><p class="first last">toluene</p></td></tr><tr><td class="NLM_term">Tr</td><td class="NLM_def"><p class="first last">trityl, triphenylmethyl</p></td></tr><tr><td class="NLM_term">Ts</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonyl</p></td></tr><tr><td class="NLM_term">UHP</td><td class="NLM_def"><p class="first last">urea hydrogen peroxide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 96 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raju, T. N. K.</span></span> <span> </span><span class="NLM_article-title">The Nobel Chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918–99), and George H Hitchings (1905–98)</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1022</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)74775-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS0140-6736%2805%2974775-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10768469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=1022&author=T.+N.+K.+Raju&title=The+Nobel+Chronicles.+1988%3A+James+Whyte+Black%2C+%28b+1924%29%2C+Gertrude+Elion+%281918%E2%80%9399%29%2C+and+George+H+Hitchings+%281905%E2%80%9398%29&doi=10.1016%2FS0140-6736%2805%2974775-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span></div><div class="casAuthors">Raju T N</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9208</span>),
    <span class="NLM_cas:pages">1022</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTWLVzWjiD66qcneEtCi92fW6udTcc2eZ8Yk7Av9bPrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D&md5=c89d64b40317d0d0cb4a76c1cceecb58</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974775-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974775-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DT.%2BN.%2BK.%26atitle%3DThe%2520Nobel%2520Chronicles.%25201988%253A%2520James%2520Whyte%2520Black%252C%2520%2528b%25201924%2529%252C%2520Gertrude%2520Elion%2520%25281918%25E2%2580%259399%2529%252C%2520and%2520George%2520H%2520Hitchings%2520%25281905%25E2%2580%259398%2529%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D1022%26doi%3D10.1016%2FS0140-6736%2805%2974775-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0liJZoqnKyCXsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0liJZoqnKyCXsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.-C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0liJZoqnKyCXsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0limAK66R0ZeZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0limAK66R0ZeZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0limAK66R0ZeZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0limAK66R0ZeZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2hR"><div class="casContent"><span class="casTitleNuber">2h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0lgduvngsci_SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0lgduvngsci_SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2jR"><div class="casContent"><span class="casTitleNuber">2j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0lgduvngsci_SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0lgduvngsci_SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2lR"><div class="casContent"><span class="casTitleNuber">2l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0lgGbNDmZA8TsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2mR"><div class="casContent"><span class="casTitleNuber">2m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0lgGbNDmZA8TsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6480</span>– <span class="NLM_lpage">6515</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6480-6515&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2015&doi=10.1021%2Facs.jmedchem.7b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2nR"><div class="casContent"><span class="casTitleNuber">2n</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2015</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K. -C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6480-6515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 29 new chem. entities (NCEs) that were approved for the first time in 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5OCn9h-Lu07Vg90H21EOLACvtfcHk0lgGbNDmZA8TsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D&md5=b10c1f677c2f4a216b11a4c89e8b3683</span></div><a href="/servlet/linkout?suffix=cit2n&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6480%26epage%3D6515%26doi%3D10.1021%2Facs.jmedchem.7b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Graul, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruces, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, M.</span></span> <span> </span><span class="NLM_article-title">The Year’s New Drugs & Biologics 2016: Part I</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1358/dot.2017.53.1.2584699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1358%2Fdot.2017.53.1.2584699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC1cvls1Wltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=27-74&author=A.+I.+Graulauthor=P.+Pinaauthor=E.+Crucesauthor=M.+Stringer&title=The+Year%E2%80%99s+New+Drugs+%26+Biologics+2016%3A+Part+I&doi=10.1358%2Fdot.2017.53.1.2584699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The year's new drugs & biologics 2016: Part I</span></div><div class="casAuthors">Graul A I; Pina P; Cruces E; Stringer M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-74</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Nearly 90 new drugs and biologics, including important new line extensions, were approved or launched for the first time globally in 2016, a comparatively lower number with respect to previous years.  Forty-four new drugs and biologics reached their first markets worldwide in 2016, nearly 10% fewer than the previous year.  Seven of the new launches were first-in-class agents, meaning the first drug with a novel mechanism of action to be approved and launched anywhere in the world.  In addition, 23 novel line extensions (i.e., new formulations, new combinations and new indications) were introduced last year.  The remaining 21 products discussed in this article were approved for the first time during the year just passed, but had not yet been launched as of December 15, 2016.  Information on these new arrivals is covered in depth in part I of our annual review of the pharma and biotech industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSx6g-UVov4FUh5eUSa2oe_fW6udTcc2eZVLJ5olLR0rLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvls1Wltw%253D%253D&md5=31d31bb9519a5ad322d53993a28557b5</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1358%2Fdot.2017.53.1.2584699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2017.53.1.2584699%26sid%3Dliteratum%253Aachs%26aulast%3DGraul%26aufirst%3DA.%2BI.%26aulast%3DPina%26aufirst%3DP.%26aulast%3DCruces%26aufirst%3DE.%26aulast%3DStringer%26aufirst%3DM.%26atitle%3DThe%2520Year%25E2%2580%2599s%2520New%2520Drugs%2520%2526%2520Biologics%25202016%253A%2520Part%2520I%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D53%26spage%3D27%26epage%3D74%26doi%3D10.1358%2Fdot.2017.53.1.2584699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span> To Market, To
Market–2016. In  <i>2017 Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">ACS Division of Medicinal Chemistry</span>, <span class="NLM_year" style="font-weight: bold;">2017</span>; Vol.  <span class="NLM_volume">52</span>, pp  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">599</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.29200%2Facsmedchemrev-v52.ch28" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+To+Market%2C+To%0AMarket%E2%80%932016.+In+2017+Medicinal+Chemistry+Reviews%3B+Bronson%2C+J.+J.%2C+Ed.%3B+ACS+Division+of+Medicinal+Chemistry%2C+2017%3B+Vol.+52%2C+pp+531%E2%80%93599."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.29200%2Facsmedchemrev-v52.ch28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.29200%252Facsmedchemrev-v52.ch28%26sid%3Dliteratum%253Aachs%26jtitle%3D2017%2520Medicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DACS%2520Division%2520of%2520Medicinal%2520Chemistry%26date%3D2017%26volume%3D52%26spage%3D531%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentles, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant-Young, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewawasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudyma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosure, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1879</span>, <span class="refDoi"> DOI: 10.1021/jm4016894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1855-1879&author=R.+G.+Gentlesauthor=M.+Dingauthor=J.+A.+Benderauthor=C.+P.+Bergstromauthor=K.+Grant-Youngauthor=P.+Hewawasamauthor=T.+Hudymaauthor=S.+Martinauthor=A.+Nickelauthor=A.+Regueiro-Renauthor=Y.+Tuauthor=Z.+Yangauthor=K.-S.+Yeungauthor=X.+Zhengauthor=B.+R.+Benoauthor=D.+M.+Camacauthor=C.-H.+Changauthor=M.+Gaoauthor=P.+E.+Morinauthor=S.+Sheriffauthor=J.+Tredupauthor=J.+Wanauthor=M.+R.+Witmerauthor=D.+Xieauthor=U.+Hanumegowdaauthor=J.+Knipeauthor=K.+Mosureauthor=K.+S.+Santoneauthor=D.+D.+Parkerauthor=X.+Zhuoauthor=J.+Lemmauthor=M.+Liuauthor=L.+Pelosiauthor=K.+Rigatauthor=S.+Vossauthor=Y.+Wangauthor=Y.-K.+Wangauthor=R.+C.+Colonnoauthor=M.+Gaoauthor=S.+B.+Robertsauthor=Q.+Gaoauthor=A.+Ngauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Discovery+and+Preclinical+Characterization+of+the+Cyclopropylindolobenzazepine+BMS-791325%2C+A+Potent+Allosteric+Inhibitor+of+the+Hepatitis+C+Virus+NS5B+Polymerase&doi=10.1021%2Fjm4016894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase</span></div><div class="casAuthors">Gentles, Robert G.; Ding, Min; Bender, John A.; Bergstrom, Carl P.; Grant-Young, Katharine; Hewawasam, Piyasena; Hudyma, Thomas; Martin, Scott; Nickel, Andrew; Regueiro-Ren, Alicia; Tu, Yong; Yang, Zhong; Yeung, Kap-Sun; Zheng, Xiaofan; Beno, Brett R.; Camac, Daniel M.; Chang, Chong-Hwan; Gao, Mian; Morin, Paul E.; Sheriff, Steven; Tredup, Jeff; Wan, John; Witmer, Mark R.; Xie, Dianlin; Hanumegowda, Umesh; Knipe, Jay; Mosure, Kathy; Santone, Kenneth S.; Parker, Dawn D.; Zhuo, Xiaoliang; Lemm, Julie; Liu, Mengping; Pelosi, Lenore; Rigat, Karen; Voss, Stacey; Wang, Yi; Wang, Ying-Kai; Colonno, Richard C.; Gao, Min; Roberts, Susan B.; Gao, Qi; Ng, Alicia; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1855-1879</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors.  Subsequent iterations of analog design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochem. properties of lead compds.  Those analogs exhibiting improved soly. and membrane permeability were shown to have notably enhanced pharmacokinetic profiles.  Addnl., a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compd. BMS-791325 (I) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4YKQoSYkS7Vg90H21EOLACvtfcHk0ljySDP4919FyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D&md5=f13f5d86a1c17737784e905c7843ff72</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm4016894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016894%26sid%3Dliteratum%253Aachs%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DBergstrom%26aufirst%3DC.%2BP.%26aulast%3DGrant-Young%26aufirst%3DK.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DHudyma%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNickel%26aufirst%3DA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DColonno%26aufirst%3DR.%2BC.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520and%2520Preclinical%2520Characterization%2520of%2520the%2520Cyclopropylindolobenzazepine%2520BMS-791325%252C%2520A%2520Potent%2520Allosteric%2520Inhibitor%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS5B%2520Polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1855%26epage%3D1879%26doi%3D10.1021%2Fjm4016894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, J. A.</span>; <span class="NLM_string-name">Ding, M.</span>; <span class="NLM_string-name">Gentles, R. G.</span>; <span class="NLM_string-name">Hewawasam, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Cyclopropyl Fused Indolobenzazepine Derivatives as Hepatitis C Virus (HCV) NS5B Polymerase Inhibitors</span>. <span class="NLM_patent">WO 20070270405</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+A.+Bender&author=M.+Ding&author=R.+G.+Gentles&author=P.+Hewawasam&title=Preparation+of+Cyclopropyl+Fused+Indolobenzazepine+Derivatives+as+Hepatitis+C+Virus+%28HCV%29+NS5B+Polymerase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DJ.%2BA.%26atitle%3DPreparation%2520of%2520Cyclopropyl%2520Fused%2520Indolobenzazepine%2520Derivatives%2520as%2520Hepatitis%2520C%2520Virus%2520%2528HCV%2529%2520NS5B%2520Polymerase%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, P. L.</span>; <span class="NLM_string-name">Brochu, C.</span>; <span class="NLM_string-name">Chabot, C.</span>; <span class="NLM_string-name">Jolicoeur, E.</span>; <span class="NLM_string-name">Kawai, S.</span>; <span class="NLM_string-name">Poupart, M.-A.</span>; <span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Indole-6-Carboxylic Acids and Related Compounds as Hepatitis C Viral Polymerase Inhibitors</span>. <span class="NLM_patent">WO 2004065367</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=P.+L.+Beaulieu&author=C.+Brochu&author=C.+Chabot&author=E.+Jolicoeur&author=S.+Kawai&author=M.-A.+Poupart&author=Y.+S.+Tsantrizos&title=Preparation+of+Indole-6-Carboxylic+Acids+and+Related+Compounds+as+Hepatitis+C+Viral+Polymerase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DPreparation%2520of%2520Indole-6-Carboxylic%2520Acids%2520and%2520Related%2520Compounds%2520as%2520Hepatitis%2520C%2520Viral%2520Polymerase%2520Inhibitors%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G.
M.</span></span> <span> </span><span class="NLM_article-title">Elbasvir/Grazoprevir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0558-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0558-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=617-624&author=G.%0AM.+Keating&title=Elbasvir%2FGrazoprevir%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0558-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0558-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0558-3%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DElbasvir%252FGrazoprevir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D617%26epage%3D624%26doi%3D10.1007%2Fs40265-016-0558-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mangion, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maligres, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krska, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavialov, I.</span></span> <span> </span><span class="NLM_article-title">Enantioselective Synthesis of an HCV NS5a Antagonist</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2310</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1021/ol500971c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol500971c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVentr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=2310-2313&author=I.+K.+Mangionauthor=C.-y.+Chenauthor=H.+Liauthor=P.+Maligresauthor=Y.+Chenauthor=M.+Christensenauthor=R.+Cohenauthor=I.+Jeonauthor=A.+Klaparsauthor=S.+Krskaauthor=H.+Nguyenauthor=R.+A.+Reamerauthor=B.+D.+Sherryauthor=I.+Zavialov&title=Enantioselective+Synthesis+of+an+HCV+NS5a+Antagonist&doi=10.1021%2Fol500971c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective synthesis of an HCV NS5a antagonist</span></div><div class="casAuthors">Mangion, Ian K.; Chen, Cheng-yi; Li, Hongmei; Maligres, Peter; Chen, Yonggang; Christensen, Melodie; Cohen, Ryan; Jeon, Ingyu; Klapars, Artis; Krska, Shane; Nguyen, Hoa; Reamer, Robert A.; Sherry, Benjamin D.; Zavialov, Ilia</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2310-2313</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A concise, enantioselective synthesis of the HCV NS5a inhibitor MK-8742 (1) is reported.  The features of the synthesis include a highly enantioselective transfer hydrogenation of an NH imine and a dynamic diastereoselective transformation.  The synthesis of this complex target requires simple starting materials and nine linear steps for completion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXConQjSyfcLVg90H21EOLACvtfcHk0lg7bVbalSiJkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVentr8%253D&md5=a58c03782898715bb002171b9b75ad50</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fol500971c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol500971c%26sid%3Dliteratum%253Aachs%26aulast%3DMangion%26aufirst%3DI.%2BK.%26aulast%3DChen%26aufirst%3DC.-y.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMaligres%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DJeon%26aufirst%3DI.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DKrska%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DReamer%26aufirst%3DR.%2BA.%26aulast%3DSherry%26aufirst%3DB.%2BD.%26aulast%3DZavialov%26aufirst%3DI.%26atitle%3DEnantioselective%2520Synthesis%2520of%2520an%2520HCV%2520NS5a%2520Antagonist%26jtitle%3DOrg.%2520Lett.%26date%3D2014%26volume%3D16%26spage%3D2310%26epage%3D2313%26doi%3D10.1021%2Fol500971c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangion, I.</span>; <span class="NLM_string-name">Chen, C.-Y.</span>; <span class="NLM_string-name">Jeon, I.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Nguyen, H. N.</span>; <span class="NLM_string-name">Maligres, P. E.</span>; <span class="NLM_string-name">Klapars, A.</span>; <span class="NLM_string-name">Zavialov, I.</span>; <span class="NLM_string-name">Yasuda, N.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing HCV NS5A Inhibitor Tetracyclic Heterocycle Compounds End-Capped with Peptides</span>. <span class="NLM_patent">WO 2015065821</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=I.+Mangion&author=C.-Y.+Chen&author=I.+Jeon&author=Y.+Chen&author=H.+Li&author=H.+N.+Nguyen&author=P.+E.+Maligres&author=A.+Klapars&author=I.+Zavialov&author=N.+Yasuda&title=Process+for+Preparing+HCV+NS5A+Inhibitor+Tetracyclic+Heterocycle+Compounds+End-Capped+with+Peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMangion%26aufirst%3DI.%26atitle%3DProcess%2520for%2520Preparing%2520HCV%2520NS5A%2520Inhibitor%2520Tetracyclic%2520Heterocycle%2520Compounds%2520End-Capped%2520with%2520Peptides%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, M.</span></span> <span> </span><span class="NLM_article-title">A Class of Ruthenium(II) Catalyst for Asymmetric Transfer Hydrogenations of Ketones</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">7318</span>– <span class="NLM_lpage">7319</span>, <span class="refDoi"> DOI: 10.1021/ja051486s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja051486s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVaktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=7318-7319&author=A.+M.+Hayesauthor=D.+J.+Morrisauthor=G.+J.+Clarksonauthor=M.+Wills&title=A+Class+of+Ruthenium%28II%29+Catalyst+for+Asymmetric+Transfer+Hydrogenations+of+Ketones&doi=10.1021%2Fja051486s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">A Class of Ruthenium(II) Catalyst for Asymmetric Transfer Hydrogenations of Ketones</span></div><div class="casAuthors">Hayes, Aidan M.; Morris, David J.; Clarkson, Guy J.; Wills, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7318-7319</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ruthenium dimer I, readily available in two steps from the corresponding N-tosyldiphenylethylenediamine (TsDPEN), is converted directly to monomeric asym. transfer hydrogenation catalyst I in situ under the conditions employed for ketone redn.  Catalyst II is a significantly more active catalyst for this application than the untethered deriv., exhibits higher enantioselectivities across a range of substrates, and appears to be highly stable to the reaction conditions.  It is active at loadings of as low as 0.01 mol %, and redns. at the 0.1 mol % level are complete within 20 min at 80 °C without significant loss of enantioselectivity.  A crystal structure of II is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1p2rYjrrfvLVg90H21EOLACvtfcHk0lht5FHUbGwUrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVaktr0%253D&md5=dff24307b573faaa42c26ee404099f09</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Fja051486s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja051486s%26sid%3Dliteratum%253Aachs%26aulast%3DHayes%26aufirst%3DA.%2BM.%26aulast%3DMorris%26aufirst%3DD.%2BJ.%26aulast%3DClarkson%26aufirst%3DG.%2BJ.%26aulast%3DWills%26aufirst%3DM.%26atitle%3DA%2520Class%2520of%2520Ruthenium%2528II%2529%2520Catalyst%2520for%2520Asymmetric%2520Transfer%2520Hydrogenations%2520of%2520Ketones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D7318%26epage%3D7319%26doi%3D10.1021%2Fja051486s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Matharu, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, M.</span></span> <span> </span><span class="NLM_article-title">A Stereochemically Well-Defined Rhodium(III) Catalyst for Asymmetric Transfer Hydrogenation of Ketones</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">5489</span>– <span class="NLM_lpage">5491</span>, <span class="refDoi"> DOI: 10.1021/ol052559f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol052559f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKlt7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=5489-5491&author=D.+S.+Matharuauthor=D.+J.+Morrisauthor=A.+M.+Kawamotoauthor=G.+J.+Clarksonauthor=M.+Wills&title=A+Stereochemically+Well-Defined+Rhodium%28III%29+Catalyst+for+Asymmetric+Transfer+Hydrogenation+of+Ketones&doi=10.1021%2Fol052559f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">A stereochemically well-defined rhodium(III) catalyst for asymmetric transfer hydrogenation of ketones</span></div><div class="casAuthors">Matharu, Daljit S.; Morris, David J.; Kawamoto, Aparecida M.; Clarkson, Guy J.; Wills, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5489-5491</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A rhodium(III) catalyst for asym. transfer hydrogenation of ketones has been designed.  The incorporation of a tethering group between the diamino group and the cyclopentadienyl unit provides extra stereochem. rigidity.  The catalyst is capable of enantioselective redn. of a range of ketones in excellent ee using formic acid/triethylamine as both the solvent and the reducing agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKRIPrHyCZ87Vg90H21EOLACvtfcHk0lht5FHUbGwUrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKlt7zM&md5=b90ca348275c338ea9fe408871f0699f</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fol052559f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol052559f%26sid%3Dliteratum%253Aachs%26aulast%3DMatharu%26aufirst%3DD.%2BS.%26aulast%3DMorris%26aufirst%3DD.%2BJ.%26aulast%3DKawamoto%26aufirst%3DA.%2BM.%26aulast%3DClarkson%26aufirst%3DG.%2BJ.%26aulast%3DWills%26aufirst%3DM.%26atitle%3DA%2520Stereochemically%2520Well-Defined%2520Rhodium%2528III%2529%2520Catalyst%2520for%2520Asymmetric%2520Transfer%2520Hydrogenation%2520of%2520Ketones%26jtitle%3DOrg.%2520Lett.%26date%3D2005%26volume%3D7%26spage%3D5489%26epage%3D5491%26doi%3D10.1021%2Fol052559f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiFilippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescenzi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMuzio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+Macrocyclic+Hepatitis+C+Virus+NS3%2F4a+Protease+Inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0lhVPsB5Zy84Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520Macrocyclic%2520Hepatitis%2520C%2520Virus%2520NS3%252F4a%2520Protease%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span>; <span class="NLM_string-name">Summa, V.</span>; <span class="NLM_string-name">Liverton, N. J.</span>; <span class="NLM_string-name">Mccauley, J. A.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors</span>. <span class="NLM_patent">WO 2010011566A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Harper&author=V.+Summa&author=N.+J.+Liverton&author=J.+A.+Mccauley&title=Macrocyclic+Quinoxaline+Compounds+as+HCV+NS3+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26atitle%3DMacrocyclic%2520Quinoxaline%2520Compounds%2520as%2520HCV%2520NS3%2520Protease%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span>; <span class="NLM_string-name">Humphrey, G.</span>; <span class="NLM_string-name">Pei, T.</span>; <span class="NLM_string-name">Song, Z. J.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Artino, L.</span></span> <span> </span><span class="NLM_article-title">Process and Intermediates for Preparing Macrolactams</span>. <span class="NLM_patent">WO 2013028470A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Xu&author=G.+Humphrey&author=T.+Pei&author=Z.+J.+Song&author=T.+Wang&author=L.+Artino&title=Process+and+Intermediates+for+Preparing+Macrolactams"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DF.%26atitle%3DProcess%2520and%2520Intermediates%2520for%2520Preparing%2520Macrolactams%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschaen, D.</span></span> <span> </span><span class="NLM_article-title">Process Chemistry in Antiviral Research</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">77</span>, <span class="refDoi"> DOI: 10.1007/s41061-016-0076-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs41061-016-0076-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=77&author=Y.-L.+Zhongauthor=N.+Yasudaauthor=H.+Liauthor=M.+McLaughlinauthor=D.+Tschaen&title=Process+Chemistry+in+Antiviral+Research&doi=10.1007%2Fs41061-016-0076-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1007%2Fs41061-016-0076-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs41061-016-0076-5%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DY.-L.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMcLaughlin%26aufirst%3DM.%26aulast%3DTschaen%26aufirst%3DD.%26atitle%3DProcess%2520Chemistry%2520in%2520Antiviral%2520Research%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D2016%26volume%3D374%26spage%3D77%26doi%3D10.1007%2Fs41061-016-0076-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Kuethe, J. T.</span>; <span class="NLM_string-name">Humphrey, G.</span>; <span class="NLM_string-name">Beutner, G. L.</span>; <span class="NLM_string-name">Zhong, Y. L.</span>; <span class="NLM_string-name">Cleator, E.</span>; <span class="NLM_string-name">Baxter, C.</span></span> <span> </span><span class="NLM_article-title">Methods and Intermediates for Preparing Macrolactams</span>. <span class="NLM_patent">WO 2013028471A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+Yasuda&author=J.+T.+Kuethe&author=G.+Humphrey&author=G.+L.+Beutner&author=Y.+L.+Zhong&author=E.+Cleator&author=C.+Baxter&title=Methods+and+Intermediates+for+Preparing+Macrolactams"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DN.%26atitle%3DMethods%2520and%2520Intermediates%2520for%2520Preparing%2520Macrolactams%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bassan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutner, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleitz, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuethe, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullens, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzzio, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span> <span> </span><span class="NLM_article-title">Multikilogram-Scale Synthesis of a Chiral Cyclopropanol and an Investigation of the Safe Use of Lithium Acetylide–Ethylene Diamine Complex</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1021/op2002497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op2002497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=87-95&author=E.+M.+Bassanauthor=C.+A.+Baxterauthor=G.+L.+Beutnerauthor=K.+M.+Emersonauthor=F.+J.+Fleitzauthor=S.+Johnsonauthor=S.+Keenauthor=M.+M.+Kimauthor=J.+T.+Kuetheauthor=W.+R.+Leonardauthor=P.+R.+Mullensauthor=D.+J.+Muzzioauthor=C.+Robergeauthor=N.+Yasuda&title=Multikilogram-Scale+Synthesis+of+a+Chiral+Cyclopropanol+and+an+Investigation+of+the+Safe+Use+of+Lithium+Acetylide%E2%80%93Ethylene+Diamine+Complex&doi=10.1021%2Fop2002497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Multikilogram-Scale Synthesis of a Chiral Cyclopropanol and an Investigation of the Safe Use of Lithium Acetylide-Ethylene Diamine Complex</span></div><div class="casAuthors">Bassan, Ephraim M.; Baxter, Carl A.; Beutner, Gregory L.; Emerson, Khateeta M.; Fleitz, Fred J.; Johnson, Simon; Keen, Stephen; Kim, Mary M.; Kuethe, Jeffrey T.; Leonard, William R.; Mullens, Peter R.; Muzzio, Daniel J.; Roberge, Christopher; Yasuda, Nobuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A six-step route starting from a readily available vinyl boronate was identified to produce an enantioenriched cyclopropanol in an overall 16% yield.  Key steps involve the use of lithium acetylide-ethylene diamine complex 5 and an enzymic resoln. of a racemic cyclopropanol acetate.  Process safety considerations surrounding the use of 5 were examd., and an improved procedure is described which was safely demonstrated at multikilogram scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSIw5QsR_O5bVg90H21EOLACvtfcHk0lgMKMUjmer8OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7K&md5=70d4062eacb1c0d044d82cbd7c058816</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fop2002497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop2002497%26sid%3Dliteratum%253Aachs%26aulast%3DBassan%26aufirst%3DE.%2BM.%26aulast%3DBaxter%26aufirst%3DC.%2BA.%26aulast%3DBeutner%26aufirst%3DG.%2BL.%26aulast%3DEmerson%26aufirst%3DK.%2BM.%26aulast%3DFleitz%26aufirst%3DF.%2BJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DKeen%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DM.%2BM.%26aulast%3DKuethe%26aufirst%3DJ.%2BT.%26aulast%3DLeonard%26aufirst%3DW.%2BR.%26aulast%3DMullens%26aufirst%3DP.%2BR.%26aulast%3DMuzzio%26aufirst%3DD.%2BJ.%26aulast%3DRoberge%26aufirst%3DC.%26aulast%3DYasuda%26aufirst%3DN.%26atitle%3DMultikilogram-Scale%2520Synthesis%2520of%2520a%2520Chiral%2520Cyclopropanol%2520and%2520an%2520Investigation%2520of%2520the%2520Safe%2520Use%2520of%2520Lithium%2520Acetylide%25E2%2580%2593Ethylene%2520Diamine%2520Complex%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D87%26epage%3D95%26doi%3D10.1021%2Fop2002497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span>; <span class="NLM_string-name">Desmond, R.</span>; <span class="NLM_string-name">Humphrey, G. R.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">QI, J.</span>; <span class="NLM_string-name">Ruck, R. T.</span>; <span class="NLM_string-name">Song, Z. J.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Zhong, Y. L.</span>; <span class="NLM_string-name">Park, J.</span></span> <span> </span><span class="NLM_article-title">Methods and Intermediates for Preparing Macrolactams</span>. <span class="NLM_patent">WO 2015057611A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=F.+Xu&author=R.+Desmond&author=G.+R.+Humphrey&author=H.+Li&author=J.+QI&author=R.+T.+Ruck&author=Z.+J.+Song&author=T.+Wang&author=Y.+L.+Zhong&author=J.+Park&title=Methods+and+Intermediates+for+Preparing+Macrolactams"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DF.%26atitle%3DMethods%2520and%2520Intermediates%2520for%2520Preparing%2520Macrolactams%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kuethe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcune, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreher, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, T.</span></span> <span> </span><span class="NLM_article-title">Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4174</span>– <span class="NLM_lpage">4177</span>, <span class="refDoi"> DOI: 10.1021/ol401864t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol401864t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=4174-4177&author=J.+Kuetheauthor=Y.+L.+Zhongauthor=N.+Yasudaauthor=G.+Beutnerauthor=K.+Linnauthor=M.+Kimauthor=B.+Marcuneauthor=S.+D.+Dreherauthor=G.+Humphreyauthor=T.+Pei&title=Development+of+a+Practical%2C+Asymmetric+Synthesis+of+the+Hepatitis+C+Virus+Protease+Inhibitor+MK-5172&doi=10.1021%2Fol401864t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172</span></div><div class="casAuthors">Kuethe, Jeffrey; Zhong, Yong-Li; Yasuda, Nobuyoshi; Beutner, Gregory; Linn, Katherine; Kim, Mary; Marcune, Benjamin; Dreher, Spencer Douglas; Humphrey, Guy; Pei, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4174-4177</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a practical, asym. synthesis of the hepatitis C virus (HCV) protease inhibitor MK-5172 (I), an 18-membered macrocycle, is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ZFtN4OuVLrVg90H21EOLACvtfcHk0lgMKMUjmer8OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrjL&md5=c4f0eafdfad3e3f2988eb9068b47a9cd</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1021%2Fol401864t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol401864t%26sid%3Dliteratum%253Aachs%26aulast%3DKuethe%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DY.%2BL.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DBeutner%26aufirst%3DG.%26aulast%3DLinn%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DMarcune%26aufirst%3DB.%26aulast%3DDreher%26aufirst%3DS.%2BD.%26aulast%3DHumphrey%26aufirst%3DG.%26aulast%3DPei%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520a%2520Practical%252C%2520Asymmetric%2520Synthesis%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520Protease%2520Inhibitor%2520MK-5172%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D4174%26epage%3D4177%26doi%3D10.1021%2Fol401864t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">A Novel Class of Tunable Zinc Reagents (RXZnCH2Y) for Efficient Cyclopropanation of Olefins</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1021/jo030312v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo030312v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFGltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=327-334&author=J.+C.+Lorenzauthor=J.+Longauthor=Z.+Yangauthor=S.+Xueauthor=Y.+Xieauthor=Y.+Shi&title=A+Novel+Class+of+Tunable+Zinc+Reagents+%28RXZnCH2Y%29+for+Efficient+Cyclopropanation+of+Olefins&doi=10.1021%2Fjo030312v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Class of Tunable Zinc Reagents (RXZnCH2Y) for Efficient Cyclopropanation of Olefins</span></div><div class="casAuthors">Lorenz, Jon C.; Long, Jiang; Yang, Zhiqiang; Xue, Song; Xie, Yinong; Shi, Yian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-334</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of zinc reagents (RXZnCH2Y) generated with an appropriate organozinc is very effective for the cyclopropanation of olefins.  The reactivity and selectivity of these reagents can be regulated by tuning the electronic and steric nature of the RX group on Zn.  A reasonable level of enantioselectivity was obtained for the cyclopropanation of unfunctionalized olefins when a chiral (iodomethyl)zinc species was used, providing a valuable approach for the asym. cyclopropanation of unfunctionalized olefins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSD-oxaRDrrVg90H21EOLACvtfcHk0lgMKMUjmer8OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFGltL4%253D&md5=aac319d827e3c162e5358276b2e4db7d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo030312v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo030312v%26sid%3Dliteratum%253Aachs%26aulast%3DLorenz%26aufirst%3DJ.%2BC.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DXue%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DA%2520Novel%2520Class%2520of%2520Tunable%2520Zinc%2520Reagents%2520%2528RXZnCH2Y%2529%2520for%2520Efficient%2520Cyclopropanation%2520of%2520Olefins%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D327%26epage%3D334%26doi%3D10.1021%2Fjo030312v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. J.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Artino, L. M.</span>; <span class="NLM_string-name">Tellers, D. M.</span>; <span class="NLM_string-name">Lieberman, D. R.</span></span> <span> </span><span class="NLM_article-title">Processes for Preparing Protease Inhibitors of Hepatitis C Virus</span>. <span class="NLM_patent">WO 2011025849A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Z.+J.+Song&author=Y.+Wang&author=L.+M.+Artino&author=D.+M.+Tellers&author=D.+R.+Lieberman&title=Processes+for+Preparing+Protease+Inhibitors+of+Hepatitis+C+Virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%2BJ.%26atitle%3DProcesses%2520for%2520Preparing%2520Protease%2520Inhibitors%2520of%2520Hepatitis%2520C%2520Virus%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruijne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reesink, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weegink, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molenkamp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treitel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vliet, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, H. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de knegt, R. J.</span></span> <span> </span><span class="NLM_article-title">Antiviral Activity of Narlaprevir Combined with Ritonavir and Pegylated Interferon in Chronic Hepatitis C Patients</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1002/hep.23899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1002%2Fhep.23899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=1590-1599&author=J.+de%0ABruijneauthor=J.+F.+Bergmannauthor=H.+W.+Reesinkauthor=C.+J.+Weeginkauthor=R.+Molenkampauthor=J.+Schinkelauthor=X.+Tongauthor=J.+Liauthor=A.+Treitelauthor=E.+A.+Hughesauthor=J.+J.+van+Lierauthor=A.+A.+van+Vlietauthor=H.+L.+A.+Janssenauthor=R.+J.+de+knegt&title=Antiviral+Activity+of+Narlaprevir+Combined+with+Ritonavir+and+Pegylated+Interferon+in+Chronic+Hepatitis+C+Patients&doi=10.1002%2Fhep.23899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fhep.23899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23899%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruijne%26aufirst%3DJ.%26aulast%3DBergmann%26aufirst%3DJ.%2BF.%26aulast%3DReesink%26aufirst%3DH.%2BW.%26aulast%3DWeegink%26aufirst%3DC.%2BJ.%26aulast%3DMolenkamp%26aufirst%3DR.%26aulast%3DSchinkel%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DTreitel%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3Dvan%2BLier%26aufirst%3DJ.%2BJ.%26aulast%3Dvan%2BVliet%26aufirst%3DA.%2BA.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%2BA.%26aulast%3Dde%2Bknegt%26aufirst%3DR.%2BJ.%26atitle%3DAntiviral%2520Activity%2520of%2520Narlaprevir%2520Combined%2520with%2520Ritonavir%2520and%2520Pegylated%2520Interferon%2520in%2520Chronic%2520Hepatitis%2520C%2520Patients%26jtitle%3DHepatology%26date%3D2010%26volume%3D52%26spage%3D1590%26epage%3D1599%26doi%3D10.1002%2Fhep.23899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arasappan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feld, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichardo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prongay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, F. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2365</span>– <span class="NLM_lpage">2370</span>, <span class="refDoi"> DOI: 10.1128/AAC.00135-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1128%2FAAC.00135-10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2365-2370&author=X.+Tongauthor=A.+Arasappanauthor=F.+Bennettauthor=R.+Chaseauthor=B.+Feldauthor=Z.+Guoauthor=A.+Hartauthor=V.+Madisonauthor=B.+Malcolmauthor=J.+Pichardoauthor=A.+Prongayauthor=R.+Ralstonauthor=A.+Skeltonauthor=E.+Xiaauthor=R.+Zhangauthor=F.+G.+Njoroge&title=Preclinical+Characterization+of+the+Antiviral+Activity+of+SCH+900518+%28Narlaprevir%29%2C+a+Novel+Mechanism-Based+Inhibitor+of+Hepatitis+C+Virus+NS3+Protease&doi=10.1128%2FAAC.00135-10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.00135-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00135-10%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DX.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DFeld%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DRalston%26aufirst%3DR.%26aulast%3DSkelton%26aufirst%3DA.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DPreclinical%2520Characterization%2520of%2520the%2520Antiviral%2520Activity%2520of%2520SCH%2520900518%2520%2528Narlaprevir%2529%252C%2520a%2520Novel%2520Mechanism-Based%2520Inhibitor%2520of%2520Hepatitis%2520C%2520Virus%2520NS3%2520Protease%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2365%26epage%3D2370%26doi%3D10.1128%2FAAC.00135-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, F. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Boceprevir and Narlaprevir: the First and Second Generation of HCV NS3 Protease Inhibitors</span>. <i>Case Stud. Mod. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1002/9781118219683.ch12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1002%2F9781118219683.ch12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlCqtrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=296-335&author=K.+X.+Chenauthor=F.+G.+Njoroge&title=Discovery+of+Boceprevir+and+Narlaprevir%3A+the+First+and+Second+Generation+of+HCV+NS3+Protease+Inhibitors&doi=10.1002%2F9781118219683.ch12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of boceprevir and narlaprevir: the first and second generation of HCV NS3 protease inhibitors</span></div><div class="casAuthors">Chen, Kevin X.; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Case Studies in Modern Drug Discovery and Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">296-335</span>CODEN:
                <span class="NLM_cas:coden">69PLHG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review discusses the discovery, clin. development, structure-activity relationship and approval of hepatitis C virus NS3 protease inhibitors, namely boceprevir and narlaprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlX5qf0d_3f7Vg90H21EOLACvtfcHk0lgLiCg8-27D6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlCqtrvP&md5=6321a64a62a79c0076a8e94cc96d8421</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2F9781118219683.ch12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9781118219683.ch12%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520Boceprevir%2520and%2520Narlaprevir%253A%2520the%2520First%2520and%2520Second%2520Generation%2520of%2520HCV%2520NS3%2520Protease%2520Inhibitors%26jtitle%3DCase%2520Stud.%2520Mod.%2520Drug%2520Discovery%2520Dev.%26date%3D2012%26spage%3D296%26epage%3D335%26doi%3D10.1002%2F9781118219683.ch12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arasappan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huelgas, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sannigrahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibulbhan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girijavallabhan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prongay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, F. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1021/ml9000276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml9000276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=64-69&author=A.+Arasappanauthor=F.+Bennettauthor=S.+L.+Bogenauthor=S.+Venkatramanauthor=M.+Blackmanauthor=K.+X.+Chenauthor=S.+Hendrataauthor=Y.+Huangauthor=R.+M.+Huelgasauthor=L.+Nairauthor=A.+I.+Padillaauthor=W.+Panauthor=R.+Pikeauthor=P.+Pintoauthor=S.+Ruanauthor=M.+Sannigrahiauthor=F.+Velazquezauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=A.+K.+Saksenaauthor=V.+Girijavallabhanauthor=N.-Y.+Shihauthor=J.+Kongauthor=T.+Mengauthor=Y.+Jinauthor=J.+Wongauthor=P.+McNamaraauthor=A.+Prongayauthor=V.+Madisonauthor=J.+J.+Piwinskiauthor=K.-C.+Chengauthor=R.+Morrisonauthor=B.+Malcolmauthor=X.+Tongauthor=R.+Ralstonauthor=F.+G.+Njoroge&title=Discovery+of+Narlaprevir+%28SCH+900518%29%3A+A+Potent%2C+Second+Generation+HCV+NS3+Serine+Protease+Inhibitor&doi=10.1021%2Fml9000276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fml9000276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml9000276%26sid%3Dliteratum%253Aachs%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBlackman%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHuelgas%26aufirst%3DR.%2BM.%26aulast%3DNair%26aufirst%3DL.%26aulast%3DPadilla%26aufirst%3DA.%2BI.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSannigrahi%26aufirst%3DM.%26aulast%3DVelazquez%26aufirst%3DF.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DShih%26aufirst%3DN.-Y.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DCheng%26aufirst%3DK.-C.%26aulast%3DMorrison%26aufirst%3DR.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DRalston%26aufirst%3DR.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520Narlaprevir%2520%2528SCH%2520900518%2529%253A%2520A%2520Potent%252C%2520Second%2520Generation%2520HCV%2520NS3%2520Serine%2520Protease%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D64%26epage%3D69%26doi%3D10.1021%2Fml9000276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span> <span> </span><span class="NLM_article-title">Computaional Study on the Molecular Mechanisms of Drug Resistance of Narlaprevir Due to V36M, R155K, V36M+R155K, T54A, and A156T Mutations of HCV NS3/4A Protease</span>. <i>Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1139/bcb-2014-0039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1139%2Fbcb-2014-0039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25178998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOmsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=357-369&author=H.+Wangauthor=L.+Gengauthor=B.-Z.+Chenauthor=M.+Ji&title=Computaional+Study+on+the+Molecular+Mechanisms+of+Drug+Resistance+of+Narlaprevir+Due+to+V36M%2C+R155K%2C+V36M%2BR155K%2C+T54A%2C+and+A156T+Mutations+of+HCV+NS3%2F4A+Protease&doi=10.1139%2Fbcb-2014-0039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease</span></div><div class="casAuthors">Wang, Huiqun; Geng, Lingling; Chen, Bo-Zhen; Ji, Mingjuan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-369</span>CODEN:
                <span class="NLM_cas:coden">BCBIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0829-8211</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">Narlaprevir is a novel NS3/4A protease inhibitor of hepatitis C virus (HCV), and it has been tested in a phase II clin. trial recently.  However, distinct drug-resistance of Narlaprevir has been discovered.  In our study, the mol. mechanisms of drug-resistance of Narlaprevir due to the mutations V36M, R155K, V36M+R155K, T54A, and A156T of NS3/4A protease have been investigated by mol. dynamics (MD) simulations, free energy calcns., and free energy decompn. anal.  The predicted binding free energies of Narlaprevir towards the wild-type and five mutants show that the mutations V36M, R155K, and T54A lead to low-level drug resistance and the mutations V36M+R155K and A156T lead to high-level drug resistance, which is consistent with the exptl. data.  The anal. of the individual energy terms indicates that the van der Waals contribution is important for distinguishing the binding affinities of these six complexes.  These findings again show that the combination of different mol. modeling techniques is an efficient way to interpret the mol. mechanism of drug-resistance.  Our work mainly elaborates the mol. mechanism of drug-resistance of Narlaprevir and further provides valuable information for developing novel, safer, and more potent HCV antiviral drugs in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom77n1Z91O17Vg90H21EOLACvtfcHk0ljceqdFr9D75A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOmsLrK&md5=d7e9fbc61369759ff7c12ff3b30ce6b8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1139%2Fbcb-2014-0039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fbcb-2014-0039%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.-Z.%26aulast%3DJi%26aufirst%3DM.%26atitle%3DComputaional%2520Study%2520on%2520the%2520Molecular%2520Mechanisms%2520of%2520Drug%2520Resistance%2520of%2520Narlaprevir%2520Due%2520to%2520V36M%252C%2520R155K%252C%2520V36M%252BR155K%252C%2520T54A%252C%2520and%2520A156T%2520Mutations%2520of%2520HCV%2520NS3%252F4A%2520Protease%26jtitle%3DBiochem.%2520Cell%2520Biol.%26date%3D2014%26volume%3D92%26spage%3D357%26epage%3D369%26doi%3D10.1139%2Fbcb-2014-0039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Traverse, J.</span>; <span class="NLM_string-name">Leong, W. M.</span>; <span class="NLM_string-name">Miller, S. P.</span>; <span class="NLM_string-name">Albaneze-Walker, J.</span>; <span class="NLM_string-name">Hunter, T. J.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Liao, H.</span>; <span class="NLM_string-name">Arasappan, A.</span>; <span class="NLM_string-name">Trzaska, S. T.</span>; <span class="NLM_string-name">Smith, R. M.</span>; <span class="NLM_string-name">Lekhal, A.</span>; <span class="NLM_string-name">Bogen, S. L.</span>; <span class="NLM_string-name">Kong, J.</span>; <span class="NLM_string-name">Bennett, F.</span>; <span class="NLM_string-name">Njoroge, F. G.</span>; <span class="NLM_string-name">Poirier, M.</span>; <span class="NLM_string-name">Kuo, S.-C.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Matthews, K. S.</span>; <span class="NLM_string-name">Demonchaux, P.</span>; <span class="NLM_string-name">Ferreira, A.</span></span> <span> </span><span class="NLM_article-title">Enantio- and Stereo Specific Synthesis of β-Amino-α-Hydroxy Amides</span>. <span class="NLM_patent">US 8680294B2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+Traverse&author=W.+M.+Leong&author=S.+P.+Miller&author=J.+Albaneze-Walker&author=T.+J.+Hunter&author=L.+Wang&author=H.+Liao&author=A.+Arasappan&author=S.+T.+Trzaska&author=R.+M.+Smith&author=A.+Lekhal&author=S.+L.+Bogen&author=J.+Kong&author=F.+Bennett&author=F.+G.+Njoroge&author=M.+Poirier&author=S.-C.+Kuo&author=Y.+Chen&author=K.+S.+Matthews&author=P.+Demonchaux&author=A.+Ferreira&title=Enantio-+and+Stereo+Specific+Synthesis+of+%CE%B2-Amino-%CE%B1-Hydroxy+Amides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTraverse%26aufirst%3DJ.%26atitle%3DEnantio-%2520and%2520Stereo%2520Specific%2520Synthesis%2520of%2520%25CE%25B2-Amino-%25CE%25B1-Hydroxy%2520Amides%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Traverse, J.</span>; <span class="NLM_string-name">Leong, W. W.</span>; <span class="NLM_string-name">Miller, S. P.</span>; <span class="NLM_string-name">Albaneze-Walker, J.</span>; <span class="NLM_string-name">Hunter, T. J.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Liao, H.</span>; <span class="NLM_string-name">Arasappan, A.</span>; <span class="NLM_string-name">Trzaska, S. T.</span>; <span class="NLM_string-name">Smith, R. M.</span>; <span class="NLM_string-name">Lekhal, A.</span>; <span class="NLM_string-name">Bogen, S. L.</span>; <span class="NLM_string-name">Kong, J.</span>; <span class="NLM_string-name">Bennett, F.</span>; <span class="NLM_string-name">Njoroge, F. G.</span>; <span class="NLM_string-name">Poirier, M.</span>; <span class="NLM_string-name">Kuo, S.-C.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Matthews, K. S.</span>; <span class="NLM_string-name">Demonchaux, P.</span>; <span class="NLM_string-name">Ferreira, A.</span></span> <span> </span><span class="NLM_article-title">Processes for Enantio- and Stereospecific Syntheses of β-Amino-α-Hydroxy Amides</span>. <span class="NLM_patent">WO 2011014494 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Traverse&author=W.+W.+Leong&author=S.+P.+Miller&author=J.+Albaneze-Walker&author=T.+J.+Hunter&author=L.+Wang&author=H.+Liao&author=A.+Arasappan&author=S.+T.+Trzaska&author=R.+M.+Smith&author=A.+Lekhal&author=S.+L.+Bogen&author=J.+Kong&author=F.+Bennett&author=F.+G.+Njoroge&author=M.+Poirier&author=S.-C.+Kuo&author=Y.+Chen&author=K.+S.+Matthews&author=P.+Demonchaux&author=A.+Ferreira&title=Processes+for+Enantio-+and+Stereospecific+Syntheses+of+%CE%B2-Amino-%CE%B1-Hydroxy+Amides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTraverse%26aufirst%3DJ.%26atitle%3DProcesses%2520for%2520Enantio-%2520and%2520Stereospecific%2520Syntheses%2520of%2520%25CE%25B2-Amino-%25CE%25B1-Hydroxy%2520Amides%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, C. J.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of the N-Terminal Component of Microginin: (2S,3R)-3-Amino-2-Hydroxydecanoic Acid, its (2R,3R)-Epimer and (3R)-3-Aminodecanoic Acid</span>. <i>Tetrahedron: Asymmetry</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/0957-4166(94)00372-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2F0957-4166%2894%2900372-I" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1995&pages=165-176&author=M.+E.+Bunnageauthor=A.+J.+Burkeauthor=S.+G.+Daviesauthor=C.+J.+Goodwin&title=Asymmetric+Synthesis+of+the+N-Terminal+Component+of+Microginin%3A+%282S%2C3R%29-3-Amino-2-Hydroxydecanoic+Acid%2C+its+%282R%2C3R%29-Epimer+and+%283R%29-3-Aminodecanoic+Acid&doi=10.1016%2F0957-4166%2894%2900372-I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2F0957-4166%2894%2900372-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0957-4166%252894%252900372-I%26sid%3Dliteratum%253Aachs%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurke%26aufirst%3DA.%2BJ.%26aulast%3DDavies%26aufirst%3DS.%2BG.%26aulast%3DGoodwin%26aufirst%3DC.%2BJ.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520the%2520N-Terminal%2520Component%2520of%2520Microginin%253A%2520%25282S%252C3R%2529-3-Amino-2-Hydroxydecanoic%2520Acid%252C%2520its%2520%25282R%252C3R%2529-Epimer%2520and%2520%25283R%2529-3-Aminodecanoic%2520Acid%26jtitle%3DTetrahedron%253A%2520Asymmetry%26date%3D1995%26volume%3D6%26spage%3D165%26epage%3D176%26doi%3D10.1016%2F0957-4166%2894%2900372-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. D.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of α-Amino Carbonyl Derivatives using Lithium (R)-N-Benzyl-N-α-Methylbenzylamide</span>. <i>Tetrahedron: Asymmetry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1565</span>, <span class="refDoi"> DOI: 10.1016/S0957-4166(02)00406-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS0957-4166%2802%2900406-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=1555-1565&author=S.+G.+Daviesauthor=S.+W.+Epsteinauthor=A.+C.+Garnerauthor=O.+Ichiharaauthor=A.+D.+Smith&title=Asymmetric+Synthesis+of+%CE%B1-Amino+Carbonyl+Derivatives+using+Lithium+%28R%29-N-Benzyl-N-%CE%B1-Methylbenzylamide&doi=10.1016%2FS0957-4166%2802%2900406-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2FS0957-4166%2802%2900406-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0957-4166%252802%252900406-8%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BG.%26aulast%3DEpstein%26aufirst%3DS.%2BW.%26aulast%3DGarner%26aufirst%3DA.%2BC.%26aulast%3DIchihara%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DA.%2BD.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520%25CE%25B1-Amino%2520Carbonyl%2520Derivatives%2520using%2520Lithium%2520%2528R%2529-N-Benzyl-N-%25CE%25B1-Methylbenzylamide%26jtitle%3DTetrahedron%253A%2520Asymmetry%26date%3D2002%26volume%3D13%26spage%3D1555%26epage%3D1565%26doi%3D10.1016%2FS0957-4166%2802%2900406-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marko, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaume, M.</span></span> <span> </span><span class="NLM_article-title">Racemic N-Sulfonyloxaziridines as Highly Diastereoselective Enolate Hydroxylating Agents: Enantioselective Synthesis of (2S,3S)-3-Amino-N-Cyclopropyl-2-Hydroxyhexanamide</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9178</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2011.09.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.tet.2011.09.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=9173-9178&author=E.+Kissauthor=I.+E.+Markoauthor=M.+Guillaume&title=Racemic+N-Sulfonyloxaziridines+as+Highly+Diastereoselective+Enolate+Hydroxylating+Agents%3A+Enantioselective+Synthesis+of+%282S%2C3S%29-3-Amino-N-Cyclopropyl-2-Hydroxyhexanamide&doi=10.1016%2Fj.tet.2011.09.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2011.09.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2011.09.090%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DE.%26aulast%3DMarko%26aufirst%3DI.%2BE.%26aulast%3DGuillaume%26aufirst%3DM.%26atitle%3DRacemic%2520N-Sulfonyloxaziridines%2520as%2520Highly%2520Diastereoselective%2520Enolate%2520Hydroxylating%2520Agents%253A%2520Enantioselective%2520Synthesis%2520of%2520%25282S%252C3S%2529-3-Amino-N-Cyclopropyl-2-Hydroxyhexanamide%26jtitle%3DTetrahedron%26date%3D2011%26volume%3D67%26spage%3D9173%26epage%3D9178%26doi%3D10.1016%2Fj.tet.2011.09.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arjona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castañer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolós, J.</span></span> <span> </span><span class="NLM_article-title">Nemonoxacin</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1358/dof.2009.034.03.1350294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1358%2Fdof.2009.034.03.1350294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=196-203&author=A.+Arjonaauthor=R.+Casta%C3%B1erauthor=J.+Bol%C3%B3s&title=Nemonoxacin&doi=10.1358%2Fdof.2009.034.03.1350294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Nemonoxacin: quinolone antibiotic</span></div><div class="casAuthors">Arjona, A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">196-203</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Although fluoroquinolones have been used over the last few decades to successfully treat multiple bacterial infections, there is a need for new compds. that, while taking advantage of the antimicrobial properties of the quinolone nucleus, show greater potency against drug-resistant bacteria, reduced drug-drug interactions and improved patient tolerability.  Nemonoxacin (TG-873870) is a nonflourinated quinolone antibiotic with remarkable in vitro activity against a wide variety of clin. relevant pathogens, including methicillin-resistant Staphylococcus aureus and multidrug-resistant Streptococcus pneumoniae.  In several murine pulmonary infection models, the efficacy of nemonoxacin was greater than most of the currently available fluoroquinolones.  Studies in lab. animals have ruled out the possibility of nemonoxacin inducing significant reproductive, cardiovascular, allergic or phototoxic adverse events.  In addn., this novel quinolone has a good pharmacokinetic profile and is well tolerated.  Nemonoxacin is currently undergoing phase II evaluation for the oral treatment of drug-sensitive and -resistant bacterial infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0MSuqgNA3RbVg90H21EOLACvtfcHk0lihKKVDJuXwvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlSisr0%253D&md5=3568bc4c8d0656ee397e583a39a64eef</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.03.1350294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.03.1350294%26sid%3Dliteratum%253Aachs%26aulast%3DArjona%26aufirst%3DA.%26aulast%3DCasta%25C3%25B1er%26aufirst%3DR.%26aulast%3DBol%25C3%25B3s%26aufirst%3DJ.%26atitle%3DNemonoxacin%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D196%26epage%3D203%26doi%3D10.1358%2Fdof.2009.034.03.1350294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span> <span> </span><span class="NLM_article-title">Nemonoxacin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1453</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0270-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-014-0270-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1445-1453&author=R.+M.+Poole&title=Nemonoxacin%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0270-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0270-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0270-0%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DNemonoxacin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1445%26epage%3D1453%26doi%3D10.1007%2Fs40265-014-0270-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oliphant, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, G. M.</span></span> <span> </span><span class="NLM_article-title">Quinolones: A Comprehensive Review</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=11858629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BD387itlCmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2002&pages=455-464&author=C.+M.+Oliphantauthor=G.+M.+Green&title=Quinolones%3A+A+Comprehensive+Review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolones: a comprehensive review</span></div><div class="casAuthors">Oliphant Catherine M; Green Gary M</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">455-64</span>
        ISSN:<span class="NLM_cas:issn">0002-838X</span>.
    </div><div class="casAbstract">With the recent introduction of agents such as gatifloxacin and moxifloxacin, the traditional gram-negative coverage of fluoroquinolones has been expanded to include specific gram-positive organisms.  Clinical applications beyond genitourinary tract infections include upper and lower respiratory infections, gastrointestinal infections, gynecologic infections, sexually transmitted diseases, and some skin and soft tissue infections.  Most quinolones have excellent oral bioavailability, with serum drug concentrations equivalent to intravenous administration.  Quinolones have few adverse effects, most notably nausea, headache, dizziness, and confusion.  Less common but more serious adverse events include prolongation of the corrected QT interval, phototoxicity, liver enzyme abnormalities, arthropathy, and cartilage and tendon abnormalities.  The new fluoroquinolones are rarely first-line agents and should be employed judiciously.  Inappropriate use of agents from this important class of antibiotics will likely worsen current problems with antibiotic resistance.  Applications of fluoroquinolones in biologic warfare are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQET9DNRhkIEloaUqgkFHkfW6udTcc2eY_Mq1GcLpL3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387itlCmtw%253D%253D&md5=732b332f68ae5f2459d60803517fdf9b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOliphant%26aufirst%3DC.%2BM.%26aulast%3DGreen%26aufirst%3DG.%2BM.%26atitle%3DQuinolones%253A%2520A%2520Comprehensive%2520Review%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2002%26volume%3D65%26spage%3D455%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledoussal, B.</span>; <span class="NLM_string-name">Almstead, J. I. K.</span>; <span class="NLM_string-name">Gray, J. L.</span>; <span class="NLM_string-name">Hu, X. E.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial Quinolones, their Compositions and Uses</span>. <span class="NLM_patent">US 6329391B1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=B.+Ledoussal&author=J.+I.+K.+Almstead&author=J.+L.+Gray&author=X.+E.+Hu&title=Antimicrobial+Quinolones%2C+their+Compositions+and+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLedoussal%26aufirst%3DB.%26atitle%3DAntimicrobial%2520Quinolones%252C%2520their%2520Compositions%2520and%2520Uses%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M.</span></span> <span> </span><span class="NLM_article-title">Coupling Process for Preparing Quinolone Intermediates</span>. <span class="NLM_patent">US 7456279B2</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=M.+Reilly&title=Coupling+Process+for+Preparing+Quinolone+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DM.%26atitle%3DCoupling%2520Process%2520for%2520Preparing%2520Quinolone%2520Intermediates%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. P.</span>; <span class="NLM_string-name">Schunk, T. T.</span></span> <span> </span><span class="NLM_article-title">Hydride Reduction Process for Preparing Quinolone Intermediates</span>. <span class="NLM_patent">US 2007232806A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+P.+Hayes&author=T.+T.+Schunk&title=Hydride+Reduction+Process+for+Preparing+Quinolone+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayes%26aufirst%3DM.%2BP.%26atitle%3DHydride%2520Reduction%2520Process%2520for%2520Preparing%2520Quinolone%2520Intermediates%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Redman-Furey, N. L.</span>; <span class="NLM_string-name">Godlewski, J. E.</span>; <span class="NLM_string-name">Dicks, M. L.</span></span> <span> </span><span class="NLM_article-title">Malate Salts, and Polymorphs of (3S,5S)-7-[3-Amino-5-Methyl-Piperidinyl]-1-Cyclopropyl-1,4-Dihydro-8-Methoxy-4-oxo-3-Quinolinecarboxylic Acid</span>. <span class="NLM_patent">US 8039485B2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+L.+Redman-Furey&author=J.+E.+Godlewski&author=M.+L.+Dicks&title=Malate+Salts%2C+and+Polymorphs+of+%283S%2C5S%29-7-%5B3-Amino-5-Methyl-Piperidinyl%5D-1-Cyclopropyl-1%2C4-Dihydro-8-Methoxy-4-oxo-3-Quinolinecarboxylic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRedman-Furey%26aufirst%3DN.%2BL.%26atitle%3DMalate%2520Salts%252C%2520and%2520Polymorphs%2520of%2520%25283S%252C5S%2529-7-%255B3-Amino-5-Methyl-Piperidinyl%255D-1-Cyclopropyl-1%252C4-Dihydro-8-Methoxy-4-oxo-3-Quinolinecarboxylic%2520Acid%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. L. Y.</span></span> <span> </span><span class="NLM_article-title">Tenofovir Alafenamide: A Review in Chronic Hepatitis B</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0754-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-017-0754-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1017-1028&author=L.+J.+Scottauthor=H.+L.+Y.+Chan&title=Tenofovir+Alafenamide%3A+A+Review+in+Chronic+Hepatitis+B&doi=10.1007%2Fs40265-017-0754-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0754-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0754-9%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26atitle%3DTenofovir%2520Alafenamide%253A%2520A%2520Review%2520in%2520Chronic%2520Hepatitis%2520B%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1017%26epage%3D1028%26doi%3D10.1007%2Fs40265-017-0754-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, M. W.</span>; <span class="NLM_string-name">Chapman, H. H.</span>; <span class="NLM_string-name">Cihlar, T.</span>; <span class="NLM_string-name">Eisenberg, E. J.</span>; <span class="NLM_string-name">He, G.-X.</span>; <span class="NLM_string-name">Kernan, M. R.</span>; <span class="NLM_string-name">Lee, W. A.</span>; <span class="NLM_string-name">Prisbe, E. J.</span>; <span class="NLM_string-name">Rohloff, J. C.</span>; <span class="NLM_string-name">Sparacino, M. L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Prodrugs Amino Acid Methoxyphosphonate Acyclic Nucleotide Analogs as Antiviral or Antitumor Agents and their Use in Therapy and Prophylaxis</span>. <span class="NLM_patent">WO 2002008241A2</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=M.+W.+Becker&author=H.+H.+Chapman&author=T.+Cihlar&author=E.+J.+Eisenberg&author=G.-X.+He&author=M.+R.+Kernan&author=W.+A.+Lee&author=E.+J.+Prisbe&author=J.+C.+Rohloff&author=M.+L.+Sparacino&title=Preparation+of+Prodrugs+Amino+Acid+Methoxyphosphonate+Acyclic+Nucleotide+Analogs+as+Antiviral+or+Antitumor+Agents+and+their+Use+in+Therapy+and+Prophylaxis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DM.%2BW.%26atitle%3DPreparation%2520of%2520Prodrugs%2520Amino%2520Acid%2520Methoxyphosphonate%2520Acyclic%2520Nucleotide%2520Analogs%2520as%2520Antiviral%2520or%2520Antitumor%2520Agents%2520and%2520their%2520Use%2520in%2520Therapy%2520and%2520Prophylaxis%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walwyn, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlin, C. D.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for the Preparation of Tenofovir Disoproxil Fumarate</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.5b00364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Sru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=742-750&author=D.+L.+Rileyauthor=D.+R.+Walwynauthor=C.+D.+Edlin&title=An+Improved+Process+for+the+Preparation+of+Tenofovir+Disoproxil+Fumarate&doi=10.1021%2Facs.oprd.5b00364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">An Improved Process for the Preparation of Tenofovir Disoproxil Fumarate</span></div><div class="casAuthors">Riley, Darren L.; Walwyn, David R.; Edlin, Chris D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The current three-step manufg. route for the prepn. of tenofovir disoproxil fumarate (1) was assessed and optimized leading to a higher yielding, simpler, and greener process.  Key improvements in the process route include the refinement of the 2nd stage through the replacement of the problematic Mg tert-butoxide (MTB) with a 1:1 ratio of a Grignard reagent and tert-BuOH.  The development of a virtually solvent-free approach and the establishment of a workup and purifn. protocol which gave a pure di-Et phosphonate ester was achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomG8B5nXtkMrVg90H21EOLACvtfcHk0ljMzm054VbrzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Sru7c%253D&md5=f4ffaf3b5820f8466be23c92f5fc1859</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00364%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DD.%2BL.%26aulast%3DWalwyn%26aufirst%3DD.%2BR.%26aulast%3DEdlin%26aufirst%3DC.%2BD.%26atitle%3DAn%2520Improved%2520Process%2520for%2520the%2520Preparation%2520of%2520Tenofovir%2520Disoproxil%2520Fumarate%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D742%26epage%3D750%26doi%3D10.1021%2Facs.oprd.5b00364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Indukuri, V. S. K.</span>; <span class="NLM_string-name">Joga, S. R.</span>; <span class="NLM_string-name">Gorantla, S. R.</span>; <span class="NLM_string-name">Chava, S.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Tenofovir</span>. <span class="NLM_patent">US 20140303368</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=V.+S.+K.+Indukuri&author=S.+R.+Joga&author=S.+R.+Gorantla&author=S.+Chava&title=Process+for+the+Preparation+of+Tenofovir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIndukuri%26aufirst%3DV.%2BS.%2BK.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Tenofovir%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strube, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haumreisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Traub, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditz, R.</span></span> <span> </span><span class="NLM_article-title">Comparison of Batch Elution and Continuous Simulated Moving Bed Chromatography</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1021/op980019a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op980019a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1998&pages=305-319&author=J.+Strubeauthor=S.+Haumreisserauthor=H.+Schmidt-Traubauthor=M.+Schulteauthor=R.+Ditz&title=Comparison+of+Batch+Elution+and+Continuous+Simulated+Moving+Bed+Chromatography&doi=10.1021%2Fop980019a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fop980019a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop980019a%26sid%3Dliteratum%253Aachs%26aulast%3DStrube%26aufirst%3DJ.%26aulast%3DHaumreisser%26aufirst%3DS.%26aulast%3DSchmidt-Traub%26aufirst%3DH.%26aulast%3DSchulte%26aufirst%3DM.%26aulast%3DDitz%26aufirst%3DR.%26atitle%3DComparison%2520of%2520Batch%2520Elution%2520and%2520Continuous%2520Simulated%2520Moving%2520Bed%2520Chromatography%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D1998%26volume%3D2%26spage%3D305%26epage%3D319%26doi%3D10.1021%2Fop980019a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colby, D. A.</span>; <span class="NLM_string-name">Martins, A. A.</span>; <span class="NLM_string-name">Roberts, B. J.</span>; <span class="NLM_string-name">Scott, R. W.</span>; <span class="NLM_string-name">Solomon, N. S.</span></span> <span> </span><span class="NLM_article-title">Methods for Preparing Anti-Viral Nucleotide Analogs</span>. <span class="NLM_patent">WO 2013052094</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+A.+Colby&author=A.+A.+Martins&author=B.+J.+Roberts&author=R.+W.+Scott&author=N.+S.+Solomon&title=Methods+for+Preparing+Anti-Viral+Nucleotide+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DColby%26aufirst%3DD.%2BA.%26atitle%3DMethods%2520for%2520Preparing%2520Anti-Viral%2520Nucleotide%2520Analogs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, S. L.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1578</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0648-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0648-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1567-1578&author=S.+L.+Greig&title=Sofosbuvir%2FVelpatasvir%3A+A+Review+in+Chronic+Hepatitis+C&doi=10.1007%2Fs40265-016-0648-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0648-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0648-2%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DSofosbuvir%252FVelpatasvir%253A%2520A%2520Review%2520in%2520Chronic%2520Hepatitis%2520C%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1567%26epage%3D1578%26doi%3D10.1007%2Fs40265-016-0648-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span> <a href="http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf" class="extLink">http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf</a> (accessed August 11, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+http%3A%2F%2Fwww.gilead.com%2F%7E%2Fmedia%2FFiles%2Fpdfs%2Fmedicines%2Fliver-disease%2Fepclusa%2Fepclusa_pi.pdf+%28accessed+August+11%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappulo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonomo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinchera, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, G.</span></span> <span> </span><span class="NLM_article-title">Investigational Direct-Acting Antivirals in Hepatitis C Treatment: The Latest Drugs in Clinical Development</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1517/13543784.2016.1161023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1517%2F13543784.2016.1161023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=557-572&author=I.+Gentileauthor=R.+Scottoauthor=E.+Zappuloauthor=A.+R.+Buonomoauthor=B.+Pincheraauthor=G.+Borgia&title=Investigational+Direct-Acting+Antivirals+in+Hepatitis+C+Treatment%3A+The+Latest+Drugs+in+Clinical+Development&doi=10.1517%2F13543784.2016.1161023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1517%2F13543784.2016.1161023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2016.1161023%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DScotto%26aufirst%3DR.%26aulast%3DZappulo%26aufirst%3DE.%26aulast%3DBuonomo%26aufirst%3DA.%2BR.%26aulast%3DPinchera%26aufirst%3DB.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DInvestigational%2520Direct-Acting%2520Antivirals%2520in%2520Hepatitis%2520C%2520Treatment%253A%2520The%2520Latest%2520Drugs%2520in%2520Clinical%2520Development%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D557%26epage%3D572%26doi%3D10.1517%2F13543784.2016.1161023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Feld, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hezode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruane, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruener, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abergel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towner, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svarovskaia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHutchison, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2599</span>– <span class="NLM_lpage">2607</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1512610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1056%2FNEJMoa1512610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=26571066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2599-2607&author=J.+J.+Feldauthor=I.+M.+Jacobsonauthor=C.+Hezodeauthor=T.+Asselahauthor=P.+J.+Ruaneauthor=N.+Gruenerauthor=A.+Abergelauthor=A.+Mangiaauthor=C.+L.+Laiauthor=H.+L.+Y.+Chanauthor=F.+Mazzottaauthor=C.+Morenoauthor=E.+Yoshidaauthor=S.+D.+Shafranauthor=W.+J.+Townerauthor=T.+T.+Tranauthor=J.+McNallyauthor=A.+Osinusiauthor=E.+Svarovskaiaauthor=Y.+Zhuauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=K.+Agarwalauthor=S.+Zeuzem&title=Sofosbuvir+and+Velpatasvir+for+HCV+Genotype+1%2C+2%2C+4%2C+5%2C+and+6+Infection&doi=10.1056%2FNEJMoa1512610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection</span></div><div class="casAuthors">Feld, J. J.; Jacobson, I. M.; Hezode, C.; Asselah, T.; Ruane, P. J.; Gruener, N.; Abergel, A.; Mangia, A.; Lai, C.-L.; Chan, H. L. Y.; Mazzotta, F.; Moreno, C.; Yoshida, E.; Shafran, S. D.; Towner, W. J.; Tran, T. T.; McNally, J.; Osinusi, A.; Svarovskaia, E.; Zhu, Y.; Brainard, D. M.; McHutchison, J. G.; Agarwal, K.; Zeuzem, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2599-2607</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.  We conducted a phase 3, double-blind, placebo-controlled study involving untreated and previously treated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection, including those with compensated cirrhosis.  Patients with HCV genotype 1, 2, 4, or 6 were randomly assigned in a 5:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tablet or matching placebo for 12 wk.  Because of the low prevalence of genotype 5 in the study regions, patients with genotype 5 did not undergo randomization but were assigned to the sofosbuvir-velpatasvir group.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Of the 624 patients who received treatment with sofosbuvir-velpatasvir, 34% had HCV genotype 1a, 19% genotype 1b, 17% genotype 2, 19% genotype 4, 6% genotype 5, and 7% genotype 6.  A total of 8% of patients were black, 19% had cirrhosis, and 32% had been previously treated for HCV.  The rate of sustained virol. response among patients receiving sofosbuvir-velpatasvir was 99% (95% confidence interval, 98 to >99).  Two patients receiving sofosbuvir-velpatasvir, both with HCV genotype 1, had a virol. relapse.  None of the 116 patients receiving placebo had a sustained virol. response.  Serious adverse events were reported in 15 patients (2%) in the sofosbuvir-velpatasvir group and none in the placebo group.  Once-daily sofosbuvir-velpatasvir for 12 wk provided high rates of sustained virol. response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIaLSuQe4dW7Vg90H21EOLACvtfcHk0lgZh6cafIHKCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjO&md5=cb66c57f7845aff86567d3b59705faf6</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512610%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DGruener%26aufirst%3DN.%26aulast%3DAbergel%26aufirst%3DA.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DC.%2BL.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DMazzotta%26aufirst%3DF.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DYoshida%26aufirst%3DE.%26aulast%3DShafran%26aufirst%3DS.%2BD.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DSofosbuvir%2520and%2520Velpatasvir%2520for%2520HCV%2520Genotype%25201%252C%25202%252C%25204%252C%25205%252C%2520and%25206%2520Infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2599%26epage%3D2607%26doi%3D10.1056%2FNEJMoa1512610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afdhal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pianko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiffman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towner, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourliere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stedman, C. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvory-Sobol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHutchison, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowski, M.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2608</span>– <span class="NLM_lpage">2617</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1512612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1056%2FNEJMoa1512612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=26575258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2608-2617&author=G.+R.+Fosterauthor=N.+Afdhalauthor=S.+K.+Robertsauthor=N.+Brauauthor=E.+J.+Ganeauthor=S.+Piankoauthor=E.+Lawitzauthor=A.+Thompsonauthor=M.+L.+Shiffmanauthor=C.+Cooperauthor=W.+J.+Townerauthor=B.+Conwayauthor=P.+Ruaneauthor=M.+Bourliereauthor=T.+Asselahauthor=T.+Bergauthor=S.+Zeuzemauthor=W.+Rosenbergauthor=K.+Agarwalauthor=C.+A.+M.+Stedmanauthor=H.+Moauthor=H.+Dvory-Sobolauthor=L.+Hanauthor=J.+Wangauthor=J.+McNallyauthor=A.+Osinusiauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=F.+Mazzottaauthor=T.+T.+Tranauthor=S.+C.+Gordonauthor=K.+Patelauthor=N.+Reauauthor=A.+Mangiaauthor=M.+Sulkowski&title=Sofosbuvir+and+Velpatasvir+for+HCV+Genotype+2+and+3+Infection&doi=10.1056%2FNEJMoa1512612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection</span></div><div class="casAuthors">Foster, G. R.; Afdhal, N.; Roberts, S. K.; Brau, N.; Gane, E. J.; Pianko, S.; Lawitz, E.; Thompson, A.; Shiffman, M. L.; Cooper, C.; Towner, W. J.; Conway, B.; Ruane, P.; Bourliere, M.; Asselah, T.; Berg, T.; Zeuzem, S.; Rosenberg, W.; Agarwal, K.; Stedman, C. A. M.; Mo, H.; Dvory-Sobol, H.; Han, L.; Wang, J.; McNally, J.; Osinusi, A.; Brainard, D. M.; McHutchison, J. G.; Mazzotta, F.; Tran, T. T.; Gordon, S. C.; Patel, K.; Reau, N.; Mangia, A.; Sulkowski, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2608-2617</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virol. response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3.  METHODS: We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV genotype 2 or 3 and those who had not received such treatment, including patients with compensated cirrhosis.  In one trial, patients with HCV genotype 2 were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tablet (134 patients), or sofosbuvir plus wt.-based ribavirin (132 patients) for 12 wk.  In a second trial, patients with HCV genotype 3 were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir for 12 wk (277 patients) or sofosbuvir-ribavirin for 24 wk (275 patients).  The primary end point for the two trials was a sustained virol. response at 12 wk after the end of therapy.  RESULTS: Among patients with HCV genotype 2, the rate of sustained virol. response in the sofosbuvir-velpatasvir group was 99% (95% confidence interval [CI], 96 to 100), which was superior to the rate of 94% (95% CI, 88 to 97) in the sofosbuvir-ribavirin group (P=0.02).  Among patients with HCV genotype 3, the rate of sustained virol. response in the sofosbuvir-velpatasvir group was 95% (95% CI, 92 to 98), which was superior to the rate of 80% (95% CI, 75 to 85) in the sofosbuvir-ribavirin group (P<0.001).  The most common adverse events in the two studies were fatigue, headache, nausea, and insomnia.  CONCLUSIONS: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 wk of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virol. response that were superior to those with std. treatment with sofosbuvir-ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLv3wkT-s6bVg90H21EOLACvtfcHk0lgZh6cafIHKCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjM&md5=d1121c329e974c100d561feda9ce76f4</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512612%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DBrau%26aufirst%3DN.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DPianko%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DRuane%26aufirst%3DP.%26aulast%3DBourliere%26aufirst%3DM.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DRosenberg%26aufirst%3DW.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DStedman%26aufirst%3DC.%2BA.%2BM.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMazzotta%26aufirst%3DF.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DReau%26aufirst%3DN.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DSulkowski%26aufirst%3DM.%26atitle%3DSofosbuvir%2520and%2520Velpatasvir%2520for%2520HCV%2520Genotype%25202%2520and%25203%2520Infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2608%26epage%3D2617%26doi%3D10.1056%2FNEJMoa1512612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunyady, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogurtsov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck-Radosavljevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiffman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurdaydin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgard, O.</span></span> <span> </span><span class="NLM_article-title">Management of Adverse Effects of Peg-IFN and Ribavirin Therapy for Hepatitis C</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nrgastro.2011.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1038%2Fnrgastro.2011.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=21386812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFKntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=212-223&author=M.+S.+Sulkowskiauthor=C.+Cooperauthor=B.+Hunyadyauthor=J.+Jiaauthor=P.+Ogurtsovauthor=M.+Peck-Radosavljevicauthor=M.+L.+Shiffmanauthor=C.+Yurdaydinauthor=O.+Dalgard&title=Management+of+Adverse+Effects+of+Peg-IFN+and+Ribavirin+Therapy+for+Hepatitis+C&doi=10.1038%2Fnrgastro.2011.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C</span></div><div class="casAuthors">Sulkowski, Mark S.; Cooper, Curtis; Hunyady, Bela; Jia, Jidong; Ogurtsov, Pavel; Peck-Radosavljevic, Markus; Shiffman, Mitchell L.; Yurdaydin, Cihan; Dalgard, Olav</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">212-223</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A major barrier to hepatitis C treatment uptake and delivery is the assocn. of this therapy with frequent, and at times serious, adverse effects.  This Review article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.  HCV infects approx. 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma.  Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the assocn. of this therapy with frequent and, at times, serious adverse effects.  Recognition and effective management of these adverse effects are crit. components of the successful treatment of chronic HCV infection.  In clin. trials, approx. 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clin. practice, the rate of treatment discontinuation has been reported to be substantially higher.  The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematol., dermatol., neurol., immunol., gastrointestinal, pulmonary, cardiovascular, and ocular.  Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact.  This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33IzKUC2BjLVg90H21EOLACvtfcHk0lgZh6cafIHKCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFKntr0%253D&md5=ca3908f7d85bd8b857c1c7e9429a769f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2011.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2011.21%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DHunyady%26aufirst%3DB.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DOgurtsov%26aufirst%3DP.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DYurdaydin%26aufirst%3DC.%26aulast%3DDalgard%26aufirst%3DO.%26atitle%3DManagement%2520of%2520Adverse%2520Effects%2520of%2520Peg-IFN%2520and%2520Ribavirin%2520Therapy%2520for%2520Hepatitis%2520C%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2011%26volume%3D8%26spage%3D212%26epage%3D223%26doi%3D10.1038%2Fnrgastro.2011.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vadali, L. R.</span>; <span class="NLM_string-name">Jayachandra, S.</span>; <span class="NLM_string-name">Ponduri, R.</span>; <span class="NLM_string-name">Padala, B. R.</span>; <span class="NLM_string-name">Yerva, E. R.</span>; <span class="NLM_string-name">Vemavarapu, G. P. S.</span>; <span class="NLM_string-name">Jaldu, R.</span>; <span class="NLM_string-name">Dandala, R.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Velpatasvir</span>. <span class="NLM_patent">WO 2017060820A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+R.+Vadali&author=S.+Jayachandra&author=R.+Ponduri&author=B.+R.+Padala&author=E.+R.+Yerva&author=G.+P.+S.+Vemavarapu&author=R.+Jaldu&author=R.+Dandala&title=Process+for+the+Preparation+of+Velpatasvir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVadali%26aufirst%3DL.%2BR.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Velpatasvir%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span>; <span class="NLM_string-name">Huang, C.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Cai, H.</span>; <span class="NLM_string-name">Wang, Q.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Velpatasvir and its Derivative</span>. <span class="NLM_patent">CN 106831737A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Fu&author=C.+Huang&author=Y.+Ren&author=H.+Cai&author=Q.+Wang&author=X.+Yang&author=W.+Li&title=Preparation+of+Velpatasvir+and+its+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Velpatasvir%2520and%2520its%2520Derivative%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allan, K. M.</span>; <span class="NLM_string-name">Fujimori, S.</span>; <span class="NLM_string-name">Heumann, L. V.</span>; <span class="NLM_string-name">Huynh, G. M.</span>; <span class="NLM_string-name">Keaton, K. A.</span>; <span class="NLM_string-name">Levins, C. M.</span>; <span class="NLM_string-name">Pamulapati, G. R.</span>; <span class="NLM_string-name">Roberts, B. J.</span>; <span class="NLM_string-name">Sarma, K.</span>; <span class="NLM_string-name">Teresk, M. G.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Wolckenhauer, S. A.</span></span> <span> </span><span class="NLM_article-title">Processes for Preparing Peptide Analog as Antiviral Agent</span>. <span class="NLM_patent">WO 2015191437A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+M.+Allan&author=S.+Fujimori&author=L.+V.+Heumann&author=G.+M.+Huynh&author=K.+A.+Keaton&author=C.+M.+Levins&author=G.+R.+Pamulapati&author=B.+J.+Roberts&author=K.+Sarma&author=M.+G.+Teresk&author=X.+Wang&author=S.+A.+Wolckenhauer&title=Processes+for+Preparing+Peptide+Analog+as+Antiviral+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllan%26aufirst%3DK.%2BM.%26atitle%3DProcesses%2520for%2520Preparing%2520Peptide%2520Analog%2520as%2520Antiviral%2520Agent%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.
L.</span></span> <span> </span><span class="NLM_article-title">Patent Highlights: Recently Approved HCV NS5a Drugs</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00241</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00241" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1404-1415&author=D.%0AL.+Hughes&title=Patent+Highlights%3A+Recently+Approved+HCV+NS5a+Drugs&doi=10.1021%2Facs.oprd.6b00241"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00241%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DPatent%2520Highlights%253A%2520Recently%2520Approved%2520HCV%2520NS5a%2520Drugs%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1404%26epage%3D1415%26doi%3D10.1021%2Facs.oprd.6b00241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K.</span></span> <span> </span><span class="NLM_article-title">Investigational Antimicrobial Agents of 2013</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">821</span>, <span class="refDoi"> DOI: 10.1128/CMR.00033-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1128%2FCMR.00033-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24092856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeisbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=792-821&author=M.+J.+Pucciauthor=K.+Bush&title=Investigational+Antimicrobial+Agents+of+2013&doi=10.1128%2FCMR.00033-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational antimicrobial agents of 2013</span></div><div class="casAuthors">Pucci, Michael J.; Bush, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">792-821</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">1098-6618</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  New antimicrobial agents are always needed to counteract the resistant pathogens that continue to be selected by current therapeutic regimens.  This review provides a survey of known antimicrobial agents that were currently in clin. development in the fall of 2012 and spring of 2013.  Data were collected from published literature primarily from 2010 to 2012, meeting abstrs. (2011 to 2012), government websites, and company websites when appropriate.  Compared to what was reported in previous surveys, a surprising no. of new agents are currently in company pipelines, particularly in phase 3 clin. development.  Familiar antibacterial classes of the quinolones, tetracyclines, oxazolidinones, glycopeptides, and cephalosporins are represented by entities with enhanced antimicrobial or pharmacol. properties.  More importantly, compds. of novel chem. structures targeting bacterial pathways not previously exploited are under development.  Some of the most promising compds. include novel β-lactamase inhibitor combinations that target many multidrug-resistant Gram-neg. bacteria, a crit. medical need.  Although new antimicrobial agents will continue to be needed to address increasing antibiotic resistance, there are novel agents in development to tackle at least some of the more worrisome pathogens in the current nosocomial setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplxIxdr3xTuLVg90H21EOLACvtfcHk0lh_8iwPkdvLRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeisbrN&md5=415944588f6321f289d3b52dafa42251</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1128%2FCMR.00033-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00033-13%26sid%3Dliteratum%253Aachs%26aulast%3DPucci%26aufirst%3DM.%2BJ.%26aulast%3DBush%26aufirst%3DK.%26atitle%3DInvestigational%2520Antimicrobial%2520Agents%2520of%25202013%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2013%26volume%3D26%26spage%3D792%26epage%3D821%26doi%3D10.1128%2FCMR.00033-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kocsis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, D.</span></span> <span> </span><span class="NLM_article-title">Zabofloxacin for Chronic Bronchitis</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1358/dot.2016.52.9.2530595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1358%2Fdot.2016.52.9.2530595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgtVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=495-500&author=B.+Kocsisauthor=D.+Szabo&title=Zabofloxacin+for+Chronic+Bronchitis&doi=10.1358%2Fdot.2016.52.9.2530595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Zabofloxacin for chronic bronchitis</span></div><div class="casAuthors">Kocsis B; Szabo D</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">495-500</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Treatment of lower respiratory tract infection poses as an ongoing challenge among respiratory tract diseases.  Bacterial infections are causes of acute exacerbations in chronic bronchitis and indications for antibacterial therapy.  Several antibiotics were applied to treat bacterial infections in chronic bronchitis, among them fluoroquinolones are considered potent, broad-spectrum agents with excellent tissue penetration.  This monograph focuses on zabofloxacin, a novel fluoroquinolone agent recently approved and launched in South Korea, and summarizes the drug's antibacterial efficacy, pharmacokinetic properties and toxicity.  Recent advances concerning fluoroquinolones in chronic bronchitis will be discussed, along with a comparison between zabofloxacin and moxifloxacin.  Zabofloxacin has proved to be noninferior to moxifloxacin against major community-acquired Gram-positive and Gram-negative respiratory tract pathogens and found to be well tolerated in both oral and parenteral administrations.  These features can make it a potential antimicrobial agent in therapy of chronic bronchitis and other lower respiratory tract infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOIXkJaUrUfaNc3HjJRoFAfW6udTcc2eYxllVyCrayZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgtVSnsg%253D%253D&md5=5f2701fa45748ac048fae1d01df41225</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.9.2530595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.9.2530595%26sid%3Dliteratum%253Aachs%26aulast%3DKocsis%26aufirst%3DB.%26aulast%3DSzabo%26aufirst%3DD.%26atitle%3DZabofloxacin%2520for%2520Chronic%2520Bronchitis%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D495%26epage%3D500%26doi%3D10.1358%2Fdot.2016.52.9.2530595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span> <a href="https://www.dong-wha.co.kr/english/customer/dnews/content.asp?t_idx=856" class="extLink">https://www.dong-wha.co.kr/english/customer/dnews/content.asp?t_idx=856</a> (accessed Aug. 12, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+https%3A%2F%2Fwww.dong-wha.co.kr%2Fenglish%2Fcustomer%2Fdnews%2Fcontent.asp%3Ft_idx%3D856+%28accessed+Aug.+12%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, J.-H.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial Activity of Zabofloxacin Against Clinically Isolated Streptococcus Pneumoniae</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1562</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.3390/molecules21111562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.3390%2Fmolecules21111562" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1-8&issue=1562&author=H.-S.+Parkauthor=S.-H.+Ohauthor=H.-S.+Kimauthor=D.-R.+Choiauthor=J.-H.+Kwak&title=Antimicrobial+Activity+of+Zabofloxacin+Against+Clinically+Isolated+Streptococcus+Pneumoniae&doi=10.3390%2Fmolecules21111562"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21111562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21111562%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.-S.%26aulast%3DOh%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DH.-S.%26aulast%3DChoi%26aufirst%3DD.-R.%26aulast%3DKwak%26aufirst%3DJ.-H.%26atitle%3DAntimicrobial%2520Activity%2520of%2520Zabofloxacin%2520Against%2520Clinically%2520Isolated%2520Streptococcus%2520Pneumoniae%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D1562%26spage%3D1%26epage%3D8%26doi%3D10.3390%2Fmolecules21111562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. J.</span>; <span class="NLM_string-name">Chung, Y. H.</span>; <span class="NLM_string-name">Lee, C. W.</span>; <span class="NLM_string-name">Oh, Y. S.</span>; <span class="NLM_string-name">Kim, N. D.</span>; <span class="NLM_string-name">Lim, J. K.</span>; <span class="NLM_string-name">Jin, Y. H.</span></span> <span> </span><span class="NLM_article-title">Quinolone Carboxylic Acid Derivatives</span>. <span class="NLM_patent">WO 1999000393A1</span>, <span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=S.+J.+Yoon&author=Y.+H.+Chung&author=C.+W.+Lee&author=Y.+S.+Oh&author=N.+D.+Kim&author=J.+K.+Lim&author=Y.+H.+Jin&title=Quinolone+Carboxylic+Acid+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26atitle%3DQuinolone%2520Carboxylic%2520Acid%2520Derivatives%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. J.</span>; <span class="NLM_string-name">Chung, Y. H.</span>; <span class="NLM_string-name">Lee, C. W.</span>; <span class="NLM_string-name">Oh, Y. S.</span>; <span class="NLM_string-name">Kim, N. D.</span>; <span class="NLM_string-name">Lim, J. K.</span>; <span class="NLM_string-name">Jin, Y. H.</span></span> <span> </span><span class="NLM_article-title">Quinolone Carboxylic Acid Derivatives</span>. <span class="NLM_patent">US 20020035258A1</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=S.+J.+Yoon&author=Y.+H.+Chung&author=C.+W.+Lee&author=Y.+S.+Oh&author=N.+D.+Kim&author=J.+K.+Lim&author=Y.+H.+Jin&title=Quinolone+Carboxylic+Acid+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26atitle%3DQuinolone%2520Carboxylic%2520Acid%2520Derivatives%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, D.-R.</span>; <span class="NLM_string-name">Lim, J.-K.</span>; <span class="NLM_string-name">Choi, J.-U.</span>; <span class="NLM_string-name">Shin, D.-H.</span>; <span class="NLM_string-name">Kim, S.-H.</span>; <span class="NLM_string-name">Won, D.-Y.</span>; <span class="NLM_string-name">Kim, J.-H.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of Zabofloxacin</span>. <span class="NLM_patent">WO 2015178663</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.-R.+Choi&author=J.-K.+Lim&author=J.-U.+Choi&author=D.-H.+Shin&author=S.-H.+Kim&author=D.-Y.+Won&author=J.-H.+Kim&title=Method+for+the+Preparation+of+Zabofloxacin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DD.-R.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%2520Zabofloxacin%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0555-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0555-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=517-522&author=A.+Markham&title=Brivaracetam%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0555-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0555-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0555-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBrivaracetam%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D517%26epage%3D522%26doi%3D10.1007%2Fs40265-016-0555-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit42b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strzelczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam in the Treatment of Focal and Idiopathic Generalized Epilepsies and of Status Epilepticus</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1586/17512433.2016.1156529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1586%2F17512433.2016.1156529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=26891946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslKhur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=637-645&author=A.+Strzelczykauthor=K.+M.+Kleinauthor=L.+M.+Willemsauthor=F.+Rosenowauthor=S.+Bauer&title=Brivaracetam+in+the+Treatment+of+Focal+and+Idiopathic+Generalized+Epilepsies+and+of+Status+Epilepticus&doi=10.1586%2F17512433.2016.1156529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42bR"><div class="casContent"><span class="casTitleNuber">42b</span><div class="casTitle"><span class="NLM_cas:atitle">Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus</span></div><div class="casAuthors">Strzelczyk, Adam; Klein, Karl Martin; Willems, Laurent M.; Rosenow, Felix; Bauer, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Brivaracetam is the latest approved antiepileptic drug in focal epilepsy and exhibits high affinity as SV2A-ligand.  More than two thousand patients have received brivaracetam within randomized placebo-controlled trials.  Significant median seizure redn. rates of 30.5% to 53.1% for 50 mg/d, 32.5% to 37.2% for 100 mg/d and 35.6% for 200 mg/d were reported.  Likewise, 50% responder rates were 32.7% to 55.8% for 50 mg/d, 36% to 38.9% for 100 mg/d and 37.8% for 200 mg/d.  Overall, brivaracetam is well tolerated.  The main adverse events are fatigue, dizziness, and somnolence.  Immediate switch from levetiracetam to brivaracetam at a conversion ratio between 10:1 to 15:1 is feasible, and might alleviate the behavioral side effects assocd. with levetiracetam.  Brivaracetam has the potential to perform as an important, possibly broad-spectrum AED, initially in patients with drug-refractory epilepsies.  Its i.v. formulation may be a new and desirable alternative for status epilepticus, but there is so far no experience in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcZJoGGzs7prVg90H21EOLACvtfcHk0lgVBQfKuxTQXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslKhur8%253D&md5=a506586431d126d2e7ea7045fc9abbad</span></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1586%2F17512433.2016.1156529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17512433.2016.1156529%26sid%3Dliteratum%253Aachs%26aulast%3DStrzelczyk%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DK.%2BM.%26aulast%3DWillems%26aufirst%3DL.%2BM.%26aulast%3DRosenow%26aufirst%3DF.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DBrivaracetam%2520in%2520the%2520Treatment%2520of%2520Focal%2520and%2520Idiopathic%2520Generalized%2520Epilepsies%2520and%2520of%2520Status%2520Epilepticus%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D9%26spage%3D637%26epage%3D645%26doi%3D10.1586%2F17512433.2016.1156529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klitgaard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matagne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberty, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ryck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niespodziany, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannestad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kervyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenda, B.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam: Rationale for Discovery and Preclinical Profile of a Selective SV2A Ligand for Epilepsy Treatment</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1111/epi.13340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1111%2Fepi.13340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=538-548&author=H.+Klitgaardauthor=A.+Matagneauthor=J.-M.+Nicolasauthor=M.+Gillardauthor=Y.+Lambertyauthor=M.+De+Ryckauthor=R.+M.+Kaminskiauthor=K.+Leclercqauthor=I.+Niespodzianyauthor=C.+Wolffauthor=M.+Woodauthor=J.+Hannestadauthor=S.+Kervynauthor=B.+Kenda&title=Brivaracetam%3A+Rationale+for+Discovery+and+Preclinical+Profile+of+a+Selective+SV2A+Ligand+for+Epilepsy+Treatment&doi=10.1111%2Fepi.13340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1111%2Fepi.13340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fepi.13340%26sid%3Dliteratum%253Aachs%26aulast%3DKlitgaard%26aufirst%3DH.%26aulast%3DMatagne%26aufirst%3DA.%26aulast%3DNicolas%26aufirst%3DJ.-M.%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DLamberty%26aufirst%3DY.%26aulast%3DDe%2BRyck%26aufirst%3DM.%26aulast%3DKaminski%26aufirst%3DR.%2BM.%26aulast%3DLeclercq%26aufirst%3DK.%26aulast%3DNiespodziany%26aufirst%3DI.%26aulast%3DWolff%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DHannestad%26aufirst%3DJ.%26aulast%3DKervyn%26aufirst%3DS.%26aulast%3DKenda%26aufirst%3DB.%26atitle%3DBrivaracetam%253A%2520Rationale%2520for%2520Discovery%2520and%2520Preclinical%2520Profile%2520of%2520a%2520Selective%2520SV2A%2520Ligand%2520for%2520Epilepsy%2520Treatment%26jtitle%3DEpilepsia%26date%3D2016%26volume%3D57%26spage%3D538%26epage%3D548%26doi%3D10.1111%2Fepi.13340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenda, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matagne, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaga, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasau, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Differding, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallemand, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frycia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moureau, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klitgaard, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1021/jm030913e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030913e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=530-549&author=B.+M.+Kendaauthor=A.+C.+Matagneauthor=P.+E.+Talagaauthor=P.+M.+Pasauauthor=E.+Differdingauthor=B.+I.+Lallemandauthor=A.+M.+Fryciaauthor=F.+G.+Moureauauthor=H.+V.+Klitgaardauthor=M.+R.+Gillardauthor=B.+Fuksauthor=P.+Michel&title=Discovery+of+4-Substituted+Pyrrolidone+Butanamides+as+New+Agents+with+Significant+Antiepileptic+Activity&doi=10.1021%2Fjm030913e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm030913e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030913e%26sid%3Dliteratum%253Aachs%26aulast%3DKenda%26aufirst%3DB.%2BM.%26aulast%3DMatagne%26aufirst%3DA.%2BC.%26aulast%3DTalaga%26aufirst%3DP.%2BE.%26aulast%3DPasau%26aufirst%3DP.%2BM.%26aulast%3DDifferding%26aufirst%3DE.%26aulast%3DLallemand%26aufirst%3DB.%2BI.%26aulast%3DFrycia%26aufirst%3DA.%2BM.%26aulast%3DMoureau%26aufirst%3DF.%2BG.%26aulast%3DKlitgaard%26aufirst%3DH.%2BV.%26aulast%3DGillard%26aufirst%3DM.%2BR.%26aulast%3DFuks%26aufirst%3DB.%26aulast%3DMichel%26aufirst%3DP.%26atitle%3DDiscovery%2520of%25204-Substituted%2520Pyrrolidone%2520Butanamides%2520as%2520New%2520Agents%2520with%2520Significant%2520Antiepileptic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D530%26epage%3D549%26doi%3D10.1021%2Fjm030913e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Surtees, J.</span>; <span class="NLM_string-name">Lurquin, F.</span>; <span class="NLM_string-name">Diouf, O.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing N-Substituted 2-oxo-Pyrrolidines Such as Levetiracetam from Dihydrofurans and Amines</span>. <span class="NLM_patent">WO 2005028435A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+Surtees&author=F.+Lurquin&author=O.+Diouf&title=Process+for+Preparing+N-Substituted+2-oxo-Pyrrolidines+Such+as+Levetiracetam+from+Dihydrofurans+and+Amines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSurtees%26aufirst%3DJ.%26atitle%3DProcess%2520for%2520Preparing%2520N-Substituted%25202-oxo-Pyrrolidines%2520Such%2520as%2520Levetiracetam%2520from%2520Dihydrofurans%2520and%2520Amines%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit45b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ates, C.</span>; <span class="NLM_string-name">Lurquin, F.</span>; <span class="NLM_string-name">Quesnel, Y.</span>; <span class="NLM_string-name">Schule, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-Substituted-Pyrrolidin-2-ones and their Uses for the Synthesis of 2-oxo-Pyrrolidin-1-yl Derivatives</span>. <span class="NLM_patent">WO 2007031263A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Ates&author=F.+Lurquin&author=Y.+Quesnel&author=A.+Schule&title=Preparation+of+4-Substituted-Pyrrolidin-2-ones+and+their+Uses+for+the+Synthesis+of+2-oxo-Pyrrolidin-1-yl+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAtes%26aufirst%3DC.%26atitle%3DPreparation%2520of%25204-Substituted-Pyrrolidin-2-ones%2520and%2520their%2520Uses%2520for%2520the%2520Synthesis%2520of%25202-oxo-Pyrrolidin-1-yl%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit45c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ates, C.</span>; <span class="NLM_string-name">Schule, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-Carbamoylalkyl-3-Carboxy-2-Oxopyrrolidines</span>. <span class="NLM_patent">WO 2007065634A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Ates&author=A.+Schule&title=Preparation+of+1-Carbamoylalkyl-3-Carboxy-2-Oxopyrrolidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAtes%26aufirst%3DC.%26atitle%3DPreparation%2520of%25201-Carbamoylalkyl-3-Carboxy-2-Oxopyrrolidines%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit45d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Defrance, T.</span>; <span class="NLM_string-name">Septavaux, J.</span>; <span class="NLM_string-name">Nuel, D.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Brivaracetam</span>. <span class="NLM_patent">WO 2017076738 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=T.+Defrance&author=J.+Septavaux&author=D.+Nuel&title=Process+for+Preparing+Brivaracetam"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDefrance%26aufirst%3DT.%26atitle%3DProcess%2520for%2520Preparing%2520Brivaracetam%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schülé, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merschaert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczepaniak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maréchal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ates, C.</span></span> <span> </span><span class="NLM_article-title">A Biocatalytic Route to the Novel Antiepileptic Drug Brivaracetam</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1566-1575&author=A.+Sch%C3%BCl%C3%A9author=A.+Merschaertauthor=C.+Szczepaniakauthor=C.+Mar%C3%A9chalauthor=N.+Carlyauthor=J.+O%E2%80%99Rourkeauthor=C.+Ates&title=A+Biocatalytic+Route+to+the+Novel+Antiepileptic+Drug+Brivaracetam&doi=10.1021%2Facs.oprd.6b00094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00094%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCl%25C3%25A9%26aufirst%3DA.%26aulast%3DMerschaert%26aufirst%3DA.%26aulast%3DSzczepaniak%26aufirst%3DC.%26aulast%3DMar%25C3%25A9chal%26aufirst%3DC.%26aulast%3DCarly%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DJ.%26aulast%3DAtes%26aufirst%3DC.%26atitle%3DA%2520Biocatalytic%2520Route%2520to%2520the%2520Novel%2520Antiepileptic%2520Drug%2520Brivaracetam%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1566%26epage%3D1575%26doi%3D10.1021%2Facs.oprd.6b00094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span>; <span class="NLM_string-name">Li, P.</span>; <span class="NLM_string-name">Wei, Q.</span>; <span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Processes to Produce Brivaracetam</span>. <span class="NLM_patent">WO 2016191435A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+Wang&author=P.+Li&author=Q.+Wei&author=Y.+Liu&title=Processes+to+Produce+Brivaracetam"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26atitle%3DProcesses%2520to%2520Produce%2520Brivaracetam%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learmonth, D. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3396</span>– <span class="NLM_lpage">3411</span>, <span class="refDoi"> DOI: 10.1021/jm1001524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1001524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3396-3411&author=L.+E.+Kissauthor=H.+S.+Ferreiraauthor=L.+Torraoauthor=M.+J.+Bonifacioauthor=P.+N.+Palmaauthor=P.+Soares-da-Silvaauthor=D.+A.+Learmonth&title=Discovery+of+a+Long-Acting%2C+Peripherally+Selective+Inhibitor+of+Catechol-O-methyltransferase&doi=10.1021%2Fjm1001524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm1001524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1001524%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DL.%2BE.%26aulast%3DFerreira%26aufirst%3DH.%2BS.%26aulast%3DTorrao%26aufirst%3DL.%26aulast%3DBonifacio%26aufirst%3DM.%2BJ.%26aulast%3DPalma%26aufirst%3DP.%2BN.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26aulast%3DLearmonth%26aufirst%3DD.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520Long-Acting%252C%2520Peripherally%2520Selective%2520Inhibitor%2520of%2520Catechol-O-methyltransferase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3396%26epage%3D3411%26doi%3D10.1021%2Fjm1001524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Opicapone: A Review in Parkinson’s Disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0623-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0623-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1293-300&author=L.+J.+Scott&title=Opicapone%3A+A+Review+in+Parkinson%E2%80%99s+Disease&doi=10.1007%2Fs40265-016-0623-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0623-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0623-y%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DOpicapone%253A%2520A%2520Review%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1293%26epage%3D300%26doi%3D10.1007%2Fs40265-016-0623-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span>; <span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Opicapone Hydrate and its Preparation</span>. <span class="NLM_patent">CN 106543160</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Yan&author=X.+Li&title=Opicapone+Hydrate+and+its+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DJ.%26atitle%3DOpicapone%2520Hydrate%2520and%2520its%2520Preparation%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit50b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Charvin, D.</span>; <span class="NLM_string-name">Conquet, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of a Brain-Penetrant Chromone Oxime Derivative for the Therapy of Levodopa-Induced Dyskinesia</span>. <span class="NLM_patent">WO 2017032874A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Charvin&author=F.+Conquet&title=Preparation+of+a+Brain-Penetrant+Chromone+Oxime+Derivative+for+the+Therapy+of+Levodopa-Induced+Dyskinesia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharvin%26aufirst%3DD.%26atitle%3DPreparation%2520of%2520a%2520Brain-Penetrant%2520Chromone%2520Oxime%2520Derivative%2520for%2520the%2520Therapy%2520of%2520Levodopa-Induced%2520Dyskinesia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit50c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss Laszlo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of Catechol O-methyltransferase (COMT) Inhibitors and their Therapeutic Utility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8692</span>– <span class="NLM_lpage">8717</span>, <span class="refDoi"> DOI: 10.1021/jm500572b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500572b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8692-8717&author=E.+Kiss+Laszloauthor=P.+Soares-da-Silva&title=Medicinal+Chemistry+of+Catechol+O-methyltransferase+%28COMT%29+Inhibitors+and+their+Therapeutic+Utility&doi=10.1021%2Fjm500572b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50c&amp;dbid=16384&amp;doi=10.1021%2Fjm500572b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500572b%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%2BLaszlo%26aufirst%3DE.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DMedicinal%2520Chemistry%2520of%2520Catechol%2520O-methyltransferase%2520%2528COMT%2529%2520Inhibitors%2520and%2520their%2520Therapeutic%2520Utility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8692%26epage%3D8717%26doi%3D10.1021%2Fjm500572b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit50d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D.</span>; <span class="NLM_string-name">Kiss, L.
E.</span>; <span class="NLM_string-name">Wahnon, J.
B. R.</span>; <span class="NLM_string-name">Learmonth, D. A.</span>; <span class="NLM_string-name">Eszenyi, T.</span>; <span class="NLM_string-name">Zimmermann, A.</span>; <span class="NLM_string-name">Schlummer, B.</span>; <span class="NLM_string-name">Kreis, M.</span>; <span class="NLM_string-name">Reiter, K.</span></span> <span> </span><span class="NLM_article-title">A [1,2,4]Oxadiazo Derivative as an Intermediate for Preparation of a Catechol-O-methyltransferase Inhibitor Useful in Treatment of Parkinson’s Disease via Demethylation and its Preparation</span>. <span class="NLM_patent">WO 2013089573A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+Russo&author=L.%0AE.+Kiss&author=J.%0AB.+R.+Wahnon&author=D.+A.+Learmonth&author=T.+Eszenyi&author=A.+Zimmermann&author=B.+Schlummer&author=M.+Kreis&author=K.+Reiter&title=A+%5B1%2C2%2C4%5DOxadiazo+Derivative+as+an+Intermediate+for+Preparation+of+a+Catechol-O-methyltransferase+Inhibitor+Useful+in+Treatment+of+Parkinson%E2%80%99s+Disease+via+Demethylation+and+its+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DD.%26atitle%3DA%2520%255B1%252C2%252C4%255DOxadiazo%2520Derivative%2520as%2520an%2520Intermediate%2520for%2520Preparation%2520of%2520a%2520Catechol-O-methyltransferase%2520Inhibitor%2520Useful%2520in%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%2520via%2520Demethylation%2520and%2520its%2520Preparation%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit50e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Learmonth, D. A.</span>; <span class="NLM_string-name">Kiss, L. E.</span>; <span class="NLM_string-name">Palma, P. N. L.</span>; <span class="NLM_string-name">Ferreira, H. d. S.</span>; <span class="NLM_string-name">Soares da Silva, P. M. V. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyridyloxadiazolylnitrobenzenediols and Related Compounds as Catechol O-methyltransferase (COMT) Inhibitors</span>. <span class="NLM_patent">WO 2007013830</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+A.+Learmonth&author=L.+E.+Kiss&author=P.+N.+L.+Palma&author=H.+d.+S.+Ferreira&author=P.+M.+V.+A.+Soares+da+Silva&title=Preparation+of+Pyridyloxadiazolylnitrobenzenediols+and+Related+Compounds+as+Catechol+O-methyltransferase+%28COMT%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLearmonth%26aufirst%3DD.%2BA.%26atitle%3DPreparation%2520of%2520Pyridyloxadiazolylnitrobenzenediols%2520and%2520Related%2520Compounds%2520as%2520Catechol%2520O-methyltransferase%2520%2528COMT%2529%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Pimavanserin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0597-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0597-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27262680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVymsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1053-1057&author=A.+Markham&title=Pimavanserin%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0597-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Pimavanserin: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Pimavanserin (Nuplazid) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions assocd. with Parkinson's disease psychosis.  Up to 60 % of patients with Parkinson's disease may develop Parkinson's disease psychosis, which is assocd. with increased morbidity and mortality and has few treatment options.  This article summarizes the milestones in the development of pimavanserin leading to this first approval for the treatment of hallucinations and delusions in patients with Parkinson's disease psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ_xydJCF-PbVg90H21EOLACvtfcHk0lgKHVH2Ey6FWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVymsbw%253D&md5=585f3e5fd625a7ea0a749e47bd26e528</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0597-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0597-9%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DPimavanserin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1053%26epage%3D1057%26doi%3D10.1007%2Fs40265-016-0597-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm</a> (accessed Aug. 12, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm498442.htm+%28accessed+Aug.+12%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. H.</span></span> <span> </span><span class="NLM_article-title">Pimavanserin for the Treatment of Parkinson’s Disease Psychosis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1969</span>– <span class="NLM_lpage">1975</span>, <span class="refDoi"> DOI: 10.1517/14656566.2013.819345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1517%2F14656566.2013.819345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24016069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVektr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1969-1975&author=J.+H.+Friedman&title=Pimavanserin+for+the+Treatment+of+Parkinson%E2%80%99s+Disease+Psychosis&doi=10.1517%2F14656566.2013.819345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Pimavanserin for the treatment of Parkinson's disease psychosis</span></div><div class="casAuthors">Friedman, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1969-1975</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Parkinson's disease (PD) is a neurobehavioral disorder defined by its motor features.  Its treatment is frequently complicated by the presence of psychotic symptoms, most prominently hallucinations and delusions.  These cause major distress and are the primary cause for nursing home placement.  Current treatment requires either a redn. in medications for mobility or the addn. of atypical antipsychotics, none of which are approved in the United States, and which are assocd. with major potential drawbacks.  Areas covered: Information from extensive personal experience, a Pubmed literature search plus a direct request to Acadia Pharmaceuticals was used for this review.  A brief review of the clin. problem and its current state of treatment will be followed by a discussion of and its potential role in treating PD psychosis (PDP).  Several observations have implicated serotonin in the physiol. of psychotic symptoms.  Lysergic acid diethylamide, phencyclidine, and similar drugs that activate 5HT2A serotonin receptors produce psychotic syndromes, and almost all antipsychotic neuroleptics share the property of blocking the 5HT2A receptor as well as the dopamine D2 receptor.  The reduced motor side effects of the second-generation antipsychotics have been ascribed to these drugs having greater 5HT2A antagonism than the first generation.  Studies in animal models of psychosis have suggested benefits from drugs blocking the 5HT2A receptor alone without the motor side effects seen with D2 receptor antagonism.  Expert opinion: Pimavanserin, a 5HT2A inverse agonist, has no motor side effects, and a remarkable safety profile that is comparable to placebo.  Its antipsychotic effects coupled with its lack of motor side effects could make it an ideal drug for treating psychotic symptoms in PD, a major unmet need.  One Phase III trial in PDP has demonstrated excellent tolerability and significant benefit.  The FDA agreed to the filing of a planned new drug approval (NDA) for an indication in the treatment of PDP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjQlHPn5mj8LVg90H21EOLACvtfcHk0lg6_R94zSABMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVektr7P&md5=a0628bdf46546aa59074695659b69644</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.819345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.819345%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DJ.%2BH.%26atitle%3DPimavanserin%2520for%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%2520Psychosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D1969%26epage%3D1975%26doi%3D10.1517%2F14656566.2013.819345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Thygesen, M.</span>; <span class="NLM_string-name">Schlienger, N.</span>; <span class="NLM_string-name">Tolf, B. R.</span>; <span class="NLM_string-name">Blatter, F.</span>; <span class="NLM_string-name">Berghausen, J.</span></span> <span> </span><span class="NLM_article-title">Salts of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-yl)-N′-(4-(2-Methylpropyloxy)phenylmethyl)carbamide and their Preparation</span>. <span class="NLM_patent">WO 2006036874A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.+Thygesen&author=N.+Schlienger&author=B.+R.+Tolf&author=F.+Blatter&author=J.+Berghausen&title=Salts+of+N-%284-Fluorobenzyl%29-N-%281-Methylpiperidin-4-yl%29-N%E2%80%B2-%284-%282-Methylpropyloxy%29phenylmethyl%29carbamide+and+their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThygesen%26aufirst%3DM.%26atitle%3DSalts%2520of%2520N-%25284-Fluorobenzyl%2529-N-%25281-Methylpiperidin-4-yl%2529-N%25E2%2580%25B2-%25284-%25282-Methylpropyloxy%2529phenylmethyl%2529carbamide%2520and%2520their%2520Preparation%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit54b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span>; <span class="NLM_string-name">Sarshar, S.</span></span> <span> </span><span class="NLM_article-title">Substituted Ureas</span>. <span class="NLM_patent">US 20080280886A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+G.+Gant&author=S.+Sarshar&title=Substituted+Ureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DSubstituted%2520Ureas%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit54c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, R.</span>; <span class="NLM_string-name">Williams, H. L.</span></span> <span> </span><span class="NLM_article-title">Methods for the Treatment of Parkinson’s Disease Psychosis using Pimavanserin</span>. <span class="NLM_patent">WO 2014085362A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+Mills&author=H.+L.+Williams&title=Methods+for+the+Treatment+of+Parkinson%E2%80%99s+Disease+Psychosis+using+Pimavanserin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DR.%26atitle%3DMethods%2520for%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%2520Psychosis%2520using%2520Pimavanserin%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Pitolisant: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0620-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0620-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27438291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cjs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1313-1318&author=Y.+Y.+Syed&title=Pitolisant%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0620-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55aR"><div class="casContent"><span class="casTitleNuber">55a</span><div class="casTitle"><span class="NLM_cas:atitle">Pitolisant: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1313-1318</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Pitolisant (Wakix) is an inverse agonist of the histamine H3 receptor that is being developed by Bioproject.  Oral pitolisant is approved in the EU for the treatment of narcolepsy with or without cataplexy in adults.  Pitolisant has received a Temporary Authorization of Use in France for this indication in case of treatment failure, intolerance or contraindication to currently available treatment.  Pitolisant has orphan drug designation in the EU and the USA.  In the pivotal HARMONY I trial, pitolisant significantly decreased excessive daytime sleepiness vs. placebo in adults with narcolepsy with or without cataplexy (primary endpoint).  Pitolisant also significantly decreased cataplexy rate vs. placebo in these patients.  This article summarizes the milestones in the development of pitolisant leading to this first approval for narcolepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD9azvoq-Jj7Vg90H21EOLACvtfcHk0lg6_R94zSABMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cjs7zK&md5=2a74af8516916b9c3d9d9c9ad1ba5cc7</span></div><a href="/servlet/linkout?suffix=cit55a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0620-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0620-1%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DPitolisant%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1313%26epage%3D1318%26doi%3D10.1007%2Fs40265-016-0620-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit55b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kollb-Sielecka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demolis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmonson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, M.</span></span> <span> </span><span class="NLM_article-title">The European Medicines Agency Review of Pitolisant for Treatment of Narcolepsy: Summary of the Scientific Assessment by the Committee for Medicinal Products for Human Use</span>. <i>Sleep Medicine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.sleep.2017.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.sleep.2017.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28449891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC1crhvVGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=125-129&author=M.+Kollb-Sieleckaauthor=P.+Demolisauthor=J.+Emmerichauthor=G.+Markeyauthor=T.+Salmonsonauthor=M.+Haas&title=The+European+Medicines+Agency+Review+of+Pitolisant+for+Treatment+of+Narcolepsy%3A+Summary+of+the+Scientific+Assessment+by+the+Committee+for+Medicinal+Products+for+Human+Use&doi=10.1016%2Fj.sleep.2017.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55bR"><div class="casContent"><span class="casTitleNuber">55b</span><div class="casTitle"><span class="NLM_cas:atitle">The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use</span></div><div class="casAuthors">Kollb-Sielecka Marta; Demolis Pierre; Emmerich Joseph; Markey Greg; Salmonson Tomas; Haas Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">125-129</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">On 31 March 2016, the European Commission issued a decision for a marketing authorisation valid throughout the European Union (EU) for pitolisant (Wakix) for the treatment of narcolepsy with or without cataplexy in adults.  Pitolisant is an antagonist/inverse agonist of the human histamine H3 receptor.  The dose should be selected using an up-titration scheme depending on individual patient response and tolerance and should not exceed 36 mg/day.  The main evidence of efficacy of pitolisant was based on two Phase III clinical trials.  The improvement on excessive daytime sleepiness was shown against placebo in the Harmony I study (-3.33 points; 95% confidence interval (CI) [-5.83; -0.83]; p = 0.024) and in Harmony CTP (-3.41 points; 95% CI [-4.95; -1.87]; p < 0.0001).  The daily cataplexy rate in Harmony I improved against placebo with a rate ratio (rR) of 0.38 whilst in the Harmony CTP the ratio of improvement on weekly cataplexy rate against placebo was 0.512.  The most commonly reported adverse reactions were headache, insomnia and nausea.  This article summarizes the scientific review leading to approval of pitolisant in the EU.  The assessment report and product information are available on the European Medicines Agency website (http://www.ema.europa.eu).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm-VCMMXIrVkNoizSOkG_FfW6udTcc2ebpMneQSvpnRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhvVGnsg%253D%253D&md5=2f820dc747146322af50c191bb0c0f98</span></div><a href="/servlet/linkout?suffix=cit55b&amp;dbid=16384&amp;doi=10.1016%2Fj.sleep.2017.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sleep.2017.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DKollb-Sielecka%26aufirst%3DM.%26aulast%3DDemolis%26aufirst%3DP.%26aulast%3DEmmerich%26aufirst%3DJ.%26aulast%3DMarkey%26aufirst%3DG.%26aulast%3DSalmonson%26aufirst%3DT.%26aulast%3DHaas%26aufirst%3DM.%26atitle%3DThe%2520European%2520Medicines%2520Agency%2520Review%2520of%2520Pitolisant%2520for%2520Treatment%2520of%2520Narcolepsy%253A%2520Summary%2520of%2520the%2520Scientific%2520Assessment%2520by%2520the%2520Committee%2520for%2520Medicinal%2520Products%2520for%2520Human%2520Use%26jtitle%3DSleep%2520Medicine%26date%3D2017%26volume%3D33%26spage%3D125%26epage%3D129%26doi%3D10.1016%2Fj.sleep.2017.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dauvilliers, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnulf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodenbeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecomte, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span> <span> </span><span class="NLM_article-title">Pitolisant Versus Placebo or Modafinil in Patients with Narcolepsy: A Double-blind, Randomised Trial</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70225-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS1474-4422%2813%2970225-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24107292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyrsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1068-1075&author=Y.+Dauvilliersauthor=C.+Bassettiauthor=G.+J.+Lammersauthor=I.+Arnulfauthor=G.+Mayerauthor=A.+Rodenbeckauthor=P.+Lehertauthor=C.-L.+Dingauthor=J.-M.+Lecomteauthor=J.-C.+Schwartz&title=Pitolisant+Versus+Placebo+or+Modafinil+in+Patients+with+Narcolepsy%3A+A+Double-blind%2C+Randomised+Trial&doi=10.1016%2FS1474-4422%2813%2970225-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial</span></div><div class="casAuthors">Dauvilliers, Yves; Bassetti, Claudio; Lammers, Gert Jan; Arnulf, Isabelle; Mayer, Geert; Rodenbeck, Andrea; Lehert, Philippe; Ding, Claire-Li; Lecomte, Jeanne-Marie; Schwartz, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1068-1075</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Narcolepsy is characterized by excessive daytime sleepiness (EDS) and cataplexy.  Histamine neurons are crucial to maintain wakefulness.  We assessed the safety and efficacy of pitolisant (previously called BF2.649), a selective histamine H3 receptor inverse agonist that activates these neurons, in patients with narcolepsy.For this double-blind, randomized, parallel-group controlled trial, we recruited patients with narcolepsy from 32 sleep disorder centers in five European countries.  Patients were eligible if they were aged 18 years or older, had not taken psychostimulants for at least 14 days, and had EDS (defined as an Epworth Sleepiness Scale [ESS] score of at least 14).  Using a computer-generated randomization sequence, we randomly allocated patients to receive pitolisant, modafinil, or placebo (1:1:1).  Treatment lasted 8 wk: 3 wk of flexible dosing according to investigator's judgment (10 mg, 20 mg, or 40 mg a day of pitolisant; 100 mg, 200 mg or 400 mg a day of modafinil) followed by 5 wk of stable dosing.  Patients took four tablets a day in a double-dummy design to ensure masking.  For the primary anal., assessed in the intention-to-treat population, we assessed the superiority of pitolisant vs. placebo, and the non-inferiority of pitolisant vs. modafinil.  This trial is registered with ClinicalTrials.gov, no. NCT01067222.Between May 26, 2009, and June 30, 2010, we screened 110 patients, 95 of whom were eligible and randomly assigned to treatment: 30 to placebo, 32 to pitolisant, and 33 to modafinil.  Over the 8-wk treatment period, mean ESS score redns. were -3·4 (SD 4·2) in the placebo group, -5·8 (6·2) in the pitolisant group, and -6·9 (6·2) in the modafinil group.  Our primary anal. of between-group differences in mean ESS score at endpoint (adjusted for baseline) showed pitolisant to be superior to placebo (difference -3·0, 95% CI -5·6 to -0·4; p=0·024), but not non-inferior to modafinil (difference 0·12, 95% CI -2·5 to 2·7; p=0·250).  We recorded 22 adverse events with pitolisant, 26 with modafinil, and ten with placebo.  Six severe adverse events were treatment-related: one with pitolisant (abdominal discomfort) and five with modafinil (abdominal pain, abnormal behavior, amphetamine-like withdrawal symptoms, lymphoadenopathy, and inner ear disorders).Pitolisant at doses up to 40 mg was efficacious on EDS compared with placebo and well tolerated compared with modafinil.  If these findings are substantiated in further studies, pitolisant could offer a new treatment option for patients with narcolepsy.Bioprojet, France.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLoL8Ilx_OjLVg90H21EOLACvtfcHk0lj-hXJPIroFeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyrsbjF&md5=644403e36dbafb473e0bc61bc7370dc8</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970225-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970225-4%26sid%3Dliteratum%253Aachs%26aulast%3DDauvilliers%26aufirst%3DY.%26aulast%3DBassetti%26aufirst%3DC.%26aulast%3DLammers%26aufirst%3DG.%2BJ.%26aulast%3DArnulf%26aufirst%3DI.%26aulast%3DMayer%26aufirst%3DG.%26aulast%3DRodenbeck%26aufirst%3DA.%26aulast%3DLehert%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DC.-L.%26aulast%3DLecomte%26aufirst%3DJ.-M.%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26atitle%3DPitolisant%2520Versus%2520Placebo%2520or%2520Modafinil%2520in%2520Patients%2520with%2520Narcolepsy%253A%2520A%2520Double-blind%252C%2520Randomised%2520Trial%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26spage%3D1068%26epage%3D1075%26doi%3D10.1016%2FS1474-4422%2813%2970225-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graßmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurquin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganellin, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Influence of Imidazole Replacement in Different Structural Classes of Histamine H(3)-Receptor Antagonists</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/S0928-0987(01)00106-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS0928-0987%2801%2900106-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=11384847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvV2qtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=249-259&author=G.+Meierauthor=J.+Apeltauthor=U.+Reichertauthor=S.+Gra%C3%9Fmannauthor=X.+Ligneauauthor=S.+Elzauthor=F.+Leurquinauthor=C.+R.+Ganellinauthor=J.-C.+Schwartzauthor=W.+Schunackauthor=H.+Stark&title=Influence+of+Imidazole+Replacement+in+Different+Structural+Classes+of+Histamine+H%283%29-Receptor+Antagonists&doi=10.1016%2FS0928-0987%2801%2900106-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57aR"><div class="casContent"><span class="casTitleNuber">57a</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists</span></div><div class="casAuthors">Meier, G.; Apelt, J.; Reichert, U.; Grassmann, S.; Ligneau, X.; Elz, S.; Leurquin, F.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-259</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The ref. compds. for histamine H3-receptor antagonists carry as a common feature an imidazole moiety substituted in the 4-position.  Very recently novel ligands lacking an imidazole ring have been described possessing a N-contg. non-arom. heterocycle instead.  In this study we investigated whether imidazole replacement, favorably by a piperidine moiety, is generally applicable to different structural classes of ref. compds., e.g., thioperamide, carboperamide, clobenpropit, FUB 181, ciproxifan, etc.  While replacement led to a loss of affinity for many of the compds., it was successfully applied to some ether derivs.  The piperidine analogs of FUB 181 and ciproxifan, 3-(4-chlorophenyl)propyl 3-piperidinopropyl ether hydrogen oxalate and cyclopropyl 4-(3-piperidinopropyloxy)phenyl methanone hydrogen maleate, almost maintained in vitro affinities, pKi values of 7.8 and 8.4, resp., and showed high potency in vivo after p.o. administration (ED50 values of 1.6 and 0.18 mg/kg, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVgXghx9IdrbVg90H21EOLACvtfcHk0lj-hXJPIroFeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvV2qtLw%253D&md5=7874e3f384d040e21a3ab8fcddea90bf</span></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=10.1016%2FS0928-0987%2801%2900106-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0928-0987%252801%252900106-3%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DG.%26aulast%3DApelt%26aufirst%3DJ.%26aulast%3DReichert%26aufirst%3DU.%26aulast%3DGra%25C3%259Fmann%26aufirst%3DS.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DElz%26aufirst%3DS.%26aulast%3DLeurquin%26aufirst%3DF.%26aulast%3DGanellin%26aufirst%3DC.%2BR.%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DInfluence%2520of%2520Imidazole%2520Replacement%2520in%2520Different%2520Structural%2520Classes%2520of%2520Histamine%2520H%25283%2529-Receptor%2520Antagonists%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2001%26volume%3D13%26spage%3D249%26epage%3D259%26doi%3D10.1016%2FS0928-0987%2801%2900106-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit57b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liedtke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlicker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span> <span> </span><span class="NLM_article-title">Replacement of Imidazole by a Piperidine Moiety Differentially Affects the Potency of Histamine H3-Receptor Antagonists</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1007/s00210-002-0649-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs00210-002-0649-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=12616340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvV2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2003&pages=43-50&author=S.+Liedtkeauthor=K.+Flauauthor=M.+Kathmannauthor=E.+Schlickerauthor=H.+Starkauthor=G.+Meierauthor=W.+Schunack&title=Replacement+of+Imidazole+by+a+Piperidine+Moiety+Differentially+Affects+the+Potency+of+Histamine+H3-Receptor+Antagonists&doi=10.1007%2Fs00210-002-0649-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57bR"><div class="casContent"><span class="casTitleNuber">57b</span><div class="casTitle"><span class="NLM_cas:atitle">Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists</span></div><div class="casAuthors">Liedtke, Susanna; Flau, Karsten; Kathmann, Markus; Schlicker, Eberhard; Stark, Holger; Meier, Galina; Schunack, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-50</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">We examd. whether replacement of imidazole by a piperidine or pyrrolidine moiety will affect the potency and affinity of six H3-receptor antagonists.  Potencies were detd. in superfused mouse brain cortex slices preincubated with [3H]noradrenaline, in which the interaction of the antagonists with histamine with respect to its inhibitory effect on the elec. evoked tritium overflow was studied.  Affinities were detd. in mouse brain cortex membranes, using the radioligand [3H]Nα-methylhistamine.  The concn.-response curve of histamine for its effect on the evoked overflow from mouse brain cortex slices was shifted to the right by the 13 compds. under study.  Replacement of the imidazole by a piperidine ring affected the pA2 value as follows: thioperamide, -2.7 log units; clobenpropit, -1.9; proxyfan, -1.3; FUB 138, -1.2.  Potency hardly changed (≤0.4 log units) when imidazole was replaced by piperidine in FUB 181 and by piperidine or pyrrolidine in FUB 153.  Binding of [3H]Nα-methylhistamine to mouse brain cortex membranes was inhibited monophasically by all compds.  The pKi values closely matched their pA2 values with three exceptions.  The pKi values of proxyfan, FUB 138, and FUB 153 exceeded their resp. pA2 values by about 1 log unit.  To reveal a potential partial agonism, the effect of the three drugs on (1) the elec. evoked tritium overflow and (2) [35S]GTPγS binding in mouse cortex prepns. was detd.  Proxyfan proved to be a partial agonist in both models (with intrinsic activities of 0.2 and 0.3, resp.) whereas FUB 138 and FUB 153 were devoid of agonistic effects.  In conclusion, replacement of imidazole by piperidine or pyrrolidine affects the antagonist potencies of six H3-receptor antagonists in a very different manner.  The piperidine analog of FUB 181 (with a pA2 value as high as 7.7) may represent a lead for the development of non-imidazole H3-receptor antagonists.  The discrepancy between the pKi and pA2 values may be accounted for by partial agonism in the case of proxyfan but can, at present, not be satisfactorily explained with respect to FUB 138 and FUB 153.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq632LlhCo9tLVg90H21EOLACvtfcHk0lj-hXJPIroFeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvV2rsA%253D%253D&md5=882e375e8c6b4a405318d7a24ceb5521</span></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=10.1007%2Fs00210-002-0649-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-002-0649-4%26sid%3Dliteratum%253Aachs%26aulast%3DLiedtke%26aufirst%3DS.%26aulast%3DFlau%26aufirst%3DK.%26aulast%3DKathmann%26aufirst%3DM.%26aulast%3DSchlicker%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMeier%26aufirst%3DG.%26aulast%3DSchunack%26aufirst%3DW.%26atitle%3DReplacement%2520of%2520Imidazole%2520by%2520a%2520Piperidine%2520Moiety%2520Differentially%2520Affects%2520the%2520Potency%2520of%2520Histamine%2520H3-Receptor%2520Antagonists%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2003%26volume%3D367%26spage%3D43%26epage%3D50%26doi%3D10.1007%2Fs00210-002-0649-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit57c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span> <span> </span><span class="NLM_article-title">The Histamine H3 Receptor: From Discovery to Clinical Trials with Pitolisant</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01286.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1111%2Fj.1476-5381.2011.01286.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=21615387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=713-721&author=J.-C.+Schwartz&title=The+Histamine+H3+Receptor%3A+From+Discovery+to+Clinical+Trials+with+Pitolisant&doi=10.1111%2Fj.1476-5381.2011.01286.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57cR"><div class="casContent"><span class="casTitleNuber">57c</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: from discovery to clinical trials with pitolisant</span></div><div class="casAuthors">Schwartz, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">713-721</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The third histamine receptor was discovered in 1983 by a traditional pharmacol. approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices.  The same in vitro test was used to design, in 1987, the first highly selective and potent H3-autoreceptor ligands, the antagonist thioperamide and the agonist alphamethylhistamine which enhances and inhibits, resp., the activity of histaminergic neurons in brain.  The use of these research tools was instrumental in establishing the main functions of cerebral histaminergic neurons, namely their role in maintenance of wakefulness, attention, learning and other cognitive processes.  In 1990, the cloning of the gene of the H3-receptor, a member of the superfamily of heptahelical receptors coupled to G proteins, paved the way to the demonstration of the high constitutive activity of the receptor, including its native form, and its participation in the tonic control of histamine release; it also facilitated the development of H3-receptor inverse agonist programs in many drug companies.  Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride) is the first inverse agonist to be introduced in the clinics.  Its wake-promotion activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson's disease or Obstructive Sleep Apnea/Hypopnea, in which this activity is characterized by a mean decrease of the Epworth Sleepiness Scale by about five units.  The procognitive activity of this novel class of drugs may also find therapeutic applications in dementias, schizophrenia or attention deficit hyperactivity disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHrkoL8T1XbbVg90H21EOLACvtfcHk0lhgKfGRO2Y8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr0%253D&md5=f8b1db02051f583d7ca6c179c29f0db2</span></div><a href="/servlet/linkout?suffix=cit57c&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01286.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01286.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26atitle%3DThe%2520Histamine%2520H3%2520Receptor%253A%2520From%2520Discovery%2520to%2520Clinical%2520Trials%2520with%2520Pitolisant%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D713%26epage%3D721%26doi%3D10.1111%2Fj.1476-5381.2011.01286.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">Zheng, Z.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Zhou, X.</span>; <span class="NLM_string-name">Zhong, W.</span>; <span class="NLM_string-name">Xiao, J.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Pitolisant Hydrochloride from 3-(4-Chlorophenyl)propionic acid</span>. <span class="NLM_patent">CN 103435575A</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Li&author=Z.+Zheng&author=L.+Li&author=H.+Wang&author=X.+Zhou&author=W.+Zhong&author=J.+Xiao&author=Y.+Liu&author=Y.+Xie&author=X.+Li&author=X.+Wang&title=Process+for+Preparation+of+Pitolisant+Hydrochloride+from+3-%284-Chlorophenyl%29propionic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Pitolisant%2520Hydrochloride%2520from%25203-%25284-Chlorophenyl%2529propionic%2520acid%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sallares, J.</span>; <span class="NLM_string-name">Petschen, I.</span>; <span class="NLM_string-name">Camps, X.</span></span> <span> </span><span class="NLM_article-title">Etherification Process for Preparing 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine from 3-(Piperidino)propanol and 3-(4-Chlorophenyl)propyl Mesylate with Sodium Hydride in an Aprotic Polar Solvent</span>. <span class="NLM_patent">WO 2007006708A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Sallares&author=I.+Petschen&author=X.+Camps&title=Etherification+Process+for+Preparing+1-%5B3-%5B3-%284-Chlorophenyl%29propoxy%5Dpropyl%5Dpiperidine+from+3-%28Piperidino%29propanol+and+3-%284-Chlorophenyl%29propyl+Mesylate+with+Sodium+Hydride+in+an+Aprotic+Polar+Solvent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSallares%26aufirst%3DJ.%26atitle%3DEtherification%2520Process%2520for%2520Preparing%25201-%255B3-%255B3-%25284-Chlorophenyl%2529propoxy%255Dpropyl%255Dpiperidine%2520from%25203-%2528Piperidino%2529propanol%2520and%25203-%25284-Chlorophenyl%2529propyl%2520Mesylate%2520with%2520Sodium%2520Hydride%2520in%2520an%2520Aprotic%2520Polar%2520Solvent%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raga M, M.</span>; <span class="NLM_string-name">Sallares, J.</span>; <span class="NLM_string-name">Guerrero, M.</span>; <span class="NLM_string-name">Guglietta, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine Monohydrochloride as a Histamine H3 Receptor Ligand</span>. <span class="NLM_patent">WO 2006084833A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.+Raga+M&author=J.+Sallares&author=M.+Guerrero&author=A.+Guglietta&title=Preparation+of+1-%5B3-%5B3-%284-Chlorophenyl%29propoxy%5Dpropyl%5Dpiperidine+Monohydrochloride+as+a+Histamine+H3+Receptor+Ligand"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRaga%2BM%26aufirst%3DM.%26atitle%3DPreparation%2520of%25201-%255B3-%255B3-%25284-Chlorophenyl%2529propoxy%255Dpropyl%255Dpiperidine%2520Monohydrochloride%2520as%2520a%2520Histamine%2520H3%2520Receptor%2520Ligand%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheape, A.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrell, D. F.</span></span> <span> </span><span class="NLM_article-title">2% Crisaborole Topical Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis</span>. <i>Expert Rev. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1080/1744666X.2017.1304820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1080%2F1744666X.2017.1304820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28290219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslOrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=415-423&author=A.%0AC.+Cheapeauthor=D.+F.+Murrell&title=2%25+Crisaborole+Topical+Ointment+for+the+Treatment+of+Mild-to-Moderate+Atopic+Dermatitis&doi=10.1080%2F1744666X.2017.1304820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis</span></div><div class="casAuthors">Cheape, Alice C.; Murrell, Dedee F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis.  So far, 7 trials have been completed in atopic dermatitis.  The 2% strength appeared to be the superior dosing regimen.  Pruritus improved significantly within one week.  The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle.  Crisaborole has several key features in its mode of action which distinguish it from existing treatments for atopic dermatitis (AD), notably its activity against the phosphodiesterase E4 (PDE4) pathway, regulating cAMP (cAMP) levels.  This is less immunosuppressive than other pathways and has no effect on skin thinning.  The pathway interrupts the itch sensation (pruritus) which means that the itch-scratch cycle, the bane in the life of patients with AD, is interrupted, usually as early as a few days into treatment.  Hence, with the promising safety profile demonstrated, early treatment of mild to moderate AD patients might help to control AD better and improve quality of life for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowRgPjgAtPPbVg90H21EOLACvtfcHk0ljjG84ztQwJMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslOrtbY%253D&md5=7df1b340674a99a697d1329e390d71eb</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1080%2F1744666X.2017.1304820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1744666X.2017.1304820%26sid%3Dliteratum%253Aachs%26aulast%3DCheape%26aufirst%3DA.%2BC.%26aulast%3DMurrell%26aufirst%3DD.%2BF.%26atitle%3D2%2525%2520Crisaborole%2520Topical%2520Ointment%2520for%2520the%2520Treatment%2520of%2520Mild-to-Moderate%2520Atopic%2520Dermatitis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2017%26volume%3D13%26spage%3D415%26epage%3D423%26doi%3D10.1080%2F1744666X.2017.1304820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paller, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boguniewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Call, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichenfield, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsha, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spellman, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein Gold, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaenglein, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zane, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, A. A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">503.e6</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2016.05.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.jaad.2016.05.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27417017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKmtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=494-503.e6&author=A.+S.+Pallerauthor=W.+L.+Tomauthor=M.+G.+Lebwohlauthor=R.+L.+Blumenthalauthor=M.+Boguniewiczauthor=R.+S.+Callauthor=L.+F.+Eichenfieldauthor=D.+W.+Forshaauthor=W.+C.+Reesauthor=E.+L.+Simpsonauthor=M.+C.+Spellmanauthor=L.+F.+Stein+Goldauthor=A.+L.+Zaengleinauthor=M.+H.+Hughesauthor=L.+T.+Zaneauthor=A.+A.+Hebert&title=Efficacy+and+Safety+of+Crisaborole+Ointment%2C+a+Novel%2C+Nonsteroidal+Phosphodiesterase+4+%28PDE4%29+Inhibitor+for+the+Topical+Treatment+of+Atopic+Dermatitis+%28AD%29+in+Children+and+Adults&doi=10.1016%2Fj.jaad.2016.05.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults</span></div><div class="casAuthors">Paller, Amy S.; Tom, Wynnis L.; Lebwohl, Mark G.; Blumenthal, Robin L.; Boguniewicz, Mark; Call, Robert S.; Eichenfield, Lawrence F.; Forsha, Douglass W.; Rees, William C.; Simpson, Eric L.; Spellman, Mary C.; Stein Gold, Linda F.; Zaenglein, Andrea L.; Hughes, Matilda H.; Zane, Lee T.; Hebert, Adelaide A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">494-503.e6</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Addnl. topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.  We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III AD studies (AD-301: NCT02118766; AD-302: NCT02118792).  Two identically designed, vehicle-controlled, double-blind studies enrolled and randomly assigned (2:1, crisaborole:vehicle) patients aged 2 years or older with an Investigator's Static Global Assessment (ISGA) score of mild or moderate for twice-daily application for 28 days.  The primary end point was ISGA score at day 29 of clear (0)/almost clear (1) with 2-grade or greater improvement from baseline.  Addnl. analyses included time to success in ISGA score, percentage of patients achieving clear/almost clear, redn. in severity of AD signs, and time to improvement in pruritus.  More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear with ≥2-grade improvement; AD-301: 32.8% vs 25.4%, P = .038; AD-302: 31.4% vs 18.0%, P < .001), with a greater percentage with clear/almost clear (51.7% vs 40.6%, P = .005; 48.5% vs 29.7%, P < .001).  Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those treated with vehicle (both P ≤ .001).  Treatment-related adverse events were infrequent and mild to moderate in severity.  Short study duration was a limitation.  Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD4IlzODC6ebVg90H21EOLACvtfcHk0ljjG84ztQwJMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKmtbvP&md5=addbe254ce72db5ae1c96874f70ee1d0</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.05.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.05.046%26sid%3Dliteratum%253Aachs%26aulast%3DPaller%26aufirst%3DA.%2BS.%26aulast%3DTom%26aufirst%3DW.%2BL.%26aulast%3DLebwohl%26aufirst%3DM.%2BG.%26aulast%3DBlumenthal%26aufirst%3DR.%2BL.%26aulast%3DBoguniewicz%26aufirst%3DM.%26aulast%3DCall%26aufirst%3DR.%2BS.%26aulast%3DEichenfield%26aufirst%3DL.%2BF.%26aulast%3DForsha%26aufirst%3DD.%2BW.%26aulast%3DRees%26aufirst%3DW.%2BC.%26aulast%3DSimpson%26aufirst%3DE.%2BL.%26aulast%3DSpellman%26aufirst%3DM.%2BC.%26aulast%3DStein%2BGold%26aufirst%3DL.%2BF.%26aulast%3DZaenglein%26aufirst%3DA.%2BL.%26aulast%3DHughes%26aufirst%3DM.%2BH.%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DHebert%26aufirst%3DA.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Crisaborole%2520Ointment%252C%2520a%2520Novel%252C%2520Nonsteroidal%2520Phosphodiesterase%25204%2520%2528PDE4%2529%2520Inhibitor%2520for%2520the%2520Topical%2520Treatment%2520of%2520Atopic%2520Dermatitis%2520%2528AD%2529%2520in%2520Children%2520and%2520Adults%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2016%26volume%3D75%26spage%3D494%26epage%3D503.e6%26doi%3D10.1016%2Fj.jaad.2016.05.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit200a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Zhang, Y.
K.</span>; <span class="NLM_string-name">Akama, T.</span>; <span class="NLM_string-name">Jarnagin, K.</span></span> <span> </span><span class="NLM_article-title">Boron-Containing Small Molecules</span>. <span class="NLM_patent">US 8461336</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Zhou&author=Y.%0AK.+Zhang&author=T.+Akama&author=K.+Jarnagin&title=Boron-Containing+Small+Molecules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26atitle%3DBoron-Containing%2520Small%2520Molecules%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit200b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Zhang, Y. K.</span>; <span class="NLM_string-name">Akama, T.</span>; <span class="NLM_string-name">Jarnagin, K.</span></span><span> </span><span class="NLM_article-title">Preparation of 6-((Aminomethyl)phenoxy)-1,3-Dihydro-1-Hydroxybenzoxaborole Derivatives as Inhibitors of Pro-Inflammatory Cytokines and Phosphodiesterases Useful in the Treatment of Inflammatory Diseases</span>. <span class="NLM_patent">WO 2010028005</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Y.+Zhou&author=Y.+K.+Zhang&author=T.+Akama&author=K.+Jarnagin&title=Preparation+of+6-%28%28Aminomethyl%29phenoxy%29-1%2C3-Dihydro-1-Hydroxybenzoxaborole+Derivatives+as+Inhibitors+of+Pro-Inflammatory+Cytokines+and+Phosphodiesterases+Useful+in+the+Treatment+of+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26atitle%3DPreparation%2520of%25206-%2528%2528Aminomethyl%2529phenoxy%2529-1%252C3-Dihydro-1-Hydroxybenzoxaborole%2520Derivatives%2520as%2520Inhibitors%2520of%2520Pro-Inflammatory%2520Cytokines%2520and%2520Phosphodiesterases%2520Useful%2520in%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit200c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span>; <span class="NLM_string-name">Sanders, V.</span>; <span class="NLM_string-name">Akama, T.</span>; <span class="NLM_string-name">Bellinger-Kawahara, C.</span>; <span class="NLM_string-name">Freund, Y.</span>; <span class="NLM_string-name">Maples, K. R.</span>; <span class="NLM_string-name">Plattner, J. J.</span>; <span class="NLM_string-name">Zhang, Y.-K.</span>; <span class="NLM_string-name">Zhou, H.</span>; <span class="NLM_string-name">Hernandez, V. S.</span></span> <span> </span><span class="NLM_article-title">Boron-Containing Small Molecules as Anti-Inflammatory Agents</span>. <span class="NLM_patent">WO 2007095638</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+J.+Baker&author=V.+Sanders&author=T.+Akama&author=C.+Bellinger-Kawahara&author=Y.+Freund&author=K.+R.+Maples&author=J.+J.+Plattner&author=Y.-K.+Zhang&author=H.+Zhou&author=V.+S.+Hernandez&title=Boron-Containing+Small+Molecules+as+Anti-Inflammatory+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DBoron-Containing%2520Small%2520Molecules%2520as%2520Anti-Inflammatory%2520Agents%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit200d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span>; <span class="NLM_string-name">Akama, T.</span>; <span class="NLM_string-name">Alley, M. R. K.</span>; <span class="NLM_string-name">Benkovic, S. J.</span>; <span class="NLM_string-name">Dipierro, M.</span>; <span class="NLM_string-name">Hernandez, V. S.</span>; <span class="NLM_string-name">Hold, K. M.</span>; <span class="NLM_string-name">Kennedy, I.</span>; <span class="NLM_string-name">Likhotvorik, I.</span>; <span class="NLM_string-name">Mao, W.</span>; <span class="NLM_string-name">Maples, K. R.</span>; <span class="NLM_string-name">Plattner, J. J.</span>; <span class="NLM_string-name">Rock, F.</span>; <span class="NLM_string-name">Sanders, V.</span>; <span class="NLM_string-name">Stemphoski, A. M.</span>; <span class="NLM_string-name">Yiannikouros, G. P.</span>; <span class="NLM_string-name">Zegar, S.</span>; <span class="NLM_string-name">Zhang, Y.-K.</span>; <span class="NLM_string-name">Zhou, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Boron-Containing Small Molecules and Nucleosides for Treating Fungal Infections</span>. <span class="NLM_patent">WO 2007078340</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+J.+Baker&author=T.+Akama&author=M.+R.+K.+Alley&author=S.+J.+Benkovic&author=M.+Dipierro&author=V.+S.+Hernandez&author=K.+M.+Hold&author=I.+Kennedy&author=I.+Likhotvorik&author=W.+Mao&author=K.+R.+Maples&author=J.+J.+Plattner&author=F.+Rock&author=V.+Sanders&author=A.+M.+Stemphoski&author=G.+P.+Yiannikouros&author=S.+Zegar&author=Y.-K.+Zhang&author=H.+Zhou&title=Preparation+of+Boron-Containing+Small+Molecules+and+Nucleosides+for+Treating+Fungal+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DPreparation%2520of%2520Boron-Containing%2520Small%2520Molecules%2520and%2520Nucleosides%2520for%2520Treating%2520Fungal%2520Infections%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit200e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maples, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structure-Activity Study of a Novel Benzoxaborole Anti-Inflammatory Agent (AN2728) for the Potential Topical Treatment of Psoriasis and Atopic Dermatitis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmcl.2009.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=19303290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2129-2132&author=T.+Akamaauthor=S.+J.+Bakerauthor=Y.-K.+Zhangauthor=V.+Hernandezauthor=H.+Zhouauthor=V.+Sandersauthor=Y.+Freundauthor=R.+Kimuraauthor=K.+R.+Maplesauthor=J.+J.+Plattner&title=Discovery+and+Structure-Activity+Study+of+a+Novel+Benzoxaborole+Anti-Inflammatory+Agent+%28AN2728%29+for+the+Potential+Topical+Treatment+of+Psoriasis+and+Atopic+Dermatitis&doi=10.1016%2Fj.bmcl.2009.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200eR"><div class="casContent"><span class="casTitleNuber">200e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis</span></div><div class="casAuthors">Akama, Tsutomu; Baker, Stephen J.; Zhang, Yong-Kang; Hernandez, Vincent; Zhou, Huchen; Sanders, Virginia; Freund, Yvonne; Kimura, Richard; Maples, Kirk R.; Plattner, Jacob J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2129-2132</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release.  5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo.  This compd. is now in clin. development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYdD-T7O2W57Vg90H21EOLACvtfcHk0lgHny2egpEO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjsb4%253D&md5=a526278d0506fc5916432cf20c6ff5e5</span></div><a href="/servlet/linkout?suffix=cit200e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSanders%26aufirst%3DV.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DR.%26aulast%3DMaples%26aufirst%3DK.%2BR.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520and%2520Structure-Activity%2520Study%2520of%2520a%2520Novel%2520Benzoxaborole%2520Anti-Inflammatory%2520Agent%2520%2528AN2728%2529%2520for%2520the%2520Potential%2520Topical%2520Treatment%2520of%2520Psoriasis%2520and%2520Atopic%2520Dermatitis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2129%26epage%3D2132%26doi%3D10.1016%2Fj.bmcl.2009.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camaioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clerici, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span> <span> </span><span class="NLM_article-title">6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3569</span>– <span class="NLM_lpage">3572</span>, <span class="refDoi"> DOI: 10.1021/jm025529g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm025529g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVSgs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3569-3572&author=R.+Pellicciariauthor=S.+Fiorucciauthor=E.+Camaioniauthor=C.+Clericiauthor=G.+Costantinoauthor=P.+R.+Maloneyauthor=A.+Morelliauthor=D.+J.+Parksauthor=T.+M.+Willson&title=6%CE%B1-Ethyl-Chenodeoxycholic+Acid+%286-ECDCA%29%2C+a+Potent+and+Selective+FXR+Agonist+Endowed+with+Anticholestatic+Activity&doi=10.1021%2Fjm025529g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity</span></div><div class="casAuthors">Pellicciari, Roberto; Fiorucci, Stefano; Camaioni, Emidio; Clerici, Carlo; Costantino, Gabriele; Maloney, Patrick R.; Morelli, Antonio; Parks, Derek J.; Willson, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3569-3572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 6α-alkyl-substituted analogs I (R = Me, Et, Pr, Bn) of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands.  Among them, 6α-ethyl-chenodeoxycholic acid (6-ECDCA) I (R = Et) was shown to be a very potent and selective FXR agonist (EC50 = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVGesAhjDtJbVg90H21EOLACvtfcHk0lgHny2egpEO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVSgs7s%253D&md5=0b6652c1ad92eb681bf96a7df7b2d367</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm025529g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm025529g%26sid%3Dliteratum%253Aachs%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DFiorucci%26aufirst%3DS.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DClerici%26aufirst%3DC.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DMorelli%26aufirst%3DA.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26atitle%3D6%25CE%25B1-Ethyl-Chenodeoxycholic%2520Acid%2520%25286-ECDCA%2529%252C%2520a%2520Potent%2520and%2520Selective%2520FXR%2520Agonist%2520Endowed%2520with%2520Anticholestatic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3569%26epage%3D3572%26doi%3D10.1021%2Fjm025529g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowlus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Invernizzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drenth, J. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pockros, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuers, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floreani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohenester, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luketic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiffman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Erpecum, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschfield, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindor, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschall, H. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooshmand-Rad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheeron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pencek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruzanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D.</span></span> <span> </span><span class="NLM_article-title">A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1056%2FNEJMoa1509840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27532829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=631-643&author=F.+Nevensauthor=P.+Andreoneauthor=G.+Mazzellaauthor=S.+I.+Strasserauthor=C.+Bowlusauthor=P.+Invernizziauthor=J.+P.+H.+Drenthauthor=P.+J.+Pockrosauthor=J.+Regulaauthor=U.+Beuersauthor=M.+Traunerauthor=D.+E.+Jonesauthor=A.+Floreaniauthor=S.+Hohenesterauthor=V.+Luketicauthor=M.+Shiffmanauthor=K.+J.+van+Erpecumauthor=V.+Vargasauthor=C.+Vincentauthor=G.+M.+Hirschfieldauthor=H.+Shahauthor=B.+Hansenauthor=K.+D.+Lindorauthor=H.+U.+Marschallauthor=K.+V.+Kowdleyauthor=R.+Hooshmand-Radauthor=T.+Marmonauthor=S.+Sheeronauthor=R.+Pencekauthor=L.+MacConellauthor=M.+Pruzanskiauthor=D.+Shapiro&title=A+Placebo-Controlled+Trial+of+Obeticholic+Acid+in+Primary+Biliary+Cholangitis&doi=10.1056%2FNEJMoa1509840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A placebo-controlled trial of obeticholic acid in primary biliary cholangitis</span></div><div class="casAuthors">Nevens, F.; Andreone, P.; Mazzella, G.; Strasser, S. I.; Bowlus, C.; Invernizzi, P.; Drenth, J. P. H.; Pockros, P. J.; Regula, J.; Beuers, U.; Trauner, M.; Jones, D. E.; Floreani, A.; Hohenester, S.; Luketic, V.; Shiffman, M.; van Erpecum, K. J.; Vargas, V.; Vincent, C.; Hirschfield, G. M.; Shah, H.; Hansen, B.; Lindor, K. D.; Marschall, H.-U.; Kowdley, K. V.; Hooshmand-Rad, R.; Marmon, T.; Sheeron, S.; Pencek, R.; MacConell, L.; Pruzanski, M.; Shapiro, D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-643</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy.  Alk. phosphatase and bilirubin levels correlate with the risk of liver transplantation or death.  Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients with this disease.  METHODS: In this 12-mo, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a dose of 10 mg (the 10-mg group), obeticholic acid at a dose of 5 mg with adjustment to 10 mg if applicable (the 5-10-mg group), or placebo.  The primary end point was an alk. phosphatase level of less than 1.67 times the upper limit of the normal range, with a redn. of at least 15% from baseline, and a normal total bilirubin level.  RESULTS: Of 216 patients who underwent randomization and received at least one dose of obeticholic acid or placebo, 93% received ursodiol as background therapy.  The primary end point occurred in more patients in the 5-10-mg group (46%) and the 10-mg group (47%) than in the placebo group (10%; P<0.001 for both comparisons).  Patients in the 5-10-mg group and those in the 10-mg group had greater decreases than those in the placebo group in the alk. phosphatase level (least-squares mean, -113 and -130 U per L, resp., vs. -14 U per L; P<0.001 for both comparisons) and total bilirubin level (-0.02 and -0.05 mg per dL [-0.3 and -0.9 μmol per L], resp., vs. 0.12 mg per dL [2.0 μmol per L]; P<0.001 for both comparisons).  Changes in noninvasive measures of liver fibrosis did not differ significantly between either treatment group and the placebo group at 12 mo.  Pruritus was more common with obeticholic acid than with placebo (56% of patients in the 5-10-mg group and 68% of those in the 10-mg group vs. 38% in the placebo group).  The rate of serious adverse events was 16% in the 5-10-mg group, 11% in the 10-mg group, and 4% in the placebo group.  CONCLUSIONS: Obeticholic acid administered with ursodiol or as monotherapy for 12 mo in patients with primary biliary cholangitis resulted in decreases from baseline in alk. phosphatase and total bilirubin levels that differed significantly from the changes obsd. with placebo.  There were more serious adverse events with obeticholic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovAIzzX9egK7Vg90H21EOLACvtfcHk0lh-YBP4Ki5rEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7zE&md5=613ba0df3a84969560534d87de20420b</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509840%26sid%3Dliteratum%253Aachs%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DAndreone%26aufirst%3DP.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DStrasser%26aufirst%3DS.%2BI.%26aulast%3DBowlus%26aufirst%3DC.%26aulast%3DInvernizzi%26aufirst%3DP.%26aulast%3DDrenth%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DRegula%26aufirst%3DJ.%26aulast%3DBeuers%26aufirst%3DU.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DD.%2BE.%26aulast%3DFloreani%26aufirst%3DA.%26aulast%3DHohenester%26aufirst%3DS.%26aulast%3DLuketic%26aufirst%3DV.%26aulast%3DShiffman%26aufirst%3DM.%26aulast%3Dvan%2BErpecum%26aufirst%3DK.%2BJ.%26aulast%3DVargas%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DC.%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DShah%26aufirst%3DH.%26aulast%3DHansen%26aufirst%3DB.%26aulast%3DLindor%26aufirst%3DK.%2BD.%26aulast%3DMarschall%26aufirst%3DH.%2BU.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DHooshmand-Rad%26aufirst%3DR.%26aulast%3DMarmon%26aufirst%3DT.%26aulast%3DSheeron%26aufirst%3DS.%26aulast%3DPencek%26aufirst%3DR.%26aulast%3DMacConell%26aufirst%3DL.%26aulast%3DPruzanski%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DD.%26atitle%3DA%2520Placebo-Controlled%2520Trial%2520of%2520Obeticholic%2520Acid%2520in%2520Primary%2520Biliary%2520Cholangitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D631%26epage%3D643%26doi%3D10.1056%2FNEJMoa1509840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit65a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, A.</span>; <span class="NLM_string-name">Waenerlund Poulsen, H.</span>; <span class="NLM_string-name">Jolibois, E.</span>; <span class="NLM_string-name">Rewolinski, M.</span>; <span class="NLM_string-name">Gross, R.</span>; <span class="NLM_string-name">Sharp, E.</span>; <span class="NLM_string-name">Dubas-Fisher, F.</span>; <span class="NLM_string-name">Eberlin, A.</span></span> <span> </span><span class="NLM_article-title">Preparation and Uses of Obeticholic Acid</span>. <span class="NLM_patent">WO 20130345188</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+Steiner&author=H.+Waenerlund+Poulsen&author=E.+Jolibois&author=M.+Rewolinski&author=R.+Gross&author=E.+Sharp&author=F.+Dubas-Fisher&author=A.+Eberlin&title=Preparation+and+Uses+of+Obeticholic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSteiner%26aufirst%3DA.%26atitle%3DPreparation%2520and%2520Uses%2520of%2520Obeticholic%2520Acid%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit65b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span>; <span class="NLM_string-name">Pellicciari, R.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing 3a(β)-7a(β)-Dihydroxy-6a(β)-Alkyl-5β-Cholanic Acid</span>. <span class="NLM_patent">US 7994352</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Ferrari&author=R.+Pellicciari&title=Process+for+Preparing+3a%28%CE%B2%29-7a%28%CE%B2%29-Dihydroxy-6a%28%CE%B2%29-Alkyl-5%CE%B2-Cholanic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DM.%26atitle%3DProcess%2520for%2520Preparing%25203a%2528%25CE%25B2%2529-7a%2528%25CE%25B2%2529-Dihydroxy-6a%2528%25CE%25B2%2529-Alkyl-5%25CE%25B2-Cholanic%2520Acid%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Migalastat: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0607-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0607-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27351440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ksFegtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1147-1152&author=A.+Markham&title=Migalastat%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0607-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Migalastat: First Global Approval</span></div><div class="casAuthors">Markham Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1147-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Migalastat (Galafold®)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations.  Fabry disease is a rare disorder that results in a deficiency or absence of α-galactosidase, leading to accumulation of globotriaosylceramide in the lysosomes of various cells.  This article summarizes the milestones in the development of migalastat leading to this first approval in the EU for the long-term treatment of adults and adolescents aged ≥16 years with a confirmed diagnosis of Fabry disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnc_DupHv-_NK0qsdY6Nc1fW6udTcc2eYazI1LIM7GyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ksFegtA%253D%253D&md5=20fde86101e0bec10aaaeabad729f05c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0607-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0607-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DMigalastat%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1147%26epage%3D1152%26doi%3D10.1007%2Fs40265-016-0607-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, P. N.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bragat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudes, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers</span>. <i>Clin. Pharmacol. Drug Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1002/cpdd.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1002%2Fcpdd.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27121667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ymsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=120-132&author=F.+K.+Johnsonauthor=P.+N.+Muddauthor=A.+Bragatauthor=M.+Aderaauthor=P.+Boudes&title=Pharmacokinetics+and+Safety+of+Migalastat+HCl+and+Effects+on+Agalsidase+Activity+in+Healthy+Volunteers&doi=10.1002%2Fcpdd.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers</span></div><div class="casAuthors">Johnson, Franklin K.; Mudd, Paul N., Jr.; Bragat, Alexander; Adera, Mathews; Boudes, Pol</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-132</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Migalastat HCl is an investigational, oral treatment for Fabry disease, an X-linked lysosomal storage disorder.  Four Phase 1 studies were conducted to det. the pharmacokinetics, pharmacodynamics, safety, and tolerability of migalastat.  Healthy volunteers (N = 124), 18-55 years old, received migalastat HCl single (25 mg-2000 mg) or twice-daily doses (50 mg, 150 mg) for 7 days in a double-blind, placebo-controlled fashion.  Migalastat pharmacokinetics were dose-proportional (AUC∞ range: 1129-72 838 ng h/mL, Cmax range: 200.5-13844 ng/mL, t1/2 3-4 h).  Steady state was achieved by Day 7.  Up to 67% of the dose was excreted as unchanged drug in urine.  Increased α-Gal A activity was dose related.  No abnormal cardiac effects, including prolonged QTc intervals, were obsd.  The pharmacokinetics of migalastat were well characterized in these Phase 1 studies conducted healthy volunteers.  The 150 mg dose of migalastat HCl administered BID for 7 days was generally safe and well tolerated.  A TQT study demonstrated lack of a pos. signal at therapeutic and supra-therapeutic doses.  Increases in α-Gal A enzyme activity for the 150 mg dose obsd. in healthy subjects suggested a successful proof of mechanism for further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOidxYesRJHLVg90H21EOLACvtfcHk0lh-YBP4Ki5rEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ymsrrP&md5=c288f51cd7d544d8966538fdb2374e05</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.1%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DF.%2BK.%26aulast%3DMudd%26aufirst%3DP.%2BN.%26aulast%3DBragat%26aufirst%3DA.%26aulast%3DAdera%26aufirst%3DM.%26aulast%3DBoudes%26aufirst%3DP.%26atitle%3DPharmacokinetics%2520and%2520Safety%2520of%2520Migalastat%2520HCl%2520and%2520Effects%2520on%2520Agalsidase%2520Activity%2520in%2520Healthy%2520Volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Drug%2520Dev.%26date%3D2013%26volume%3D2%26spage%3D120%26epage%3D132%26doi%3D10.1002%2Fcpdd.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit68a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, M. K.</span>; <span class="NLM_string-name">Mahajan, S.</span>; <span class="NLM_string-name">Bhandya, S. R.</span>; <span class="NLM_string-name">Anish, K.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for the Preparation of 1-Deoxynojirimycin, an Intermediate of Miglitol</span>. IN 2013CH03275, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+K.+Sethi&author=S.+Mahajan&author=S.+R.+Bhandya&author=K.+Anish&title=An+Improved+Process+for+the+Preparation+of+1-Deoxynojirimycin%2C+an+Intermediate+of+Miglitol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSethi%26aufirst%3DM.%2BK.%26atitle%3DAn%2520Improved%2520Process%2520for%2520the%2520Preparation%2520of%25201-Deoxynojirimycin%252C%2520an%2520Intermediate%2520of%2520Miglitol%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit68b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myeong, I.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, W.-H.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Chirality Extension of syn,anti- and syn,syn-Oxazine and Stereochemical Analysis of Chiral 1,3-Oxazines: Stereoselective Total Syntheses of (+)-1-Deoxygalactonojirimycin and (−)-1-Deoxygulonojirimycin</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">7432</span>– <span class="NLM_lpage">7438</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.6b01079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.6b01079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=7432-7438&author=J.-S.+Kimauthor=Y.-T.+Leeauthor=K.-H.+Leeauthor=I.-S.+Myeongauthor=J.-C.+Kangauthor=C.+Jungauthor=S.-H.+Parkauthor=W.-H.+Ham&title=Stereoselective+Chirality+Extension+of+syn%2Canti-+and+syn%2Csyn-Oxazine+and+Stereochemical+Analysis+of+Chiral+1%2C3-Oxazines%3A+Stereoselective+Total+Syntheses+of+%28%2B%29-1-Deoxygalactonojirimycin+and+%28%E2%88%92%29-1-Deoxygulonojirimycin&doi=10.1021%2Facs.joc.6b01079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68b&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.6b01079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.6b01079%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.-S.%26aulast%3DLee%26aufirst%3DY.-T.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DMyeong%26aufirst%3DI.-S.%26aulast%3DKang%26aufirst%3DJ.-C.%26aulast%3DJung%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DS.-H.%26aulast%3DHam%26aufirst%3DW.-H.%26atitle%3DStereoselective%2520Chirality%2520Extension%2520of%2520syn%252Canti-%2520and%2520syn%252Csyn-Oxazine%2520and%2520Stereochemical%2520Analysis%2520of%2520Chiral%25201%252C3-Oxazines%253A%2520Stereoselective%2520Total%2520Syntheses%2520of%2520%2528%252B%2529-1-Deoxygalactonojirimycin%2520and%2520%2528%25E2%2588%2592%2529-1-Deoxygulonojirimycin%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2016%26volume%3D81%26spage%3D7432%26epage%3D7438%26doi%3D10.1021%2Facs.joc.6b01079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chacko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramapanicker, R.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective Synthesis of 1-Deoxygalactonojirimycin, 1-Deoxyaltronojirimycin, and N-Boc-(2S,3S)-3-Hydroxypipecolic Acid via Proline Catalyzed α-Aminoxylation of Aldehydes</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">4776</span>– <span class="NLM_lpage">4782</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.5b00424</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.5b00424" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2015&pages=4776-4782&author=S.+Chackoauthor=R.+Ramapanicker&title=Diastereoselective+Synthesis+of+1-Deoxygalactonojirimycin%2C+1-Deoxyaltronojirimycin%2C+and+N-Boc-%282S%2C3S%29-3-Hydroxypipecolic+Acid+via+Proline+Catalyzed+%CE%B1-Aminoxylation+of+Aldehydes&doi=10.1021%2Facs.joc.5b00424"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68c&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.5b00424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.5b00424%26sid%3Dliteratum%253Aachs%26aulast%3DChacko%26aufirst%3DS.%26aulast%3DRamapanicker%26aufirst%3DR.%26atitle%3DDiastereoselective%2520Synthesis%2520of%25201-Deoxygalactonojirimycin%252C%25201-Deoxyaltronojirimycin%252C%2520and%2520N-Boc-%25282S%252C3S%2529-3-Hydroxypipecolic%2520Acid%2520via%2520Proline%2520Catalyzed%2520%25CE%25B1-Aminoxylation%2520of%2520Aldehydes%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2015%26volume%3D80%26spage%3D4776%26epage%3D4782%26doi%3D10.1021%2Facs.joc.5b00424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Timmer, M. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangerfield, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulab, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, B. L.</span></span> <span> </span><span class="NLM_article-title">Rapid Synthesis of 1-Deoxygalactonojirimycin Using a Carbamate Annulation</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4803</span>– <span class="NLM_lpage">4805</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2011.07.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.tetlet.2011.07.044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=4803-4805&author=M.+S.+M.+Timmerauthor=E.+M.+Dangerfieldauthor=J.+M.+H.+Chengauthor=S.+A.+Gulabauthor=B.+L.+Stocker&title=Rapid+Synthesis+of+1-Deoxygalactonojirimycin+Using+a+Carbamate+Annulation&doi=10.1016%2Fj.tetlet.2011.07.044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68d&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2011.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2011.07.044%26sid%3Dliteratum%253Aachs%26aulast%3DTimmer%26aufirst%3DM.%2BS.%2BM.%26aulast%3DDangerfield%26aufirst%3DE.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%2BM.%2BH.%26aulast%3DGulab%26aufirst%3DS.%2BA.%26aulast%3DStocker%26aufirst%3DB.%2BL.%26atitle%3DRapid%2520Synthesis%2520of%25201-Deoxygalactonojirimycin%2520Using%2520a%2520Carbamate%2520Annulation%26jtitle%3DTetrahedron%2520Lett.%26date%3D2011%26volume%3D52%26spage%3D4803%26epage%3D4805%26doi%3D10.1016%2Fj.tetlet.2011.07.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkinson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleet, G. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, A.</span></span> <span> </span><span class="NLM_article-title">Looking-Glass Synergistic Pharmacological Chaperones: DGJ and L-DGJ from the Enantiomers of Tagatose</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4064</span>– <span class="NLM_lpage">4067</span>, <span class="refDoi"> DOI: 10.1021/ol201552q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol201552q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=4064-4067&author=S.+F.+Jenkinsonauthor=G.+W.+J.+Fleetauthor=R.+J.+Nashauthor=Y.+Koikeauthor=I.+Adachiauthor=A.+Yoshiharaauthor=K.+Morimotoauthor=K.+Izumoriauthor=A.+Kato&title=Looking-Glass+Synergistic+Pharmacological+Chaperones%3A+DGJ+and+L-DGJ+from+the+Enantiomers+of+Tagatose&doi=10.1021%2Fol201552q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68e&amp;dbid=16384&amp;doi=10.1021%2Fol201552q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol201552q%26sid%3Dliteratum%253Aachs%26aulast%3DJenkinson%26aufirst%3DS.%2BF.%26aulast%3DFleet%26aufirst%3DG.%2BW.%2BJ.%26aulast%3DNash%26aufirst%3DR.%2BJ.%26aulast%3DKoike%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DI.%26aulast%3DYoshihara%26aufirst%3DA.%26aulast%3DMorimoto%26aufirst%3DK.%26aulast%3DIzumori%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DA.%26atitle%3DLooking-Glass%2520Synergistic%2520Pharmacological%2520Chaperones%253A%2520DGJ%2520and%2520L-DGJ%2520from%2520the%2520Enantiomers%2520of%2520Tagatose%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D4064%26epage%3D4067%26doi%3D10.1021%2Fol201552q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schitter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheucher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuetz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thonhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarling, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Withers, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahuran, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigat, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrodnigg, T. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Lipophilic 1-Deoxygalactonojirimycin Derivatives as D-Galactosidase Inhibitors</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">No 21</span>),  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.3762/bjoc.6.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.3762%2Fbjoc.6.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=20485585" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=1&issue=No+21&author=G.+Schitterauthor=E.+Scheucherauthor=A.+J.+Steinerauthor=A.+E.+Stuetzauthor=M.+Thonhoferauthor=C.+A.+Tarlingauthor=S.+G.+Withersauthor=J.+Wickiauthor=K.+Fanturauthor=E.+Paschkeauthor=D.+J.+Mahuranauthor=B.+A.+Rigatauthor=M.+Tropakauthor=T.+M.+Wrodnigg&title=Synthesis+of+Lipophilic+1-Deoxygalactonojirimycin+Derivatives+as+D-Galactosidase+Inhibitors&doi=10.3762%2Fbjoc.6.21"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68f&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.6.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.6.21%26sid%3Dliteratum%253Aachs%26aulast%3DSchitter%26aufirst%3DG.%26aulast%3DScheucher%26aufirst%3DE.%26aulast%3DSteiner%26aufirst%3DA.%2BJ.%26aulast%3DStuetz%26aufirst%3DA.%2BE.%26aulast%3DThonhofer%26aufirst%3DM.%26aulast%3DTarling%26aufirst%3DC.%2BA.%26aulast%3DWithers%26aufirst%3DS.%2BG.%26aulast%3DWicki%26aufirst%3DJ.%26aulast%3DFantur%26aufirst%3DK.%26aulast%3DPaschke%26aufirst%3DE.%26aulast%3DMahuran%26aufirst%3DD.%2BJ.%26aulast%3DRigat%26aufirst%3DB.%2BA.%26aulast%3DTropak%26aufirst%3DM.%26aulast%3DWrodnigg%26aufirst%3DT.%2BM.%26atitle%3DSynthesis%2520of%2520Lipophilic%25201-Deoxygalactonojirimycin%2520Derivatives%2520as%2520D-Galactosidase%2520Inhibitors%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2010%26volume%3D6%26issue%3DNo%252021%26spage%3D1%26doi%3D10.3762%2Fbjoc.6.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gandy, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piggott, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span> <span> </span><span class="NLM_article-title">An Expeditious Synthesis of Iminosugars</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1071/CH10211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1071%2FCH10211" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2010&pages=1409-1412&author=M.+N.+Gandyauthor=M.+J.+Piggottauthor=K.+A.+Stubbs&title=An+Expeditious+Synthesis+of+Iminosugars&doi=10.1071%2FCH10211"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68g&amp;dbid=16384&amp;doi=10.1071%2FCH10211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1071%252FCH10211%26sid%3Dliteratum%253Aachs%26aulast%3DGandy%26aufirst%3DM.%2BN.%26aulast%3DPiggott%26aufirst%3DM.%2BJ.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26atitle%3DAn%2520Expeditious%2520Synthesis%2520of%2520Iminosugars%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2010%26volume%3D63%26spage%3D1409%26epage%3D1412%26doi%3D10.1071%2FCH10211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.-C.</span></span> <span> </span><span class="NLM_article-title">Straightforward Synthesis of Diverse 1-Deoxyazapyranosides via Stereocontrolled Nucleophilic Additions to Six-Membered Cyclic Nitrones</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">5555</span>– <span class="NLM_lpage">5559</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201001045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1002%2Fejoc.201001045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=5555-5559&author=T.-H.+Chanauthor=Y.-F.+Changauthor=J.-J.+Hsuauthor=W.-C.+Cheng&title=Straightforward+Synthesis+of+Diverse+1-Deoxyazapyranosides+via+Stereocontrolled+Nucleophilic+Additions+to+Six-Membered+Cyclic+Nitrones&doi=10.1002%2Fejoc.201001045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68h&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201001045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201001045%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DT.-H.%26aulast%3DChang%26aufirst%3DY.-F.%26aulast%3DHsu%26aufirst%3DJ.-J.%26aulast%3DCheng%26aufirst%3DW.-C.%26atitle%3DStraightforward%2520Synthesis%2520of%2520Diverse%25201-Deoxyazapyranosides%2520via%2520Stereocontrolled%2520Nucleophilic%2520Additions%2520to%2520Six-Membered%2520Cyclic%2520Nitrones%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2010%26volume%3D2010%26spage%3D5555%26epage%3D5559%26doi%3D10.1002%2Fejoc.201001045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Stuetz, A.</span>; <span class="NLM_string-name">Steiner, A.</span>; <span class="NLM_string-name">Wrodnigg, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imino-Sugar Glycopeptide Conjugates via Catalytic Intramolecular Reductive Amination Reaction</span>. <span class="NLM_patent">EP 1903034</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=A.+Stuetz&author=A.+Steiner&author=T.+Wrodnigg&title=Preparation+of+Imino-Sugar+Glycopeptide+Conjugates+via+Catalytic+Intramolecular+Reductive+Amination+Reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68i&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStuetz%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Imino-Sugar%2520Glycopeptide%2520Conjugates%2520via%2520Catalytic%2520Intramolecular%2520Reductive%2520Amination%2520Reaction%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit68j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, H.</span>; <span class="NLM_string-name">Toyota, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-Deoxygalactonojirimycin and its Intermediates</span>. <span class="NLM_patent">JP 2007055960</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=H.+Nagai&author=A.+Toyota&title=Preparation+of+1-Deoxygalactonojirimycin+and+its+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagai%26aufirst%3DH.%26atitle%3DPreparation%2520of%25201-Deoxygalactonojirimycin%2520and%2520its%2520Intermediates%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit68k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, H.</span>; <span class="NLM_string-name">Toyota, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-Deoxygalactonojirimycin and their Intermediates</span>. <span class="NLM_patent">JP 2007055961</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=H.+Nagai&author=A.+Toyota&title=Preparation+of+1-Deoxygalactonojirimycin+and+their+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68k&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagai%26aufirst%3DH.%26atitle%3DPreparation%2520of%25201-Deoxygalactonojirimycin%2520and%2520their%2520Intermediates%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit68l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, O. R.</span></span> <span> </span><span class="NLM_article-title">A Stereo-Divergent Approach to 1-Deoxynojirimycin, 1-Deoxygalactonojirimycin and 1-Deoxymannojirimycin Derivatives</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3081</span>– <span class="NLM_lpage">3084</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2006.02.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.tetlet.2006.02.157" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=3081-3084&author=C.+Boucheronauthor=P.+Compainauthor=O.+R.+Martin&title=A+Stereo-Divergent+Approach+to+1-Deoxynojirimycin%2C+1-Deoxygalactonojirimycin+and+1-Deoxymannojirimycin+Derivatives&doi=10.1016%2Fj.tetlet.2006.02.157"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68l&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2006.02.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2006.02.157%26sid%3Dliteratum%253Aachs%26aulast%3DBoucheron%26aufirst%3DC.%26aulast%3DCompain%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DO.%2BR.%26atitle%3DA%2520Stereo-Divergent%2520Approach%2520to%25201-Deoxynojirimycin%252C%25201-Deoxygalactonojirimycin%2520and%25201-Deoxymannojirimycin%2520Derivatives%26jtitle%3DTetrahedron%2520Lett.%26date%3D2006%26volume%3D47%26spage%3D3081%26epage%3D3084%26doi%3D10.1016%2Fj.tetlet.2006.02.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pyun, S.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, C.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, W.</span></span> <span> </span><span class="NLM_article-title">-h. Synthesis of (+)-1-Deoxygalactonojirimycin</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.3987/COM-03-S(P)12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.3987%2FCOM-03-S%28P%2912" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2004&pages=333-341&author=S.-j.+Pyunauthor=K.-y.+Leeauthor=C.-y.+Ohauthor=W.+Ham&title=-h.+Synthesis+of+%28%2B%29-1-Deoxygalactonojirimycin&doi=10.3987%2FCOM-03-S%28P%2912"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68m&amp;dbid=16384&amp;doi=10.3987%2FCOM-03-S%28P%2912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-03-S%2528P%252912%26sid%3Dliteratum%253Aachs%26aulast%3DPyun%26aufirst%3DS.-j.%26aulast%3DLee%26aufirst%3DK.-y.%26aulast%3DOh%26aufirst%3DC.-y.%26aulast%3DHam%26aufirst%3DW.%26atitle%3D-h.%2520Synthesis%2520of%2520%2528%252B%2529-1-Deoxygalactonojirimycin%26jtitle%3DHeterocycles%26date%3D2004%26volume%3D62%26spage%3D333%26epage%3D341%26doi%3D10.3987%2FCOM-03-S%28P%2912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. V.</span></span> <span> </span><span class="NLM_article-title">A General Synthesis of Iminosugars</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">3565</span>– <span class="NLM_lpage">3568</span>, <span class="refDoi"> DOI: 10.1021/jo035763u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo035763u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3565-3568&author=C.+McDonnellauthor=L.+Croninauthor=J.+L.+O%E2%80%99Brienauthor=P.+V.+Murphy&title=A+General+Synthesis+of+Iminosugars&doi=10.1021%2Fjo035763u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68n&amp;dbid=16384&amp;doi=10.1021%2Fjo035763u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo035763u%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DC.%26aulast%3DCronin%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DP.%2BV.%26atitle%3DA%2520General%2520Synthesis%2520of%2520Iminosugars%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3565%26epage%3D3568%26doi%3D10.1021%2Fjo035763u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (+)-Galactostatin and (+)-1-Deoxygalactostatin Utilizing L-Quebrachitol as a Chiral Building Block</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1248</span>, <span class="refDoi"> DOI: 10.1039/c39940001247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68o&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1039%2Fc39940001247" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&pages=1247-1248&author=N.+Chidaauthor=T.+Tanikawaauthor=T.+Tobeauthor=S.+Ogawa&title=Synthesis+of+%28%2B%29-Galactostatin+and+%28%2B%29-1-Deoxygalactostatin+Utilizing+L-Quebrachitol+as+a+Chiral+Building+Block&doi=10.1039%2Fc39940001247"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68o&amp;dbid=16384&amp;doi=10.1039%2Fc39940001247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39940001247%26sid%3Dliteratum%253Aachs%26aulast%3DChida%26aufirst%3DN.%26aulast%3DTanikawa%26aufirst%3DT.%26aulast%3DTobe%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520%2528%252B%2529-Galactostatin%2520and%2520%2528%252B%2529-1-Deoxygalactostatin%2520Utilizing%2520L-Quebrachitol%2520as%2520a%2520Chiral%2520Building%2520Block%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1994%26spage%3D1247%26epage%3D1248%26doi%3D10.1039%2Fc39940001247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit68p"><span><span class="NLM_label">(p) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Legler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 5-Amino-5-Deoxy-D-Galactopyranose and 1,5-Dideoxy-1,5-Imino-D-Galactitol, and their Inhibition of Alpha- and Beta-D-Galactosidases</span>. <i>Carbohydr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/S0008-6215(00)90138-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68p&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS0008-6215%2800%2990138-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1986&pages=119-129&author=G.+Leglerauthor=S.+Pohl&title=Synthesis+of+5-Amino-5-Deoxy-D-Galactopyranose+and+1%2C5-Dideoxy-1%2C5-Imino-D-Galactitol%2C+and+their+Inhibition+of+Alpha-+and+Beta-D-Galactosidases&doi=10.1016%2FS0008-6215%2800%2990138-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68p&amp;dbid=16384&amp;doi=10.1016%2FS0008-6215%2800%2990138-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6215%252800%252990138-1%26sid%3Dliteratum%253Aachs%26aulast%3DLegler%26aufirst%3DG.%26aulast%3DPohl%26aufirst%3DS.%26atitle%3DSynthesis%2520of%25205-Amino-5-Deoxy-D-Galactopyranose%2520and%25201%252C5-Dideoxy-1%252C5-Imino-D-Galactitol%252C%2520and%2520their%2520Inhibition%2520of%2520Alpha-%2520and%2520Beta-D-Galactosidases%26jtitle%3DCarbohydr.%2520Res.%26date%3D1986%26volume%3D155%26spage%3D119%26epage%3D129%26doi%3D10.1016%2FS0008-6215%2800%2990138-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Ruiz, E.</span>; <span class="NLM_string-name">Collis, A. J.</span>; <span class="NLM_string-name">Dann, A. S.</span>; <span class="NLM_string-name">Fosberry, A. P.</span>; <span class="NLM_string-name">Ready, S. J.</span>; <span class="NLM_string-name">Vazquez Muniz, M. J.</span></span> <span> </span><span class="NLM_article-title">Fermentative Prodn. of Migalastat</span>. <span class="NLM_patent">WO 2015121488</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=E.+Alvarez-Ruiz&author=A.+J.+Collis&author=A.+S.+Dann&author=A.+P.+Fosberry&author=S.+J.+Ready&author=M.+J.+Vazquez+Muniz&title=Fermentative+Prodn.+of+Migalastat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Ruiz%26aufirst%3DE.%26atitle%3DFermentative%2520Prodn.%2520of%2520Migalastat%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uriel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoyo-Gonzalez, F.</span></span> <span> </span><span class="NLM_article-title">A Short and Efficient Synthesis of 1,5-Dideoxy-1,5-Imino-D-Galactitol (1-Deoxy-D-Galactostatin) and 1,5-Dideoxy-1,5-Imino-L-Altritol (1-Deoxy-L-Altrostatin) from D-Galactose</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>1999</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1055/s-1999-3158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1055%2Fs-1999-3158" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1999&publication_year=1999&pages=593-595&author=C.+Urielauthor=F.+Santoyo-Gonzalez&title=A+Short+and+Efficient+Synthesis+of+1%2C5-Dideoxy-1%2C5-Imino-D-Galactitol+%281-Deoxy-D-Galactostatin%29+and+1%2C5-Dideoxy-1%2C5-Imino-L-Altritol+%281-Deoxy-L-Altrostatin%29+from+D-Galactose&doi=10.1055%2Fs-1999-3158"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1055%2Fs-1999-3158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1999-3158%26sid%3Dliteratum%253Aachs%26aulast%3DUriel%26aufirst%3DC.%26aulast%3DSantoyo-Gonzalez%26aufirst%3DF.%26atitle%3DA%2520Short%2520and%2520Efficient%2520Synthesis%2520of%25201%252C5-Dideoxy-1%252C5-Imino-D-Galactitol%2520%25281-Deoxy-D-Galactostatin%2529%2520and%25201%252C5-Dideoxy-1%252C5-Imino-L-Altritol%2520%25281-Deoxy-L-Altrostatin%2529%2520from%2520D-Galactose%26jtitle%3DSynlett%26date%3D1999%26volume%3D1999%26spage%3D593%26epage%3D595%26doi%3D10.1055%2Fs-1999-3158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit71a"><span><span class="NLM_label">(a) </span> <a href="https://www.boehringer-ingelheim.com/press-release/south-korea-first-approve-next-generation-lung-cancer" class="extLink">https://www.boehringer-ingelheim.com/press-release/south-korea-first-approve-next-generation-lung-cancer</a> (accessed July 18, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+https%3A%2F%2Fwww.boehringer-ingelheim.com%2Fpress-release%2Fsouth-korea-first-approve-next-generation-lung-cancer+%28accessed+July+18%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit71b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1157</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0606-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0606-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27357069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1153-1157&author=E.+S.+Kim&title=Olmutinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0606-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71bR"><div class="casContent"><span class="casTitleNuber">71b</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1157</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co.  Ltd for the treatment of non-small cell lung cancer (NSCLC).  Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.  In Dec. 2015, olmutinib was granted breakthrough therapy designation in NSCLC by the US FDA.  In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-pos. NSCLC.  This article summarizes the milestones in the development of olmutinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY-HbqvpWrrVg90H21EOLACvtfcHk0lj3prDUzGnEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP&md5=749828b58c3a4ce11f607c2dcfef6b9c</span></div><a href="/servlet/linkout?suffix=cit71b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0606-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0606-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DOlmutinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1153%26epage%3D1157%26doi%3D10.1007%2Fs40265-016-0606-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit72a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer: Comparative Pharmacokinetics and Drug-Drug Interactions</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.ctrv.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25027951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=917-926&author=S.+Petersauthor=S.+Zimmermannauthor=A.+A.+Adjei&title=Oral+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+for+the+Treatment+of+Non-Small+Cell+Lung+Cancer%3A+Comparative+Pharmacokinetics+and+Drug-Drug+Interactions&doi=10.1016%2Fj.ctrv.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72aR"><div class="casContent"><span class="casTitleNuber">72a</span><div class="casTitle"><span class="NLM_cas:atitle">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions</span></div><div class="casAuthors">Peters, Solange; Zimmermann, Stefan; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of orally active small mol. inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC).  Patients with activating mutations of the EGFR gene show sensitivity to, and clin. benefit from, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls).  First generation reversible ATP-competitive EGFR-TKls, gefitinib and erlotinib, are effective as first, second-line or maintenance therapy.  Despite initial benefit, most patients develop resistance within a year, 50-60% of cases being related to the appearance of a T790M gatekeeper mutation.  Newer, irreversible EGFR-TKls - afatinib and dacomitinib - covalently bind to and inhibit multiple receptors in the ErbB family (EGFR, HER2 and HER4).  These agents have been mainly evaluated for first-line treatment but also in the setting of acquired resistance to first-generation EGFR-TKls.  Afatinib is the first ErbB family blocker approved for patients with NSCLC with activating EGFR mutations; dacomitinib is in late stage clin. development.  Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development.  The EGFR-TKIs differ in their spectrum of target kinases, reversibility of binding to EGFR receptor, pharmacokinetics and potential for drug-drug interactions, as discussed in this review.  For the clinician, these differences are relevant in the setting of polymedicated patients with NSCLC, as well as from the perspective of innovative anticancer drug combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFElQmV4ha7Vg90H21EOLACvtfcHk0lj3prDUzGnEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP&md5=31253f81e203aa012a5d87ad29ff6fc3</span></div><a href="/servlet/linkout?suffix=cit72a&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DOral%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Comparative%2520Pharmacokinetics%2520and%2520Drug-Drug%2520Interactions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.ctrv.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit72b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacey, S.</span></span> <span> </span><span class="NLM_article-title">Treatment Approaches for EGFR-Inhibitor-Resistant Patients with Non-Small-Cell Lung Cancer</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">e447</span>– <span class="NLM_lpage">e459</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00246-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS1470-2045%2815%2900246-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=26370354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOntLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=e447-e459&author=C.-S.+Tanauthor=D.+Gilliganauthor=S.+Pacey&title=Treatment+Approaches+for+EGFR-Inhibitor-Resistant+Patients+with+Non-Small-Cell+Lung+Cancer&doi=10.1016%2FS1470-2045%2815%2900246-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72bR"><div class="casContent"><span class="casTitleNuber">72b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer</span></div><div class="casAuthors">Tan, Chee-Seng; Gilligan, David; Pacey, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e447-e459</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of patients with advanced EGFR-mutant non-small-cell lung cancer (NSCLC).  At present, first-line treatment with EGFR TKIs (gefitinib, erlotinib, and afatinib) has been approved for patients harbouring exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations.  These agents improve response rates, time to progression, and overall survival.  Unfortunately, patients develop resistance, limiting patient benefit and posing a challenge to oncologists.  Optimum treatment after progression is not clearly defined.  A more detailed understanding of the biol. of EGFR-mutant NSCLC and the mechanisms of resistance to targeted therapy mean that an era of treatment approaches based on rationally developed drugs or therapeutic strategies has begun.  Combination approaches-eg, dual EGFR blockade-to overcome resistance have been trialled and seem to be promising but are potentially limited by toxicity.  Third-generation EGFR-mutant-selective TKIs, such as AZD9291 or rociletininb, which target Thr790Met-mutant tumors, the most common mechanism of EGFR TKI resistance, have entered clin. trials, and exciting, albeit preliminary, efficacy data have been reported.  In this Review, we summarise the scientific literature and evidence on therapy options after EGFR TKI treatment for patients with NSCLC, aiming to provide a guide to oncologists, and consider how to maximise therapeutic advances in outcomes in this rapidly advancing area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CJqM1DDS3rVg90H21EOLACvtfcHk0lj3prDUzGnEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOntLjM&md5=1e04e573a62e12a4abeb88e0c4f8acb2</span></div><a href="/servlet/linkout?suffix=cit72b&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900246-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900246-6%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DC.-S.%26aulast%3DGilligan%26aufirst%3DD.%26aulast%3DPacey%26aufirst%3DS.%26atitle%3DTreatment%2520Approaches%2520for%2520EGFR-Inhibitor-Resistant%2520Patients%2520with%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3De447%26epage%3De459%26doi%3D10.1016%2FS1470-2045%2815%2900246-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">Recent Updates on Third Generation EGFR Inhibitors and Emergence of Fourth Generation EGFR Inhibitors to Combat C797S Resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.ejmech.2017.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28526474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=32-47&author=H.+Patelauthor=R.+Pawaraauthor=A.+Ansariauthor=S.+Surana&title=Recent+Updates+on+Third+Generation+EGFR+Inhibitors+and+Emergence+of+Fourth+Generation+EGFR+Inhibitors+to+Combat+C797S+Resistance&doi=10.1016%2Fj.ejmech.2017.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span></div><div class="casAuthors">Patel, Harun; Pawara, Rahul; Ansari, Azim; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  EGFR T790M mutation leads to resistance to most of clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development, which includes osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  On the other hand recently EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third generation inhibitors.  This review summarizes the third generation inhibitors, synthesis, their mechanism of resistance and latest development on the discovery of a fourth-generation EGFR TKIs and U to Y allosteric strategies to combat the C797S EGFR resistance problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprj-V5hUSHGrVg90H21EOLACvtfcHk0lg_xc50S0LiZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D&md5=d0ed35bc7deae5ea37a95910df356c1d</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DRecent%2520Updates%2520on%2520Third%2520Generation%2520EGFR%2520Inhibitors%2520and%2520Emergence%2520of%2520Fourth%2520Generation%2520EGFR%2520Inhibitors%2520to%2520Combat%2520C797S%2520Resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D142%26spage%3D32%26epage%3D47%26doi%3D10.1016%2Fj.ejmech.2017.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit74a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cha, M. Y.</span>; <span class="NLM_string-name">Kang, S. J.</span>; <span class="NLM_string-name">Kim, M. R.</span>; <span class="NLM_string-name">Lee, J. Y.</span>; <span class="NLM_string-name">Jeon, J. Y.</span>; <span class="NLM_string-name">Jo, M. G.</span>; <span class="NLM_string-name">Kwak, E. J.</span>; <span class="NLM_string-name">Lee, K. O.</span>; <span class="NLM_string-name">Ha, T. H.</span>; <span class="NLM_string-name">Suh, K. H.</span>; <span class="NLM_string-name">Kim, M. S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Novel Fused Pyrimidine Derivatives for Inhibition of Tyrosine Kinase Activity</span>. <span class="NLM_patent">WO 2011162515</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Y.+Cha&author=S.+J.+Kang&author=M.+R.+Kim&author=J.+Y.+Lee&author=J.+Y.+Jeon&author=M.+G.+Jo&author=E.+J.+Kwak&author=K.+O.+Lee&author=T.+H.+Ha&author=K.+H.+Suh&author=M.+S.+Kim&title=Preparation+of+Novel+Fused+Pyrimidine+Derivatives+for+Inhibition+of+Tyrosine+Kinase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26atitle%3DPreparation%2520of%2520Novel%2520Fused%2520Pyrimidine%2520Derivatives%2520for%2520Inhibition%2520of%2520Tyrosine%2520Kinase%2520Activity%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit74b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baek, J. O.</span>; <span class="NLM_string-name">Jung, J. H.</span>; <span class="NLM_string-name">Kim, H. S.</span>; <span class="NLM_string-name">Ha, T.
H.</span>; <span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Thienopyrimidine Compound and Intermediates Thereof</span>. <span class="NLM_patent">WO 2016108623</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+O.+Baek&author=J.+H.+Jung&author=H.+S.+Kim&author=T.%0AH.+Ha&author=K.+H.+Suh&title=Process+for+Preparation+of+Thienopyrimidine+Compound+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaek%26aufirst%3DJ.%2BO.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Thienopyrimidine%2520Compound%2520and%2520Intermediates%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, W.</span>; <span class="NLM_string-name">Moon, Y.
H.</span>; <span class="NLM_string-name">Ha, T. H.</span>; <span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of Thienopyrimidine Compound and Intermediates Thereof</span>. <span class="NLM_patent">WO 2017074147</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=W.+Jang&author=Y.%0AH.+Moon&author=T.+H.+Ha&author=K.+H.+Suh&title=Method+for+the+Preparation+of+Thienopyrimidine+Compound+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DW.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%2520Thienopyrimidine%2520Compound%2520and%2520Intermediates%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Rucaparib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0716-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-017-0716-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28247266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFGru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=585-592&author=Y.+Y.+Syed&title=Rucaparib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0716-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Rucaparib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">585-592</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Rucaparib (Rubraca) is an oral, small mol., poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncol., Inc.  (Boulder, CO, USA) for the treatment of solid tumors.  It has been approved in the USA as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) assocd. advanced ovarian cancer who have been treated with two or more chemotherapies.  A marketing authorization application for rucaparib for the same indication has been submitted to the European Medicines Agency.  Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer.  This article summarizes the milestones in the development of rucaparib leading to this first approval for ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjcxvUxCoC_LVg90H21EOLACvtfcHk0lg_xc50S0LiZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFGru7w%253D&md5=3e79c0e50599d5f1916765b506517b18</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0716-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0716-2%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DRucaparib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D585%26epage%3D592%26doi%3D10.1007%2Fs40265-017-0716-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit77"><span><a href="http://clovisoncology.com/files/rubraca-prescribing-info.pdf" class="extLink">http://clovisoncology.com/files/rubraca-prescribing-info.pdf</a> (accessed July 22, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fclovisoncology.com%2Ffiles%2Frubraca-prescribing-info.pdf+%28accessed+July+22%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Rucaparib and Companion Diagnostics in the PARP Inhibitor Landscape for Recurrent Ovarian Cancer Therapy</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.2217/fon-2016-0002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2217%2Ffon-2016-0002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27087632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVSqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1439-1456&author=Z.+B.+Jennerauthor=A.+K.+Soodauthor=R.+L.+Coleman&title=Evaluation+of+Rucaparib+and+Companion+Diagnostics+in+the+PARP+Inhibitor+Landscape+for+Recurrent+Ovarian+Cancer+Therapy&doi=10.2217%2Ffon-2016-0002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy</span></div><div class="casAuthors">Jenner, Zachary B.; Sood, Anil K.; Coleman, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1456</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Rucaparib camsylate (CO-338; 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid salt) is a PARP1, 2 and 3 inhibitor.  Phase I studies identified a recommended Phase II dose of 600 mg orally twice daily.  ARIEL2 Part 1 established a tumor genomic profiling test for homologous recombination loss of heterozygosity quantification using a next-generation sequencing companion diagnostic (CDx).  Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.  Comparable to rucaparib development, other PARP inhibitors, such as olaparib, niraparib, veliparib and talazoparib, are developing CDx tests for targeted therapy.  PARP inhibitor clin. trials and CDx assays are discussed in this review, as are potential PARP inhibitor combination therapies and likely resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrADXfrLLTKLVg90H21EOLACvtfcHk0lg_xc50S0LiZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVSqt7k%253D&md5=1d4258979dbc52465ac599266091bb99</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2217%2Ffon-2016-0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2016-0002%26sid%3Dliteratum%253Aachs%26aulast%3DJenner%26aufirst%3DZ.%2BB.%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26atitle%3DEvaluation%2520of%2520Rucaparib%2520and%2520Companion%2520Diagnostics%2520in%2520the%2520PARP%2520Inhibitor%2520Landscape%2520for%2520Recurrent%2520Ovarian%2520Cancer%2520Therapy%26jtitle%3DFuture%2520Oncol.%26date%3D2016%26volume%3D12%26spage%3D1439%26epage%3D1456%26doi%3D10.2217%2Ffon-2016-0002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1158%2F1535-7163.MCT-13-0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24356813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=433-443&author=J.+Muraiauthor=S.-Y.+N.+Huangauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+Jiauthor=S.+Takedaauthor=J.+Morrisauthor=B.+Teicherauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Stereospecific+PARP+Trapping+by+BMN+673+and+Comparison+with+Olaparib+and+Rucaparib&doi=10.1158%2F1535-7163.MCT-13-0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-Yin N.; Renaud, Amelie; Zhang, Yiping; Ji, Jiuping; Takeda, Shunichi; Morris, Joel; Teicher, Beverly; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks.  We recently reported that several PARP inhibitors have an addnl. cytotoxic mechanism by trapping PARP-DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacol. concns.  Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP-DNA trapping.  Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clin. PARP inhibitors, olaparib and rucaparib, using biochem. and cellular assays in genetically modified chicken DT40 and human cancer cell lines.  Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP-DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP-DNA complexes.  The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2.  Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient.  BMN 673 is also approx. 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents Me methane sulfonate (MMS) and temozolomide.  Our study demonstrates that BMN 673 is the most potent clin. PARP inhibitor tested to date with the highest efficiency at trapping PARP-DNA complexes.  Mol Cancer Ther; 13(2); 433-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8p5YTwAneh7Vg90H21EOLACvtfcHk0ljYv_dg3AG93Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D&md5=513c544d1cb5c2203e7696af76201afd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0803%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.-Y.%2BN.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DStereospecific%2520PARP%2520Trapping%2520by%2520BMN%2520673%2520and%2520Comparison%2520with%2520Olaparib%2520and%2520Rucaparib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D433%26epage%3D443%26doi%3D10.1158%2F1535-7163.MCT-13-0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kern, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalinsky, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. D.</span></span> <span> </span><span class="NLM_article-title">Comparative PARP Enzyme Inhibition of PF-01367338, Olaparib, and MK-4827</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">e13552</span>, <span class="refDoi"> DOI: 10.1200/jco.2011.29.15_suppl.e13552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1200%2Fjco.2011.29.15_suppl.e13552" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=e13552&author=K.+A.+Kernauthor=S.+Zhangauthor=D.+R.+Shalinskyauthor=D.+D.+Wang&title=Comparative+PARP+Enzyme+Inhibition+of+PF-01367338%2C+Olaparib%2C+and+MK-4827&doi=10.1200%2Fjco.2011.29.15_suppl.e13552"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.29.15_suppl.e13552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.29.15_suppl.e13552%26sid%3Dliteratum%253Aachs%26aulast%3DKern%26aufirst%3DK.%2BA.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DD.%2BD.%26atitle%3DComparative%2520PARP%2520Enzyme%2520Inhibition%2520of%2520PF-01367338%252C%2520Olaparib%252C%2520and%2520MK-4827%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3De13552%26doi%3D10.1200%2Fjco.2011.29.15_suppl.e13552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telfer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCrudden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamjoo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. J.</span></span> <span> </span><span class="NLM_article-title">Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6106</span>– <span class="NLM_lpage">6112</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1158%2F1078-0432.CCR-09-0398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=19789326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2lur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6106-6112&author=M.+Aliauthor=B.+A.+Telferauthor=C.+McCruddenauthor=M.+O%E2%80%99Rourkeauthor=H.+D.+Thomasauthor=M.+Kamjooauthor=S.+Kyleauthor=T.+Robsonauthor=C.+Shawauthor=D.+G.+Hirstauthor=N.+J.+Curtinauthor=K.+J.+Williams&title=Vasoactivity+of+AG014699%2C+a+Clinically+Active+Small+Molecule+Inhibitor+of+Poly%28ADP-ribose%29+Polymerase%3A+a+Contributory+Factor+to+Chemopotentiation+In+vivo%3F&doi=10.1158%2F1078-0432.CCR-09-0398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?</span></div><div class="casAuthors">Ali, Majid; Telfer, Brian A.; McCrudden, Cian; O'Rourke, Martin; Thomas, Huw D.; Kamjoo, Marzieh; Kyle, Suzanne; Robson, Tracy; Shaw, Chris; Hirst, David G.; Curtin, Nicola J.; Williams, Kaye J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6106-6112</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP) plays an important role in DNA repair, and PARP inhibitors can enhance the activity of DNA-damaging agents in vitro and in vivo.  AG014699 is a potent PARP inhibitor in phase II clin. development.  However, the range of therapeutics with which AG014699 could interact via a DNA-repair based mechanism is limited.  We aimed to investigate a novel, vascular-based activity of AG014699, underlying in vivo chemosensitization, which could widen its clin. application.  Temozolomide response was analyzed in vitro and in vivo.  Vessel dynamics were monitored using "mismatch" following the administration of perfusion markers and real-time anal. of fluorescently labeled albumin uptake in to tumors established in dorsal window chambers.  Further mechanistic investigations used ex vivo assays of vascular smooth muscle relaxation, gut motility, and myosin light chain kinase (MLCK) inhibition.  AG014699 failed to sensitize SW620 cells to temozolomide in vitro but induced pronounced enhancement in vivo.  AG014699 (1 mg/kg) improved tumor perfusion comparably with the control agents nicotinamide (1 g/kg) and AG14361 (forerunner to AG014699; 10 mg/kg).  AG014699 and AG14361 relaxed preconstricted vascular smooth muscle more potently than the std. agent, hydralazine, with no impact on gut motility.  AG014699 inhibited MLCK at concns. that relaxed isolated arteries, whereas AG14361 had no effect.  Increased vessel perfusion elicited by AG014699 could increase tumor drug accumulation and therapeutic response.  Vasoactive concns. of AG014699 do not cause detrimental side effects to gut motility and may increase the range of therapeutics with which AG014699 could be combined with for clin. benefit. (Clin Cancer Res 2009;15(19):6106-12).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqAJypUhLMRLVg90H21EOLACvtfcHk0ljYv_dg3AG93Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2lur%252FF&md5=64878c792dc5029396129ff5c6ef32a1</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0398%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DM.%26aulast%3DTelfer%26aufirst%3DB.%2BA.%26aulast%3DMcCrudden%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DKamjoo%26aufirst%3DM.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DRobson%26aufirst%3DT.%26aulast%3DShaw%26aufirst%3DC.%26aulast%3DHirst%26aufirst%3DD.%2BG.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DWilliams%26aufirst%3DK.%2BJ.%26atitle%3DVasoactivity%2520of%2520AG014699%252C%2520a%2520Clinically%2520Active%2520Small%2520Molecule%2520Inhibitor%2520of%2520Poly%2528ADP-ribose%2529%2520Polymerase%253A%2520a%2520Contributory%2520Factor%2520to%2520Chemopotentiation%2520In%2520vivo%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6106%26epage%3D6112%26doi%3D10.1158%2F1078-0432.CCR-09-0398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihnen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">zu Eulenburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolarova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manivong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalukya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginther, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winterhoff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenicke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konecny, G. E.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1002</span>– <span class="NLM_lpage">1015</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1158%2F1535-7163.MCT-12-0813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=23729402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1002-1015&author=M.+Ihnenauthor=C.+zu+Eulenburgauthor=T.+Kolarovaauthor=J.+W.+Qiauthor=K.+Manivongauthor=M.+Chalukyaauthor=J.+Deringauthor=L.+Andersonauthor=C.+Gintherauthor=A.+Meuterauthor=B.+Winterhoffauthor=S.+Jonesauthor=V.+E.+Velculescuauthor=N.+Venkatesanauthor=H.-M.+Rongauthor=S.+Dandekarauthor=N.+Udarauthor=F.+Jaenickeauthor=G.+Losauthor=D.+J.+Slamonauthor=G.+E.+Konecny&title=Therapeutic+Potential+of+the+Poly%28ADP-ribose%29+Polymerase+Inhibitor+Rucaparib+for+the+Treatment+of+Sporadic+Human+Ovarian+Cancer&doi=10.1158%2F1535-7163.MCT-12-0813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer</span></div><div class="casAuthors">Ihnen, Maike; zu Eulenburg, Christine; Kolarova, Teodora; Qi, Jing Wei; Manivong, Kanthinh; Chalukya, Meenal; Dering, Judy; Anderson, Lee; Ginther, Charles; Meuter, Alexandra; Winterhoff, Boris; Jones, Sian; Velculescu, Victor E.; Venkatesan, Natarajan; Rong, Hong-Mei; Dandekar, Sugandha; Udar, Nitin; Jaenicke, Fritz; Los, Gerrit; Slamon, Dennis J.; Konecny, Gottfried E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1002-1015</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer.  We studied the growth inhibitory effects of rucaparib in a panel of 39 ovarian cancer cell lines that were each characterized for mutation and methylation status of BRCA1/2, baseline gene expression signatures, copy no. variations of selected genes, PTEN status, and sensitivity to platinum-based chemotherapy.  To study interactions with chemotherapy, we used multiple drug effect analyses and assessed apoptosis, DNA fragmentation, and γH2AX formation.  Concn.-dependent antiproliferative effects of rucaparib were seen in 26 of 39 (67%) cell lines and were not restricted to cell lines with BRCA1/2 mutations.  Low expression of other genes involved in homologous repair (e.g., BCCIP, BRCC3, ATM, RAD51L1), amplification of AURKA or EMSY, and response to platinum-based chemotherapy was assocd. with sensitivity to rucaparib.  Drug interactions with rucaparib were synergistic for topotecan, synergistic, or additive for carboplatin, doxorubicin or paclitaxel, and additive for gemcitabine.  Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in enhanced apoptosis, DNA fragmentation, and γH2AX formation.  Importantly, rucaparib potentiated chemotherapy independent of its activity as a single agent.  PARP inhibition may be a useful therapeutic strategy for a wider range of ovarian cancers bearing deficiencies in the homologous recombination pathway other than just BRCA1/2 mutations.  These results support further clin. evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe7ZBqJCdQobVg90H21EOLACvtfcHk0lgI6yNSCeM2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOltLw%253D&md5=4eaf35f1dd521263a63ee6cb5a8c8ad6</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0813%26sid%3Dliteratum%253Aachs%26aulast%3DIhnen%26aufirst%3DM.%26aulast%3Dzu%2BEulenburg%26aufirst%3DC.%26aulast%3DKolarova%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%2BW.%26aulast%3DManivong%26aufirst%3DK.%26aulast%3DChalukya%26aufirst%3DM.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DMeuter%26aufirst%3DA.%26aulast%3DWinterhoff%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DVenkatesan%26aufirst%3DN.%26aulast%3DRong%26aufirst%3DH.-M.%26aulast%3DDandekar%26aufirst%3DS.%26aulast%3DUdar%26aufirst%3DN.%26aulast%3DJaenicke%26aufirst%3DF.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26atitle%3DTherapeutic%2520Potential%2520of%2520the%2520Poly%2528ADP-ribose%2529%2520Polymerase%2520Inhibitor%2520Rucaparib%2520for%2520the%2520Treatment%2520of%2520Sporadic%2520Human%2520Ovarian%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1002%26epage%3D1015%26doi%3D10.1158%2F1535-7163.MCT-12-0813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span>; <span class="NLM_string-name">Tong, Y.</span>; <span class="NLM_string-name">Jones, D.
R.</span>; <span class="NLM_string-name">Walsh, T.</span>; <span class="NLM_string-name">Danso, M. A.</span>; <span class="NLM_string-name">Ma, C. X.</span>; <span class="NLM_string-name">Silverman, P.</span>; <span class="NLM_string-name">King, M.-C.</span>; <span class="NLM_string-name">Badve, S. S.</span>; <span class="NLM_string-name">Perkins, S. M.</span></span> <span> </span><span class="NLM_article-title">Cisplatin With or Without Rucaparib After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer: Final Efficacy Results of Hoosier Oncology Group BRE09–146</span>.  <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span> <span class="NLM_fpage">1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=1&author=K.+Miller&author=Y.+Tong&author=D.%0AR.+Jones&author=T.+Walsh&author=M.+A.+Danso&author=C.+X.+Ma&author=P.+Silverman&author=M.-C.+King&author=S.+S.+Badve&author=S.+M.+Perkins&title=Cisplatin+With+or+Without+Rucaparib+After+Preoperative+Chemotherapy+in+Patients+with+Triple+Negative+Breast+Cancer%3A+Final+Efficacy+Results+of+Hoosier+Oncology+Group+BRE09%E2%80%93146"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DK.%26atitle%3DCisplatin%2520With%2520or%2520Without%2520Rucaparib%2520After%2520Preoperative%2520Chemotherapy%2520in%2520Patients%2520with%2520Triple%2520Negative%2520Breast%2520Cancer%253A%2520Final%2520Efficacy%2520Results%2520of%2520Hoosier%2520Oncology%2520Group%2520BRE09%25E2%2580%2593146%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span>; <span class="NLM_string-name">Hendifar, A. E.</span>; <span class="NLM_string-name">McWilliams, R. R.</span>; <span class="NLM_string-name">Geva, R.</span>; <span class="NLM_string-name">Epelbaum, R.</span>; <span class="NLM_string-name">Biankin, A.</span>; <span class="NLM_string-name">Vonderheide, R. H.</span>; <span class="NLM_string-name">Wolff, R. A.</span>; <span class="NLM_string-name">Alberts, S. R.</span>; <span class="NLM_string-name">Giordano, H.</span>; <span class="NLM_string-name">Goble, S.</span>; <span class="NLM_string-name">Lin, K.
K.</span>; <span class="NLM_string-name">Shroff, R.
T.</span></span> <span> </span><span class="NLM_article-title">RUCAPANC: An Open-Label, Phase 2 Trial of the PARP Inhibitor Rucaparib in Patients (pts) with Pancreatic Cancer (PC) and a Known Deleterious Germline or Somatic BRCA Mutation</span>.  <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span> <span class="NLM_fpage">1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1&author=S.+M.+Domchek&author=A.+E.+Hendifar&author=R.+R.+McWilliams&author=R.+Geva&author=R.+Epelbaum&author=A.+Biankin&author=R.+H.+Vonderheide&author=R.+A.+Wolff&author=S.+R.+Alberts&author=H.+Giordano&author=S.+Goble&author=K.%0AK.+Lin&author=R.%0AT.+Shroff&title=RUCAPANC%3A+An+Open-Label%2C+Phase+2+Trial+of+the+PARP+Inhibitor+Rucaparib+in+Patients+%28pts%29+with+Pancreatic+Cancer+%28PC%29+and+a+Known+Deleterious+Germline+or+Somatic+BRCA+Mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26atitle%3DRUCAPANC%253A%2520An%2520Open-Label%252C%2520Phase%25202%2520Trial%2520of%2520the%2520PARP%2520Inhibitor%2520Rucaparib%2520in%2520Patients%2520%2528pts%2529%2520with%2520Pancreatic%2520Cancer%2520%2528PC%2529%2520and%2520a%2520Known%2520Deleterious%2520Germline%2520or%2520Somatic%2520BRCA%2520Mutation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillmore, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critcher, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fussell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kougoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlinson, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherlock, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, R.</span></span> <span> </span><span class="NLM_article-title">Multkilogram Scale-Up of a Reductive Alkylation Route to a Novel PARP Inhibitor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1897</span>– <span class="NLM_lpage">1904</span>, <span class="refDoi"> DOI: 10.1021/op200238p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op200238p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ohs73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=1897-1904&author=A.+T.+Gillmoreauthor=M.+Badlandauthor=C.+L.+Crookauthor=N.+M.+Castroauthor=D.+J.+Critcherauthor=S.+J.+Fussellauthor=K.+J.+Jonesauthor=M.+C.+Jonesauthor=E.+Kougoulosauthor=J.+S.+Mathewauthor=L.+McMillanauthor=J.+E.+Pearceauthor=F.+L.+Rawlinsonauthor=A.+E.+Sherlockauthor=R.+Walton&title=Multkilogram+Scale-Up+of+a+Reductive+Alkylation+Route+to+a+Novel+PARP+Inhibitor&doi=10.1021%2Fop200238p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Multkilogram Scale-Up of a Reductive Alkylation Route to a Novel PARP Inhibitor</span></div><div class="casAuthors">Gillmore, Adam T.; Badland, Matthew; Crook, Clare L.; Castro, Nieves M.; Critcher, Douglas J.; Fussell, Steven J.; Jones, Katherine J.; Jones, Matthew C.; Kougoulos, Eleftherios; Mathew, Jinu S.; McMillan, Lynne; Pearce, John E.; Rawlinson, Fiona L.; Sherlock, Alexandra E.; Walton, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1897-1904</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel PARP inhibitor 1 is a promising new candidate for treatment of breast and ovarian cancer.  A modified synthetic route to 1 has been developed and demonstrated on 7 kg scale.  In order to scale up the synthesis to multikilogram scale, several synthetic challenges needed to be overcome.  The key issues included significant thermal hazards present in a Leimgruber-Batcho indole synthesis, a low-yielding side-chain installation, a nonrobust Suzuki coupling and hydrogen cyanide generation during a reductive amination.  In addn. to these issues, changing from i.v. to oral delivery required a new salt form and therefore a new crystn. procedure.  This contribution describes development work to solve these issues and scaling up of the new process in the pilot plant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfbJQx6OSuJrVg90H21EOLACvtfcHk0lgI6yNSCeM2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ohs73F&md5=e4810016551595a26f4a6db30302681e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fop200238p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop200238p%26sid%3Dliteratum%253Aachs%26aulast%3DGillmore%26aufirst%3DA.%2BT.%26aulast%3DBadland%26aufirst%3DM.%26aulast%3DCrook%26aufirst%3DC.%2BL.%26aulast%3DCastro%26aufirst%3DN.%2BM.%26aulast%3DCritcher%26aufirst%3DD.%2BJ.%26aulast%3DFussell%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DK.%2BJ.%26aulast%3DJones%26aufirst%3DM.%2BC.%26aulast%3DKougoulos%26aufirst%3DE.%26aulast%3DMathew%26aufirst%3DJ.%2BS.%26aulast%3DMcMillan%26aufirst%3DL.%26aulast%3DPearce%26aufirst%3DJ.%2BE.%26aulast%3DRawlinson%26aufirst%3DF.%2BL.%26aulast%3DSherlock%26aufirst%3DA.%2BE.%26aulast%3DWalton%26aufirst%3DR.%26atitle%3DMultkilogram%2520Scale-Up%2520of%2520a%2520Reductive%2520Alkylation%2520Route%2520to%2520a%2520Novel%2520PARP%2520Inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D1897%26epage%3D1904%26doi%3D10.1021%2Fop200238p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vincentis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">An Efficient Synthesis of Ecopladib</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7871</span>– <span class="NLM_lpage">7876</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2008.06.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.tet.2008.06.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=7871-7876&author=W.+Liauthor=J.+Liauthor=D.+De+Vincentisauthor=T.+S.+Mansour&title=An+Efficient+Synthesis+of+Ecopladib&doi=10.1016%2Fj.tet.2008.06.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2008.06.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2008.06.045%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDe%2BVincentis%26aufirst%3DD.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DAn%2520Efficient%2520Synthesis%2520of%2520Ecopladib%26jtitle%3DTetrahedron%26date%3D2008%26volume%3D64%26spage%3D7871%26epage%3D7876%26doi%3D10.1016%2Fj.tet.2008.06.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit87"><span><a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm</a> (accessed July 15, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm495253.htm+%28accessed+July+15%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit88a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Venetoclax: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0596-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0596-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27260335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVymtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=979-987&author=E.+D.+Deeks&title=Venetoclax%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0596-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88aR"><div class="casContent"><span class="casTitleNuber">88a</span><div class="casTitle"><span class="NLM_cas:atitle">Venetoclax: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">979-987</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Venetoclax (Venclexta) is an oral selective inhibitor of the prosurvival protein BCL-2 and therefore restores the apoptotic ability of malignant cells.  The drug arose from research by Abbott Labs. (now AbbVie) during a collaboration with Genentech and is being co-developed by AbbVie and Genentech/Roche primarily for the treatment of haematol. malignancies.  Venetoclax is approved in the USA for use as monotherapy in patients with chronic lymphocytic leukemia (CLL) with the 17p deletion (as detected by an approved FDA test) who have received at least one prior therapy, and is awaiting approval for similar indications in the EU and Canada.  Venetoclax is also in phase I-III development as combination therapy for CLL, phase I/II development as monotherapy and/or combination therapy for non-Hodgkin lymphomas (including diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma) and acute myeloid leukemia, and phase I development for multiple myeloma, systemic lupus erythematosus and breast cancer.  This article summarizes the milestones in the development of venetoclax leading to this first approval for CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo-_C1vJNwpLVg90H21EOLACvtfcHk0lj8OYlDF8DZ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVymtLo%253D&md5=e0f99ba8fb7665bba95ac42626c6aaa3</span></div><a href="/servlet/linkout?suffix=cit88a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0596-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0596-x%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DVenetoclax%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D979%26epage%3D987%26doi%3D10.1007%2Fs40265-016-0596-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit88b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Besbes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirshahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besbes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirshahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billard, C.</span></span> <span> </span><span class="NLM_article-title">New Dimension in Therapeutic Targeting of BCL-2 Family Proteins</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12862</span>– <span class="NLM_lpage">12871</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.18632%2Foncotarget.3868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25970783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2MfjsF2jsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=12862-12871&author=S.+Besbesauthor=M.+Mirshahiauthor=M.+Pocardauthor=C.+Billardauthor=S.+Besbesauthor=M.+Mirshahiauthor=M.+Pocardauthor=C.+Billard&title=New+Dimension+in+Therapeutic+Targeting+of+BCL-2+Family+Proteins&doi=10.18632%2Foncotarget.3868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88bR"><div class="casContent"><span class="casTitleNuber">88b</span><div class="casTitle"><span class="NLM_cas:atitle">New dimension in therapeutic targeting of BCL-2 family proteins</span></div><div class="casAuthors">Besbes Samaher; Mirshahi Massoud; Pocard Marc; Billard Christian; Besbes Samaher; Mirshahi Massoud; Pocard Marc; Billard Christian</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">12862-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Proteins of the BCL-2 family control the mitochondrial pathway of apoptosis.  Targeting these proteins proves to be an attractive strategy for anticancer therapy.  The biological context is based on the fact that BH3-only members of the family are specific antagonists of prosurvival members.  This prompted the identification of "BH3 mimetic" compounds.  These small peptides or organic molecules indeed mimic the BH3 domain of BH3-only proteins: by selectively binding and antagonizing prosurvival proteins, they can induce apoptosis in malignant cells.  Some small-molecule inhibitors of prosurvival proteins have already entered clinical trials in cancer patients and two of them have shown significant therapeutic effects.  The latest developments in the field of targeting BCL-2 family proteins highlight several new antagonists of prosurvival proteins as well as direct activators of proapoptotic proteins.  These compounds open up novel prospects for the development of BH3 mimetic anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRn1i1qso7YZ__I8Jvzw4xCfW6udTcc2eaOmFMO3yR9prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfjsF2jsA%253D%253D&md5=54c3652f33c8cd70a38ef6d0f17ebbff</span></div><a href="/servlet/linkout?suffix=cit88b&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3868%26sid%3Dliteratum%253Aachs%26aulast%3DBesbes%26aufirst%3DS.%26aulast%3DMirshahi%26aufirst%3DM.%26aulast%3DPocard%26aufirst%3DM.%26aulast%3DBillard%26aufirst%3DC.%26aulast%3DBesbes%26aufirst%3DS.%26aulast%3DMirshahi%26aufirst%3DM.%26aulast%3DPocard%26aufirst%3DM.%26aulast%3DBillard%26aufirst%3DC.%26atitle%3DNew%2520Dimension%2520in%2520Therapeutic%2520Targeting%2520of%2520BCL-2%2520Family%2520Proteins%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D12862%26epage%3D12871%26doi%3D10.18632%2Foncotarget.3868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J.</span></span> <span> </span><span class="NLM_article-title">ABT-199 for Chronic Lymphocytic Leukemia</span>. <i>Clin. Adv. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">700</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25658896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2MrjsVegtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=698-700&author=J.+Seymour&title=ABT-199+for+Chronic+Lymphocytic+Leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-199 for chronic lymphocytic leukemia</span></div><div class="casAuthors">Seymour John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">698-700</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUWQOZeWcSnIIRAdBLKY41fW6udTcc2eaOmFMO3yR9prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrjsVegtQ%253D%253D&md5=9a7e1fec1b8716ea718f8ff6708c5d95</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeymour%26aufirst%3DJ.%26atitle%3DABT-199%2520for%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D12%26spage%3D698%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit90a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, V. S.</span>; <span class="NLM_string-name">Christesen, A. C.</span>; <span class="NLM_string-name">Grieme, T. A.</span>; <span class="NLM_string-name">Ku, Y.-Y.</span>; <span class="NLM_string-name">Mulhern, M. M.</span>; <span class="NLM_string-name">Pu, Y.-M. M.</span></span> <span> </span><span class="NLM_article-title">Processes for the Preparation of an Apoptosis-Inducing Agent</span>. <span class="NLM_patent">US 20140275540</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=V.+S.+Chan&author=A.+C.+Christesen&author=T.+A.+Grieme&author=Y.-Y.+Ku&author=M.+M.+Mulhern&author=Y.-M.+M.+Pu&title=Processes+for+the+Preparation+of+an+Apoptosis-Inducing+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DV.%2BS.%26atitle%3DProcesses%2520for%2520the%2520Preparation%2520of%2520an%2520Apoptosis-Inducing%2520Agent%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit90b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and Venetoclax</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2028</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00374</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWnu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=2028-2042&author=D.+L.+Hughes&title=Patent+Review+of+Manufacturing+Routes+to+Oncology+Drugs%3A+Carfilzomib%2C+Osimertinib%2C+and+Venetoclax&doi=10.1021%2Facs.oprd.6b00374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90bR"><div class="casContent"><span class="casTitleNuber">90b</span><div class="casTitle"><span class="NLM_cas:atitle">Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and Venetoclax</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2028-2042</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Synthetic routes and final forms for three recently approved oncol. drugs are reviewed: carfilzomib (Kyprolis), osimertinib (Tagrisso), and venetoclax (Venclexta).  Several patent applications have been filed for the major synthetic challenge for carfilzomib, installation of the chiral epoxide.  The apparent manufg. route to osimertinib involves seven steps and a longest linear sequence of six steps with a yield of 56%.  The apparent manufg. route to venetoclax is a ten-step convergent synthesis with a seven-step longest linear sequence that proceeds in 52% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoYYa5DvhU6rVg90H21EOLACvtfcHk0lgT57n7fNp4Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWnu73J&md5=ab2cfca1cc98e4265693ed68fd96a0ad</span></div><a href="/servlet/linkout?suffix=cit90b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00374%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DPatent%2520Review%2520of%2520Manufacturing%2520Routes%2520to%2520Oncology%2520Drugs%253A%2520Carfilzomib%252C%2520Osimertinib%252C%2520and%2520Venetoclax%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D2028%26epage%3D2042%26doi%3D10.1021%2Facs.oprd.6b00374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catron, N. D.</span>; <span class="NLM_string-name">Chen, S.</span>; <span class="NLM_string-name">Gong, Y.</span>; <span class="NLM_string-name">Zhang, G.
G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Chlorophenyldimethylcyclohexenylmethylpiperazinylnitrotetrahydropyranylmethylaminophenylsulfonylpyrrolopyridinyloxybenzamide Salts and Crystalline Forms for Use as Apoptosis-Inducing Agents</span>. <span class="NLM_patent">WO 2012071336</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+D.+Catron&author=S.+Chen&author=Y.+Gong&author=G.%0AG.+Zhang&title=Preparation+of+Chlorophenyldimethylcyclohexenylmethylpiperazinylnitrotetrahydropyranylmethylaminophenylsulfonylpyrrolopyridinyloxybenzamide+Salts+and+Crystalline+Forms+for+Use+as+Apoptosis-Inducing+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCatron%26aufirst%3DN.%2BD.%26atitle%3DPreparation%2520of%2520Chlorophenyldimethylcyclohexenylmethylpiperazinylnitrotetrahydropyranylmethylaminophenylsulfonylpyrrolopyridinyloxybenzamide%2520Salts%2520and%2520Crystalline%2520Forms%2520for%2520Use%2520as%2520Apoptosis-Inducing%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93a"><span><span class="NLM_label">(a) </span><a href="https://www.shire.com/newsroom/2016/july/9pks5v" class="extLink">https://www.shire.com/newsroom/2016/july/9pks5v</a> (accessed August
12, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.shire.com%2Fnewsroom%2F2016%2Fjuly%2F9pks5v+%28accessed+August%0A12%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit93b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Abidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span> <span> </span><span class="NLM_article-title">Lifitegrast: A Novel Drug for Treatment of Dry Eye Disease</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.195920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit93b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.4103%2F0976-500X.195920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit93b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28163544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit93b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVChsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=194-198&author=A.+Abidiauthor=P.+Shuklaauthor=A.+Ahmad&title=Lifitegrast%3A+A+Novel+Drug+for+Treatment+of+Dry+Eye+Disease&doi=10.4103%2F0976-500X.195920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93bR"><div class="casContent"><span class="casTitleNuber">92b</span><div class="casTitle"><span class="NLM_cas:atitle">Lifitegrast: a novel drug for treatment of dry eye disease</span></div><div class="casAuthors">Abidi, Afroz; Shukla, Pooja; Ahmad, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">194-198</span>CODEN:
                <span class="NLM_cas:coden">JPPOGN</span>;
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">Dry eye disease (DED) is an inflammatory disorder of ocular surfaces leading to severe disability, esp. in the elderly age group.  The mainstay of therapy includes artificial tears, punctual plugs, topical antiinflammatory agents, and corticosteroids.  In the past few years, only cyclosporine-A emulsions have been added to the existing therapy, but it is discontinued by most patients as it causes burning sensation in the eye.  Hence, progress in new research for a better therapeutic option led to the discovery of lymphocyte function-assocd. antigen intercellular adhesion mol. 1 antagonist, lifitegrast.  It hinders the T-cell activation, release of inflammatory mediators, and consequently inhibits the inflammatory pathways in DED.  It was approved by the US Food and Drug Administration in July 2016 for the treatment of DED.  This review highlights the development process and approval of lifitegrast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGShJCw1byCrVg90H21EOLACvtfcHk0lgT57n7fNp4Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVChsrg%253D&md5=5c2f2e417aa1de1c176b7bca2fe889c6</span></div><a href="/servlet/linkout?suffix=cit93b&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.195920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.195920%26sid%3Dliteratum%253Aachs%26aulast%3DAbidi%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DP.%26aulast%3DAhmad%26aufirst%3DA.%26atitle%3DLifitegrast%253A%2520A%2520Novel%2520Drug%2520for%2520Treatment%2520of%2520Dry%2520Eye%2520Disease%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2016%26volume%3D7%26spage%3D194%26epage%3D198%26doi%3D10.4103%2F0976-500X.195920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit93c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0681-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit93c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0681-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=201-208&author=G.+M.+Keating&title=Lifitegrast+Ophthalmic+Solution+5%25%3A+A+Review+in+Dry+Eye+Disease&doi=10.1007%2Fs40265-016-0681-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93c&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0681-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0681-1%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DLifitegrast%2520Ophthalmic%2520Solution%25205%2525%253A%2520A%2520Review%2520in%2520Dry%2520Eye%2520Disease%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D201%26epage%3D208%26doi%3D10.1007%2Fs40265-016-0681-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, D. M.</span></span> <span> </span><span class="NLM_article-title">Lifitegrast: First LFA-1/ICAM-1 Antagonist for Treatment of Dry Eye Disease</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1358/dot.2016.52.9.2542066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1358%2Fdot.2016.52.9.2542066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgtVSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=485-493&author=D.+M.+Paton&title=Lifitegrast%3A+First+LFA-1%2FICAM-1+Antagonist+for+Treatment+of+Dry+Eye+Disease&doi=10.1358%2Fdot.2016.52.9.2542066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease</span></div><div class="casAuthors">Paton D M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">485-493</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Dry eye disease is an extremely common condition affecting millions worldwide.  The underlying pathophysiological mechanism is thought to be localized inflammation of the ocular surface resulting in the localization of T cells at this surface followed by their activation and subsequent liberation of cytokines.  This effect on T cells results from the binding of lymphocyte function-associated antigen-1 (LFA-1) located on T cells to intercellular adhesion molecule 1 (ICAM-1) expressed on inflamed epithelium and endothelium, and on T cells.  Lifitegrast is a T-cell integrin antagonist designed to mimic ICAM-1, thus blocking the interaction of LFA-1 and ICAM-1.  Lifitegrast enters the systemic circulation to a limited extent thus reducing the likelihood of unwanted systemic reactions.  Clinical trials in over 2,500 subjects with dry eye disease have shown that 5.0% lifitegrast given by ocular instillation causes a significant reduction in objective and subjective signs and symptoms of the disease.  These beneficial effects are associated with a relatively low incidence of unwanted effects, almost all local in nature.  In light of these findings, lifitegrast was approved by the Food and Drug Administration (FDA) in 2016 for the treatment of dry eye disease, the first drug with this mechanism of action to be so approved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOIXkJaUrUfax48Rj5GnGofW6udTcc2eYX1vlqQmwQlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgtVSguw%253D%253D&md5=f78738ca410cfac0ffc943d8cabb049a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.9.2542066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.9.2542066%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DD.%2BM.%26atitle%3DLifitegrast%253A%2520First%2520LFA-1%252FICAM-1%2520Antagonist%2520for%2520Treatment%2520of%2520Dry%2520Eye%2520Disease%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D485%26epage%3D493%26doi%3D10.1358%2Fdot.2016.52.9.2542066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadek, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oslob, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evanchik, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1021/ml2002482</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml2002482" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVGlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=203-206&author=M.+Zhongauthor=T.+R.+Gadekauthor=M.+Buiauthor=W.+Shenauthor=J.+Burnierauthor=K.+J.+Barrauthor=E.+J.+Hananauthor=J.+D.+Oslobauthor=C.+H.+Yuauthor=J.+Zhuauthor=M.+R.+Arkinauthor=M.+J.+Evanchikauthor=W.+M.+Flanaganauthor=U.+Hochauthor=J.+Hydeauthor=S.+Prabhuauthor=J.+A.+Silvermanauthor=J.+Wright&title=Discovery+and+Development+of+Potent+LFA-1%2FICAM-1+Antagonist+SAR+1118+as+an+Ophthalmic+Solution+for+Treating+Dry+Eye&doi=10.1021%2Fml2002482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye</span></div><div class="casAuthors">Zhong, Min; Gadek, Thomas R.; Bui, Minna; Shen, Wang; Burnier, John; Barr, Kenneth J.; Hanan, Emily J.; Oslob, Johan D.; Yu, Chul H.; Zhu, Jiang; Arkin, Michelle R.; Evanchik, Marc J.; Flanagan, W. Mike; Hoch, Ute; Hyde, Jennifer; Prabhu, Saileta; Silverman, Jeffrey A.; Wright, Jasmin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-206</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunol. synapse, and augmentation of T-cell receptor signaling.  The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was obsd. in animal models and patients diagnosed with dry eye.  Therefore, it has been hypothesized that small mol. LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye.  In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic soln. for treating dry eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxdplnevXUtbVg90H21EOLACvtfcHk0ljHjBfblpw5WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVGlsLs%253D&md5=e233d520e901644639e7cf4b235dde5a</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fml2002482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml2002482%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DGadek%26aufirst%3DT.%2BR.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DBurnier%26aufirst%3DJ.%26aulast%3DBarr%26aufirst%3DK.%2BJ.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DOslob%26aufirst%3DJ.%2BD.%26aulast%3DYu%26aufirst%3DC.%2BH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DEvanchik%26aufirst%3DM.%2BJ.%26aulast%3DFlanagan%26aufirst%3DW.%2BM.%26aulast%3DHoch%26aufirst%3DU.%26aulast%3DHyde%26aufirst%3DJ.%26aulast%3DPrabhu%26aufirst%3DS.%26aulast%3DSilverman%26aufirst%3DJ.%2BA.%26aulast%3DWright%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Potent%2520LFA-1%252FICAM-1%2520Antagonist%2520SAR%25201118%2520as%2520an%2520Ophthalmic%2520Solution%2520for%2520Treating%2520Dry%2520Eye%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D203%26epage%3D206%26doi%3D10.1021%2Fml2002482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit95a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnier, J.</span></span> <span> </span><span class="NLM_article-title">Crystalline Pharmaceutical and Methods of Preparation and Use Thereof</span>. <span class="NLM_patent">WO 2011050175A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Burnier&title=Crystalline+Pharmaceutical+and+Methods+of+Preparation+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurnier%26aufirst%3DJ.%26atitle%3DCrystalline%2520Pharmaceutical%2520and%2520Methods%2520of%2520Preparation%2520and%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit95b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnier, J.</span>; <span class="NLM_string-name">Gadek, T.</span>; <span class="NLM_string-name">Naud, F.</span></span> <span> </span><span class="NLM_article-title">Crystalline Pharmaceutical and Methods of Preparation and Use Thereof</span>. <span class="NLM_patent">WO 2009139817A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+Burnier&author=T.+Gadek&author=F.+Naud&title=Crystalline+Pharmaceutical+and+Methods+of+Preparation+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurnier%26aufirst%3DJ.%26atitle%3DCrystalline%2520Pharmaceutical%2520and%2520Methods%2520of%2520Preparation%2520and%2520Use%2520Thereof%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit95c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeller, J. R.</span>; <span class="NLM_string-name">Venkatraman, S.</span>; <span class="NLM_string-name">BROT, E. C. A.</span>; <span class="NLM_string-name">IYER, S.</span>; <span class="NLM_string-name">Hall, M.</span></span> <span> </span><span class="NLM_article-title">LFA-1 Inhibitor and Polymorph Thereof</span>. <span class="NLM_patent">WO 2014018748A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+R.+Zeller&author=S.+Venkatraman&author=E.+C.+A.+BROT&author=S.+IYER&author=M.+Hall&title=LFA-1+Inhibitor+and+Polymorph+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZeller%26aufirst%3DJ.%2BR.%26atitle%3DLFA-1%2520Inhibitor%2520and%2520Polymorph%2520Thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e','cit2f','cit2g','cit2h','cit2i','cit2j','cit2k','cit2l','cit2m','cit2n'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b','cit10c','cit10d'],'ref11':['cit11a','cit11b','cit11c','cit11d'],'ref12':['cit12'],'ref13':['cit13'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref100':['cit100'],'ref19':['cit19a','cit19b'],'ref20':['cit20a','cit20b','cit20c'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24a','cit24b','cit24c','cit24d'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31a','cit31b'],'ref32':['cit32a','cit32b','cit32c'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40a','cit40b'],'ref41':['cit41a','cit41b','cit41c'],'ref42':['cit42a','cit42b'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45a','cit45b','cit45c','cit45d'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50a','cit50b','cit50c','cit50d','cit50e'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54a','cit54b','cit54c'],'ref55':['cit55a','cit55b'],'ref56':['cit56'],'ref57':['cit57a','cit57b','cit57c'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref200':['cit200a','cit200b','cit200c','cit200d','cit200e'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65a','cit65b'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68a','cit68b','cit68c','cit68d','cit68e','cit68f','cit68g','cit68h','cit68i','cit68j','cit68k','cit68l','cit68m','cit68n','cit68o','cit68p'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71a','cit71b'],'ref72':['cit72a','cit72b'],'ref73':['cit73'],'ref74':['cit74a','cit74b'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88a','cit88b'],'ref89':['cit89'],'ref90':['cit90a','cit90b'],'ref91':['cit91'],'ref92':['cit93a','cit93b','cit93c'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95a','cit95b','cit95c']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marco Robello, Elisabetta Barresi, Emma Baglini, Silvia Salerno, Sabrina Taliani, <span class="NLM_string-name hlFld-ContribAuthor">Federico Da Settimo</span>. </span><span class="cited-content_cbyCitation_article-title">The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3508-3545. <a href="https://doi.org/10.1021/acs.jmedchem.0c01808" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01808</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01808%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BAlpha%252BKeto%252BAmide%252BMoiety%252Bas%252Ba%252BPrivileged%252BMotif%252Bin%252BMedicinal%252BChemistry%25253A%252BCurrent%252BInsights%252Band%252BEmerging%252BOpportunities%26aulast%3DRobello%26aufirst%3DMarco%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D16102020%26date%3D25032021%26volume%3D64%26issue%3D7%26spage%3D3508%26epage%3D3545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Henning J. Loui, Arun Suneja, <span class="NLM_string-name hlFld-ContribAuthor">Christoph Schneider</span>. </span><span class="cited-content_cbyCitation_article-title">Cooperative Rh/Chiral Phosphoric Acid Catalysis toward the Highly Stereoselective (3 + 3)-Cycloannulation of Carbonyl Ylides and Indolyl-2-methides. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (7)
                                     , 2578-2583. <a href="https://doi.org/10.1021/acs.orglett.1c00489" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c00489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c00489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c00489%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCooperative%252BRh%25252FChiral%252BPhosphoric%252BAcid%252BCatalysis%252Btoward%252Bthe%252BHighly%252BStereoselective%252B%2525283%252B%25252B%252B3%252529-Cycloannulation%252Bof%252BCarbonyl%252BYlides%252Band%252BIndolyl-2-methides%26aulast%3DLoui%26aufirst%3DHenning%2BJ.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D09022021%26date%3D15032021%26volume%3D23%26issue%3D7%26spage%3D2578%26epage%3D2583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lei Ning, Hengzhao Li, Zemin Lai, Michal Szostak, Xingyue Chen, Yanhong Dong, Shuhui Jin, <span class="NLM_string-name hlFld-ContribAuthor">Jie An</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of α-Deuterated Primary Amines via Reductive Deuteration of Oximes Using D2O as a Deuterium Source. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (3)
                                     , 2907-2916. <a href="https://doi.org/10.1021/acs.joc.0c02829" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02829%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B%2525CE%2525B1-Deuterated%252BPrimary%252BAmines%252Bvia%252BReductive%252BDeuteration%252Bof%252BOximes%252BUsing%252BD2O%252Bas%252Ba%252BDeuterium%252BSource%26aulast%3DNing%26aufirst%3DLei%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26112020%26date%3D25012021%26volume%3D86%26issue%3D3%26spage%3D2907%26epage%3D2916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sixi Wang, Bin Yu, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Min Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Pd(II)-Catalyzed Intramolecular C(sp2)–H Arylation of Tryptamines Using the Nonsteric NH2 as a Directing Group. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (1)
                                     , 42-48. <a href="https://doi.org/10.1021/acs.orglett.0c03668" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03668</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03668%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPd%252528II%252529-Catalyzed%252BIntramolecular%252BC%252528sp2%252529%2525E2%252580%252593H%252BArylation%252Bof%252BTryptamines%252BUsing%252Bthe%252BNonsteric%252BNH2%252Bas%252Ba%252BDirecting%252BGroup%26aulast%3DWang%26aufirst%3DSixi%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D04112020%26date%3D17122020%26volume%3D23%26issue%3D1%26spage%3D42%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Jacob C. DeForest, Peter D. Morse, Subham Mahapatra, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to New Drugs Approved during 2018. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10652-10704. <a href="https://doi.org/10.1021/acs.jmedchem.0c00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252BNew%252BDrugs%252BApproved%252Bduring%252B2018%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D22052020%26date%3D27042020%26volume%3D63%26issue%3D19%26spage%3D10652%26epage%3D10704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Phani Ghanakota, Pieter H. Bos, Kyle D. Konze, Joshua Staker, Gabriel Marques, Kyle Marshall, Karl Leswing, Robert Abel, <span class="NLM_string-name hlFld-ContribAuthor">Sathesh Bhat</span>. </span><span class="cited-content_cbyCitation_article-title">Combining Cloud-Based Free-Energy Calculations, Synthetically Aware Enumerations, and Goal-Directed Generative Machine Learning for Rapid Large-Scale Chemical Exploration and Optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (9)
                                     , 4311-4325. <a href="https://doi.org/10.1021/acs.jcim.0c00120" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00120%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DCombining%252BCloud-Based%252BFree-Energy%252BCalculations%25252C%252BSynthetically%252BAware%252BEnumerations%25252C%252Band%252BGoal-Directed%252BGenerative%252BMachine%252BLearning%252Bfor%252BRapid%252BLarge-Scale%252BChemical%252BExploration%252Band%252BOptimization%26aulast%3DGhanakota%26aufirst%3DPhani%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31012020%26date%3D19062020%26date%3D02062020%26volume%3D60%26issue%3D9%26spage%3D4311%26epage%3D4325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hengzhao Li, Yuxia Hou, Chengwei Liu, Zemin Lai, Lei Ning, Roman Szostak, Michal Szostak, <span class="NLM_string-name hlFld-ContribAuthor">Jie An</span>. </span><span class="cited-content_cbyCitation_article-title">Pentafluorophenyl Esters: Highly Chemoselective Ketyl Precursors for the Synthesis of α,α-Dideuterio Alcohols Using SmI2 and D2O as a Deuterium Source. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (4)
                                     , 1249-1253. <a href="https://doi.org/10.1021/acs.orglett.9b04383" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b04383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b04383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b04383%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPentafluorophenyl%252BEsters%25253A%252BHighly%252BChemoselective%252BKetyl%252BPrecursors%252Bfor%252Bthe%252BSynthesis%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B1-Dideuterio%252BAlcohols%252BUsing%252BSmI2%252Band%252BD2O%252Bas%252Ba%252BDeuterium%252BSource%26aulast%3DLi%26aufirst%3DHengzhao%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D06122019%26date%3D08012020%26volume%3D22%26issue%3D4%26spage%3D1249%26epage%3D1253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew
C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved During 2017. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (16)
                                     , 7340-7382. <a href="https://doi.org/10.1021/acs.jmedchem.9b00196" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252BDuring%252B2017%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30012019%26date%3D15042019%26date%3D02042019%26volume%3D62%26issue%3D16%26spage%3D7340%26epage%3D7382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chenxin Ge, Guohua Wang, Panpan Wu, <span class="NLM_string-name hlFld-ContribAuthor">Chao Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Naphthalenyl Triflates via the Cationic Annulation of Benzodiynes with Triflic Acid. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (13)
                                     , 5010-5014. <a href="https://doi.org/10.1021/acs.orglett.9b01590" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b01590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b01590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b01590%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BNaphthalenyl%252BTriflates%252Bvia%252Bthe%252BCationic%252BAnnulation%252Bof%252BBenzodiynes%252Bwith%252BTriflic%252BAcid%26aulast%3DGe%26aufirst%3DChenxin%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06052019%26date%3D24062019%26volume%3D21%26issue%3D13%26spage%3D5010%26epage%3D5014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rocío Rísquez-Cuadro, Reimi Matsumoto, Fernando Ortega-Caballero, Eiji Nanba, Katsumi Higaki, José Manuel García Fernández, <span class="NLM_string-name hlFld-ContribAuthor">Carmen Ortiz Mellet</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Chaperones for the Treatment of α-Mannosidosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (12)
                                     , 5832-5843. <a href="https://doi.org/10.1021/acs.jmedchem.9b00153" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00153%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPharmacological%252BChaperones%252Bfor%252Bthe%252BTreatment%252Bof%252B%2525CE%2525B1-Mannosidosis%26aulast%3DR%25C3%25ADsquez-Cuadro%26aufirst%3DRoc%25C3%25ADo%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25012019%26date%3D02052019%26date%3D24042019%26volume%3D62%26issue%3D12%26spage%3D5832%26epage%3D5843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tsuyoshi Yamada, Tomohiro Matsuo, Aya Ogawa, Tomohiro Ichikawa, Yutaka Kobayashi, Hayato Masuda, Riichi Miyamoto, Hongzhi Bai, Kanji Meguro, Yoshinari Sawama, Yasunari Monguchi, <span class="NLM_string-name hlFld-ContribAuthor">Hironao Sajiki</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Thiol-Modified Dual-Pore Silica Beads as a Practical Scavenger of Leached Palladium Catalyst in C–C Coupling Reactions. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (4)
                                     , 462-469. <a href="https://doi.org/10.1021/acs.oprd.8b00291" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00291%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DApplication%252Bof%252BThiol-Modified%252BDual-Pore%252BSilica%252BBeads%252Bas%252Ba%252BPractical%252BScavenger%252Bof%252BLeached%252BPalladium%252BCatalyst%252Bin%252BC%2525E2%252580%252593C%252BCoupling%252BReactions%26aulast%3DYamada%26aufirst%3DTsuyoshi%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D05092018%26date%3D13122018%26date%3D20112018%26volume%3D23%26issue%3D4%26spage%3D462%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guoshun Luo, Ming Xiang, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Krische</span>. </span><span class="cited-content_cbyCitation_article-title">Successive Nucleophilic and Electrophilic Allylation for the Catalytic Enantioselective Synthesis of 2,4-Disubstituted Pyrrolidines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (8)
                                     , 2493-2497. <a href="https://doi.org/10.1021/acs.orglett.9b00508" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b00508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b00508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b00508%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSuccessive%252BNucleophilic%252Band%252BElectrophilic%252BAllylation%252Bfor%252Bthe%252BCatalytic%252BEnantioselective%252BSynthesis%252Bof%252B2%25252C4-Disubstituted%252BPyrrolidines%26aulast%3DLuo%26aufirst%3DGuoshun%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07022019%26date%3D28022019%26volume%3D21%26issue%3D8%26spage%3D2493%26epage%3D2497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Mousavi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive survey upon diverse and prolific applications of chitosan-based catalytic systems in one-pot multi-component synthesis of heterocyclic rings. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1016/j.ijbiomac.2021.06.123" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.06.123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.06.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.06.123%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DA%252Bcomprehensive%252Bsurvey%252Bupon%252Bdiverse%252Band%252Bprolific%252Bapplications%252Bof%252Bchitosan-based%252Bcatalytic%252Bsystems%252Bin%252Bone-pot%252Bmulti-component%252Bsynthesis%252Bof%252Bheterocyclic%252Brings%26aulast%3DMousavi%26aufirst%3DHossein%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Han  Yuan</span>, <span class="hlFld-ContribAuthor ">Sai-Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiao-Bing  Chen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113218. <a href="https://doi.org/10.1016/j.ejmech.2021.113218" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113218%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFDA-approved%252Bpyrimidine-fused%252Bbicyclic%252Bheterocycles%252Bfor%252Bcancer%252Btherapy%25253A%252BSynthesis%252Band%252Bclinical%252Bapplication%26aulast%3DWang%26aufirst%3DShuai%26date%3D2021%26volume%3D214%26spage%3D113218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garima  Tripathi</span>, <span class="hlFld-ContribAuthor ">Abhijeet  Kumar</span>, <span class="hlFld-ContribAuthor ">Sanchayita  Rajkhowa</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of biologically relevant heterocyclic skeletons under solvent-free condition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 421-459. <a href="https://doi.org/10.1016/B978-0-12-820586-0.00013-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-820586-0.00013-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820586-0.00013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820586-0.00013-3%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Bof%252Bbiologically%252Brelevant%252Bheterocyclic%252Bskeletons%252Bunder%252Bsolvent-free%252Bcondition%26aulast%3DTripathi%26aufirst%3DGarima%26date%3D2021%26spage%3D421%26epage%3D459%26pub%3DElsevier%26atitle%3DGreen%252BSynthetic%252BApproaches%252Bfor%252BBiologically%252BRelevant%252BHeterocycles%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priyanka  Bose</span>, <span class="hlFld-ContribAuthor ">Anand K.  Agrahari</span>, <span class="hlFld-ContribAuthor ">Sumit K.  Singh</span>, <span class="hlFld-ContribAuthor ">Anoop S.  Singh</span>, <span class="hlFld-ContribAuthor ">Mangal S.  Yadav</span>, <span class="hlFld-ContribAuthor ">Sanchayita  Rajkhowa</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments on ionic liquids-mediated synthetic protocols for biologically relevant five- and six-membered heterocyclic skeletons. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 301-364. <a href="https://doi.org/10.1016/B978-0-12-820792-5.00015-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-820792-5.00015-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820792-5.00015-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820792-5.00015-9%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252Bdevelopments%252Bon%252Bionic%252Bliquids-mediated%252Bsynthetic%252Bprotocols%252Bfor%252Bbiologically%252Brelevant%252Bfive-%252Band%252Bsix-membered%252Bheterocyclic%252Bskeletons%26aulast%3DBose%26aufirst%3DPriyanka%26date%3D2021%26spage%3D301%26epage%3D364%26pub%3DElsevier%26atitle%3DGreen%252BSynthetic%252BApproaches%252Bfor%252BBiologically%252BRelevant%252BHeterocycles%26date%3D2021%26volume%3D1%25E2%2580%259315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tsuyoshi  Yamada</span>, <span class="hlFld-ContribAuthor ">Jing  Jiang</span>, <span class="hlFld-ContribAuthor ">Naoya  Ito</span>, <span class="hlFld-ContribAuthor ">Kwihwan  Park</span>, <span class="hlFld-ContribAuthor ">Hayato  Masuda</span>, <span class="hlFld-ContribAuthor ">Chikara  Furugen</span>, <span class="hlFld-ContribAuthor ">Moeka  Ishida</span>, <span class="hlFld-ContribAuthor ">Seiya  Ōtori</span>, <span class="hlFld-ContribAuthor ">Hironao  Sajiki</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Facile and Simple Processes for the Heterogeneous Pd-Catalyzed Ligand-Free Continuous-Flow Suzuki–Miyaura Coupling. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2020,</strong> <em>10 </em>
                                    (10)
                                     , 1209. <a href="https://doi.org/10.3390/catal10101209" title="DOI URL">https://doi.org/10.3390/catal10101209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal10101209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal10101209%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DDevelopment%252Bof%252BFacile%252Band%252BSimple%252BProcesses%252Bfor%252Bthe%252BHeterogeneous%252BPd-Catalyzed%252BLigand-Free%252BContinuous-Flow%252BSuzuki%2525E2%252580%252593Miyaura%252BCoupling%26aulast%3DYamada%26aufirst%3DTsuyoshi%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D10%26spage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tejas M.  Dhameliya</span>, <span class="hlFld-ContribAuthor ">Hiren A.  Donga</span>, <span class="hlFld-ContribAuthor ">Punit V.  Vaghela</span>, <span class="hlFld-ContribAuthor ">Bhoomi G.  Panchal</span>, <span class="hlFld-ContribAuthor ">Dipen K.  Sureja</span>, <span class="hlFld-ContribAuthor ">Kunjan B.  Bodiwala</span>, <span class="hlFld-ContribAuthor ">Mahesh T.  Chhabria</span>. </span><span class="cited-content_cbyCitation_article-title">A decennary update on applications of metal nanoparticles (MNPs) in the synthesis of nitrogen- and oxygen-containing heterocyclic scaffolds. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (54)
                                     , 32740-32820. <a href="https://doi.org/10.1039/D0RA02272A" title="DOI URL">https://doi.org/10.1039/D0RA02272A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA02272A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA02272A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bdecennary%252Bupdate%252Bon%252Bapplications%252Bof%252Bmetal%252Bnanoparticles%252B%252528MNPs%252529%252Bin%252Bthe%252Bsynthesis%252Bof%252Bnitrogen-%252Band%252Boxygen-containing%252Bheterocyclic%252Bscaffolds%26aulast%3DDhameliya%26aufirst%3DTejas%2BM.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D54%26spage%3D32740%26epage%3D32820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Cai</span>, <span class="hlFld-ContribAuthor ">Wei  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Ullmann‐Ma
              Reaction: Development, Scope and Applications in Organic Synthesis
              †. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2020,</strong> <em>38 </em>
                                    (8)
                                     , 879-893. <a href="https://doi.org/10.1002/cjoc.202000075" title="DOI URL">https://doi.org/10.1002/cjoc.202000075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.202000075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.202000075%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DUllmann%2525E2%252580%252590Ma%252BReaction%25253A%252BDevelopment%25252C%252BScope%252Band%252BApplications%252Bin%252BOrganic%252BSynthesis%252B%2525E2%252580%2525A0%26aulast%3DCai%26aufirst%3DQian%26date%3D2020%26date%3D2020%26volume%3D38%26issue%3D8%26spage%3D879%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Xian  Li</span>, <span class="hlFld-ContribAuthor ">Cheng  Cheng</span>, <span class="hlFld-ContribAuthor ">Lei  Tang</span>, <span class="hlFld-ContribAuthor ">Yuan-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium catalyzed asymmetric allylic alkylation of isoquinolinedione derivatives in the preparation of quaternary carbon stereocenters. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (24)
                                     , 4551-4555. <a href="https://doi.org/10.1039/D0OB00765J" title="DOI URL">https://doi.org/10.1039/D0OB00765J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00765J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00765J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DPalladium%252Bcatalyzed%252Basymmetric%252Ballylic%252Balkylation%252Bof%252Bisoquinolinedione%252Bderivatives%252Bin%252Bthe%252Bpreparation%252Bof%252Bquaternary%252Bcarbon%252Bstereocenters%26aulast%3DLi%26aufirst%3DYing-Xian%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D24%26spage%3D4551%26epage%3D4555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Baihui  Li</span>, <span class="hlFld-ContribAuthor ">Yangli  Shen</span>, <span class="hlFld-ContribAuthor ">Hu  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Wu</span>, <span class="hlFld-ContribAuthor ">Lvjiang  Yuan</span>, <span class="hlFld-ContribAuthor ">Qinggang  Ji</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase inhibitors and antifungal agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>195 </em>, 112278. <a href="https://doi.org/10.1016/j.ejmech.2020.112278" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112278</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112278%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B3%25252C4-dihydro-2%2525281H%252529-quinolinone%252Bderivatives%252Bas%252Bpotential%252Bchitin%252Bsynthase%252Binhibitors%252Band%252Bantifungal%252Bagents%26aulast%3DLi%26aufirst%3DBaihui%26date%3D2020%26volume%3D195%26spage%3D112278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Pintilie</span>, <span class="hlFld-ContribAuthor ">Amalia  Stefaniu</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico
              Drug Design and Molecular Docking Studies of Some Quinolone Compound. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,<a href="https://doi.org/10.5772/intechopen.85970" title="DOI URL">https://doi.org/10.5772/intechopen.85970</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.85970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.85970%26sid%3Dliteratum%253Aachs%26atitle%3DIn%252BSilico%252BDrug%252BDesign%252Band%252BMolecular%252BDocking%252BStudies%252Bof%252BSome%252BQuinolone%252BCompound%26aulast%3DPintilie%26aufirst%3DLucia%26date%3D2019%26date%3D2019%26pub%3DIntechOpen%26atitle%3DMolecular%252BDocking%252Band%252BMolecular%252BDynamics%26aulast%3DStefaniu%26aufirst%3DAmalia%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shoji  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Tomoki  Tamura</span>, <span class="hlFld-ContribAuthor ">Saki  Yoshimoto</span>, <span class="hlFld-ContribAuthor ">Takashi  Kawakami</span>, <span class="hlFld-ContribAuthor ">Araki  Masuyama</span>. </span><span class="cited-content_cbyCitation_article-title">4‐Methyltetrahydropyran (4‐MeTHP): Application as an Organic Reaction Solvent. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – An Asian Journal</span><span> <strong>2019,</strong> <em>14 </em>
                                    (21)
                                     , 3921-3937. <a href="https://doi.org/10.1002/asia.201901169" title="DOI URL">https://doi.org/10.1002/asia.201901169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.201901169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.201901169%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520An%2520Asian%2520Journal%26atitle%3D4%2525E2%252580%252590Methyltetrahydropyran%252B%2525284%2525E2%252580%252590MeTHP%252529%25253A%252BApplication%252Bas%252Ban%252BOrganic%252BReaction%252BSolvent%26aulast%3DKobayashi%26aufirst%3DShoji%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D21%26spage%3D3921%26epage%3D3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John F.  Hartwig</span>, <span class="hlFld-ContribAuthor ">Kevin H.  Shaughnessy</span>, <span class="hlFld-ContribAuthor ">Shashank  Shekhar</span>, <span class="hlFld-ContribAuthor ">Rebecca A.  Green</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium‐Catalyzed Amination of Aryl Halides. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 853-958. <a href="https://doi.org/10.1002/0471264180.or100.14" title="DOI URL">https://doi.org/10.1002/0471264180.or100.14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471264180.or100.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471264180.or100.14%26sid%3Dliteratum%253Aachs%26atitle%3DPalladium%2525E2%252580%252590Catalyzed%252BAmination%252Bof%252BAryl%252BHalides%26aulast%3DHartwig%26aufirst%3DJohn%2BF.%26date%3D2019%26date%3D2019%26spage%3D853%26epage%3D958%26pub%3DWiley%26atitle%3DOrganic%252BReactions%26date%3D2004%26date%3D2004%26volume%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virendra  Prasad</span>, <span class="hlFld-ContribAuthor ">Nidhi  Mishra</span>, <span class="hlFld-ContribAuthor ">Anand K.  Agrahari</span>, <span class="hlFld-ContribAuthor ">Sumit K.  Singh</span>, <span class="hlFld-ContribAuthor ">Prabhu P.  Mohapatra</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Cycloelimination-assisted Combinatorial Synthesis of Diverse Heterocyclic Scaffolds of Chemotherapeutic Values. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2019,</strong> <em>23 </em>
                                    (7)
                                     , 768-808. <a href="https://doi.org/10.2174/1385272823666190405145805" title="DOI URL">https://doi.org/10.2174/1385272823666190405145805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666190405145805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666190405145805%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DCycloelimination-assisted%252BCombinatorial%252BSynthesis%252Bof%252BDiverse%252BHeterocyclic%252BScaffolds%252Bof%252BChemotherapeutic%252BValues%26aulast%3DPrasad%26aufirst%3DVirendra%26date%3D2019%26volume%3D23%26issue%3D7%26spage%3D768%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavlo  Nikolaienko</span>, <span class="hlFld-ContribAuthor ">Marc  Jentsch</span>, <span class="hlFld-ContribAuthor ">Ajit P.  Kale</span>, <span class="hlFld-ContribAuthor ">Yunfei  Cai</span>, <span class="hlFld-ContribAuthor ">Magnus  Rueping</span>. </span><span class="cited-content_cbyCitation_article-title">Electrochemical and Scalable Dehydrogenative C(sp
              3
              )−H Amination via Remote Hydrogen Atom Transfer in Batch and Continuous Flow. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (29)
                                     , 7177-7184. <a href="https://doi.org/10.1002/chem.201806092" title="DOI URL">https://doi.org/10.1002/chem.201806092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201806092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201806092%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DElectrochemical%252Band%252BScalable%252BDehydrogenative%252BC%252528sp%252B3%252B%252529%2525E2%252588%252592H%252BAmination%252Bvia%252BRemote%252BHydrogen%252BAtom%252BTransfer%252Bin%252BBatch%252Band%252BContinuous%252BFlow%26aulast%3DNikolaienko%26aufirst%3DPavlo%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D29%26spage%3D7177%26epage%3D7184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0037.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0001.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 19 NCEs approved in 2016.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Beclabuvir (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Dibromoarene Fragment <b>20</b> for Elbasvir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Elbasvir (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Pyrrolidino Bromoimidazole Fragment <b>21</b> for Elbasvir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Chloroquinoxaline Fragment <b>29</b> for Grazoprevir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Chiral Cyclopropanol Fragment <b>ent-32</b> for Grazoprevir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Grazoprevir Hydrate (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Aminovinylcyclopropane Fragment <b>38</b> for Grazoprevir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Narlaprevir (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Cyclohexane Amino Fragment <b>48</b> for Narlaprevir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Nemonoxacin (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Aminopiperidine Fragment <b>65</b> for Nemonoxacin</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Tenofovir Alafenamide Fumarate (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of Tetralone Fragment <b>86</b> for Velpatasvir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Preparation of Velpatasvir Ethereal Pyrrolidine <b>91</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Methyl Pyrrolidine Fragment <b>96</b> for Velpatasvir</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Velpatasvir (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Zabofloxacin <span class="smallcaps smallerCapital">d</span>-Aspartate (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Brivaracetam (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Opicapone (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of Acid Chloride Fragment <b>119</b> for Opicapone</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0023.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Pimavanserin Tartrate (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0024.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Benzylamine Fragment <b>129</b> for Pimavanserin</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0025.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Pitolisant Hydrochloride (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch25" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0026.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Crisaborole (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch26" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0027.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Obeticholic Acid (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch27" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0028.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Migalastat Hydrochloride (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch28" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0029.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Synthesis of Olmutinib (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch29" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0030.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Rucaparib Camsylate (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch30" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0031.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Azaindole Fragment <b>162</b> for Venetoclax</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch31" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0032.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Synthesis of Sulfonamide Fragment <b>165</b> for Venetoclax</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch32" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0033.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Piperazine Hydrochloride Amine Fragment <b>172</b> for Venetoclax</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch33" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0034.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Venetoclax (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch34" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0035.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Lifitegrast (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch35" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/medium/jm-2018-00260b_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0036.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Tetrahydroisoquinoline-6-carboxylic Acid Fragment <b>179</b> for Lifitegrast</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00260/20180816/images/large/jm-2018-00260b_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00260&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61573" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61573" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 96 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raju, T. N. K.</span></span> <span> </span><span class="NLM_article-title">The Nobel Chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918–99), and George H Hitchings (1905–98)</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1022</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)74775-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS0140-6736%2805%2974775-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10768469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=1022&author=T.+N.+K.+Raju&title=The+Nobel+Chronicles.+1988%3A+James+Whyte+Black%2C+%28b+1924%29%2C+Gertrude+Elion+%281918%E2%80%9399%29%2C+and+George+H+Hitchings+%281905%E2%80%9398%29&doi=10.1016%2FS0140-6736%2805%2974775-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span></div><div class="casAuthors">Raju T N</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9208</span>),
    <span class="NLM_cas:pages">1022</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTWLVzWjiD66qcneEtCi92fW6udTcc2eYAmR5-lxKM5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D&md5=c89d64b40317d0d0cb4a76c1cceecb58</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974775-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974775-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DT.%2BN.%2BK.%26atitle%3DThe%2520Nobel%2520Chronicles.%25201988%253A%2520James%2520Whyte%2520Black%252C%2520%2528b%25201924%2529%252C%2520Gertrude%2520Elion%2520%25281918%25E2%2580%259399%2529%252C%2520and%2520George%2520H%2520Hitchings%2520%25281905%25E2%2580%259398%2529%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D1022%26doi%3D10.1016%2FS0140-6736%2805%2974775-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0lirrxG3d_qxXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0lirrxG3d_qxXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.-C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0lilhOiQm_r_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0lilhOiQm_r_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0lilhOiQm_r_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0lilhOiQm_r_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0lhfXa91xjMUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2hR"><div class="casContent"><span class="casTitleNuber">2h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0lhfXa91xjMUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0lhfXa91xjMUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2jR"><div class="casContent"><span class="casTitleNuber">2j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0lhfXa91xjMUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0lgwto3Jke7qRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2lR"><div class="casContent"><span class="casTitleNuber">2l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0lgwto3Jke7qRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2mR"><div class="casContent"><span class="casTitleNuber">2m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0lgwto3Jke7qRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6480</span>– <span class="NLM_lpage">6515</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6480-6515&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2015&doi=10.1021%2Facs.jmedchem.7b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2nR"><div class="casContent"><span class="casTitleNuber">2n</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2015</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K. -C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6480-6515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 29 new chem. entities (NCEs) that were approved for the first time in 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5OCn9h-Lu07Vg90H21EOLACvtfcHk0ljdz03fMQTxbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D&md5=b10c1f677c2f4a216b11a4c89e8b3683</span></div><a href="/servlet/linkout?suffix=cit2n&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6480%26epage%3D6515%26doi%3D10.1021%2Facs.jmedchem.7b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Graul, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruces, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, M.</span></span> <span> </span><span class="NLM_article-title">The Year’s New Drugs & Biologics 2016: Part I</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1358/dot.2017.53.1.2584699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1358%2Fdot.2017.53.1.2584699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC1cvls1Wltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=27-74&author=A.+I.+Graulauthor=P.+Pinaauthor=E.+Crucesauthor=M.+Stringer&title=The+Year%E2%80%99s+New+Drugs+%26+Biologics+2016%3A+Part+I&doi=10.1358%2Fdot.2017.53.1.2584699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The year's new drugs & biologics 2016: Part I</span></div><div class="casAuthors">Graul A I; Pina P; Cruces E; Stringer M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-74</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Nearly 90 new drugs and biologics, including important new line extensions, were approved or launched for the first time globally in 2016, a comparatively lower number with respect to previous years.  Forty-four new drugs and biologics reached their first markets worldwide in 2016, nearly 10% fewer than the previous year.  Seven of the new launches were first-in-class agents, meaning the first drug with a novel mechanism of action to be approved and launched anywhere in the world.  In addition, 23 novel line extensions (i.e., new formulations, new combinations and new indications) were introduced last year.  The remaining 21 products discussed in this article were approved for the first time during the year just passed, but had not yet been launched as of December 15, 2016.  Information on these new arrivals is covered in depth in part I of our annual review of the pharma and biotech industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSx6g-UVov4FUh5eUSa2oe_fW6udTcc2eYZEDbOOp0z5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvls1Wltw%253D%253D&md5=31d31bb9519a5ad322d53993a28557b5</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1358%2Fdot.2017.53.1.2584699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2017.53.1.2584699%26sid%3Dliteratum%253Aachs%26aulast%3DGraul%26aufirst%3DA.%2BI.%26aulast%3DPina%26aufirst%3DP.%26aulast%3DCruces%26aufirst%3DE.%26aulast%3DStringer%26aufirst%3DM.%26atitle%3DThe%2520Year%25E2%2580%2599s%2520New%2520Drugs%2520%2526%2520Biologics%25202016%253A%2520Part%2520I%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D53%26spage%3D27%26epage%3D74%26doi%3D10.1358%2Fdot.2017.53.1.2584699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span> To Market, To
Market–2016. In  <i>2017 Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">ACS Division of Medicinal Chemistry</span>, <span class="NLM_year" style="font-weight: bold;">2017</span>; Vol.  <span class="NLM_volume">52</span>, pp  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">599</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.29200%2Facsmedchemrev-v52.ch28" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+To+Market%2C+To%0AMarket%E2%80%932016.+In+2017+Medicinal+Chemistry+Reviews%3B+Bronson%2C+J.+J.%2C+Ed.%3B+ACS+Division+of+Medicinal+Chemistry%2C+2017%3B+Vol.+52%2C+pp+531%E2%80%93599."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.29200%2Facsmedchemrev-v52.ch28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.29200%252Facsmedchemrev-v52.ch28%26sid%3Dliteratum%253Aachs%26jtitle%3D2017%2520Medicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DACS%2520Division%2520of%2520Medicinal%2520Chemistry%26date%3D2017%26volume%3D52%26spage%3D531%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentles, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant-Young, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewawasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudyma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regueiro-Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camac, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosure, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1879</span>, <span class="refDoi"> DOI: 10.1021/jm4016894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1855-1879&author=R.+G.+Gentlesauthor=M.+Dingauthor=J.+A.+Benderauthor=C.+P.+Bergstromauthor=K.+Grant-Youngauthor=P.+Hewawasamauthor=T.+Hudymaauthor=S.+Martinauthor=A.+Nickelauthor=A.+Regueiro-Renauthor=Y.+Tuauthor=Z.+Yangauthor=K.-S.+Yeungauthor=X.+Zhengauthor=B.+R.+Benoauthor=D.+M.+Camacauthor=C.-H.+Changauthor=M.+Gaoauthor=P.+E.+Morinauthor=S.+Sheriffauthor=J.+Tredupauthor=J.+Wanauthor=M.+R.+Witmerauthor=D.+Xieauthor=U.+Hanumegowdaauthor=J.+Knipeauthor=K.+Mosureauthor=K.+S.+Santoneauthor=D.+D.+Parkerauthor=X.+Zhuoauthor=J.+Lemmauthor=M.+Liuauthor=L.+Pelosiauthor=K.+Rigatauthor=S.+Vossauthor=Y.+Wangauthor=Y.-K.+Wangauthor=R.+C.+Colonnoauthor=M.+Gaoauthor=S.+B.+Robertsauthor=Q.+Gaoauthor=A.+Ngauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Discovery+and+Preclinical+Characterization+of+the+Cyclopropylindolobenzazepine+BMS-791325%2C+A+Potent+Allosteric+Inhibitor+of+the+Hepatitis+C+Virus+NS5B+Polymerase&doi=10.1021%2Fjm4016894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase</span></div><div class="casAuthors">Gentles, Robert G.; Ding, Min; Bender, John A.; Bergstrom, Carl P.; Grant-Young, Katharine; Hewawasam, Piyasena; Hudyma, Thomas; Martin, Scott; Nickel, Andrew; Regueiro-Ren, Alicia; Tu, Yong; Yang, Zhong; Yeung, Kap-Sun; Zheng, Xiaofan; Beno, Brett R.; Camac, Daniel M.; Chang, Chong-Hwan; Gao, Mian; Morin, Paul E.; Sheriff, Steven; Tredup, Jeff; Wan, John; Witmer, Mark R.; Xie, Dianlin; Hanumegowda, Umesh; Knipe, Jay; Mosure, Kathy; Santone, Kenneth S.; Parker, Dawn D.; Zhuo, Xiaoliang; Lemm, Julie; Liu, Mengping; Pelosi, Lenore; Rigat, Karen; Voss, Stacey; Wang, Yi; Wang, Ying-Kai; Colonno, Richard C.; Gao, Min; Roberts, Susan B.; Gao, Qi; Ng, Alicia; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1855-1879</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors.  Subsequent iterations of analog design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochem. properties of lead compds.  Those analogs exhibiting improved soly. and membrane permeability were shown to have notably enhanced pharmacokinetic profiles.  Addnl., a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compd. BMS-791325 (I) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4YKQoSYkS7Vg90H21EOLACvtfcHk0ljPggZrGKoCkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D&md5=f13f5d86a1c17737784e905c7843ff72</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm4016894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016894%26sid%3Dliteratum%253Aachs%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DBergstrom%26aufirst%3DC.%2BP.%26aulast%3DGrant-Young%26aufirst%3DK.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DHudyma%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNickel%26aufirst%3DA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DColonno%26aufirst%3DR.%2BC.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520and%2520Preclinical%2520Characterization%2520of%2520the%2520Cyclopropylindolobenzazepine%2520BMS-791325%252C%2520A%2520Potent%2520Allosteric%2520Inhibitor%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS5B%2520Polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1855%26epage%3D1879%26doi%3D10.1021%2Fjm4016894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, J. A.</span>; <span class="NLM_string-name">Ding, M.</span>; <span class="NLM_string-name">Gentles, R. G.</span>; <span class="NLM_string-name">Hewawasam, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of Cyclopropyl Fused Indolobenzazepine Derivatives as Hepatitis C Virus (HCV) NS5B Polymerase Inhibitors</span>. <span class="NLM_patent">WO 20070270405</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+A.+Bender&author=M.+Ding&author=R.+G.+Gentles&author=P.+Hewawasam&title=Preparation+of+Cyclopropyl+Fused+Indolobenzazepine+Derivatives+as+Hepatitis+C+Virus+%28HCV%29+NS5B+Polymerase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DJ.%2BA.%26atitle%3DPreparation%2520of%2520Cyclopropyl%2520Fused%2520Indolobenzazepine%2520Derivatives%2520as%2520Hepatitis%2520C%2520Virus%2520%2528HCV%2529%2520NS5B%2520Polymerase%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, P. L.</span>; <span class="NLM_string-name">Brochu, C.</span>; <span class="NLM_string-name">Chabot, C.</span>; <span class="NLM_string-name">Jolicoeur, E.</span>; <span class="NLM_string-name">Kawai, S.</span>; <span class="NLM_string-name">Poupart, M.-A.</span>; <span class="NLM_string-name">Tsantrizos, Y. S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Indole-6-Carboxylic Acids and Related Compounds as Hepatitis C Viral Polymerase Inhibitors</span>. <span class="NLM_patent">WO 2004065367</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=P.+L.+Beaulieu&author=C.+Brochu&author=C.+Chabot&author=E.+Jolicoeur&author=S.+Kawai&author=M.-A.+Poupart&author=Y.+S.+Tsantrizos&title=Preparation+of+Indole-6-Carboxylic+Acids+and+Related+Compounds+as+Hepatitis+C+Viral+Polymerase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DPreparation%2520of%2520Indole-6-Carboxylic%2520Acids%2520and%2520Related%2520Compounds%2520as%2520Hepatitis%2520C%2520Viral%2520Polymerase%2520Inhibitors%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G.
M.</span></span> <span> </span><span class="NLM_article-title">Elbasvir/Grazoprevir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0558-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0558-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=617-624&author=G.%0AM.+Keating&title=Elbasvir%2FGrazoprevir%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0558-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0558-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0558-3%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DElbasvir%252FGrazoprevir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D617%26epage%3D624%26doi%3D10.1007%2Fs40265-016-0558-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mangion, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maligres, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krska, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavialov, I.</span></span> <span> </span><span class="NLM_article-title">Enantioselective Synthesis of an HCV NS5a Antagonist</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2310</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1021/ol500971c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol500971c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVentr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=2310-2313&author=I.+K.+Mangionauthor=C.-y.+Chenauthor=H.+Liauthor=P.+Maligresauthor=Y.+Chenauthor=M.+Christensenauthor=R.+Cohenauthor=I.+Jeonauthor=A.+Klaparsauthor=S.+Krskaauthor=H.+Nguyenauthor=R.+A.+Reamerauthor=B.+D.+Sherryauthor=I.+Zavialov&title=Enantioselective+Synthesis+of+an+HCV+NS5a+Antagonist&doi=10.1021%2Fol500971c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective synthesis of an HCV NS5a antagonist</span></div><div class="casAuthors">Mangion, Ian K.; Chen, Cheng-yi; Li, Hongmei; Maligres, Peter; Chen, Yonggang; Christensen, Melodie; Cohen, Ryan; Jeon, Ingyu; Klapars, Artis; Krska, Shane; Nguyen, Hoa; Reamer, Robert A.; Sherry, Benjamin D.; Zavialov, Ilia</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2310-2313</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A concise, enantioselective synthesis of the HCV NS5a inhibitor MK-8742 (1) is reported.  The features of the synthesis include a highly enantioselective transfer hydrogenation of an NH imine and a dynamic diastereoselective transformation.  The synthesis of this complex target requires simple starting materials and nine linear steps for completion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXConQjSyfcLVg90H21EOLACvtfcHk0ljPggZrGKoCkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVentr8%253D&md5=a58c03782898715bb002171b9b75ad50</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fol500971c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol500971c%26sid%3Dliteratum%253Aachs%26aulast%3DMangion%26aufirst%3DI.%2BK.%26aulast%3DChen%26aufirst%3DC.-y.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMaligres%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DJeon%26aufirst%3DI.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DKrska%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DReamer%26aufirst%3DR.%2BA.%26aulast%3DSherry%26aufirst%3DB.%2BD.%26aulast%3DZavialov%26aufirst%3DI.%26atitle%3DEnantioselective%2520Synthesis%2520of%2520an%2520HCV%2520NS5a%2520Antagonist%26jtitle%3DOrg.%2520Lett.%26date%3D2014%26volume%3D16%26spage%3D2310%26epage%3D2313%26doi%3D10.1021%2Fol500971c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangion, I.</span>; <span class="NLM_string-name">Chen, C.-Y.</span>; <span class="NLM_string-name">Jeon, I.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Nguyen, H. N.</span>; <span class="NLM_string-name">Maligres, P. E.</span>; <span class="NLM_string-name">Klapars, A.</span>; <span class="NLM_string-name">Zavialov, I.</span>; <span class="NLM_string-name">Yasuda, N.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing HCV NS5A Inhibitor Tetracyclic Heterocycle Compounds End-Capped with Peptides</span>. <span class="NLM_patent">WO 2015065821</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=I.+Mangion&author=C.-Y.+Chen&author=I.+Jeon&author=Y.+Chen&author=H.+Li&author=H.+N.+Nguyen&author=P.+E.+Maligres&author=A.+Klapars&author=I.+Zavialov&author=N.+Yasuda&title=Process+for+Preparing+HCV+NS5A+Inhibitor+Tetracyclic+Heterocycle+Compounds+End-Capped+with+Peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMangion%26aufirst%3DI.%26atitle%3DProcess%2520for%2520Preparing%2520HCV%2520NS5A%2520Inhibitor%2520Tetracyclic%2520Heterocycle%2520Compounds%2520End-Capped%2520with%2520Peptides%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, M.</span></span> <span> </span><span class="NLM_article-title">A Class of Ruthenium(II) Catalyst for Asymmetric Transfer Hydrogenations of Ketones</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">7318</span>– <span class="NLM_lpage">7319</span>, <span class="refDoi"> DOI: 10.1021/ja051486s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja051486s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVaktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=7318-7319&author=A.+M.+Hayesauthor=D.+J.+Morrisauthor=G.+J.+Clarksonauthor=M.+Wills&title=A+Class+of+Ruthenium%28II%29+Catalyst+for+Asymmetric+Transfer+Hydrogenations+of+Ketones&doi=10.1021%2Fja051486s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">A Class of Ruthenium(II) Catalyst for Asymmetric Transfer Hydrogenations of Ketones</span></div><div class="casAuthors">Hayes, Aidan M.; Morris, David J.; Clarkson, Guy J.; Wills, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7318-7319</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ruthenium dimer I, readily available in two steps from the corresponding N-tosyldiphenylethylenediamine (TsDPEN), is converted directly to monomeric asym. transfer hydrogenation catalyst I in situ under the conditions employed for ketone redn.  Catalyst II is a significantly more active catalyst for this application than the untethered deriv., exhibits higher enantioselectivities across a range of substrates, and appears to be highly stable to the reaction conditions.  It is active at loadings of as low as 0.01 mol %, and redns. at the 0.1 mol % level are complete within 20 min at 80 °C without significant loss of enantioselectivity.  A crystal structure of II is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1p2rYjrrfvLVg90H21EOLACvtfcHk0litpMvOTbRRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVaktr0%253D&md5=dff24307b573faaa42c26ee404099f09</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Fja051486s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja051486s%26sid%3Dliteratum%253Aachs%26aulast%3DHayes%26aufirst%3DA.%2BM.%26aulast%3DMorris%26aufirst%3DD.%2BJ.%26aulast%3DClarkson%26aufirst%3DG.%2BJ.%26aulast%3DWills%26aufirst%3DM.%26atitle%3DA%2520Class%2520of%2520Ruthenium%2528II%2529%2520Catalyst%2520for%2520Asymmetric%2520Transfer%2520Hydrogenations%2520of%2520Ketones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D7318%26epage%3D7319%26doi%3D10.1021%2Fja051486s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Matharu, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, M.</span></span> <span> </span><span class="NLM_article-title">A Stereochemically Well-Defined Rhodium(III) Catalyst for Asymmetric Transfer Hydrogenation of Ketones</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">5489</span>– <span class="NLM_lpage">5491</span>, <span class="refDoi"> DOI: 10.1021/ol052559f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol052559f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKlt7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=5489-5491&author=D.+S.+Matharuauthor=D.+J.+Morrisauthor=A.+M.+Kawamotoauthor=G.+J.+Clarksonauthor=M.+Wills&title=A+Stereochemically+Well-Defined+Rhodium%28III%29+Catalyst+for+Asymmetric+Transfer+Hydrogenation+of+Ketones&doi=10.1021%2Fol052559f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">A stereochemically well-defined rhodium(III) catalyst for asymmetric transfer hydrogenation of ketones</span></div><div class="casAuthors">Matharu, Daljit S.; Morris, David J.; Kawamoto, Aparecida M.; Clarkson, Guy J.; Wills, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5489-5491</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A rhodium(III) catalyst for asym. transfer hydrogenation of ketones has been designed.  The incorporation of a tethering group between the diamino group and the cyclopentadienyl unit provides extra stereochem. rigidity.  The catalyst is capable of enantioselective redn. of a range of ketones in excellent ee using formic acid/triethylamine as both the solvent and the reducing agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKRIPrHyCZ87Vg90H21EOLACvtfcHk0litpMvOTbRRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKlt7zM&md5=b90ca348275c338ea9fe408871f0699f</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fol052559f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol052559f%26sid%3Dliteratum%253Aachs%26aulast%3DMatharu%26aufirst%3DD.%2BS.%26aulast%3DMorris%26aufirst%3DD.%2BJ.%26aulast%3DKawamoto%26aufirst%3DA.%2BM.%26aulast%3DClarkson%26aufirst%3DG.%2BJ.%26aulast%3DWills%26aufirst%3DM.%26atitle%3DA%2520Stereochemically%2520Well-Defined%2520Rhodium%2528III%2529%2520Catalyst%2520for%2520Asymmetric%2520Transfer%2520Hydrogenation%2520of%2520Ketones%26jtitle%3DOrg.%2520Lett.%26date%3D2005%26volume%3D7%26spage%3D5489%26epage%3D5491%26doi%3D10.1021%2Fol052559f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiFilippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescenzi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMuzio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+Macrocyclic+Hepatitis+C+Virus+NS3%2F4a+Protease+Inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0litpMvOTbRRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520Macrocyclic%2520Hepatitis%2520C%2520Virus%2520NS3%252F4a%2520Protease%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span>; <span class="NLM_string-name">Summa, V.</span>; <span class="NLM_string-name">Liverton, N. J.</span>; <span class="NLM_string-name">Mccauley, J. A.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors</span>. <span class="NLM_patent">WO 2010011566A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Harper&author=V.+Summa&author=N.+J.+Liverton&author=J.+A.+Mccauley&title=Macrocyclic+Quinoxaline+Compounds+as+HCV+NS3+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26atitle%3DMacrocyclic%2520Quinoxaline%2520Compounds%2520as%2520HCV%2520NS3%2520Protease%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span>; <span class="NLM_string-name">Humphrey, G.</span>; <span class="NLM_string-name">Pei, T.</span>; <span class="NLM_string-name">Song, Z. J.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Artino, L.</span></span> <span> </span><span class="NLM_article-title">Process and Intermediates for Preparing Macrolactams</span>. <span class="NLM_patent">WO 2013028470A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Xu&author=G.+Humphrey&author=T.+Pei&author=Z.+J.+Song&author=T.+Wang&author=L.+Artino&title=Process+and+Intermediates+for+Preparing+Macrolactams"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DF.%26atitle%3DProcess%2520and%2520Intermediates%2520for%2520Preparing%2520Macrolactams%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschaen, D.</span></span> <span> </span><span class="NLM_article-title">Process Chemistry in Antiviral Research</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">77</span>, <span class="refDoi"> DOI: 10.1007/s41061-016-0076-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs41061-016-0076-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=77&author=Y.-L.+Zhongauthor=N.+Yasudaauthor=H.+Liauthor=M.+McLaughlinauthor=D.+Tschaen&title=Process+Chemistry+in+Antiviral+Research&doi=10.1007%2Fs41061-016-0076-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1007%2Fs41061-016-0076-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs41061-016-0076-5%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DY.-L.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMcLaughlin%26aufirst%3DM.%26aulast%3DTschaen%26aufirst%3DD.%26atitle%3DProcess%2520Chemistry%2520in%2520Antiviral%2520Research%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D2016%26volume%3D374%26spage%3D77%26doi%3D10.1007%2Fs41061-016-0076-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Kuethe, J. T.</span>; <span class="NLM_string-name">Humphrey, G.</span>; <span class="NLM_string-name">Beutner, G. L.</span>; <span class="NLM_string-name">Zhong, Y. L.</span>; <span class="NLM_string-name">Cleator, E.</span>; <span class="NLM_string-name">Baxter, C.</span></span> <span> </span><span class="NLM_article-title">Methods and Intermediates for Preparing Macrolactams</span>. <span class="NLM_patent">WO 2013028471A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+Yasuda&author=J.+T.+Kuethe&author=G.+Humphrey&author=G.+L.+Beutner&author=Y.+L.+Zhong&author=E.+Cleator&author=C.+Baxter&title=Methods+and+Intermediates+for+Preparing+Macrolactams"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DN.%26atitle%3DMethods%2520and%2520Intermediates%2520for%2520Preparing%2520Macrolactams%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bassan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutner, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleitz, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuethe, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullens, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzzio, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span> <span> </span><span class="NLM_article-title">Multikilogram-Scale Synthesis of a Chiral Cyclopropanol and an Investigation of the Safe Use of Lithium Acetylide–Ethylene Diamine Complex</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1021/op2002497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op2002497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=87-95&author=E.+M.+Bassanauthor=C.+A.+Baxterauthor=G.+L.+Beutnerauthor=K.+M.+Emersonauthor=F.+J.+Fleitzauthor=S.+Johnsonauthor=S.+Keenauthor=M.+M.+Kimauthor=J.+T.+Kuetheauthor=W.+R.+Leonardauthor=P.+R.+Mullensauthor=D.+J.+Muzzioauthor=C.+Robergeauthor=N.+Yasuda&title=Multikilogram-Scale+Synthesis+of+a+Chiral+Cyclopropanol+and+an+Investigation+of+the+Safe+Use+of+Lithium+Acetylide%E2%80%93Ethylene+Diamine+Complex&doi=10.1021%2Fop2002497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Multikilogram-Scale Synthesis of a Chiral Cyclopropanol and an Investigation of the Safe Use of Lithium Acetylide-Ethylene Diamine Complex</span></div><div class="casAuthors">Bassan, Ephraim M.; Baxter, Carl A.; Beutner, Gregory L.; Emerson, Khateeta M.; Fleitz, Fred J.; Johnson, Simon; Keen, Stephen; Kim, Mary M.; Kuethe, Jeffrey T.; Leonard, William R.; Mullens, Peter R.; Muzzio, Daniel J.; Roberge, Christopher; Yasuda, Nobuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A six-step route starting from a readily available vinyl boronate was identified to produce an enantioenriched cyclopropanol in an overall 16% yield.  Key steps involve the use of lithium acetylide-ethylene diamine complex 5 and an enzymic resoln. of a racemic cyclopropanol acetate.  Process safety considerations surrounding the use of 5 were examd., and an improved procedure is described which was safely demonstrated at multikilogram scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSIw5QsR_O5bVg90H21EOLACvtfcHk0liBcHnNtc7pog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7K&md5=70d4062eacb1c0d044d82cbd7c058816</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fop2002497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop2002497%26sid%3Dliteratum%253Aachs%26aulast%3DBassan%26aufirst%3DE.%2BM.%26aulast%3DBaxter%26aufirst%3DC.%2BA.%26aulast%3DBeutner%26aufirst%3DG.%2BL.%26aulast%3DEmerson%26aufirst%3DK.%2BM.%26aulast%3DFleitz%26aufirst%3DF.%2BJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DKeen%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DM.%2BM.%26aulast%3DKuethe%26aufirst%3DJ.%2BT.%26aulast%3DLeonard%26aufirst%3DW.%2BR.%26aulast%3DMullens%26aufirst%3DP.%2BR.%26aulast%3DMuzzio%26aufirst%3DD.%2BJ.%26aulast%3DRoberge%26aufirst%3DC.%26aulast%3DYasuda%26aufirst%3DN.%26atitle%3DMultikilogram-Scale%2520Synthesis%2520of%2520a%2520Chiral%2520Cyclopropanol%2520and%2520an%2520Investigation%2520of%2520the%2520Safe%2520Use%2520of%2520Lithium%2520Acetylide%25E2%2580%2593Ethylene%2520Diamine%2520Complex%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D87%26epage%3D95%26doi%3D10.1021%2Fop2002497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span>; <span class="NLM_string-name">Desmond, R.</span>; <span class="NLM_string-name">Humphrey, G. R.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">QI, J.</span>; <span class="NLM_string-name">Ruck, R. T.</span>; <span class="NLM_string-name">Song, Z. J.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Zhong, Y. L.</span>; <span class="NLM_string-name">Park, J.</span></span> <span> </span><span class="NLM_article-title">Methods and Intermediates for Preparing Macrolactams</span>. <span class="NLM_patent">WO 2015057611A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=F.+Xu&author=R.+Desmond&author=G.+R.+Humphrey&author=H.+Li&author=J.+QI&author=R.+T.+Ruck&author=Z.+J.+Song&author=T.+Wang&author=Y.+L.+Zhong&author=J.+Park&title=Methods+and+Intermediates+for+Preparing+Macrolactams"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DF.%26atitle%3DMethods%2520and%2520Intermediates%2520for%2520Preparing%2520Macrolactams%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kuethe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcune, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreher, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, T.</span></span> <span> </span><span class="NLM_article-title">Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4174</span>– <span class="NLM_lpage">4177</span>, <span class="refDoi"> DOI: 10.1021/ol401864t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol401864t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=4174-4177&author=J.+Kuetheauthor=Y.+L.+Zhongauthor=N.+Yasudaauthor=G.+Beutnerauthor=K.+Linnauthor=M.+Kimauthor=B.+Marcuneauthor=S.+D.+Dreherauthor=G.+Humphreyauthor=T.+Pei&title=Development+of+a+Practical%2C+Asymmetric+Synthesis+of+the+Hepatitis+C+Virus+Protease+Inhibitor+MK-5172&doi=10.1021%2Fol401864t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172</span></div><div class="casAuthors">Kuethe, Jeffrey; Zhong, Yong-Li; Yasuda, Nobuyoshi; Beutner, Gregory; Linn, Katherine; Kim, Mary; Marcune, Benjamin; Dreher, Spencer Douglas; Humphrey, Guy; Pei, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4174-4177</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a practical, asym. synthesis of the hepatitis C virus (HCV) protease inhibitor MK-5172 (I), an 18-membered macrocycle, is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ZFtN4OuVLrVg90H21EOLACvtfcHk0liBcHnNtc7pog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrjL&md5=c4f0eafdfad3e3f2988eb9068b47a9cd</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1021%2Fol401864t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol401864t%26sid%3Dliteratum%253Aachs%26aulast%3DKuethe%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DY.%2BL.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DBeutner%26aufirst%3DG.%26aulast%3DLinn%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DMarcune%26aufirst%3DB.%26aulast%3DDreher%26aufirst%3DS.%2BD.%26aulast%3DHumphrey%26aufirst%3DG.%26aulast%3DPei%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520a%2520Practical%252C%2520Asymmetric%2520Synthesis%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520Protease%2520Inhibitor%2520MK-5172%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D4174%26epage%3D4177%26doi%3D10.1021%2Fol401864t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">A Novel Class of Tunable Zinc Reagents (RXZnCH2Y) for Efficient Cyclopropanation of Olefins</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1021/jo030312v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo030312v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFGltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=327-334&author=J.+C.+Lorenzauthor=J.+Longauthor=Z.+Yangauthor=S.+Xueauthor=Y.+Xieauthor=Y.+Shi&title=A+Novel+Class+of+Tunable+Zinc+Reagents+%28RXZnCH2Y%29+for+Efficient+Cyclopropanation+of+Olefins&doi=10.1021%2Fjo030312v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Class of Tunable Zinc Reagents (RXZnCH2Y) for Efficient Cyclopropanation of Olefins</span></div><div class="casAuthors">Lorenz, Jon C.; Long, Jiang; Yang, Zhiqiang; Xue, Song; Xie, Yinong; Shi, Yian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-334</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of zinc reagents (RXZnCH2Y) generated with an appropriate organozinc is very effective for the cyclopropanation of olefins.  The reactivity and selectivity of these reagents can be regulated by tuning the electronic and steric nature of the RX group on Zn.  A reasonable level of enantioselectivity was obtained for the cyclopropanation of unfunctionalized olefins when a chiral (iodomethyl)zinc species was used, providing a valuable approach for the asym. cyclopropanation of unfunctionalized olefins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSD-oxaRDrrVg90H21EOLACvtfcHk0liz_BMnqISJ-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFGltL4%253D&md5=aac319d827e3c162e5358276b2e4db7d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo030312v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo030312v%26sid%3Dliteratum%253Aachs%26aulast%3DLorenz%26aufirst%3DJ.%2BC.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DXue%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DA%2520Novel%2520Class%2520of%2520Tunable%2520Zinc%2520Reagents%2520%2528RXZnCH2Y%2529%2520for%2520Efficient%2520Cyclopropanation%2520of%2520Olefins%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D327%26epage%3D334%26doi%3D10.1021%2Fjo030312v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. J.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Artino, L. M.</span>; <span class="NLM_string-name">Tellers, D. M.</span>; <span class="NLM_string-name">Lieberman, D. R.</span></span> <span> </span><span class="NLM_article-title">Processes for Preparing Protease Inhibitors of Hepatitis C Virus</span>. <span class="NLM_patent">WO 2011025849A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Z.+J.+Song&author=Y.+Wang&author=L.+M.+Artino&author=D.+M.+Tellers&author=D.+R.+Lieberman&title=Processes+for+Preparing+Protease+Inhibitors+of+Hepatitis+C+Virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%2BJ.%26atitle%3DProcesses%2520for%2520Preparing%2520Protease%2520Inhibitors%2520of%2520Hepatitis%2520C%2520Virus%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruijne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reesink, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weegink, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molenkamp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treitel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vliet, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, H. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de knegt, R. J.</span></span> <span> </span><span class="NLM_article-title">Antiviral Activity of Narlaprevir Combined with Ritonavir and Pegylated Interferon in Chronic Hepatitis C Patients</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1002/hep.23899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1002%2Fhep.23899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=1590-1599&author=J.+de%0ABruijneauthor=J.+F.+Bergmannauthor=H.+W.+Reesinkauthor=C.+J.+Weeginkauthor=R.+Molenkampauthor=J.+Schinkelauthor=X.+Tongauthor=J.+Liauthor=A.+Treitelauthor=E.+A.+Hughesauthor=J.+J.+van+Lierauthor=A.+A.+van+Vlietauthor=H.+L.+A.+Janssenauthor=R.+J.+de+knegt&title=Antiviral+Activity+of+Narlaprevir+Combined+with+Ritonavir+and+Pegylated+Interferon+in+Chronic+Hepatitis+C+Patients&doi=10.1002%2Fhep.23899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fhep.23899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23899%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruijne%26aufirst%3DJ.%26aulast%3DBergmann%26aufirst%3DJ.%2BF.%26aulast%3DReesink%26aufirst%3DH.%2BW.%26aulast%3DWeegink%26aufirst%3DC.%2BJ.%26aulast%3DMolenkamp%26aufirst%3DR.%26aulast%3DSchinkel%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DTreitel%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3Dvan%2BLier%26aufirst%3DJ.%2BJ.%26aulast%3Dvan%2BVliet%26aufirst%3DA.%2BA.%26aulast%3DJanssen%26aufirst%3DH.%2BL.%2BA.%26aulast%3Dde%2Bknegt%26aufirst%3DR.%2BJ.%26atitle%3DAntiviral%2520Activity%2520of%2520Narlaprevir%2520Combined%2520with%2520Ritonavir%2520and%2520Pegylated%2520Interferon%2520in%2520Chronic%2520Hepatitis%2520C%2520Patients%26jtitle%3DHepatology%26date%3D2010%26volume%3D52%26spage%3D1590%26epage%3D1599%26doi%3D10.1002%2Fhep.23899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arasappan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feld, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichardo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prongay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, F. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2365</span>– <span class="NLM_lpage">2370</span>, <span class="refDoi"> DOI: 10.1128/AAC.00135-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1128%2FAAC.00135-10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2365-2370&author=X.+Tongauthor=A.+Arasappanauthor=F.+Bennettauthor=R.+Chaseauthor=B.+Feldauthor=Z.+Guoauthor=A.+Hartauthor=V.+Madisonauthor=B.+Malcolmauthor=J.+Pichardoauthor=A.+Prongayauthor=R.+Ralstonauthor=A.+Skeltonauthor=E.+Xiaauthor=R.+Zhangauthor=F.+G.+Njoroge&title=Preclinical+Characterization+of+the+Antiviral+Activity+of+SCH+900518+%28Narlaprevir%29%2C+a+Novel+Mechanism-Based+Inhibitor+of+Hepatitis+C+Virus+NS3+Protease&doi=10.1128%2FAAC.00135-10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.00135-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00135-10%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DX.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DFeld%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DRalston%26aufirst%3DR.%26aulast%3DSkelton%26aufirst%3DA.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DPreclinical%2520Characterization%2520of%2520the%2520Antiviral%2520Activity%2520of%2520SCH%2520900518%2520%2528Narlaprevir%2529%252C%2520a%2520Novel%2520Mechanism-Based%2520Inhibitor%2520of%2520Hepatitis%2520C%2520Virus%2520NS3%2520Protease%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2365%26epage%3D2370%26doi%3D10.1128%2FAAC.00135-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, F. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Boceprevir and Narlaprevir: the First and Second Generation of HCV NS3 Protease Inhibitors</span>. <i>Case Stud. Mod. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1002/9781118219683.ch12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1002%2F9781118219683.ch12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlCqtrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=296-335&author=K.+X.+Chenauthor=F.+G.+Njoroge&title=Discovery+of+Boceprevir+and+Narlaprevir%3A+the+First+and+Second+Generation+of+HCV+NS3+Protease+Inhibitors&doi=10.1002%2F9781118219683.ch12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of boceprevir and narlaprevir: the first and second generation of HCV NS3 protease inhibitors</span></div><div class="casAuthors">Chen, Kevin X.; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Case Studies in Modern Drug Discovery and Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">296-335</span>CODEN:
                <span class="NLM_cas:coden">69PLHG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review discusses the discovery, clin. development, structure-activity relationship and approval of hepatitis C virus NS3 protease inhibitors, namely boceprevir and narlaprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlX5qf0d_3f7Vg90H21EOLACvtfcHk0lhJBdjJdP49zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlCqtrvP&md5=6321a64a62a79c0076a8e94cc96d8421</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2F9781118219683.ch12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9781118219683.ch12%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520Boceprevir%2520and%2520Narlaprevir%253A%2520the%2520First%2520and%2520Second%2520Generation%2520of%2520HCV%2520NS3%2520Protease%2520Inhibitors%26jtitle%3DCase%2520Stud.%2520Mod.%2520Drug%2520Discovery%2520Dev.%26date%3D2012%26spage%3D296%26epage%3D335%26doi%3D10.1002%2F9781118219683.ch12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arasappan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huelgas, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sannigrahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibulbhan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girijavallabhan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prongay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, F. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1021/ml9000276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml9000276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=64-69&author=A.+Arasappanauthor=F.+Bennettauthor=S.+L.+Bogenauthor=S.+Venkatramanauthor=M.+Blackmanauthor=K.+X.+Chenauthor=S.+Hendrataauthor=Y.+Huangauthor=R.+M.+Huelgasauthor=L.+Nairauthor=A.+I.+Padillaauthor=W.+Panauthor=R.+Pikeauthor=P.+Pintoauthor=S.+Ruanauthor=M.+Sannigrahiauthor=F.+Velazquezauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=A.+K.+Saksenaauthor=V.+Girijavallabhanauthor=N.-Y.+Shihauthor=J.+Kongauthor=T.+Mengauthor=Y.+Jinauthor=J.+Wongauthor=P.+McNamaraauthor=A.+Prongayauthor=V.+Madisonauthor=J.+J.+Piwinskiauthor=K.-C.+Chengauthor=R.+Morrisonauthor=B.+Malcolmauthor=X.+Tongauthor=R.+Ralstonauthor=F.+G.+Njoroge&title=Discovery+of+Narlaprevir+%28SCH+900518%29%3A+A+Potent%2C+Second+Generation+HCV+NS3+Serine+Protease+Inhibitor&doi=10.1021%2Fml9000276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fml9000276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml9000276%26sid%3Dliteratum%253Aachs%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBlackman%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHuelgas%26aufirst%3DR.%2BM.%26aulast%3DNair%26aufirst%3DL.%26aulast%3DPadilla%26aufirst%3DA.%2BI.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSannigrahi%26aufirst%3DM.%26aulast%3DVelazquez%26aufirst%3DF.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DShih%26aufirst%3DN.-Y.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DCheng%26aufirst%3DK.-C.%26aulast%3DMorrison%26aufirst%3DR.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DRalston%26aufirst%3DR.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520Narlaprevir%2520%2528SCH%2520900518%2529%253A%2520A%2520Potent%252C%2520Second%2520Generation%2520HCV%2520NS3%2520Serine%2520Protease%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D64%26epage%3D69%26doi%3D10.1021%2Fml9000276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span> <span> </span><span class="NLM_article-title">Computaional Study on the Molecular Mechanisms of Drug Resistance of Narlaprevir Due to V36M, R155K, V36M+R155K, T54A, and A156T Mutations of HCV NS3/4A Protease</span>. <i>Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1139/bcb-2014-0039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1139%2Fbcb-2014-0039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25178998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOmsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=357-369&author=H.+Wangauthor=L.+Gengauthor=B.-Z.+Chenauthor=M.+Ji&title=Computaional+Study+on+the+Molecular+Mechanisms+of+Drug+Resistance+of+Narlaprevir+Due+to+V36M%2C+R155K%2C+V36M%2BR155K%2C+T54A%2C+and+A156T+Mutations+of+HCV+NS3%2F4A+Protease&doi=10.1139%2Fbcb-2014-0039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease</span></div><div class="casAuthors">Wang, Huiqun; Geng, Lingling; Chen, Bo-Zhen; Ji, Mingjuan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">357-369</span>CODEN:
                <span class="NLM_cas:coden">BCBIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0829-8211</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">Narlaprevir is a novel NS3/4A protease inhibitor of hepatitis C virus (HCV), and it has been tested in a phase II clin. trial recently.  However, distinct drug-resistance of Narlaprevir has been discovered.  In our study, the mol. mechanisms of drug-resistance of Narlaprevir due to the mutations V36M, R155K, V36M+R155K, T54A, and A156T of NS3/4A protease have been investigated by mol. dynamics (MD) simulations, free energy calcns., and free energy decompn. anal.  The predicted binding free energies of Narlaprevir towards the wild-type and five mutants show that the mutations V36M, R155K, and T54A lead to low-level drug resistance and the mutations V36M+R155K and A156T lead to high-level drug resistance, which is consistent with the exptl. data.  The anal. of the individual energy terms indicates that the van der Waals contribution is important for distinguishing the binding affinities of these six complexes.  These findings again show that the combination of different mol. modeling techniques is an efficient way to interpret the mol. mechanism of drug-resistance.  Our work mainly elaborates the mol. mechanism of drug-resistance of Narlaprevir and further provides valuable information for developing novel, safer, and more potent HCV antiviral drugs in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom77n1Z91O17Vg90H21EOLACvtfcHk0lhJBdjJdP49zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOmsLrK&md5=d7e9fbc61369759ff7c12ff3b30ce6b8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1139%2Fbcb-2014-0039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fbcb-2014-0039%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.-Z.%26aulast%3DJi%26aufirst%3DM.%26atitle%3DComputaional%2520Study%2520on%2520the%2520Molecular%2520Mechanisms%2520of%2520Drug%2520Resistance%2520of%2520Narlaprevir%2520Due%2520to%2520V36M%252C%2520R155K%252C%2520V36M%252BR155K%252C%2520T54A%252C%2520and%2520A156T%2520Mutations%2520of%2520HCV%2520NS3%252F4A%2520Protease%26jtitle%3DBiochem.%2520Cell%2520Biol.%26date%3D2014%26volume%3D92%26spage%3D357%26epage%3D369%26doi%3D10.1139%2Fbcb-2014-0039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Traverse, J.</span>; <span class="NLM_string-name">Leong, W. M.</span>; <span class="NLM_string-name">Miller, S. P.</span>; <span class="NLM_string-name">Albaneze-Walker, J.</span>; <span class="NLM_string-name">Hunter, T. J.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Liao, H.</span>; <span class="NLM_string-name">Arasappan, A.</span>; <span class="NLM_string-name">Trzaska, S. T.</span>; <span class="NLM_string-name">Smith, R. M.</span>; <span class="NLM_string-name">Lekhal, A.</span>; <span class="NLM_string-name">Bogen, S. L.</span>; <span class="NLM_string-name">Kong, J.</span>; <span class="NLM_string-name">Bennett, F.</span>; <span class="NLM_string-name">Njoroge, F. G.</span>; <span class="NLM_string-name">Poirier, M.</span>; <span class="NLM_string-name">Kuo, S.-C.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Matthews, K. S.</span>; <span class="NLM_string-name">Demonchaux, P.</span>; <span class="NLM_string-name">Ferreira, A.</span></span> <span> </span><span class="NLM_article-title">Enantio- and Stereo Specific Synthesis of β-Amino-α-Hydroxy Amides</span>. <span class="NLM_patent">US 8680294B2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+Traverse&author=W.+M.+Leong&author=S.+P.+Miller&author=J.+Albaneze-Walker&author=T.+J.+Hunter&author=L.+Wang&author=H.+Liao&author=A.+Arasappan&author=S.+T.+Trzaska&author=R.+M.+Smith&author=A.+Lekhal&author=S.+L.+Bogen&author=J.+Kong&author=F.+Bennett&author=F.+G.+Njoroge&author=M.+Poirier&author=S.-C.+Kuo&author=Y.+Chen&author=K.+S.+Matthews&author=P.+Demonchaux&author=A.+Ferreira&title=Enantio-+and+Stereo+Specific+Synthesis+of+%CE%B2-Amino-%CE%B1-Hydroxy+Amides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTraverse%26aufirst%3DJ.%26atitle%3DEnantio-%2520and%2520Stereo%2520Specific%2520Synthesis%2520of%2520%25CE%25B2-Amino-%25CE%25B1-Hydroxy%2520Amides%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Traverse, J.</span>; <span class="NLM_string-name">Leong, W. W.</span>; <span class="NLM_string-name">Miller, S. P.</span>; <span class="NLM_string-name">Albaneze-Walker, J.</span>; <span class="NLM_string-name">Hunter, T. J.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Liao, H.</span>; <span class="NLM_string-name">Arasappan, A.</span>; <span class="NLM_string-name">Trzaska, S. T.</span>; <span class="NLM_string-name">Smith, R. M.</span>; <span class="NLM_string-name">Lekhal, A.</span>; <span class="NLM_string-name">Bogen, S. L.</span>; <span class="NLM_string-name">Kong, J.</span>; <span class="NLM_string-name">Bennett, F.</span>; <span class="NLM_string-name">Njoroge, F. G.</span>; <span class="NLM_string-name">Poirier, M.</span>; <span class="NLM_string-name">Kuo, S.-C.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Matthews, K. S.</span>; <span class="NLM_string-name">Demonchaux, P.</span>; <span class="NLM_string-name">Ferreira, A.</span></span> <span> </span><span class="NLM_article-title">Processes for Enantio- and Stereospecific Syntheses of β-Amino-α-Hydroxy Amides</span>. <span class="NLM_patent">WO 2011014494 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Traverse&author=W.+W.+Leong&author=S.+P.+Miller&author=J.+Albaneze-Walker&author=T.+J.+Hunter&author=L.+Wang&author=H.+Liao&author=A.+Arasappan&author=S.+T.+Trzaska&author=R.+M.+Smith&author=A.+Lekhal&author=S.+L.+Bogen&author=J.+Kong&author=F.+Bennett&author=F.+G.+Njoroge&author=M.+Poirier&author=S.-C.+Kuo&author=Y.+Chen&author=K.+S.+Matthews&author=P.+Demonchaux&author=A.+Ferreira&title=Processes+for+Enantio-+and+Stereospecific+Syntheses+of+%CE%B2-Amino-%CE%B1-Hydroxy+Amides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTraverse%26aufirst%3DJ.%26atitle%3DProcesses%2520for%2520Enantio-%2520and%2520Stereospecific%2520Syntheses%2520of%2520%25CE%25B2-Amino-%25CE%25B1-Hydroxy%2520Amides%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, C. J.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of the N-Terminal Component of Microginin: (2S,3R)-3-Amino-2-Hydroxydecanoic Acid, its (2R,3R)-Epimer and (3R)-3-Aminodecanoic Acid</span>. <i>Tetrahedron: Asymmetry</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/0957-4166(94)00372-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2F0957-4166%2894%2900372-I" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1995&pages=165-176&author=M.+E.+Bunnageauthor=A.+J.+Burkeauthor=S.+G.+Daviesauthor=C.+J.+Goodwin&title=Asymmetric+Synthesis+of+the+N-Terminal+Component+of+Microginin%3A+%282S%2C3R%29-3-Amino-2-Hydroxydecanoic+Acid%2C+its+%282R%2C3R%29-Epimer+and+%283R%29-3-Aminodecanoic+Acid&doi=10.1016%2F0957-4166%2894%2900372-I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2F0957-4166%2894%2900372-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0957-4166%252894%252900372-I%26sid%3Dliteratum%253Aachs%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurke%26aufirst%3DA.%2BJ.%26aulast%3DDavies%26aufirst%3DS.%2BG.%26aulast%3DGoodwin%26aufirst%3DC.%2BJ.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520the%2520N-Terminal%2520Component%2520of%2520Microginin%253A%2520%25282S%252C3R%2529-3-Amino-2-Hydroxydecanoic%2520Acid%252C%2520its%2520%25282R%252C3R%2529-Epimer%2520and%2520%25283R%2529-3-Aminodecanoic%2520Acid%26jtitle%3DTetrahedron%253A%2520Asymmetry%26date%3D1995%26volume%3D6%26spage%3D165%26epage%3D176%26doi%3D10.1016%2F0957-4166%2894%2900372-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. D.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of α-Amino Carbonyl Derivatives using Lithium (R)-N-Benzyl-N-α-Methylbenzylamide</span>. <i>Tetrahedron: Asymmetry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1565</span>, <span class="refDoi"> DOI: 10.1016/S0957-4166(02)00406-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS0957-4166%2802%2900406-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=1555-1565&author=S.+G.+Daviesauthor=S.+W.+Epsteinauthor=A.+C.+Garnerauthor=O.+Ichiharaauthor=A.+D.+Smith&title=Asymmetric+Synthesis+of+%CE%B1-Amino+Carbonyl+Derivatives+using+Lithium+%28R%29-N-Benzyl-N-%CE%B1-Methylbenzylamide&doi=10.1016%2FS0957-4166%2802%2900406-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2FS0957-4166%2802%2900406-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0957-4166%252802%252900406-8%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BG.%26aulast%3DEpstein%26aufirst%3DS.%2BW.%26aulast%3DGarner%26aufirst%3DA.%2BC.%26aulast%3DIchihara%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DA.%2BD.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520%25CE%25B1-Amino%2520Carbonyl%2520Derivatives%2520using%2520Lithium%2520%2528R%2529-N-Benzyl-N-%25CE%25B1-Methylbenzylamide%26jtitle%3DTetrahedron%253A%2520Asymmetry%26date%3D2002%26volume%3D13%26spage%3D1555%26epage%3D1565%26doi%3D10.1016%2FS0957-4166%2802%2900406-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marko, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaume, M.</span></span> <span> </span><span class="NLM_article-title">Racemic N-Sulfonyloxaziridines as Highly Diastereoselective Enolate Hydroxylating Agents: Enantioselective Synthesis of (2S,3S)-3-Amino-N-Cyclopropyl-2-Hydroxyhexanamide</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9178</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2011.09.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.tet.2011.09.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=9173-9178&author=E.+Kissauthor=I.+E.+Markoauthor=M.+Guillaume&title=Racemic+N-Sulfonyloxaziridines+as+Highly+Diastereoselective+Enolate+Hydroxylating+Agents%3A+Enantioselective+Synthesis+of+%282S%2C3S%29-3-Amino-N-Cyclopropyl-2-Hydroxyhexanamide&doi=10.1016%2Fj.tet.2011.09.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2011.09.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2011.09.090%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DE.%26aulast%3DMarko%26aufirst%3DI.%2BE.%26aulast%3DGuillaume%26aufirst%3DM.%26atitle%3DRacemic%2520N-Sulfonyloxaziridines%2520as%2520Highly%2520Diastereoselective%2520Enolate%2520Hydroxylating%2520Agents%253A%2520Enantioselective%2520Synthesis%2520of%2520%25282S%252C3S%2529-3-Amino-N-Cyclopropyl-2-Hydroxyhexanamide%26jtitle%3DTetrahedron%26date%3D2011%26volume%3D67%26spage%3D9173%26epage%3D9178%26doi%3D10.1016%2Fj.tet.2011.09.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arjona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castañer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolós, J.</span></span> <span> </span><span class="NLM_article-title">Nemonoxacin</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1358/dof.2009.034.03.1350294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1358%2Fdof.2009.034.03.1350294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=196-203&author=A.+Arjonaauthor=R.+Casta%C3%B1erauthor=J.+Bol%C3%B3s&title=Nemonoxacin&doi=10.1358%2Fdof.2009.034.03.1350294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Nemonoxacin: quinolone antibiotic</span></div><div class="casAuthors">Arjona, A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">196-203</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Although fluoroquinolones have been used over the last few decades to successfully treat multiple bacterial infections, there is a need for new compds. that, while taking advantage of the antimicrobial properties of the quinolone nucleus, show greater potency against drug-resistant bacteria, reduced drug-drug interactions and improved patient tolerability.  Nemonoxacin (TG-873870) is a nonflourinated quinolone antibiotic with remarkable in vitro activity against a wide variety of clin. relevant pathogens, including methicillin-resistant Staphylococcus aureus and multidrug-resistant Streptococcus pneumoniae.  In several murine pulmonary infection models, the efficacy of nemonoxacin was greater than most of the currently available fluoroquinolones.  Studies in lab. animals have ruled out the possibility of nemonoxacin inducing significant reproductive, cardiovascular, allergic or phototoxic adverse events.  In addn., this novel quinolone has a good pharmacokinetic profile and is well tolerated.  Nemonoxacin is currently undergoing phase II evaluation for the oral treatment of drug-sensitive and -resistant bacterial infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0MSuqgNA3RbVg90H21EOLACvtfcHk0lgBi5y1dNSVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlSisr0%253D&md5=3568bc4c8d0656ee397e583a39a64eef</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.03.1350294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.03.1350294%26sid%3Dliteratum%253Aachs%26aulast%3DArjona%26aufirst%3DA.%26aulast%3DCasta%25C3%25B1er%26aufirst%3DR.%26aulast%3DBol%25C3%25B3s%26aufirst%3DJ.%26atitle%3DNemonoxacin%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D196%26epage%3D203%26doi%3D10.1358%2Fdof.2009.034.03.1350294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span> <span> </span><span class="NLM_article-title">Nemonoxacin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1453</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0270-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-014-0270-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1445-1453&author=R.+M.+Poole&title=Nemonoxacin%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0270-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0270-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0270-0%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DNemonoxacin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1445%26epage%3D1453%26doi%3D10.1007%2Fs40265-014-0270-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oliphant, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, G. M.</span></span> <span> </span><span class="NLM_article-title">Quinolones: A Comprehensive Review</span>. <i>Am. Fam. Physician</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=11858629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BD387itlCmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2002&pages=455-464&author=C.+M.+Oliphantauthor=G.+M.+Green&title=Quinolones%3A+A+Comprehensive+Review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolones: a comprehensive review</span></div><div class="casAuthors">Oliphant Catherine M; Green Gary M</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">455-64</span>
        ISSN:<span class="NLM_cas:issn">0002-838X</span>.
    </div><div class="casAbstract">With the recent introduction of agents such as gatifloxacin and moxifloxacin, the traditional gram-negative coverage of fluoroquinolones has been expanded to include specific gram-positive organisms.  Clinical applications beyond genitourinary tract infections include upper and lower respiratory infections, gastrointestinal infections, gynecologic infections, sexually transmitted diseases, and some skin and soft tissue infections.  Most quinolones have excellent oral bioavailability, with serum drug concentrations equivalent to intravenous administration.  Quinolones have few adverse effects, most notably nausea, headache, dizziness, and confusion.  Less common but more serious adverse events include prolongation of the corrected QT interval, phototoxicity, liver enzyme abnormalities, arthropathy, and cartilage and tendon abnormalities.  The new fluoroquinolones are rarely first-line agents and should be employed judiciously.  Inappropriate use of agents from this important class of antibiotics will likely worsen current problems with antibiotic resistance.  Applications of fluoroquinolones in biologic warfare are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQET9DNRhkIEloaUqgkFHkfW6udTcc2eZdaBMhTCGQC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387itlCmtw%253D%253D&md5=732b332f68ae5f2459d60803517fdf9b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOliphant%26aufirst%3DC.%2BM.%26aulast%3DGreen%26aufirst%3DG.%2BM.%26atitle%3DQuinolones%253A%2520A%2520Comprehensive%2520Review%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2002%26volume%3D65%26spage%3D455%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledoussal, B.</span>; <span class="NLM_string-name">Almstead, J. I. K.</span>; <span class="NLM_string-name">Gray, J. L.</span>; <span class="NLM_string-name">Hu, X. E.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial Quinolones, their Compositions and Uses</span>. <span class="NLM_patent">US 6329391B1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=B.+Ledoussal&author=J.+I.+K.+Almstead&author=J.+L.+Gray&author=X.+E.+Hu&title=Antimicrobial+Quinolones%2C+their+Compositions+and+Uses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLedoussal%26aufirst%3DB.%26atitle%3DAntimicrobial%2520Quinolones%252C%2520their%2520Compositions%2520and%2520Uses%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M.</span></span> <span> </span><span class="NLM_article-title">Coupling Process for Preparing Quinolone Intermediates</span>. <span class="NLM_patent">US 7456279B2</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=M.+Reilly&title=Coupling+Process+for+Preparing+Quinolone+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DM.%26atitle%3DCoupling%2520Process%2520for%2520Preparing%2520Quinolone%2520Intermediates%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. P.</span>; <span class="NLM_string-name">Schunk, T. T.</span></span> <span> </span><span class="NLM_article-title">Hydride Reduction Process for Preparing Quinolone Intermediates</span>. <span class="NLM_patent">US 2007232806A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+P.+Hayes&author=T.+T.+Schunk&title=Hydride+Reduction+Process+for+Preparing+Quinolone+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayes%26aufirst%3DM.%2BP.%26atitle%3DHydride%2520Reduction%2520Process%2520for%2520Preparing%2520Quinolone%2520Intermediates%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Redman-Furey, N. L.</span>; <span class="NLM_string-name">Godlewski, J. E.</span>; <span class="NLM_string-name">Dicks, M. L.</span></span> <span> </span><span class="NLM_article-title">Malate Salts, and Polymorphs of (3S,5S)-7-[3-Amino-5-Methyl-Piperidinyl]-1-Cyclopropyl-1,4-Dihydro-8-Methoxy-4-oxo-3-Quinolinecarboxylic Acid</span>. <span class="NLM_patent">US 8039485B2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+L.+Redman-Furey&author=J.+E.+Godlewski&author=M.+L.+Dicks&title=Malate+Salts%2C+and+Polymorphs+of+%283S%2C5S%29-7-%5B3-Amino-5-Methyl-Piperidinyl%5D-1-Cyclopropyl-1%2C4-Dihydro-8-Methoxy-4-oxo-3-Quinolinecarboxylic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRedman-Furey%26aufirst%3DN.%2BL.%26atitle%3DMalate%2520Salts%252C%2520and%2520Polymorphs%2520of%2520%25283S%252C5S%2529-7-%255B3-Amino-5-Methyl-Piperidinyl%255D-1-Cyclopropyl-1%252C4-Dihydro-8-Methoxy-4-oxo-3-Quinolinecarboxylic%2520Acid%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. L. Y.</span></span> <span> </span><span class="NLM_article-title">Tenofovir Alafenamide: A Review in Chronic Hepatitis B</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0754-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-017-0754-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1017-1028&author=L.+J.+Scottauthor=H.+L.+Y.+Chan&title=Tenofovir+Alafenamide%3A+A+Review+in+Chronic+Hepatitis+B&doi=10.1007%2Fs40265-017-0754-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0754-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0754-9%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26atitle%3DTenofovir%2520Alafenamide%253A%2520A%2520Review%2520in%2520Chronic%2520Hepatitis%2520B%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1017%26epage%3D1028%26doi%3D10.1007%2Fs40265-017-0754-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, M. W.</span>; <span class="NLM_string-name">Chapman, H. H.</span>; <span class="NLM_string-name">Cihlar, T.</span>; <span class="NLM_string-name">Eisenberg, E. J.</span>; <span class="NLM_string-name">He, G.-X.</span>; <span class="NLM_string-name">Kernan, M. R.</span>; <span class="NLM_string-name">Lee, W. A.</span>; <span class="NLM_string-name">Prisbe, E. J.</span>; <span class="NLM_string-name">Rohloff, J. C.</span>; <span class="NLM_string-name">Sparacino, M. L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Prodrugs Amino Acid Methoxyphosphonate Acyclic Nucleotide Analogs as Antiviral or Antitumor Agents and their Use in Therapy and Prophylaxis</span>. <span class="NLM_patent">WO 2002008241A2</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=M.+W.+Becker&author=H.+H.+Chapman&author=T.+Cihlar&author=E.+J.+Eisenberg&author=G.-X.+He&author=M.+R.+Kernan&author=W.+A.+Lee&author=E.+J.+Prisbe&author=J.+C.+Rohloff&author=M.+L.+Sparacino&title=Preparation+of+Prodrugs+Amino+Acid+Methoxyphosphonate+Acyclic+Nucleotide+Analogs+as+Antiviral+or+Antitumor+Agents+and+their+Use+in+Therapy+and+Prophylaxis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DM.%2BW.%26atitle%3DPreparation%2520of%2520Prodrugs%2520Amino%2520Acid%2520Methoxyphosphonate%2520Acyclic%2520Nucleotide%2520Analogs%2520as%2520Antiviral%2520or%2520Antitumor%2520Agents%2520and%2520their%2520Use%2520in%2520Therapy%2520and%2520Prophylaxis%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walwyn, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlin, C. D.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for the Preparation of Tenofovir Disoproxil Fumarate</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.5b00364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Sru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=742-750&author=D.+L.+Rileyauthor=D.+R.+Walwynauthor=C.+D.+Edlin&title=An+Improved+Process+for+the+Preparation+of+Tenofovir+Disoproxil+Fumarate&doi=10.1021%2Facs.oprd.5b00364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">An Improved Process for the Preparation of Tenofovir Disoproxil Fumarate</span></div><div class="casAuthors">Riley, Darren L.; Walwyn, David R.; Edlin, Chris D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The current three-step manufg. route for the prepn. of tenofovir disoproxil fumarate (1) was assessed and optimized leading to a higher yielding, simpler, and greener process.  Key improvements in the process route include the refinement of the 2nd stage through the replacement of the problematic Mg tert-butoxide (MTB) with a 1:1 ratio of a Grignard reagent and tert-BuOH.  The development of a virtually solvent-free approach and the establishment of a workup and purifn. protocol which gave a pure di-Et phosphonate ester was achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomG8B5nXtkMrVg90H21EOLACvtfcHk0lhQ5ZqIdaeBiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Sru7c%253D&md5=f4ffaf3b5820f8466be23c92f5fc1859</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00364%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DD.%2BL.%26aulast%3DWalwyn%26aufirst%3DD.%2BR.%26aulast%3DEdlin%26aufirst%3DC.%2BD.%26atitle%3DAn%2520Improved%2520Process%2520for%2520the%2520Preparation%2520of%2520Tenofovir%2520Disoproxil%2520Fumarate%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D742%26epage%3D750%26doi%3D10.1021%2Facs.oprd.5b00364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Indukuri, V. S. K.</span>; <span class="NLM_string-name">Joga, S. R.</span>; <span class="NLM_string-name">Gorantla, S. R.</span>; <span class="NLM_string-name">Chava, S.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Tenofovir</span>. <span class="NLM_patent">US 20140303368</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=V.+S.+K.+Indukuri&author=S.+R.+Joga&author=S.+R.+Gorantla&author=S.+Chava&title=Process+for+the+Preparation+of+Tenofovir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIndukuri%26aufirst%3DV.%2BS.%2BK.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Tenofovir%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strube, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haumreisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt-Traub, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditz, R.</span></span> <span> </span><span class="NLM_article-title">Comparison of Batch Elution and Continuous Simulated Moving Bed Chromatography</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1021/op980019a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op980019a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1998&pages=305-319&author=J.+Strubeauthor=S.+Haumreisserauthor=H.+Schmidt-Traubauthor=M.+Schulteauthor=R.+Ditz&title=Comparison+of+Batch+Elution+and+Continuous+Simulated+Moving+Bed+Chromatography&doi=10.1021%2Fop980019a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fop980019a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop980019a%26sid%3Dliteratum%253Aachs%26aulast%3DStrube%26aufirst%3DJ.%26aulast%3DHaumreisser%26aufirst%3DS.%26aulast%3DSchmidt-Traub%26aufirst%3DH.%26aulast%3DSchulte%26aufirst%3DM.%26aulast%3DDitz%26aufirst%3DR.%26atitle%3DComparison%2520of%2520Batch%2520Elution%2520and%2520Continuous%2520Simulated%2520Moving%2520Bed%2520Chromatography%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D1998%26volume%3D2%26spage%3D305%26epage%3D319%26doi%3D10.1021%2Fop980019a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colby, D. A.</span>; <span class="NLM_string-name">Martins, A. A.</span>; <span class="NLM_string-name">Roberts, B. J.</span>; <span class="NLM_string-name">Scott, R. W.</span>; <span class="NLM_string-name">Solomon, N. S.</span></span> <span> </span><span class="NLM_article-title">Methods for Preparing Anti-Viral Nucleotide Analogs</span>. <span class="NLM_patent">WO 2013052094</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+A.+Colby&author=A.+A.+Martins&author=B.+J.+Roberts&author=R.+W.+Scott&author=N.+S.+Solomon&title=Methods+for+Preparing+Anti-Viral+Nucleotide+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DColby%26aufirst%3DD.%2BA.%26atitle%3DMethods%2520for%2520Preparing%2520Anti-Viral%2520Nucleotide%2520Analogs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, S. L.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1578</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0648-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0648-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1567-1578&author=S.+L.+Greig&title=Sofosbuvir%2FVelpatasvir%3A+A+Review+in+Chronic+Hepatitis+C&doi=10.1007%2Fs40265-016-0648-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0648-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0648-2%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DSofosbuvir%252FVelpatasvir%253A%2520A%2520Review%2520in%2520Chronic%2520Hepatitis%2520C%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1567%26epage%3D1578%26doi%3D10.1007%2Fs40265-016-0648-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span> <a href="http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf" class="extLink">http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf</a> (accessed August 11, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+http%3A%2F%2Fwww.gilead.com%2F%7E%2Fmedia%2FFiles%2Fpdfs%2Fmedicines%2Fliver-disease%2Fepclusa%2Fepclusa_pi.pdf+%28accessed+August+11%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scotto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappulo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonomo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinchera, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, G.</span></span> <span> </span><span class="NLM_article-title">Investigational Direct-Acting Antivirals in Hepatitis C Treatment: The Latest Drugs in Clinical Development</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1517/13543784.2016.1161023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1517%2F13543784.2016.1161023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=557-572&author=I.+Gentileauthor=R.+Scottoauthor=E.+Zappuloauthor=A.+R.+Buonomoauthor=B.+Pincheraauthor=G.+Borgia&title=Investigational+Direct-Acting+Antivirals+in+Hepatitis+C+Treatment%3A+The+Latest+Drugs+in+Clinical+Development&doi=10.1517%2F13543784.2016.1161023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1517%2F13543784.2016.1161023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2016.1161023%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DScotto%26aufirst%3DR.%26aulast%3DZappulo%26aufirst%3DE.%26aulast%3DBuonomo%26aufirst%3DA.%2BR.%26aulast%3DPinchera%26aufirst%3DB.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DInvestigational%2520Direct-Acting%2520Antivirals%2520in%2520Hepatitis%2520C%2520Treatment%253A%2520The%2520Latest%2520Drugs%2520in%2520Clinical%2520Development%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D557%26epage%3D572%26doi%3D10.1517%2F13543784.2016.1161023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Feld, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hezode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruane, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruener, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abergel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towner, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svarovskaia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHutchison, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2599</span>– <span class="NLM_lpage">2607</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1512610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1056%2FNEJMoa1512610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=26571066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2599-2607&author=J.+J.+Feldauthor=I.+M.+Jacobsonauthor=C.+Hezodeauthor=T.+Asselahauthor=P.+J.+Ruaneauthor=N.+Gruenerauthor=A.+Abergelauthor=A.+Mangiaauthor=C.+L.+Laiauthor=H.+L.+Y.+Chanauthor=F.+Mazzottaauthor=C.+Morenoauthor=E.+Yoshidaauthor=S.+D.+Shafranauthor=W.+J.+Townerauthor=T.+T.+Tranauthor=J.+McNallyauthor=A.+Osinusiauthor=E.+Svarovskaiaauthor=Y.+Zhuauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=K.+Agarwalauthor=S.+Zeuzem&title=Sofosbuvir+and+Velpatasvir+for+HCV+Genotype+1%2C+2%2C+4%2C+5%2C+and+6+Infection&doi=10.1056%2FNEJMoa1512610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection</span></div><div class="casAuthors">Feld, J. J.; Jacobson, I. M.; Hezode, C.; Asselah, T.; Ruane, P. J.; Gruener, N.; Abergel, A.; Mangia, A.; Lai, C.-L.; Chan, H. L. Y.; Mazzotta, F.; Moreno, C.; Yoshida, E.; Shafran, S. D.; Towner, W. J.; Tran, T. T.; McNally, J.; Osinusi, A.; Svarovskaia, E.; Zhu, Y.; Brainard, D. M.; McHutchison, J. G.; Agarwal, K.; Zeuzem, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2599-2607</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.  We conducted a phase 3, double-blind, placebo-controlled study involving untreated and previously treated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection, including those with compensated cirrhosis.  Patients with HCV genotype 1, 2, 4, or 6 were randomly assigned in a 5:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tablet or matching placebo for 12 wk.  Because of the low prevalence of genotype 5 in the study regions, patients with genotype 5 did not undergo randomization but were assigned to the sofosbuvir-velpatasvir group.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Of the 624 patients who received treatment with sofosbuvir-velpatasvir, 34% had HCV genotype 1a, 19% genotype 1b, 17% genotype 2, 19% genotype 4, 6% genotype 5, and 7% genotype 6.  A total of 8% of patients were black, 19% had cirrhosis, and 32% had been previously treated for HCV.  The rate of sustained virol. response among patients receiving sofosbuvir-velpatasvir was 99% (95% confidence interval, 98 to >99).  Two patients receiving sofosbuvir-velpatasvir, both with HCV genotype 1, had a virol. relapse.  None of the 116 patients receiving placebo had a sustained virol. response.  Serious adverse events were reported in 15 patients (2%) in the sofosbuvir-velpatasvir group and none in the placebo group.  Once-daily sofosbuvir-velpatasvir for 12 wk provided high rates of sustained virol. response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIaLSuQe4dW7Vg90H21EOLACvtfcHk0lhQ5ZqIdaeBiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjO&md5=cb66c57f7845aff86567d3b59705faf6</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512610%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DGruener%26aufirst%3DN.%26aulast%3DAbergel%26aufirst%3DA.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DC.%2BL.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DMazzotta%26aufirst%3DF.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DYoshida%26aufirst%3DE.%26aulast%3DShafran%26aufirst%3DS.%2BD.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DSofosbuvir%2520and%2520Velpatasvir%2520for%2520HCV%2520Genotype%25201%252C%25202%252C%25204%252C%25205%252C%2520and%25206%2520Infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2599%26epage%3D2607%26doi%3D10.1056%2FNEJMoa1512610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afdhal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pianko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiffman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towner, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourliere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeuzem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stedman, C. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvory-Sobol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHutchison, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowski, M.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2608</span>– <span class="NLM_lpage">2617</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1512612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1056%2FNEJMoa1512612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=26575258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2608-2617&author=G.+R.+Fosterauthor=N.+Afdhalauthor=S.+K.+Robertsauthor=N.+Brauauthor=E.+J.+Ganeauthor=S.+Piankoauthor=E.+Lawitzauthor=A.+Thompsonauthor=M.+L.+Shiffmanauthor=C.+Cooperauthor=W.+J.+Townerauthor=B.+Conwayauthor=P.+Ruaneauthor=M.+Bourliereauthor=T.+Asselahauthor=T.+Bergauthor=S.+Zeuzemauthor=W.+Rosenbergauthor=K.+Agarwalauthor=C.+A.+M.+Stedmanauthor=H.+Moauthor=H.+Dvory-Sobolauthor=L.+Hanauthor=J.+Wangauthor=J.+McNallyauthor=A.+Osinusiauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=F.+Mazzottaauthor=T.+T.+Tranauthor=S.+C.+Gordonauthor=K.+Patelauthor=N.+Reauauthor=A.+Mangiaauthor=M.+Sulkowski&title=Sofosbuvir+and+Velpatasvir+for+HCV+Genotype+2+and+3+Infection&doi=10.1056%2FNEJMoa1512612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection</span></div><div class="casAuthors">Foster, G. R.; Afdhal, N.; Roberts, S. K.; Brau, N.; Gane, E. J.; Pianko, S.; Lawitz, E.; Thompson, A.; Shiffman, M. L.; Cooper, C.; Towner, W. J.; Conway, B.; Ruane, P.; Bourliere, M.; Asselah, T.; Berg, T.; Zeuzem, S.; Rosenberg, W.; Agarwal, K.; Stedman, C. A. M.; Mo, H.; Dvory-Sobol, H.; Han, L.; Wang, J.; McNally, J.; Osinusi, A.; Brainard, D. M.; McHutchison, J. G.; Mazzotta, F.; Tran, T. T.; Gordon, S. C.; Patel, K.; Reau, N.; Mangia, A.; Sulkowski, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2608-2617</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virol. response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3.  METHODS: We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV genotype 2 or 3 and those who had not received such treatment, including patients with compensated cirrhosis.  In one trial, patients with HCV genotype 2 were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir, in a once-daily, fixed-dose combination tablet (134 patients), or sofosbuvir plus wt.-based ribavirin (132 patients) for 12 wk.  In a second trial, patients with HCV genotype 3 were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir for 12 wk (277 patients) or sofosbuvir-ribavirin for 24 wk (275 patients).  The primary end point for the two trials was a sustained virol. response at 12 wk after the end of therapy.  RESULTS: Among patients with HCV genotype 2, the rate of sustained virol. response in the sofosbuvir-velpatasvir group was 99% (95% confidence interval [CI], 96 to 100), which was superior to the rate of 94% (95% CI, 88 to 97) in the sofosbuvir-ribavirin group (P=0.02).  Among patients with HCV genotype 3, the rate of sustained virol. response in the sofosbuvir-velpatasvir group was 95% (95% CI, 92 to 98), which was superior to the rate of 80% (95% CI, 75 to 85) in the sofosbuvir-ribavirin group (P<0.001).  The most common adverse events in the two studies were fatigue, headache, nausea, and insomnia.  CONCLUSIONS: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 wk of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virol. response that were superior to those with std. treatment with sofosbuvir-ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLv3wkT-s6bVg90H21EOLACvtfcHk0lh1Uk7zuvA1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjM&md5=d1121c329e974c100d561feda9ce76f4</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512612%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DBrau%26aufirst%3DN.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DPianko%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DRuane%26aufirst%3DP.%26aulast%3DBourliere%26aufirst%3DM.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DRosenberg%26aufirst%3DW.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DStedman%26aufirst%3DC.%2BA.%2BM.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMazzotta%26aufirst%3DF.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DReau%26aufirst%3DN.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DSulkowski%26aufirst%3DM.%26atitle%3DSofosbuvir%2520and%2520Velpatasvir%2520for%2520HCV%2520Genotype%25202%2520and%25203%2520Infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2608%26epage%3D2617%26doi%3D10.1056%2FNEJMoa1512612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulkowski, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunyady, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogurtsov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck-Radosavljevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiffman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurdaydin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgard, O.</span></span> <span> </span><span class="NLM_article-title">Management of Adverse Effects of Peg-IFN and Ribavirin Therapy for Hepatitis C</span>. <i>Nat. Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nrgastro.2011.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1038%2Fnrgastro.2011.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=21386812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFKntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=212-223&author=M.+S.+Sulkowskiauthor=C.+Cooperauthor=B.+Hunyadyauthor=J.+Jiaauthor=P.+Ogurtsovauthor=M.+Peck-Radosavljevicauthor=M.+L.+Shiffmanauthor=C.+Yurdaydinauthor=O.+Dalgard&title=Management+of+Adverse+Effects+of+Peg-IFN+and+Ribavirin+Therapy+for+Hepatitis+C&doi=10.1038%2Fnrgastro.2011.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C</span></div><div class="casAuthors">Sulkowski, Mark S.; Cooper, Curtis; Hunyady, Bela; Jia, Jidong; Ogurtsov, Pavel; Peck-Radosavljevic, Markus; Shiffman, Mitchell L.; Yurdaydin, Cihan; Dalgard, Olav</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">212-223</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A major barrier to hepatitis C treatment uptake and delivery is the assocn. of this therapy with frequent, and at times serious, adverse effects.  This Review article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.  HCV infects approx. 2-3% of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma.  Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the assocn. of this therapy with frequent and, at times, serious adverse effects.  Recognition and effective management of these adverse effects are crit. components of the successful treatment of chronic HCV infection.  In clin. trials, approx. 10-15% of patients discontinue Peg-IFN and ribavirin therapy due to adverse effects; however, in clin. practice, the rate of treatment discontinuation has been reported to be substantially higher.  The off-target effect of Peg-IFN and ribavirin impacts most, if not all, organ systems; the most common adverse effects are hematol., dermatol., neurol., immunol., gastrointestinal, pulmonary, cardiovascular, and ocular.  Regional and global variability exists in the nature of these adverse effects and the strategies employed to ameliorate their impact.  This article provides a comprehensive literature review that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and, more importantly, recommends consensus approaches to managing those effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33IzKUC2BjLVg90H21EOLACvtfcHk0lh1Uk7zuvA1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFKntr0%253D&md5=ca3908f7d85bd8b857c1c7e9429a769f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2011.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2011.21%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DHunyady%26aufirst%3DB.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DOgurtsov%26aufirst%3DP.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DYurdaydin%26aufirst%3DC.%26aulast%3DDalgard%26aufirst%3DO.%26atitle%3DManagement%2520of%2520Adverse%2520Effects%2520of%2520Peg-IFN%2520and%2520Ribavirin%2520Therapy%2520for%2520Hepatitis%2520C%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2011%26volume%3D8%26spage%3D212%26epage%3D223%26doi%3D10.1038%2Fnrgastro.2011.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vadali, L. R.</span>; <span class="NLM_string-name">Jayachandra, S.</span>; <span class="NLM_string-name">Ponduri, R.</span>; <span class="NLM_string-name">Padala, B. R.</span>; <span class="NLM_string-name">Yerva, E. R.</span>; <span class="NLM_string-name">Vemavarapu, G. P. S.</span>; <span class="NLM_string-name">Jaldu, R.</span>; <span class="NLM_string-name">Dandala, R.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Velpatasvir</span>. <span class="NLM_patent">WO 2017060820A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+R.+Vadali&author=S.+Jayachandra&author=R.+Ponduri&author=B.+R.+Padala&author=E.+R.+Yerva&author=G.+P.+S.+Vemavarapu&author=R.+Jaldu&author=R.+Dandala&title=Process+for+the+Preparation+of+Velpatasvir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVadali%26aufirst%3DL.%2BR.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Velpatasvir%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span>; <span class="NLM_string-name">Huang, C.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Cai, H.</span>; <span class="NLM_string-name">Wang, Q.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Velpatasvir and its Derivative</span>. <span class="NLM_patent">CN 106831737A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Fu&author=C.+Huang&author=Y.+Ren&author=H.+Cai&author=Q.+Wang&author=X.+Yang&author=W.+Li&title=Preparation+of+Velpatasvir+and+its+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Velpatasvir%2520and%2520its%2520Derivative%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allan, K. M.</span>; <span class="NLM_string-name">Fujimori, S.</span>; <span class="NLM_string-name">Heumann, L. V.</span>; <span class="NLM_string-name">Huynh, G. M.</span>; <span class="NLM_string-name">Keaton, K. A.</span>; <span class="NLM_string-name">Levins, C. M.</span>; <span class="NLM_string-name">Pamulapati, G. R.</span>; <span class="NLM_string-name">Roberts, B. J.</span>; <span class="NLM_string-name">Sarma, K.</span>; <span class="NLM_string-name">Teresk, M. G.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Wolckenhauer, S. A.</span></span> <span> </span><span class="NLM_article-title">Processes for Preparing Peptide Analog as Antiviral Agent</span>. <span class="NLM_patent">WO 2015191437A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+M.+Allan&author=S.+Fujimori&author=L.+V.+Heumann&author=G.+M.+Huynh&author=K.+A.+Keaton&author=C.+M.+Levins&author=G.+R.+Pamulapati&author=B.+J.+Roberts&author=K.+Sarma&author=M.+G.+Teresk&author=X.+Wang&author=S.+A.+Wolckenhauer&title=Processes+for+Preparing+Peptide+Analog+as+Antiviral+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllan%26aufirst%3DK.%2BM.%26atitle%3DProcesses%2520for%2520Preparing%2520Peptide%2520Analog%2520as%2520Antiviral%2520Agent%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.
L.</span></span> <span> </span><span class="NLM_article-title">Patent Highlights: Recently Approved HCV NS5a Drugs</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00241</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00241" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1404-1415&author=D.%0AL.+Hughes&title=Patent+Highlights%3A+Recently+Approved+HCV+NS5a+Drugs&doi=10.1021%2Facs.oprd.6b00241"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00241%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DPatent%2520Highlights%253A%2520Recently%2520Approved%2520HCV%2520NS5a%2520Drugs%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1404%26epage%3D1415%26doi%3D10.1021%2Facs.oprd.6b00241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K.</span></span> <span> </span><span class="NLM_article-title">Investigational Antimicrobial Agents of 2013</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">821</span>, <span class="refDoi"> DOI: 10.1128/CMR.00033-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1128%2FCMR.00033-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24092856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeisbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=792-821&author=M.+J.+Pucciauthor=K.+Bush&title=Investigational+Antimicrobial+Agents+of+2013&doi=10.1128%2FCMR.00033-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational antimicrobial agents of 2013</span></div><div class="casAuthors">Pucci, Michael J.; Bush, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">792-821</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">1098-6618</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  New antimicrobial agents are always needed to counteract the resistant pathogens that continue to be selected by current therapeutic regimens.  This review provides a survey of known antimicrobial agents that were currently in clin. development in the fall of 2012 and spring of 2013.  Data were collected from published literature primarily from 2010 to 2012, meeting abstrs. (2011 to 2012), government websites, and company websites when appropriate.  Compared to what was reported in previous surveys, a surprising no. of new agents are currently in company pipelines, particularly in phase 3 clin. development.  Familiar antibacterial classes of the quinolones, tetracyclines, oxazolidinones, glycopeptides, and cephalosporins are represented by entities with enhanced antimicrobial or pharmacol. properties.  More importantly, compds. of novel chem. structures targeting bacterial pathways not previously exploited are under development.  Some of the most promising compds. include novel β-lactamase inhibitor combinations that target many multidrug-resistant Gram-neg. bacteria, a crit. medical need.  Although new antimicrobial agents will continue to be needed to address increasing antibiotic resistance, there are novel agents in development to tackle at least some of the more worrisome pathogens in the current nosocomial setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplxIxdr3xTuLVg90H21EOLACvtfcHk0lhVWKRsbAnkLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeisbrN&md5=415944588f6321f289d3b52dafa42251</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1128%2FCMR.00033-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00033-13%26sid%3Dliteratum%253Aachs%26aulast%3DPucci%26aufirst%3DM.%2BJ.%26aulast%3DBush%26aufirst%3DK.%26atitle%3DInvestigational%2520Antimicrobial%2520Agents%2520of%25202013%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2013%26volume%3D26%26spage%3D792%26epage%3D821%26doi%3D10.1128%2FCMR.00033-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kocsis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, D.</span></span> <span> </span><span class="NLM_article-title">Zabofloxacin for Chronic Bronchitis</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1358/dot.2016.52.9.2530595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1358%2Fdot.2016.52.9.2530595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgtVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=495-500&author=B.+Kocsisauthor=D.+Szabo&title=Zabofloxacin+for+Chronic+Bronchitis&doi=10.1358%2Fdot.2016.52.9.2530595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Zabofloxacin for chronic bronchitis</span></div><div class="casAuthors">Kocsis B; Szabo D</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">495-500</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Treatment of lower respiratory tract infection poses as an ongoing challenge among respiratory tract diseases.  Bacterial infections are causes of acute exacerbations in chronic bronchitis and indications for antibacterial therapy.  Several antibiotics were applied to treat bacterial infections in chronic bronchitis, among them fluoroquinolones are considered potent, broad-spectrum agents with excellent tissue penetration.  This monograph focuses on zabofloxacin, a novel fluoroquinolone agent recently approved and launched in South Korea, and summarizes the drug's antibacterial efficacy, pharmacokinetic properties and toxicity.  Recent advances concerning fluoroquinolones in chronic bronchitis will be discussed, along with a comparison between zabofloxacin and moxifloxacin.  Zabofloxacin has proved to be noninferior to moxifloxacin against major community-acquired Gram-positive and Gram-negative respiratory tract pathogens and found to be well tolerated in both oral and parenteral administrations.  These features can make it a potential antimicrobial agent in therapy of chronic bronchitis and other lower respiratory tract infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOIXkJaUrUfaNc3HjJRoFAfW6udTcc2eZ0l3RySnzorrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgtVSnsg%253D%253D&md5=5f2701fa45748ac048fae1d01df41225</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.9.2530595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.9.2530595%26sid%3Dliteratum%253Aachs%26aulast%3DKocsis%26aufirst%3DB.%26aulast%3DSzabo%26aufirst%3DD.%26atitle%3DZabofloxacin%2520for%2520Chronic%2520Bronchitis%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D495%26epage%3D500%26doi%3D10.1358%2Fdot.2016.52.9.2530595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span> <a href="https://www.dong-wha.co.kr/english/customer/dnews/content.asp?t_idx=856" class="extLink">https://www.dong-wha.co.kr/english/customer/dnews/content.asp?t_idx=856</a> (accessed Aug. 12, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+https%3A%2F%2Fwww.dong-wha.co.kr%2Fenglish%2Fcustomer%2Fdnews%2Fcontent.asp%3Ft_idx%3D856+%28accessed+Aug.+12%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, J.-H.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial Activity of Zabofloxacin Against Clinically Isolated Streptococcus Pneumoniae</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1562</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.3390/molecules21111562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.3390%2Fmolecules21111562" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1-8&issue=1562&author=H.-S.+Parkauthor=S.-H.+Ohauthor=H.-S.+Kimauthor=D.-R.+Choiauthor=J.-H.+Kwak&title=Antimicrobial+Activity+of+Zabofloxacin+Against+Clinically+Isolated+Streptococcus+Pneumoniae&doi=10.3390%2Fmolecules21111562"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21111562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21111562%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.-S.%26aulast%3DOh%26aufirst%3DS.-H.%26aulast%3DKim%26aufirst%3DH.-S.%26aulast%3DChoi%26aufirst%3DD.-R.%26aulast%3DKwak%26aufirst%3DJ.-H.%26atitle%3DAntimicrobial%2520Activity%2520of%2520Zabofloxacin%2520Against%2520Clinically%2520Isolated%2520Streptococcus%2520Pneumoniae%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D1562%26spage%3D1%26epage%3D8%26doi%3D10.3390%2Fmolecules21111562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. J.</span>; <span class="NLM_string-name">Chung, Y. H.</span>; <span class="NLM_string-name">Lee, C. W.</span>; <span class="NLM_string-name">Oh, Y. S.</span>; <span class="NLM_string-name">Kim, N. D.</span>; <span class="NLM_string-name">Lim, J. K.</span>; <span class="NLM_string-name">Jin, Y. H.</span></span> <span> </span><span class="NLM_article-title">Quinolone Carboxylic Acid Derivatives</span>. <span class="NLM_patent">WO 1999000393A1</span>, <span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=S.+J.+Yoon&author=Y.+H.+Chung&author=C.+W.+Lee&author=Y.+S.+Oh&author=N.+D.+Kim&author=J.+K.+Lim&author=Y.+H.+Jin&title=Quinolone+Carboxylic+Acid+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26atitle%3DQuinolone%2520Carboxylic%2520Acid%2520Derivatives%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. J.</span>; <span class="NLM_string-name">Chung, Y. H.</span>; <span class="NLM_string-name">Lee, C. W.</span>; <span class="NLM_string-name">Oh, Y. S.</span>; <span class="NLM_string-name">Kim, N. D.</span>; <span class="NLM_string-name">Lim, J. K.</span>; <span class="NLM_string-name">Jin, Y. H.</span></span> <span> </span><span class="NLM_article-title">Quinolone Carboxylic Acid Derivatives</span>. <span class="NLM_patent">US 20020035258A1</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=S.+J.+Yoon&author=Y.+H.+Chung&author=C.+W.+Lee&author=Y.+S.+Oh&author=N.+D.+Kim&author=J.+K.+Lim&author=Y.+H.+Jin&title=Quinolone+Carboxylic+Acid+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26atitle%3DQuinolone%2520Carboxylic%2520Acid%2520Derivatives%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, D.-R.</span>; <span class="NLM_string-name">Lim, J.-K.</span>; <span class="NLM_string-name">Choi, J.-U.</span>; <span class="NLM_string-name">Shin, D.-H.</span>; <span class="NLM_string-name">Kim, S.-H.</span>; <span class="NLM_string-name">Won, D.-Y.</span>; <span class="NLM_string-name">Kim, J.-H.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of Zabofloxacin</span>. <span class="NLM_patent">WO 2015178663</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=D.-R.+Choi&author=J.-K.+Lim&author=J.-U.+Choi&author=D.-H.+Shin&author=S.-H.+Kim&author=D.-Y.+Won&author=J.-H.+Kim&title=Method+for+the+Preparation+of+Zabofloxacin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DD.-R.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%2520Zabofloxacin%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0555-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0555-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=517-522&author=A.+Markham&title=Brivaracetam%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0555-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0555-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0555-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBrivaracetam%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D517%26epage%3D522%26doi%3D10.1007%2Fs40265-016-0555-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit42b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strzelczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam in the Treatment of Focal and Idiopathic Generalized Epilepsies and of Status Epilepticus</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1586/17512433.2016.1156529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1586%2F17512433.2016.1156529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=26891946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslKhur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=637-645&author=A.+Strzelczykauthor=K.+M.+Kleinauthor=L.+M.+Willemsauthor=F.+Rosenowauthor=S.+Bauer&title=Brivaracetam+in+the+Treatment+of+Focal+and+Idiopathic+Generalized+Epilepsies+and+of+Status+Epilepticus&doi=10.1586%2F17512433.2016.1156529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42bR"><div class="casContent"><span class="casTitleNuber">42b</span><div class="casTitle"><span class="NLM_cas:atitle">Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus</span></div><div class="casAuthors">Strzelczyk, Adam; Klein, Karl Martin; Willems, Laurent M.; Rosenow, Felix; Bauer, Sebastian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Brivaracetam is the latest approved antiepileptic drug in focal epilepsy and exhibits high affinity as SV2A-ligand.  More than two thousand patients have received brivaracetam within randomized placebo-controlled trials.  Significant median seizure redn. rates of 30.5% to 53.1% for 50 mg/d, 32.5% to 37.2% for 100 mg/d and 35.6% for 200 mg/d were reported.  Likewise, 50% responder rates were 32.7% to 55.8% for 50 mg/d, 36% to 38.9% for 100 mg/d and 37.8% for 200 mg/d.  Overall, brivaracetam is well tolerated.  The main adverse events are fatigue, dizziness, and somnolence.  Immediate switch from levetiracetam to brivaracetam at a conversion ratio between 10:1 to 15:1 is feasible, and might alleviate the behavioral side effects assocd. with levetiracetam.  Brivaracetam has the potential to perform as an important, possibly broad-spectrum AED, initially in patients with drug-refractory epilepsies.  Its i.v. formulation may be a new and desirable alternative for status epilepticus, but there is so far no experience in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcZJoGGzs7prVg90H21EOLACvtfcHk0lg7yg8b1MyK-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslKhur8%253D&md5=a506586431d126d2e7ea7045fc9abbad</span></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1586%2F17512433.2016.1156529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17512433.2016.1156529%26sid%3Dliteratum%253Aachs%26aulast%3DStrzelczyk%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DK.%2BM.%26aulast%3DWillems%26aufirst%3DL.%2BM.%26aulast%3DRosenow%26aufirst%3DF.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DBrivaracetam%2520in%2520the%2520Treatment%2520of%2520Focal%2520and%2520Idiopathic%2520Generalized%2520Epilepsies%2520and%2520of%2520Status%2520Epilepticus%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D9%26spage%3D637%26epage%3D645%26doi%3D10.1586%2F17512433.2016.1156529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klitgaard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matagne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberty, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ryck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niespodziany, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannestad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kervyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenda, B.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam: Rationale for Discovery and Preclinical Profile of a Selective SV2A Ligand for Epilepsy Treatment</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1111/epi.13340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1111%2Fepi.13340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=538-548&author=H.+Klitgaardauthor=A.+Matagneauthor=J.-M.+Nicolasauthor=M.+Gillardauthor=Y.+Lambertyauthor=M.+De+Ryckauthor=R.+M.+Kaminskiauthor=K.+Leclercqauthor=I.+Niespodzianyauthor=C.+Wolffauthor=M.+Woodauthor=J.+Hannestadauthor=S.+Kervynauthor=B.+Kenda&title=Brivaracetam%3A+Rationale+for+Discovery+and+Preclinical+Profile+of+a+Selective+SV2A+Ligand+for+Epilepsy+Treatment&doi=10.1111%2Fepi.13340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1111%2Fepi.13340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fepi.13340%26sid%3Dliteratum%253Aachs%26aulast%3DKlitgaard%26aufirst%3DH.%26aulast%3DMatagne%26aufirst%3DA.%26aulast%3DNicolas%26aufirst%3DJ.-M.%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DLamberty%26aufirst%3DY.%26aulast%3DDe%2BRyck%26aufirst%3DM.%26aulast%3DKaminski%26aufirst%3DR.%2BM.%26aulast%3DLeclercq%26aufirst%3DK.%26aulast%3DNiespodziany%26aufirst%3DI.%26aulast%3DWolff%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DHannestad%26aufirst%3DJ.%26aulast%3DKervyn%26aufirst%3DS.%26aulast%3DKenda%26aufirst%3DB.%26atitle%3DBrivaracetam%253A%2520Rationale%2520for%2520Discovery%2520and%2520Preclinical%2520Profile%2520of%2520a%2520Selective%2520SV2A%2520Ligand%2520for%2520Epilepsy%2520Treatment%26jtitle%3DEpilepsia%26date%3D2016%26volume%3D57%26spage%3D538%26epage%3D548%26doi%3D10.1111%2Fepi.13340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenda, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matagne, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaga, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasau, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Differding, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallemand, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frycia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moureau, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klitgaard, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuks, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1021/jm030913e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030913e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=530-549&author=B.+M.+Kendaauthor=A.+C.+Matagneauthor=P.+E.+Talagaauthor=P.+M.+Pasauauthor=E.+Differdingauthor=B.+I.+Lallemandauthor=A.+M.+Fryciaauthor=F.+G.+Moureauauthor=H.+V.+Klitgaardauthor=M.+R.+Gillardauthor=B.+Fuksauthor=P.+Michel&title=Discovery+of+4-Substituted+Pyrrolidone+Butanamides+as+New+Agents+with+Significant+Antiepileptic+Activity&doi=10.1021%2Fjm030913e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm030913e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030913e%26sid%3Dliteratum%253Aachs%26aulast%3DKenda%26aufirst%3DB.%2BM.%26aulast%3DMatagne%26aufirst%3DA.%2BC.%26aulast%3DTalaga%26aufirst%3DP.%2BE.%26aulast%3DPasau%26aufirst%3DP.%2BM.%26aulast%3DDifferding%26aufirst%3DE.%26aulast%3DLallemand%26aufirst%3DB.%2BI.%26aulast%3DFrycia%26aufirst%3DA.%2BM.%26aulast%3DMoureau%26aufirst%3DF.%2BG.%26aulast%3DKlitgaard%26aufirst%3DH.%2BV.%26aulast%3DGillard%26aufirst%3DM.%2BR.%26aulast%3DFuks%26aufirst%3DB.%26aulast%3DMichel%26aufirst%3DP.%26atitle%3DDiscovery%2520of%25204-Substituted%2520Pyrrolidone%2520Butanamides%2520as%2520New%2520Agents%2520with%2520Significant%2520Antiepileptic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D530%26epage%3D549%26doi%3D10.1021%2Fjm030913e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Surtees, J.</span>; <span class="NLM_string-name">Lurquin, F.</span>; <span class="NLM_string-name">Diouf, O.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing N-Substituted 2-oxo-Pyrrolidines Such as Levetiracetam from Dihydrofurans and Amines</span>. <span class="NLM_patent">WO 2005028435A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+Surtees&author=F.+Lurquin&author=O.+Diouf&title=Process+for+Preparing+N-Substituted+2-oxo-Pyrrolidines+Such+as+Levetiracetam+from+Dihydrofurans+and+Amines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSurtees%26aufirst%3DJ.%26atitle%3DProcess%2520for%2520Preparing%2520N-Substituted%25202-oxo-Pyrrolidines%2520Such%2520as%2520Levetiracetam%2520from%2520Dihydrofurans%2520and%2520Amines%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ates, C.</span>; <span class="NLM_string-name">Lurquin, F.</span>; <span class="NLM_string-name">Quesnel, Y.</span>; <span class="NLM_string-name">Schule, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-Substituted-Pyrrolidin-2-ones and their Uses for the Synthesis of 2-oxo-Pyrrolidin-1-yl Derivatives</span>. <span class="NLM_patent">WO 2007031263A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Ates&author=F.+Lurquin&author=Y.+Quesnel&author=A.+Schule&title=Preparation+of+4-Substituted-Pyrrolidin-2-ones+and+their+Uses+for+the+Synthesis+of+2-oxo-Pyrrolidin-1-yl+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAtes%26aufirst%3DC.%26atitle%3DPreparation%2520of%25204-Substituted-Pyrrolidin-2-ones%2520and%2520their%2520Uses%2520for%2520the%2520Synthesis%2520of%25202-oxo-Pyrrolidin-1-yl%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit45c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ates, C.</span>; <span class="NLM_string-name">Schule, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-Carbamoylalkyl-3-Carboxy-2-Oxopyrrolidines</span>. <span class="NLM_patent">WO 2007065634A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=C.+Ates&author=A.+Schule&title=Preparation+of+1-Carbamoylalkyl-3-Carboxy-2-Oxopyrrolidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAtes%26aufirst%3DC.%26atitle%3DPreparation%2520of%25201-Carbamoylalkyl-3-Carboxy-2-Oxopyrrolidines%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit45d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Defrance, T.</span>; <span class="NLM_string-name">Septavaux, J.</span>; <span class="NLM_string-name">Nuel, D.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Brivaracetam</span>. <span class="NLM_patent">WO 2017076738 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=T.+Defrance&author=J.+Septavaux&author=D.+Nuel&title=Process+for+Preparing+Brivaracetam"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDefrance%26aufirst%3DT.%26atitle%3DProcess%2520for%2520Preparing%2520Brivaracetam%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schülé, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merschaert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczepaniak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maréchal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ates, C.</span></span> <span> </span><span class="NLM_article-title">A Biocatalytic Route to the Novel Antiepileptic Drug Brivaracetam</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1566-1575&author=A.+Sch%C3%BCl%C3%A9author=A.+Merschaertauthor=C.+Szczepaniakauthor=C.+Mar%C3%A9chalauthor=N.+Carlyauthor=J.+O%E2%80%99Rourkeauthor=C.+Ates&title=A+Biocatalytic+Route+to+the+Novel+Antiepileptic+Drug+Brivaracetam&doi=10.1021%2Facs.oprd.6b00094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00094%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCl%25C3%25A9%26aufirst%3DA.%26aulast%3DMerschaert%26aufirst%3DA.%26aulast%3DSzczepaniak%26aufirst%3DC.%26aulast%3DMar%25C3%25A9chal%26aufirst%3DC.%26aulast%3DCarly%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DJ.%26aulast%3DAtes%26aufirst%3DC.%26atitle%3DA%2520Biocatalytic%2520Route%2520to%2520the%2520Novel%2520Antiepileptic%2520Drug%2520Brivaracetam%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1566%26epage%3D1575%26doi%3D10.1021%2Facs.oprd.6b00094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span>; <span class="NLM_string-name">Li, P.</span>; <span class="NLM_string-name">Wei, Q.</span>; <span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Processes to Produce Brivaracetam</span>. <span class="NLM_patent">WO 2016191435A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+Wang&author=P.+Li&author=Q.+Wei&author=Y.+Liu&title=Processes+to+Produce+Brivaracetam"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26atitle%3DProcesses%2520to%2520Produce%2520Brivaracetam%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learmonth, D. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3396</span>– <span class="NLM_lpage">3411</span>, <span class="refDoi"> DOI: 10.1021/jm1001524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1001524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3396-3411&author=L.+E.+Kissauthor=H.+S.+Ferreiraauthor=L.+Torraoauthor=M.+J.+Bonifacioauthor=P.+N.+Palmaauthor=P.+Soares-da-Silvaauthor=D.+A.+Learmonth&title=Discovery+of+a+Long-Acting%2C+Peripherally+Selective+Inhibitor+of+Catechol-O-methyltransferase&doi=10.1021%2Fjm1001524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm1001524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1001524%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DL.%2BE.%26aulast%3DFerreira%26aufirst%3DH.%2BS.%26aulast%3DTorrao%26aufirst%3DL.%26aulast%3DBonifacio%26aufirst%3DM.%2BJ.%26aulast%3DPalma%26aufirst%3DP.%2BN.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26aulast%3DLearmonth%26aufirst%3DD.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520Long-Acting%252C%2520Peripherally%2520Selective%2520Inhibitor%2520of%2520Catechol-O-methyltransferase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3396%26epage%3D3411%26doi%3D10.1021%2Fjm1001524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Opicapone: A Review in Parkinson’s Disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0623-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0623-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1293-300&author=L.+J.+Scott&title=Opicapone%3A+A+Review+in+Parkinson%E2%80%99s+Disease&doi=10.1007%2Fs40265-016-0623-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0623-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0623-y%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DOpicapone%253A%2520A%2520Review%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1293%26epage%3D300%26doi%3D10.1007%2Fs40265-016-0623-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span>; <span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Opicapone Hydrate and its Preparation</span>. <span class="NLM_patent">CN 106543160</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Yan&author=X.+Li&title=Opicapone+Hydrate+and+its+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DJ.%26atitle%3DOpicapone%2520Hydrate%2520and%2520its%2520Preparation%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit50b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Charvin, D.</span>; <span class="NLM_string-name">Conquet, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of a Brain-Penetrant Chromone Oxime Derivative for the Therapy of Levodopa-Induced Dyskinesia</span>. <span class="NLM_patent">WO 2017032874A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Charvin&author=F.+Conquet&title=Preparation+of+a+Brain-Penetrant+Chromone+Oxime+Derivative+for+the+Therapy+of+Levodopa-Induced+Dyskinesia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharvin%26aufirst%3DD.%26atitle%3DPreparation%2520of%2520a%2520Brain-Penetrant%2520Chromone%2520Oxime%2520Derivative%2520for%2520the%2520Therapy%2520of%2520Levodopa-Induced%2520Dyskinesia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit50c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss Laszlo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of Catechol O-methyltransferase (COMT) Inhibitors and their Therapeutic Utility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8692</span>– <span class="NLM_lpage">8717</span>, <span class="refDoi"> DOI: 10.1021/jm500572b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500572b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8692-8717&author=E.+Kiss+Laszloauthor=P.+Soares-da-Silva&title=Medicinal+Chemistry+of+Catechol+O-methyltransferase+%28COMT%29+Inhibitors+and+their+Therapeutic+Utility&doi=10.1021%2Fjm500572b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50c&amp;dbid=16384&amp;doi=10.1021%2Fjm500572b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500572b%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%2BLaszlo%26aufirst%3DE.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DMedicinal%2520Chemistry%2520of%2520Catechol%2520O-methyltransferase%2520%2528COMT%2529%2520Inhibitors%2520and%2520their%2520Therapeutic%2520Utility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8692%26epage%3D8717%26doi%3D10.1021%2Fjm500572b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit50d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D.</span>; <span class="NLM_string-name">Kiss, L.
E.</span>; <span class="NLM_string-name">Wahnon, J.
B. R.</span>; <span class="NLM_string-name">Learmonth, D. A.</span>; <span class="NLM_string-name">Eszenyi, T.</span>; <span class="NLM_string-name">Zimmermann, A.</span>; <span class="NLM_string-name">Schlummer, B.</span>; <span class="NLM_string-name">Kreis, M.</span>; <span class="NLM_string-name">Reiter, K.</span></span> <span> </span><span class="NLM_article-title">A [1,2,4]Oxadiazo Derivative as an Intermediate for Preparation of a Catechol-O-methyltransferase Inhibitor Useful in Treatment of Parkinson’s Disease via Demethylation and its Preparation</span>. <span class="NLM_patent">WO 2013089573A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+Russo&author=L.%0AE.+Kiss&author=J.%0AB.+R.+Wahnon&author=D.+A.+Learmonth&author=T.+Eszenyi&author=A.+Zimmermann&author=B.+Schlummer&author=M.+Kreis&author=K.+Reiter&title=A+%5B1%2C2%2C4%5DOxadiazo+Derivative+as+an+Intermediate+for+Preparation+of+a+Catechol-O-methyltransferase+Inhibitor+Useful+in+Treatment+of+Parkinson%E2%80%99s+Disease+via+Demethylation+and+its+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DD.%26atitle%3DA%2520%255B1%252C2%252C4%255DOxadiazo%2520Derivative%2520as%2520an%2520Intermediate%2520for%2520Preparation%2520of%2520a%2520Catechol-O-methyltransferase%2520Inhibitor%2520Useful%2520in%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%2520via%2520Demethylation%2520and%2520its%2520Preparation%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit50e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Learmonth, D. A.</span>; <span class="NLM_string-name">Kiss, L. E.</span>; <span class="NLM_string-name">Palma, P. N. L.</span>; <span class="NLM_string-name">Ferreira, H. d. S.</span>; <span class="NLM_string-name">Soares da Silva, P. M. V. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyridyloxadiazolylnitrobenzenediols and Related Compounds as Catechol O-methyltransferase (COMT) Inhibitors</span>. <span class="NLM_patent">WO 2007013830</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+A.+Learmonth&author=L.+E.+Kiss&author=P.+N.+L.+Palma&author=H.+d.+S.+Ferreira&author=P.+M.+V.+A.+Soares+da+Silva&title=Preparation+of+Pyridyloxadiazolylnitrobenzenediols+and+Related+Compounds+as+Catechol+O-methyltransferase+%28COMT%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLearmonth%26aufirst%3DD.%2BA.%26atitle%3DPreparation%2520of%2520Pyridyloxadiazolylnitrobenzenediols%2520and%2520Related%2520Compounds%2520as%2520Catechol%2520O-methyltransferase%2520%2528COMT%2529%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Pimavanserin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0597-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0597-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27262680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVymsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1053-1057&author=A.+Markham&title=Pimavanserin%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0597-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Pimavanserin: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Pimavanserin (Nuplazid) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions assocd. with Parkinson's disease psychosis.  Up to 60 % of patients with Parkinson's disease may develop Parkinson's disease psychosis, which is assocd. with increased morbidity and mortality and has few treatment options.  This article summarizes the milestones in the development of pimavanserin leading to this first approval for the treatment of hallucinations and delusions in patients with Parkinson's disease psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ_xydJCF-PbVg90H21EOLACvtfcHk0lgGasXge2UQHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVymsbw%253D&md5=585f3e5fd625a7ea0a749e47bd26e528</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0597-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0597-9%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DPimavanserin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1053%26epage%3D1057%26doi%3D10.1007%2Fs40265-016-0597-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm</a> (accessed Aug. 12, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm498442.htm+%28accessed+Aug.+12%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. H.</span></span> <span> </span><span class="NLM_article-title">Pimavanserin for the Treatment of Parkinson’s Disease Psychosis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1969</span>– <span class="NLM_lpage">1975</span>, <span class="refDoi"> DOI: 10.1517/14656566.2013.819345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1517%2F14656566.2013.819345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24016069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVektr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=1969-1975&author=J.+H.+Friedman&title=Pimavanserin+for+the+Treatment+of+Parkinson%E2%80%99s+Disease+Psychosis&doi=10.1517%2F14656566.2013.819345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Pimavanserin for the treatment of Parkinson's disease psychosis</span></div><div class="casAuthors">Friedman, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1969-1975</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Parkinson's disease (PD) is a neurobehavioral disorder defined by its motor features.  Its treatment is frequently complicated by the presence of psychotic symptoms, most prominently hallucinations and delusions.  These cause major distress and are the primary cause for nursing home placement.  Current treatment requires either a redn. in medications for mobility or the addn. of atypical antipsychotics, none of which are approved in the United States, and which are assocd. with major potential drawbacks.  Areas covered: Information from extensive personal experience, a Pubmed literature search plus a direct request to Acadia Pharmaceuticals was used for this review.  A brief review of the clin. problem and its current state of treatment will be followed by a discussion of and its potential role in treating PD psychosis (PDP).  Several observations have implicated serotonin in the physiol. of psychotic symptoms.  Lysergic acid diethylamide, phencyclidine, and similar drugs that activate 5HT2A serotonin receptors produce psychotic syndromes, and almost all antipsychotic neuroleptics share the property of blocking the 5HT2A receptor as well as the dopamine D2 receptor.  The reduced motor side effects of the second-generation antipsychotics have been ascribed to these drugs having greater 5HT2A antagonism than the first generation.  Studies in animal models of psychosis have suggested benefits from drugs blocking the 5HT2A receptor alone without the motor side effects seen with D2 receptor antagonism.  Expert opinion: Pimavanserin, a 5HT2A inverse agonist, has no motor side effects, and a remarkable safety profile that is comparable to placebo.  Its antipsychotic effects coupled with its lack of motor side effects could make it an ideal drug for treating psychotic symptoms in PD, a major unmet need.  One Phase III trial in PDP has demonstrated excellent tolerability and significant benefit.  The FDA agreed to the filing of a planned new drug approval (NDA) for an indication in the treatment of PDP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjQlHPn5mj8LVg90H21EOLACvtfcHk0lgGasXge2UQHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVektr7P&md5=a0628bdf46546aa59074695659b69644</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.819345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.819345%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DJ.%2BH.%26atitle%3DPimavanserin%2520for%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%2520Psychosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D1969%26epage%3D1975%26doi%3D10.1517%2F14656566.2013.819345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Thygesen, M.</span>; <span class="NLM_string-name">Schlienger, N.</span>; <span class="NLM_string-name">Tolf, B. R.</span>; <span class="NLM_string-name">Blatter, F.</span>; <span class="NLM_string-name">Berghausen, J.</span></span> <span> </span><span class="NLM_article-title">Salts of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-yl)-N′-(4-(2-Methylpropyloxy)phenylmethyl)carbamide and their Preparation</span>. <span class="NLM_patent">WO 2006036874A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.+Thygesen&author=N.+Schlienger&author=B.+R.+Tolf&author=F.+Blatter&author=J.+Berghausen&title=Salts+of+N-%284-Fluorobenzyl%29-N-%281-Methylpiperidin-4-yl%29-N%E2%80%B2-%284-%282-Methylpropyloxy%29phenylmethyl%29carbamide+and+their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThygesen%26aufirst%3DM.%26atitle%3DSalts%2520of%2520N-%25284-Fluorobenzyl%2529-N-%25281-Methylpiperidin-4-yl%2529-N%25E2%2580%25B2-%25284-%25282-Methylpropyloxy%2529phenylmethyl%2529carbamide%2520and%2520their%2520Preparation%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit54b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span>; <span class="NLM_string-name">Sarshar, S.</span></span> <span> </span><span class="NLM_article-title">Substituted Ureas</span>. <span class="NLM_patent">US 20080280886A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+G.+Gant&author=S.+Sarshar&title=Substituted+Ureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DSubstituted%2520Ureas%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit54c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, R.</span>; <span class="NLM_string-name">Williams, H. L.</span></span> <span> </span><span class="NLM_article-title">Methods for the Treatment of Parkinson’s Disease Psychosis using Pimavanserin</span>. <span class="NLM_patent">WO 2014085362A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+Mills&author=H.+L.+Williams&title=Methods+for+the+Treatment+of+Parkinson%E2%80%99s+Disease+Psychosis+using+Pimavanserin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DR.%26atitle%3DMethods%2520for%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%2520Psychosis%2520using%2520Pimavanserin%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Pitolisant: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0620-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0620-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27438291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cjs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1313-1318&author=Y.+Y.+Syed&title=Pitolisant%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0620-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55aR"><div class="casContent"><span class="casTitleNuber">55a</span><div class="casTitle"><span class="NLM_cas:atitle">Pitolisant: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1313-1318</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Pitolisant (Wakix) is an inverse agonist of the histamine H3 receptor that is being developed by Bioproject.  Oral pitolisant is approved in the EU for the treatment of narcolepsy with or without cataplexy in adults.  Pitolisant has received a Temporary Authorization of Use in France for this indication in case of treatment failure, intolerance or contraindication to currently available treatment.  Pitolisant has orphan drug designation in the EU and the USA.  In the pivotal HARMONY I trial, pitolisant significantly decreased excessive daytime sleepiness vs. placebo in adults with narcolepsy with or without cataplexy (primary endpoint).  Pitolisant also significantly decreased cataplexy rate vs. placebo in these patients.  This article summarizes the milestones in the development of pitolisant leading to this first approval for narcolepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD9azvoq-Jj7Vg90H21EOLACvtfcHk0lgGasXge2UQHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cjs7zK&md5=2a74af8516916b9c3d9d9c9ad1ba5cc7</span></div><a href="/servlet/linkout?suffix=cit55a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0620-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0620-1%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DPitolisant%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1313%26epage%3D1318%26doi%3D10.1007%2Fs40265-016-0620-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit55b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kollb-Sielecka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demolis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmonson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, M.</span></span> <span> </span><span class="NLM_article-title">The European Medicines Agency Review of Pitolisant for Treatment of Narcolepsy: Summary of the Scientific Assessment by the Committee for Medicinal Products for Human Use</span>. <i>Sleep Medicine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.sleep.2017.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.sleep.2017.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28449891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC1crhvVGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=125-129&author=M.+Kollb-Sieleckaauthor=P.+Demolisauthor=J.+Emmerichauthor=G.+Markeyauthor=T.+Salmonsonauthor=M.+Haas&title=The+European+Medicines+Agency+Review+of+Pitolisant+for+Treatment+of+Narcolepsy%3A+Summary+of+the+Scientific+Assessment+by+the+Committee+for+Medicinal+Products+for+Human+Use&doi=10.1016%2Fj.sleep.2017.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55bR"><div class="casContent"><span class="casTitleNuber">55b</span><div class="casTitle"><span class="NLM_cas:atitle">The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use</span></div><div class="casAuthors">Kollb-Sielecka Marta; Demolis Pierre; Emmerich Joseph; Markey Greg; Salmonson Tomas; Haas Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">125-129</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">On 31 March 2016, the European Commission issued a decision for a marketing authorisation valid throughout the European Union (EU) for pitolisant (Wakix) for the treatment of narcolepsy with or without cataplexy in adults.  Pitolisant is an antagonist/inverse agonist of the human histamine H3 receptor.  The dose should be selected using an up-titration scheme depending on individual patient response and tolerance and should not exceed 36 mg/day.  The main evidence of efficacy of pitolisant was based on two Phase III clinical trials.  The improvement on excessive daytime sleepiness was shown against placebo in the Harmony I study (-3.33 points; 95% confidence interval (CI) [-5.83; -0.83]; p = 0.024) and in Harmony CTP (-3.41 points; 95% CI [-4.95; -1.87]; p < 0.0001).  The daily cataplexy rate in Harmony I improved against placebo with a rate ratio (rR) of 0.38 whilst in the Harmony CTP the ratio of improvement on weekly cataplexy rate against placebo was 0.512.  The most commonly reported adverse reactions were headache, insomnia and nausea.  This article summarizes the scientific review leading to approval of pitolisant in the EU.  The assessment report and product information are available on the European Medicines Agency website (http://www.ema.europa.eu).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm-VCMMXIrVkNoizSOkG_FfW6udTcc2eY0AvVOrWl6jLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhvVGnsg%253D%253D&md5=2f820dc747146322af50c191bb0c0f98</span></div><a href="/servlet/linkout?suffix=cit55b&amp;dbid=16384&amp;doi=10.1016%2Fj.sleep.2017.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sleep.2017.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DKollb-Sielecka%26aufirst%3DM.%26aulast%3DDemolis%26aufirst%3DP.%26aulast%3DEmmerich%26aufirst%3DJ.%26aulast%3DMarkey%26aufirst%3DG.%26aulast%3DSalmonson%26aufirst%3DT.%26aulast%3DHaas%26aufirst%3DM.%26atitle%3DThe%2520European%2520Medicines%2520Agency%2520Review%2520of%2520Pitolisant%2520for%2520Treatment%2520of%2520Narcolepsy%253A%2520Summary%2520of%2520the%2520Scientific%2520Assessment%2520by%2520the%2520Committee%2520for%2520Medicinal%2520Products%2520for%2520Human%2520Use%26jtitle%3DSleep%2520Medicine%26date%3D2017%26volume%3D33%26spage%3D125%26epage%3D129%26doi%3D10.1016%2Fj.sleep.2017.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dauvilliers, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnulf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodenbeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecomte, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span> <span> </span><span class="NLM_article-title">Pitolisant Versus Placebo or Modafinil in Patients with Narcolepsy: A Double-blind, Randomised Trial</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70225-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS1474-4422%2813%2970225-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24107292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyrsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1068-1075&author=Y.+Dauvilliersauthor=C.+Bassettiauthor=G.+J.+Lammersauthor=I.+Arnulfauthor=G.+Mayerauthor=A.+Rodenbeckauthor=P.+Lehertauthor=C.-L.+Dingauthor=J.-M.+Lecomteauthor=J.-C.+Schwartz&title=Pitolisant+Versus+Placebo+or+Modafinil+in+Patients+with+Narcolepsy%3A+A+Double-blind%2C+Randomised+Trial&doi=10.1016%2FS1474-4422%2813%2970225-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial</span></div><div class="casAuthors">Dauvilliers, Yves; Bassetti, Claudio; Lammers, Gert Jan; Arnulf, Isabelle; Mayer, Geert; Rodenbeck, Andrea; Lehert, Philippe; Ding, Claire-Li; Lecomte, Jeanne-Marie; Schwartz, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1068-1075</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Narcolepsy is characterized by excessive daytime sleepiness (EDS) and cataplexy.  Histamine neurons are crucial to maintain wakefulness.  We assessed the safety and efficacy of pitolisant (previously called BF2.649), a selective histamine H3 receptor inverse agonist that activates these neurons, in patients with narcolepsy.For this double-blind, randomized, parallel-group controlled trial, we recruited patients with narcolepsy from 32 sleep disorder centers in five European countries.  Patients were eligible if they were aged 18 years or older, had not taken psychostimulants for at least 14 days, and had EDS (defined as an Epworth Sleepiness Scale [ESS] score of at least 14).  Using a computer-generated randomization sequence, we randomly allocated patients to receive pitolisant, modafinil, or placebo (1:1:1).  Treatment lasted 8 wk: 3 wk of flexible dosing according to investigator's judgment (10 mg, 20 mg, or 40 mg a day of pitolisant; 100 mg, 200 mg or 400 mg a day of modafinil) followed by 5 wk of stable dosing.  Patients took four tablets a day in a double-dummy design to ensure masking.  For the primary anal., assessed in the intention-to-treat population, we assessed the superiority of pitolisant vs. placebo, and the non-inferiority of pitolisant vs. modafinil.  This trial is registered with ClinicalTrials.gov, no. NCT01067222.Between May 26, 2009, and June 30, 2010, we screened 110 patients, 95 of whom were eligible and randomly assigned to treatment: 30 to placebo, 32 to pitolisant, and 33 to modafinil.  Over the 8-wk treatment period, mean ESS score redns. were -3·4 (SD 4·2) in the placebo group, -5·8 (6·2) in the pitolisant group, and -6·9 (6·2) in the modafinil group.  Our primary anal. of between-group differences in mean ESS score at endpoint (adjusted for baseline) showed pitolisant to be superior to placebo (difference -3·0, 95% CI -5·6 to -0·4; p=0·024), but not non-inferior to modafinil (difference 0·12, 95% CI -2·5 to 2·7; p=0·250).  We recorded 22 adverse events with pitolisant, 26 with modafinil, and ten with placebo.  Six severe adverse events were treatment-related: one with pitolisant (abdominal discomfort) and five with modafinil (abdominal pain, abnormal behavior, amphetamine-like withdrawal symptoms, lymphoadenopathy, and inner ear disorders).Pitolisant at doses up to 40 mg was efficacious on EDS compared with placebo and well tolerated compared with modafinil.  If these findings are substantiated in further studies, pitolisant could offer a new treatment option for patients with narcolepsy.Bioprojet, France.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLoL8Ilx_OjLVg90H21EOLACvtfcHk0lhaHJUmZyX8KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyrsbjF&md5=644403e36dbafb473e0bc61bc7370dc8</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970225-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970225-4%26sid%3Dliteratum%253Aachs%26aulast%3DDauvilliers%26aufirst%3DY.%26aulast%3DBassetti%26aufirst%3DC.%26aulast%3DLammers%26aufirst%3DG.%2BJ.%26aulast%3DArnulf%26aufirst%3DI.%26aulast%3DMayer%26aufirst%3DG.%26aulast%3DRodenbeck%26aufirst%3DA.%26aulast%3DLehert%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DC.-L.%26aulast%3DLecomte%26aufirst%3DJ.-M.%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26atitle%3DPitolisant%2520Versus%2520Placebo%2520or%2520Modafinil%2520in%2520Patients%2520with%2520Narcolepsy%253A%2520A%2520Double-blind%252C%2520Randomised%2520Trial%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26spage%3D1068%26epage%3D1075%26doi%3D10.1016%2FS1474-4422%2813%2970225-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graßmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurquin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganellin, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Influence of Imidazole Replacement in Different Structural Classes of Histamine H(3)-Receptor Antagonists</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/S0928-0987(01)00106-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS0928-0987%2801%2900106-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=11384847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvV2qtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=249-259&author=G.+Meierauthor=J.+Apeltauthor=U.+Reichertauthor=S.+Gra%C3%9Fmannauthor=X.+Ligneauauthor=S.+Elzauthor=F.+Leurquinauthor=C.+R.+Ganellinauthor=J.-C.+Schwartzauthor=W.+Schunackauthor=H.+Stark&title=Influence+of+Imidazole+Replacement+in+Different+Structural+Classes+of+Histamine+H%283%29-Receptor+Antagonists&doi=10.1016%2FS0928-0987%2801%2900106-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57aR"><div class="casContent"><span class="casTitleNuber">57a</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists</span></div><div class="casAuthors">Meier, G.; Apelt, J.; Reichert, U.; Grassmann, S.; Ligneau, X.; Elz, S.; Leurquin, F.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-259</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The ref. compds. for histamine H3-receptor antagonists carry as a common feature an imidazole moiety substituted in the 4-position.  Very recently novel ligands lacking an imidazole ring have been described possessing a N-contg. non-arom. heterocycle instead.  In this study we investigated whether imidazole replacement, favorably by a piperidine moiety, is generally applicable to different structural classes of ref. compds., e.g., thioperamide, carboperamide, clobenpropit, FUB 181, ciproxifan, etc.  While replacement led to a loss of affinity for many of the compds., it was successfully applied to some ether derivs.  The piperidine analogs of FUB 181 and ciproxifan, 3-(4-chlorophenyl)propyl 3-piperidinopropyl ether hydrogen oxalate and cyclopropyl 4-(3-piperidinopropyloxy)phenyl methanone hydrogen maleate, almost maintained in vitro affinities, pKi values of 7.8 and 8.4, resp., and showed high potency in vivo after p.o. administration (ED50 values of 1.6 and 0.18 mg/kg, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVgXghx9IdrbVg90H21EOLACvtfcHk0lhaHJUmZyX8KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvV2qtLw%253D&md5=7874e3f384d040e21a3ab8fcddea90bf</span></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=10.1016%2FS0928-0987%2801%2900106-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0928-0987%252801%252900106-3%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DG.%26aulast%3DApelt%26aufirst%3DJ.%26aulast%3DReichert%26aufirst%3DU.%26aulast%3DGra%25C3%259Fmann%26aufirst%3DS.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DElz%26aufirst%3DS.%26aulast%3DLeurquin%26aufirst%3DF.%26aulast%3DGanellin%26aufirst%3DC.%2BR.%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DInfluence%2520of%2520Imidazole%2520Replacement%2520in%2520Different%2520Structural%2520Classes%2520of%2520Histamine%2520H%25283%2529-Receptor%2520Antagonists%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2001%26volume%3D13%26spage%3D249%26epage%3D259%26doi%3D10.1016%2FS0928-0987%2801%2900106-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit57b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liedtke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlicker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span> <span> </span><span class="NLM_article-title">Replacement of Imidazole by a Piperidine Moiety Differentially Affects the Potency of Histamine H3-Receptor Antagonists</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1007/s00210-002-0649-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs00210-002-0649-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=12616340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvV2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2003&pages=43-50&author=S.+Liedtkeauthor=K.+Flauauthor=M.+Kathmannauthor=E.+Schlickerauthor=H.+Starkauthor=G.+Meierauthor=W.+Schunack&title=Replacement+of+Imidazole+by+a+Piperidine+Moiety+Differentially+Affects+the+Potency+of+Histamine+H3-Receptor+Antagonists&doi=10.1007%2Fs00210-002-0649-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57bR"><div class="casContent"><span class="casTitleNuber">57b</span><div class="casTitle"><span class="NLM_cas:atitle">Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists</span></div><div class="casAuthors">Liedtke, Susanna; Flau, Karsten; Kathmann, Markus; Schlicker, Eberhard; Stark, Holger; Meier, Galina; Schunack, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-50</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">We examd. whether replacement of imidazole by a piperidine or pyrrolidine moiety will affect the potency and affinity of six H3-receptor antagonists.  Potencies were detd. in superfused mouse brain cortex slices preincubated with [3H]noradrenaline, in which the interaction of the antagonists with histamine with respect to its inhibitory effect on the elec. evoked tritium overflow was studied.  Affinities were detd. in mouse brain cortex membranes, using the radioligand [3H]Nα-methylhistamine.  The concn.-response curve of histamine for its effect on the evoked overflow from mouse brain cortex slices was shifted to the right by the 13 compds. under study.  Replacement of the imidazole by a piperidine ring affected the pA2 value as follows: thioperamide, -2.7 log units; clobenpropit, -1.9; proxyfan, -1.3; FUB 138, -1.2.  Potency hardly changed (≤0.4 log units) when imidazole was replaced by piperidine in FUB 181 and by piperidine or pyrrolidine in FUB 153.  Binding of [3H]Nα-methylhistamine to mouse brain cortex membranes was inhibited monophasically by all compds.  The pKi values closely matched their pA2 values with three exceptions.  The pKi values of proxyfan, FUB 138, and FUB 153 exceeded their resp. pA2 values by about 1 log unit.  To reveal a potential partial agonism, the effect of the three drugs on (1) the elec. evoked tritium overflow and (2) [35S]GTPγS binding in mouse cortex prepns. was detd.  Proxyfan proved to be a partial agonist in both models (with intrinsic activities of 0.2 and 0.3, resp.) whereas FUB 138 and FUB 153 were devoid of agonistic effects.  In conclusion, replacement of imidazole by piperidine or pyrrolidine affects the antagonist potencies of six H3-receptor antagonists in a very different manner.  The piperidine analog of FUB 181 (with a pA2 value as high as 7.7) may represent a lead for the development of non-imidazole H3-receptor antagonists.  The discrepancy between the pKi and pA2 values may be accounted for by partial agonism in the case of proxyfan but can, at present, not be satisfactorily explained with respect to FUB 138 and FUB 153.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq632LlhCo9tLVg90H21EOLACvtfcHk0lgUVsUkBz91pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvV2rsA%253D%253D&md5=882e375e8c6b4a405318d7a24ceb5521</span></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=10.1007%2Fs00210-002-0649-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-002-0649-4%26sid%3Dliteratum%253Aachs%26aulast%3DLiedtke%26aufirst%3DS.%26aulast%3DFlau%26aufirst%3DK.%26aulast%3DKathmann%26aufirst%3DM.%26aulast%3DSchlicker%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMeier%26aufirst%3DG.%26aulast%3DSchunack%26aufirst%3DW.%26atitle%3DReplacement%2520of%2520Imidazole%2520by%2520a%2520Piperidine%2520Moiety%2520Differentially%2520Affects%2520the%2520Potency%2520of%2520Histamine%2520H3-Receptor%2520Antagonists%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2003%26volume%3D367%26spage%3D43%26epage%3D50%26doi%3D10.1007%2Fs00210-002-0649-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit57c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span> <span> </span><span class="NLM_article-title">The Histamine H3 Receptor: From Discovery to Clinical Trials with Pitolisant</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01286.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1111%2Fj.1476-5381.2011.01286.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=21615387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=713-721&author=J.-C.+Schwartz&title=The+Histamine+H3+Receptor%3A+From+Discovery+to+Clinical+Trials+with+Pitolisant&doi=10.1111%2Fj.1476-5381.2011.01286.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57cR"><div class="casContent"><span class="casTitleNuber">57c</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: from discovery to clinical trials with pitolisant</span></div><div class="casAuthors">Schwartz, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">713-721</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The third histamine receptor was discovered in 1983 by a traditional pharmacol. approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices.  The same in vitro test was used to design, in 1987, the first highly selective and potent H3-autoreceptor ligands, the antagonist thioperamide and the agonist alphamethylhistamine which enhances and inhibits, resp., the activity of histaminergic neurons in brain.  The use of these research tools was instrumental in establishing the main functions of cerebral histaminergic neurons, namely their role in maintenance of wakefulness, attention, learning and other cognitive processes.  In 1990, the cloning of the gene of the H3-receptor, a member of the superfamily of heptahelical receptors coupled to G proteins, paved the way to the demonstration of the high constitutive activity of the receptor, including its native form, and its participation in the tonic control of histamine release; it also facilitated the development of H3-receptor inverse agonist programs in many drug companies.  Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride) is the first inverse agonist to be introduced in the clinics.  Its wake-promotion activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson's disease or Obstructive Sleep Apnea/Hypopnea, in which this activity is characterized by a mean decrease of the Epworth Sleepiness Scale by about five units.  The procognitive activity of this novel class of drugs may also find therapeutic applications in dementias, schizophrenia or attention deficit hyperactivity disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHrkoL8T1XbbVg90H21EOLACvtfcHk0lgUVsUkBz91pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr0%253D&md5=f8b1db02051f583d7ca6c179c29f0db2</span></div><a href="/servlet/linkout?suffix=cit57c&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01286.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01286.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26atitle%3DThe%2520Histamine%2520H3%2520Receptor%253A%2520From%2520Discovery%2520to%2520Clinical%2520Trials%2520with%2520Pitolisant%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D713%26epage%3D721%26doi%3D10.1111%2Fj.1476-5381.2011.01286.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">Zheng, Z.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Zhou, X.</span>; <span class="NLM_string-name">Zhong, W.</span>; <span class="NLM_string-name">Xiao, J.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Pitolisant Hydrochloride from 3-(4-Chlorophenyl)propionic acid</span>. <span class="NLM_patent">CN 103435575A</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Li&author=Z.+Zheng&author=L.+Li&author=H.+Wang&author=X.+Zhou&author=W.+Zhong&author=J.+Xiao&author=Y.+Liu&author=Y.+Xie&author=X.+Li&author=X.+Wang&title=Process+for+Preparation+of+Pitolisant+Hydrochloride+from+3-%284-Chlorophenyl%29propionic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Pitolisant%2520Hydrochloride%2520from%25203-%25284-Chlorophenyl%2529propionic%2520acid%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sallares, J.</span>; <span class="NLM_string-name">Petschen, I.</span>; <span class="NLM_string-name">Camps, X.</span></span> <span> </span><span class="NLM_article-title">Etherification Process for Preparing 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine from 3-(Piperidino)propanol and 3-(4-Chlorophenyl)propyl Mesylate with Sodium Hydride in an Aprotic Polar Solvent</span>. <span class="NLM_patent">WO 2007006708A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Sallares&author=I.+Petschen&author=X.+Camps&title=Etherification+Process+for+Preparing+1-%5B3-%5B3-%284-Chlorophenyl%29propoxy%5Dpropyl%5Dpiperidine+from+3-%28Piperidino%29propanol+and+3-%284-Chlorophenyl%29propyl+Mesylate+with+Sodium+Hydride+in+an+Aprotic+Polar+Solvent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSallares%26aufirst%3DJ.%26atitle%3DEtherification%2520Process%2520for%2520Preparing%25201-%255B3-%255B3-%25284-Chlorophenyl%2529propoxy%255Dpropyl%255Dpiperidine%2520from%25203-%2528Piperidino%2529propanol%2520and%25203-%25284-Chlorophenyl%2529propyl%2520Mesylate%2520with%2520Sodium%2520Hydride%2520in%2520an%2520Aprotic%2520Polar%2520Solvent%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raga M, M.</span>; <span class="NLM_string-name">Sallares, J.</span>; <span class="NLM_string-name">Guerrero, M.</span>; <span class="NLM_string-name">Guglietta, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine Monohydrochloride as a Histamine H3 Receptor Ligand</span>. <span class="NLM_patent">WO 2006084833A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.+Raga+M&author=J.+Sallares&author=M.+Guerrero&author=A.+Guglietta&title=Preparation+of+1-%5B3-%5B3-%284-Chlorophenyl%29propoxy%5Dpropyl%5Dpiperidine+Monohydrochloride+as+a+Histamine+H3+Receptor+Ligand"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRaga%2BM%26aufirst%3DM.%26atitle%3DPreparation%2520of%25201-%255B3-%255B3-%25284-Chlorophenyl%2529propoxy%255Dpropyl%255Dpiperidine%2520Monohydrochloride%2520as%2520a%2520Histamine%2520H3%2520Receptor%2520Ligand%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheape, A.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrell, D. F.</span></span> <span> </span><span class="NLM_article-title">2% Crisaborole Topical Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis</span>. <i>Expert Rev. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1080/1744666X.2017.1304820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1080%2F1744666X.2017.1304820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28290219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslOrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=415-423&author=A.%0AC.+Cheapeauthor=D.+F.+Murrell&title=2%25+Crisaborole+Topical+Ointment+for+the+Treatment+of+Mild-to-Moderate+Atopic+Dermatitis&doi=10.1080%2F1744666X.2017.1304820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis</span></div><div class="casAuthors">Cheape, Alice C.; Murrell, Dedee F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis.  So far, 7 trials have been completed in atopic dermatitis.  The 2% strength appeared to be the superior dosing regimen.  Pruritus improved significantly within one week.  The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle.  Crisaborole has several key features in its mode of action which distinguish it from existing treatments for atopic dermatitis (AD), notably its activity against the phosphodiesterase E4 (PDE4) pathway, regulating cAMP (cAMP) levels.  This is less immunosuppressive than other pathways and has no effect on skin thinning.  The pathway interrupts the itch sensation (pruritus) which means that the itch-scratch cycle, the bane in the life of patients with AD, is interrupted, usually as early as a few days into treatment.  Hence, with the promising safety profile demonstrated, early treatment of mild to moderate AD patients might help to control AD better and improve quality of life for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowRgPjgAtPPbVg90H21EOLACvtfcHk0lgUVsUkBz91pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslOrtbY%253D&md5=7df1b340674a99a697d1329e390d71eb</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1080%2F1744666X.2017.1304820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1744666X.2017.1304820%26sid%3Dliteratum%253Aachs%26aulast%3DCheape%26aufirst%3DA.%2BC.%26aulast%3DMurrell%26aufirst%3DD.%2BF.%26atitle%3D2%2525%2520Crisaborole%2520Topical%2520Ointment%2520for%2520the%2520Treatment%2520of%2520Mild-to-Moderate%2520Atopic%2520Dermatitis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2017%26volume%3D13%26spage%3D415%26epage%3D423%26doi%3D10.1080%2F1744666X.2017.1304820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paller, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boguniewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Call, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichenfield, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsha, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spellman, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein Gold, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaenglein, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zane, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, A. A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">503.e6</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2016.05.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.jaad.2016.05.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27417017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKmtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=494-503.e6&author=A.+S.+Pallerauthor=W.+L.+Tomauthor=M.+G.+Lebwohlauthor=R.+L.+Blumenthalauthor=M.+Boguniewiczauthor=R.+S.+Callauthor=L.+F.+Eichenfieldauthor=D.+W.+Forshaauthor=W.+C.+Reesauthor=E.+L.+Simpsonauthor=M.+C.+Spellmanauthor=L.+F.+Stein+Goldauthor=A.+L.+Zaengleinauthor=M.+H.+Hughesauthor=L.+T.+Zaneauthor=A.+A.+Hebert&title=Efficacy+and+Safety+of+Crisaborole+Ointment%2C+a+Novel%2C+Nonsteroidal+Phosphodiesterase+4+%28PDE4%29+Inhibitor+for+the+Topical+Treatment+of+Atopic+Dermatitis+%28AD%29+in+Children+and+Adults&doi=10.1016%2Fj.jaad.2016.05.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults</span></div><div class="casAuthors">Paller, Amy S.; Tom, Wynnis L.; Lebwohl, Mark G.; Blumenthal, Robin L.; Boguniewicz, Mark; Call, Robert S.; Eichenfield, Lawrence F.; Forsha, Douglass W.; Rees, William C.; Simpson, Eric L.; Spellman, Mary C.; Stein Gold, Linda F.; Zaenglein, Andrea L.; Hughes, Matilda H.; Zane, Lee T.; Hebert, Adelaide A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">494-503.e6</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Addnl. topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.  We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III AD studies (AD-301: NCT02118766; AD-302: NCT02118792).  Two identically designed, vehicle-controlled, double-blind studies enrolled and randomly assigned (2:1, crisaborole:vehicle) patients aged 2 years or older with an Investigator's Static Global Assessment (ISGA) score of mild or moderate for twice-daily application for 28 days.  The primary end point was ISGA score at day 29 of clear (0)/almost clear (1) with 2-grade or greater improvement from baseline.  Addnl. analyses included time to success in ISGA score, percentage of patients achieving clear/almost clear, redn. in severity of AD signs, and time to improvement in pruritus.  More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear with ≥2-grade improvement; AD-301: 32.8% vs 25.4%, P = .038; AD-302: 31.4% vs 18.0%, P < .001), with a greater percentage with clear/almost clear (51.7% vs 40.6%, P = .005; 48.5% vs 29.7%, P < .001).  Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those treated with vehicle (both P ≤ .001).  Treatment-related adverse events were infrequent and mild to moderate in severity.  Short study duration was a limitation.  Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD4IlzODC6ebVg90H21EOLACvtfcHk0lhnXGwbEjyu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKmtbvP&md5=addbe254ce72db5ae1c96874f70ee1d0</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.05.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.05.046%26sid%3Dliteratum%253Aachs%26aulast%3DPaller%26aufirst%3DA.%2BS.%26aulast%3DTom%26aufirst%3DW.%2BL.%26aulast%3DLebwohl%26aufirst%3DM.%2BG.%26aulast%3DBlumenthal%26aufirst%3DR.%2BL.%26aulast%3DBoguniewicz%26aufirst%3DM.%26aulast%3DCall%26aufirst%3DR.%2BS.%26aulast%3DEichenfield%26aufirst%3DL.%2BF.%26aulast%3DForsha%26aufirst%3DD.%2BW.%26aulast%3DRees%26aufirst%3DW.%2BC.%26aulast%3DSimpson%26aufirst%3DE.%2BL.%26aulast%3DSpellman%26aufirst%3DM.%2BC.%26aulast%3DStein%2BGold%26aufirst%3DL.%2BF.%26aulast%3DZaenglein%26aufirst%3DA.%2BL.%26aulast%3DHughes%26aufirst%3DM.%2BH.%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DHebert%26aufirst%3DA.%2BA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Crisaborole%2520Ointment%252C%2520a%2520Novel%252C%2520Nonsteroidal%2520Phosphodiesterase%25204%2520%2528PDE4%2529%2520Inhibitor%2520for%2520the%2520Topical%2520Treatment%2520of%2520Atopic%2520Dermatitis%2520%2528AD%2529%2520in%2520Children%2520and%2520Adults%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2016%26volume%3D75%26spage%3D494%26epage%3D503.e6%26doi%3D10.1016%2Fj.jaad.2016.05.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit200a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Zhang, Y.
K.</span>; <span class="NLM_string-name">Akama, T.</span>; <span class="NLM_string-name">Jarnagin, K.</span></span> <span> </span><span class="NLM_article-title">Boron-Containing Small Molecules</span>. <span class="NLM_patent">US 8461336</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Zhou&author=Y.%0AK.+Zhang&author=T.+Akama&author=K.+Jarnagin&title=Boron-Containing+Small+Molecules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26atitle%3DBoron-Containing%2520Small%2520Molecules%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit200b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span>; <span class="NLM_string-name">Zhang, Y. K.</span>; <span class="NLM_string-name">Akama, T.</span>; <span class="NLM_string-name">Jarnagin, K.</span></span><span> </span><span class="NLM_article-title">Preparation of 6-((Aminomethyl)phenoxy)-1,3-Dihydro-1-Hydroxybenzoxaborole Derivatives as Inhibitors of Pro-Inflammatory Cytokines and Phosphodiesterases Useful in the Treatment of Inflammatory Diseases</span>. <span class="NLM_patent">WO 2010028005</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Y.+Zhou&author=Y.+K.+Zhang&author=T.+Akama&author=K.+Jarnagin&title=Preparation+of+6-%28%28Aminomethyl%29phenoxy%29-1%2C3-Dihydro-1-Hydroxybenzoxaborole+Derivatives+as+Inhibitors+of+Pro-Inflammatory+Cytokines+and+Phosphodiesterases+Useful+in+the+Treatment+of+Inflammatory+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26atitle%3DPreparation%2520of%25206-%2528%2528Aminomethyl%2529phenoxy%2529-1%252C3-Dihydro-1-Hydroxybenzoxaborole%2520Derivatives%2520as%2520Inhibitors%2520of%2520Pro-Inflammatory%2520Cytokines%2520and%2520Phosphodiesterases%2520Useful%2520in%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit200c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span>; <span class="NLM_string-name">Sanders, V.</span>; <span class="NLM_string-name">Akama, T.</span>; <span class="NLM_string-name">Bellinger-Kawahara, C.</span>; <span class="NLM_string-name">Freund, Y.</span>; <span class="NLM_string-name">Maples, K. R.</span>; <span class="NLM_string-name">Plattner, J. J.</span>; <span class="NLM_string-name">Zhang, Y.-K.</span>; <span class="NLM_string-name">Zhou, H.</span>; <span class="NLM_string-name">Hernandez, V. S.</span></span> <span> </span><span class="NLM_article-title">Boron-Containing Small Molecules as Anti-Inflammatory Agents</span>. <span class="NLM_patent">WO 2007095638</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+J.+Baker&author=V.+Sanders&author=T.+Akama&author=C.+Bellinger-Kawahara&author=Y.+Freund&author=K.+R.+Maples&author=J.+J.+Plattner&author=Y.-K.+Zhang&author=H.+Zhou&author=V.+S.+Hernandez&title=Boron-Containing+Small+Molecules+as+Anti-Inflammatory+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DBoron-Containing%2520Small%2520Molecules%2520as%2520Anti-Inflammatory%2520Agents%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit200d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span>; <span class="NLM_string-name">Akama, T.</span>; <span class="NLM_string-name">Alley, M. R. K.</span>; <span class="NLM_string-name">Benkovic, S. J.</span>; <span class="NLM_string-name">Dipierro, M.</span>; <span class="NLM_string-name">Hernandez, V. S.</span>; <span class="NLM_string-name">Hold, K. M.</span>; <span class="NLM_string-name">Kennedy, I.</span>; <span class="NLM_string-name">Likhotvorik, I.</span>; <span class="NLM_string-name">Mao, W.</span>; <span class="NLM_string-name">Maples, K. R.</span>; <span class="NLM_string-name">Plattner, J. J.</span>; <span class="NLM_string-name">Rock, F.</span>; <span class="NLM_string-name">Sanders, V.</span>; <span class="NLM_string-name">Stemphoski, A. M.</span>; <span class="NLM_string-name">Yiannikouros, G. P.</span>; <span class="NLM_string-name">Zegar, S.</span>; <span class="NLM_string-name">Zhang, Y.-K.</span>; <span class="NLM_string-name">Zhou, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Boron-Containing Small Molecules and Nucleosides for Treating Fungal Infections</span>. <span class="NLM_patent">WO 2007078340</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+J.+Baker&author=T.+Akama&author=M.+R.+K.+Alley&author=S.+J.+Benkovic&author=M.+Dipierro&author=V.+S.+Hernandez&author=K.+M.+Hold&author=I.+Kennedy&author=I.+Likhotvorik&author=W.+Mao&author=K.+R.+Maples&author=J.+J.+Plattner&author=F.+Rock&author=V.+Sanders&author=A.+M.+Stemphoski&author=G.+P.+Yiannikouros&author=S.+Zegar&author=Y.-K.+Zhang&author=H.+Zhou&title=Preparation+of+Boron-Containing+Small+Molecules+and+Nucleosides+for+Treating+Fungal+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DPreparation%2520of%2520Boron-Containing%2520Small%2520Molecules%2520and%2520Nucleosides%2520for%2520Treating%2520Fungal%2520Infections%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit200e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maples, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structure-Activity Study of a Novel Benzoxaborole Anti-Inflammatory Agent (AN2728) for the Potential Topical Treatment of Psoriasis and Atopic Dermatitis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.bmcl.2009.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=19303290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2129-2132&author=T.+Akamaauthor=S.+J.+Bakerauthor=Y.-K.+Zhangauthor=V.+Hernandezauthor=H.+Zhouauthor=V.+Sandersauthor=Y.+Freundauthor=R.+Kimuraauthor=K.+R.+Maplesauthor=J.+J.+Plattner&title=Discovery+and+Structure-Activity+Study+of+a+Novel+Benzoxaborole+Anti-Inflammatory+Agent+%28AN2728%29+for+the+Potential+Topical+Treatment+of+Psoriasis+and+Atopic+Dermatitis&doi=10.1016%2Fj.bmcl.2009.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200eR"><div class="casContent"><span class="casTitleNuber">200e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis</span></div><div class="casAuthors">Akama, Tsutomu; Baker, Stephen J.; Zhang, Yong-Kang; Hernandez, Vincent; Zhou, Huchen; Sanders, Virginia; Freund, Yvonne; Kimura, Richard; Maples, Kirk R.; Plattner, Jacob J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2129-2132</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release.  5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo.  This compd. is now in clin. development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYdD-T7O2W57Vg90H21EOLACvtfcHk0lhnXGwbEjyu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjsb4%253D&md5=a526278d0506fc5916432cf20c6ff5e5</span></div><a href="/servlet/linkout?suffix=cit200e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSanders%26aufirst%3DV.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DR.%26aulast%3DMaples%26aufirst%3DK.%2BR.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520and%2520Structure-Activity%2520Study%2520of%2520a%2520Novel%2520Benzoxaborole%2520Anti-Inflammatory%2520Agent%2520%2528AN2728%2529%2520for%2520the%2520Potential%2520Topical%2520Treatment%2520of%2520Psoriasis%2520and%2520Atopic%2520Dermatitis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2129%26epage%3D2132%26doi%3D10.1016%2Fj.bmcl.2009.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camaioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clerici, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span> <span> </span><span class="NLM_article-title">6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3569</span>– <span class="NLM_lpage">3572</span>, <span class="refDoi"> DOI: 10.1021/jm025529g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm025529g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVSgs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3569-3572&author=R.+Pellicciariauthor=S.+Fiorucciauthor=E.+Camaioniauthor=C.+Clericiauthor=G.+Costantinoauthor=P.+R.+Maloneyauthor=A.+Morelliauthor=D.+J.+Parksauthor=T.+M.+Willson&title=6%CE%B1-Ethyl-Chenodeoxycholic+Acid+%286-ECDCA%29%2C+a+Potent+and+Selective+FXR+Agonist+Endowed+with+Anticholestatic+Activity&doi=10.1021%2Fjm025529g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity</span></div><div class="casAuthors">Pellicciari, Roberto; Fiorucci, Stefano; Camaioni, Emidio; Clerici, Carlo; Costantino, Gabriele; Maloney, Patrick R.; Morelli, Antonio; Parks, Derek J.; Willson, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3569-3572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 6α-alkyl-substituted analogs I (R = Me, Et, Pr, Bn) of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands.  Among them, 6α-ethyl-chenodeoxycholic acid (6-ECDCA) I (R = Et) was shown to be a very potent and selective FXR agonist (EC50 = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVGesAhjDtJbVg90H21EOLACvtfcHk0lhQVA7C5roHWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVSgs7s%253D&md5=0b6652c1ad92eb681bf96a7df7b2d367</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm025529g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm025529g%26sid%3Dliteratum%253Aachs%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DFiorucci%26aufirst%3DS.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DClerici%26aufirst%3DC.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DMorelli%26aufirst%3DA.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26atitle%3D6%25CE%25B1-Ethyl-Chenodeoxycholic%2520Acid%2520%25286-ECDCA%2529%252C%2520a%2520Potent%2520and%2520Selective%2520FXR%2520Agonist%2520Endowed%2520with%2520Anticholestatic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3569%26epage%3D3572%26doi%3D10.1021%2Fjm025529g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowlus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Invernizzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drenth, J. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pockros, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuers, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floreani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohenester, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luketic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiffman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Erpecum, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschfield, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindor, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschall, H. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooshmand-Rad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheeron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pencek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruzanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D.</span></span> <span> </span><span class="NLM_article-title">A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1056%2FNEJMoa1509840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27532829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=631-643&author=F.+Nevensauthor=P.+Andreoneauthor=G.+Mazzellaauthor=S.+I.+Strasserauthor=C.+Bowlusauthor=P.+Invernizziauthor=J.+P.+H.+Drenthauthor=P.+J.+Pockrosauthor=J.+Regulaauthor=U.+Beuersauthor=M.+Traunerauthor=D.+E.+Jonesauthor=A.+Floreaniauthor=S.+Hohenesterauthor=V.+Luketicauthor=M.+Shiffmanauthor=K.+J.+van+Erpecumauthor=V.+Vargasauthor=C.+Vincentauthor=G.+M.+Hirschfieldauthor=H.+Shahauthor=B.+Hansenauthor=K.+D.+Lindorauthor=H.+U.+Marschallauthor=K.+V.+Kowdleyauthor=R.+Hooshmand-Radauthor=T.+Marmonauthor=S.+Sheeronauthor=R.+Pencekauthor=L.+MacConellauthor=M.+Pruzanskiauthor=D.+Shapiro&title=A+Placebo-Controlled+Trial+of+Obeticholic+Acid+in+Primary+Biliary+Cholangitis&doi=10.1056%2FNEJMoa1509840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A placebo-controlled trial of obeticholic acid in primary biliary cholangitis</span></div><div class="casAuthors">Nevens, F.; Andreone, P.; Mazzella, G.; Strasser, S. I.; Bowlus, C.; Invernizzi, P.; Drenth, J. P. H.; Pockros, P. J.; Regula, J.; Beuers, U.; Trauner, M.; Jones, D. E.; Floreani, A.; Hohenester, S.; Luketic, V.; Shiffman, M.; van Erpecum, K. J.; Vargas, V.; Vincent, C.; Hirschfield, G. M.; Shah, H.; Hansen, B.; Lindor, K. D.; Marschall, H.-U.; Kowdley, K. V.; Hooshmand-Rad, R.; Marmon, T.; Sheeron, S.; Pencek, R.; MacConell, L.; Pruzanski, M.; Shapiro, D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-643</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy.  Alk. phosphatase and bilirubin levels correlate with the risk of liver transplantation or death.  Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients with this disease.  METHODS: In this 12-mo, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a dose of 10 mg (the 10-mg group), obeticholic acid at a dose of 5 mg with adjustment to 10 mg if applicable (the 5-10-mg group), or placebo.  The primary end point was an alk. phosphatase level of less than 1.67 times the upper limit of the normal range, with a redn. of at least 15% from baseline, and a normal total bilirubin level.  RESULTS: Of 216 patients who underwent randomization and received at least one dose of obeticholic acid or placebo, 93% received ursodiol as background therapy.  The primary end point occurred in more patients in the 5-10-mg group (46%) and the 10-mg group (47%) than in the placebo group (10%; P<0.001 for both comparisons).  Patients in the 5-10-mg group and those in the 10-mg group had greater decreases than those in the placebo group in the alk. phosphatase level (least-squares mean, -113 and -130 U per L, resp., vs. -14 U per L; P<0.001 for both comparisons) and total bilirubin level (-0.02 and -0.05 mg per dL [-0.3 and -0.9 μmol per L], resp., vs. 0.12 mg per dL [2.0 μmol per L]; P<0.001 for both comparisons).  Changes in noninvasive measures of liver fibrosis did not differ significantly between either treatment group and the placebo group at 12 mo.  Pruritus was more common with obeticholic acid than with placebo (56% of patients in the 5-10-mg group and 68% of those in the 10-mg group vs. 38% in the placebo group).  The rate of serious adverse events was 16% in the 5-10-mg group, 11% in the 10-mg group, and 4% in the placebo group.  CONCLUSIONS: Obeticholic acid administered with ursodiol or as monotherapy for 12 mo in patients with primary biliary cholangitis resulted in decreases from baseline in alk. phosphatase and total bilirubin levels that differed significantly from the changes obsd. with placebo.  There were more serious adverse events with obeticholic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovAIzzX9egK7Vg90H21EOLACvtfcHk0lhQVA7C5roHWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7zE&md5=613ba0df3a84969560534d87de20420b</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509840%26sid%3Dliteratum%253Aachs%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DAndreone%26aufirst%3DP.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DStrasser%26aufirst%3DS.%2BI.%26aulast%3DBowlus%26aufirst%3DC.%26aulast%3DInvernizzi%26aufirst%3DP.%26aulast%3DDrenth%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DRegula%26aufirst%3DJ.%26aulast%3DBeuers%26aufirst%3DU.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DD.%2BE.%26aulast%3DFloreani%26aufirst%3DA.%26aulast%3DHohenester%26aufirst%3DS.%26aulast%3DLuketic%26aufirst%3DV.%26aulast%3DShiffman%26aufirst%3DM.%26aulast%3Dvan%2BErpecum%26aufirst%3DK.%2BJ.%26aulast%3DVargas%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DC.%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DShah%26aufirst%3DH.%26aulast%3DHansen%26aufirst%3DB.%26aulast%3DLindor%26aufirst%3DK.%2BD.%26aulast%3DMarschall%26aufirst%3DH.%2BU.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DHooshmand-Rad%26aufirst%3DR.%26aulast%3DMarmon%26aufirst%3DT.%26aulast%3DSheeron%26aufirst%3DS.%26aulast%3DPencek%26aufirst%3DR.%26aulast%3DMacConell%26aufirst%3DL.%26aulast%3DPruzanski%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DD.%26atitle%3DA%2520Placebo-Controlled%2520Trial%2520of%2520Obeticholic%2520Acid%2520in%2520Primary%2520Biliary%2520Cholangitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D631%26epage%3D643%26doi%3D10.1056%2FNEJMoa1509840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit65a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, A.</span>; <span class="NLM_string-name">Waenerlund Poulsen, H.</span>; <span class="NLM_string-name">Jolibois, E.</span>; <span class="NLM_string-name">Rewolinski, M.</span>; <span class="NLM_string-name">Gross, R.</span>; <span class="NLM_string-name">Sharp, E.</span>; <span class="NLM_string-name">Dubas-Fisher, F.</span>; <span class="NLM_string-name">Eberlin, A.</span></span> <span> </span><span class="NLM_article-title">Preparation and Uses of Obeticholic Acid</span>. <span class="NLM_patent">WO 20130345188</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+Steiner&author=H.+Waenerlund+Poulsen&author=E.+Jolibois&author=M.+Rewolinski&author=R.+Gross&author=E.+Sharp&author=F.+Dubas-Fisher&author=A.+Eberlin&title=Preparation+and+Uses+of+Obeticholic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSteiner%26aufirst%3DA.%26atitle%3DPreparation%2520and%2520Uses%2520of%2520Obeticholic%2520Acid%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit65b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span>; <span class="NLM_string-name">Pellicciari, R.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing 3a(β)-7a(β)-Dihydroxy-6a(β)-Alkyl-5β-Cholanic Acid</span>. <span class="NLM_patent">US 7994352</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Ferrari&author=R.+Pellicciari&title=Process+for+Preparing+3a%28%CE%B2%29-7a%28%CE%B2%29-Dihydroxy-6a%28%CE%B2%29-Alkyl-5%CE%B2-Cholanic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DM.%26atitle%3DProcess%2520for%2520Preparing%25203a%2528%25CE%25B2%2529-7a%2528%25CE%25B2%2529-Dihydroxy-6a%2528%25CE%25B2%2529-Alkyl-5%25CE%25B2-Cholanic%2520Acid%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Migalastat: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0607-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0607-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27351440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ksFegtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1147-1152&author=A.+Markham&title=Migalastat%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0607-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Migalastat: First Global Approval</span></div><div class="casAuthors">Markham Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1147-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Migalastat (Galafold®)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations.  Fabry disease is a rare disorder that results in a deficiency or absence of α-galactosidase, leading to accumulation of globotriaosylceramide in the lysosomes of various cells.  This article summarizes the milestones in the development of migalastat leading to this first approval in the EU for the long-term treatment of adults and adolescents aged ≥16 years with a confirmed diagnosis of Fabry disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnc_DupHv-_NK0qsdY6Nc1fW6udTcc2eZy0hRKhdCDhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ksFegtA%253D%253D&md5=20fde86101e0bec10aaaeabad729f05c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0607-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0607-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DMigalastat%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1147%26epage%3D1152%26doi%3D10.1007%2Fs40265-016-0607-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudd, P. N.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bragat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudes, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers</span>. <i>Clin. Pharmacol. Drug Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1002/cpdd.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1002%2Fcpdd.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27121667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ymsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=120-132&author=F.+K.+Johnsonauthor=P.+N.+Muddauthor=A.+Bragatauthor=M.+Aderaauthor=P.+Boudes&title=Pharmacokinetics+and+Safety+of+Migalastat+HCl+and+Effects+on+Agalsidase+Activity+in+Healthy+Volunteers&doi=10.1002%2Fcpdd.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers</span></div><div class="casAuthors">Johnson, Franklin K.; Mudd, Paul N., Jr.; Bragat, Alexander; Adera, Mathews; Boudes, Pol</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-132</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Migalastat HCl is an investigational, oral treatment for Fabry disease, an X-linked lysosomal storage disorder.  Four Phase 1 studies were conducted to det. the pharmacokinetics, pharmacodynamics, safety, and tolerability of migalastat.  Healthy volunteers (N = 124), 18-55 years old, received migalastat HCl single (25 mg-2000 mg) or twice-daily doses (50 mg, 150 mg) for 7 days in a double-blind, placebo-controlled fashion.  Migalastat pharmacokinetics were dose-proportional (AUC∞ range: 1129-72 838 ng h/mL, Cmax range: 200.5-13844 ng/mL, t1/2 3-4 h).  Steady state was achieved by Day 7.  Up to 67% of the dose was excreted as unchanged drug in urine.  Increased α-Gal A activity was dose related.  No abnormal cardiac effects, including prolonged QTc intervals, were obsd.  The pharmacokinetics of migalastat were well characterized in these Phase 1 studies conducted healthy volunteers.  The 150 mg dose of migalastat HCl administered BID for 7 days was generally safe and well tolerated.  A TQT study demonstrated lack of a pos. signal at therapeutic and supra-therapeutic doses.  Increases in α-Gal A enzyme activity for the 150 mg dose obsd. in healthy subjects suggested a successful proof of mechanism for further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOidxYesRJHLVg90H21EOLACvtfcHk0li3Zr4gNMNpsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ymsrrP&md5=c288f51cd7d544d8966538fdb2374e05</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.1%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DF.%2BK.%26aulast%3DMudd%26aufirst%3DP.%2BN.%26aulast%3DBragat%26aufirst%3DA.%26aulast%3DAdera%26aufirst%3DM.%26aulast%3DBoudes%26aufirst%3DP.%26atitle%3DPharmacokinetics%2520and%2520Safety%2520of%2520Migalastat%2520HCl%2520and%2520Effects%2520on%2520Agalsidase%2520Activity%2520in%2520Healthy%2520Volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Drug%2520Dev.%26date%3D2013%26volume%3D2%26spage%3D120%26epage%3D132%26doi%3D10.1002%2Fcpdd.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit68a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, M. K.</span>; <span class="NLM_string-name">Mahajan, S.</span>; <span class="NLM_string-name">Bhandya, S. R.</span>; <span class="NLM_string-name">Anish, K.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for the Preparation of 1-Deoxynojirimycin, an Intermediate of Miglitol</span>. IN 2013CH03275, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+K.+Sethi&author=S.+Mahajan&author=S.+R.+Bhandya&author=K.+Anish&title=An+Improved+Process+for+the+Preparation+of+1-Deoxynojirimycin%2C+an+Intermediate+of+Miglitol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSethi%26aufirst%3DM.%2BK.%26atitle%3DAn%2520Improved%2520Process%2520for%2520the%2520Preparation%2520of%25201-Deoxynojirimycin%252C%2520an%2520Intermediate%2520of%2520Miglitol%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit68b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myeong, I.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, W.-H.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Chirality Extension of syn,anti- and syn,syn-Oxazine and Stereochemical Analysis of Chiral 1,3-Oxazines: Stereoselective Total Syntheses of (+)-1-Deoxygalactonojirimycin and (−)-1-Deoxygulonojirimycin</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">7432</span>– <span class="NLM_lpage">7438</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.6b01079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.6b01079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=7432-7438&author=J.-S.+Kimauthor=Y.-T.+Leeauthor=K.-H.+Leeauthor=I.-S.+Myeongauthor=J.-C.+Kangauthor=C.+Jungauthor=S.-H.+Parkauthor=W.-H.+Ham&title=Stereoselective+Chirality+Extension+of+syn%2Canti-+and+syn%2Csyn-Oxazine+and+Stereochemical+Analysis+of+Chiral+1%2C3-Oxazines%3A+Stereoselective+Total+Syntheses+of+%28%2B%29-1-Deoxygalactonojirimycin+and+%28%E2%88%92%29-1-Deoxygulonojirimycin&doi=10.1021%2Facs.joc.6b01079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68b&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.6b01079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.6b01079%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.-S.%26aulast%3DLee%26aufirst%3DY.-T.%26aulast%3DLee%26aufirst%3DK.-H.%26aulast%3DMyeong%26aufirst%3DI.-S.%26aulast%3DKang%26aufirst%3DJ.-C.%26aulast%3DJung%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DS.-H.%26aulast%3DHam%26aufirst%3DW.-H.%26atitle%3DStereoselective%2520Chirality%2520Extension%2520of%2520syn%252Canti-%2520and%2520syn%252Csyn-Oxazine%2520and%2520Stereochemical%2520Analysis%2520of%2520Chiral%25201%252C3-Oxazines%253A%2520Stereoselective%2520Total%2520Syntheses%2520of%2520%2528%252B%2529-1-Deoxygalactonojirimycin%2520and%2520%2528%25E2%2588%2592%2529-1-Deoxygulonojirimycin%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2016%26volume%3D81%26spage%3D7432%26epage%3D7438%26doi%3D10.1021%2Facs.joc.6b01079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chacko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramapanicker, R.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective Synthesis of 1-Deoxygalactonojirimycin, 1-Deoxyaltronojirimycin, and N-Boc-(2S,3S)-3-Hydroxypipecolic Acid via Proline Catalyzed α-Aminoxylation of Aldehydes</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">4776</span>– <span class="NLM_lpage">4782</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.5b00424</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.5b00424" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2015&pages=4776-4782&author=S.+Chackoauthor=R.+Ramapanicker&title=Diastereoselective+Synthesis+of+1-Deoxygalactonojirimycin%2C+1-Deoxyaltronojirimycin%2C+and+N-Boc-%282S%2C3S%29-3-Hydroxypipecolic+Acid+via+Proline+Catalyzed+%CE%B1-Aminoxylation+of+Aldehydes&doi=10.1021%2Facs.joc.5b00424"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68c&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.5b00424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.5b00424%26sid%3Dliteratum%253Aachs%26aulast%3DChacko%26aufirst%3DS.%26aulast%3DRamapanicker%26aufirst%3DR.%26atitle%3DDiastereoselective%2520Synthesis%2520of%25201-Deoxygalactonojirimycin%252C%25201-Deoxyaltronojirimycin%252C%2520and%2520N-Boc-%25282S%252C3S%2529-3-Hydroxypipecolic%2520Acid%2520via%2520Proline%2520Catalyzed%2520%25CE%25B1-Aminoxylation%2520of%2520Aldehydes%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2015%26volume%3D80%26spage%3D4776%26epage%3D4782%26doi%3D10.1021%2Facs.joc.5b00424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Timmer, M. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangerfield, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulab, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, B. L.</span></span> <span> </span><span class="NLM_article-title">Rapid Synthesis of 1-Deoxygalactonojirimycin Using a Carbamate Annulation</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4803</span>– <span class="NLM_lpage">4805</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2011.07.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.tetlet.2011.07.044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=4803-4805&author=M.+S.+M.+Timmerauthor=E.+M.+Dangerfieldauthor=J.+M.+H.+Chengauthor=S.+A.+Gulabauthor=B.+L.+Stocker&title=Rapid+Synthesis+of+1-Deoxygalactonojirimycin+Using+a+Carbamate+Annulation&doi=10.1016%2Fj.tetlet.2011.07.044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68d&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2011.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2011.07.044%26sid%3Dliteratum%253Aachs%26aulast%3DTimmer%26aufirst%3DM.%2BS.%2BM.%26aulast%3DDangerfield%26aufirst%3DE.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%2BM.%2BH.%26aulast%3DGulab%26aufirst%3DS.%2BA.%26aulast%3DStocker%26aufirst%3DB.%2BL.%26atitle%3DRapid%2520Synthesis%2520of%25201-Deoxygalactonojirimycin%2520Using%2520a%2520Carbamate%2520Annulation%26jtitle%3DTetrahedron%2520Lett.%26date%3D2011%26volume%3D52%26spage%3D4803%26epage%3D4805%26doi%3D10.1016%2Fj.tetlet.2011.07.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkinson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleet, G. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, A.</span></span> <span> </span><span class="NLM_article-title">Looking-Glass Synergistic Pharmacological Chaperones: DGJ and L-DGJ from the Enantiomers of Tagatose</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4064</span>– <span class="NLM_lpage">4067</span>, <span class="refDoi"> DOI: 10.1021/ol201552q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol201552q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=4064-4067&author=S.+F.+Jenkinsonauthor=G.+W.+J.+Fleetauthor=R.+J.+Nashauthor=Y.+Koikeauthor=I.+Adachiauthor=A.+Yoshiharaauthor=K.+Morimotoauthor=K.+Izumoriauthor=A.+Kato&title=Looking-Glass+Synergistic+Pharmacological+Chaperones%3A+DGJ+and+L-DGJ+from+the+Enantiomers+of+Tagatose&doi=10.1021%2Fol201552q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68e&amp;dbid=16384&amp;doi=10.1021%2Fol201552q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol201552q%26sid%3Dliteratum%253Aachs%26aulast%3DJenkinson%26aufirst%3DS.%2BF.%26aulast%3DFleet%26aufirst%3DG.%2BW.%2BJ.%26aulast%3DNash%26aufirst%3DR.%2BJ.%26aulast%3DKoike%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DI.%26aulast%3DYoshihara%26aufirst%3DA.%26aulast%3DMorimoto%26aufirst%3DK.%26aulast%3DIzumori%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DA.%26atitle%3DLooking-Glass%2520Synergistic%2520Pharmacological%2520Chaperones%253A%2520DGJ%2520and%2520L-DGJ%2520from%2520the%2520Enantiomers%2520of%2520Tagatose%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D4064%26epage%3D4067%26doi%3D10.1021%2Fol201552q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schitter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheucher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuetz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thonhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarling, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Withers, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahuran, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigat, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrodnigg, T. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Lipophilic 1-Deoxygalactonojirimycin Derivatives as D-Galactosidase Inhibitors</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">No 21</span>),  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.3762/bjoc.6.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.3762%2Fbjoc.6.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=20485585" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=1&issue=No+21&author=G.+Schitterauthor=E.+Scheucherauthor=A.+J.+Steinerauthor=A.+E.+Stuetzauthor=M.+Thonhoferauthor=C.+A.+Tarlingauthor=S.+G.+Withersauthor=J.+Wickiauthor=K.+Fanturauthor=E.+Paschkeauthor=D.+J.+Mahuranauthor=B.+A.+Rigatauthor=M.+Tropakauthor=T.+M.+Wrodnigg&title=Synthesis+of+Lipophilic+1-Deoxygalactonojirimycin+Derivatives+as+D-Galactosidase+Inhibitors&doi=10.3762%2Fbjoc.6.21"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68f&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.6.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.6.21%26sid%3Dliteratum%253Aachs%26aulast%3DSchitter%26aufirst%3DG.%26aulast%3DScheucher%26aufirst%3DE.%26aulast%3DSteiner%26aufirst%3DA.%2BJ.%26aulast%3DStuetz%26aufirst%3DA.%2BE.%26aulast%3DThonhofer%26aufirst%3DM.%26aulast%3DTarling%26aufirst%3DC.%2BA.%26aulast%3DWithers%26aufirst%3DS.%2BG.%26aulast%3DWicki%26aufirst%3DJ.%26aulast%3DFantur%26aufirst%3DK.%26aulast%3DPaschke%26aufirst%3DE.%26aulast%3DMahuran%26aufirst%3DD.%2BJ.%26aulast%3DRigat%26aufirst%3DB.%2BA.%26aulast%3DTropak%26aufirst%3DM.%26aulast%3DWrodnigg%26aufirst%3DT.%2BM.%26atitle%3DSynthesis%2520of%2520Lipophilic%25201-Deoxygalactonojirimycin%2520Derivatives%2520as%2520D-Galactosidase%2520Inhibitors%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2010%26volume%3D6%26issue%3DNo%252021%26spage%3D1%26doi%3D10.3762%2Fbjoc.6.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gandy, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piggott, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, K. A.</span></span> <span> </span><span class="NLM_article-title">An Expeditious Synthesis of Iminosugars</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1071/CH10211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1071%2FCH10211" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2010&pages=1409-1412&author=M.+N.+Gandyauthor=M.+J.+Piggottauthor=K.+A.+Stubbs&title=An+Expeditious+Synthesis+of+Iminosugars&doi=10.1071%2FCH10211"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68g&amp;dbid=16384&amp;doi=10.1071%2FCH10211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1071%252FCH10211%26sid%3Dliteratum%253Aachs%26aulast%3DGandy%26aufirst%3DM.%2BN.%26aulast%3DPiggott%26aufirst%3DM.%2BJ.%26aulast%3DStubbs%26aufirst%3DK.%2BA.%26atitle%3DAn%2520Expeditious%2520Synthesis%2520of%2520Iminosugars%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2010%26volume%3D63%26spage%3D1409%26epage%3D1412%26doi%3D10.1071%2FCH10211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.-C.</span></span> <span> </span><span class="NLM_article-title">Straightforward Synthesis of Diverse 1-Deoxyazapyranosides via Stereocontrolled Nucleophilic Additions to Six-Membered Cyclic Nitrones</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span>,  <span class="NLM_fpage">5555</span>– <span class="NLM_lpage">5559</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201001045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1002%2Fejoc.201001045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=5555-5559&author=T.-H.+Chanauthor=Y.-F.+Changauthor=J.-J.+Hsuauthor=W.-C.+Cheng&title=Straightforward+Synthesis+of+Diverse+1-Deoxyazapyranosides+via+Stereocontrolled+Nucleophilic+Additions+to+Six-Membered+Cyclic+Nitrones&doi=10.1002%2Fejoc.201001045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68h&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201001045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201001045%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DT.-H.%26aulast%3DChang%26aufirst%3DY.-F.%26aulast%3DHsu%26aufirst%3DJ.-J.%26aulast%3DCheng%26aufirst%3DW.-C.%26atitle%3DStraightforward%2520Synthesis%2520of%2520Diverse%25201-Deoxyazapyranosides%2520via%2520Stereocontrolled%2520Nucleophilic%2520Additions%2520to%2520Six-Membered%2520Cyclic%2520Nitrones%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2010%26volume%3D2010%26spage%3D5555%26epage%3D5559%26doi%3D10.1002%2Fejoc.201001045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Stuetz, A.</span>; <span class="NLM_string-name">Steiner, A.</span>; <span class="NLM_string-name">Wrodnigg, T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imino-Sugar Glycopeptide Conjugates via Catalytic Intramolecular Reductive Amination Reaction</span>. <span class="NLM_patent">EP 1903034</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=A.+Stuetz&author=A.+Steiner&author=T.+Wrodnigg&title=Preparation+of+Imino-Sugar+Glycopeptide+Conjugates+via+Catalytic+Intramolecular+Reductive+Amination+Reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68i&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStuetz%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Imino-Sugar%2520Glycopeptide%2520Conjugates%2520via%2520Catalytic%2520Intramolecular%2520Reductive%2520Amination%2520Reaction%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit68j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, H.</span>; <span class="NLM_string-name">Toyota, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-Deoxygalactonojirimycin and its Intermediates</span>. <span class="NLM_patent">JP 2007055960</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=H.+Nagai&author=A.+Toyota&title=Preparation+of+1-Deoxygalactonojirimycin+and+its+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagai%26aufirst%3DH.%26atitle%3DPreparation%2520of%25201-Deoxygalactonojirimycin%2520and%2520its%2520Intermediates%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit68k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, H.</span>; <span class="NLM_string-name">Toyota, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1-Deoxygalactonojirimycin and their Intermediates</span>. <span class="NLM_patent">JP 2007055961</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=H.+Nagai&author=A.+Toyota&title=Preparation+of+1-Deoxygalactonojirimycin+and+their+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68k&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagai%26aufirst%3DH.%26atitle%3DPreparation%2520of%25201-Deoxygalactonojirimycin%2520and%2520their%2520Intermediates%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit68l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, O. R.</span></span> <span> </span><span class="NLM_article-title">A Stereo-Divergent Approach to 1-Deoxynojirimycin, 1-Deoxygalactonojirimycin and 1-Deoxymannojirimycin Derivatives</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3081</span>– <span class="NLM_lpage">3084</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2006.02.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.tetlet.2006.02.157" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=3081-3084&author=C.+Boucheronauthor=P.+Compainauthor=O.+R.+Martin&title=A+Stereo-Divergent+Approach+to+1-Deoxynojirimycin%2C+1-Deoxygalactonojirimycin+and+1-Deoxymannojirimycin+Derivatives&doi=10.1016%2Fj.tetlet.2006.02.157"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68l&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2006.02.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2006.02.157%26sid%3Dliteratum%253Aachs%26aulast%3DBoucheron%26aufirst%3DC.%26aulast%3DCompain%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DO.%2BR.%26atitle%3DA%2520Stereo-Divergent%2520Approach%2520to%25201-Deoxynojirimycin%252C%25201-Deoxygalactonojirimycin%2520and%25201-Deoxymannojirimycin%2520Derivatives%26jtitle%3DTetrahedron%2520Lett.%26date%3D2006%26volume%3D47%26spage%3D3081%26epage%3D3084%26doi%3D10.1016%2Fj.tetlet.2006.02.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pyun, S.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, C.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, W.</span></span> <span> </span><span class="NLM_article-title">-h. Synthesis of (+)-1-Deoxygalactonojirimycin</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.3987/COM-03-S(P)12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.3987%2FCOM-03-S%28P%2912" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2004&pages=333-341&author=S.-j.+Pyunauthor=K.-y.+Leeauthor=C.-y.+Ohauthor=W.+Ham&title=-h.+Synthesis+of+%28%2B%29-1-Deoxygalactonojirimycin&doi=10.3987%2FCOM-03-S%28P%2912"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68m&amp;dbid=16384&amp;doi=10.3987%2FCOM-03-S%28P%2912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-03-S%2528P%252912%26sid%3Dliteratum%253Aachs%26aulast%3DPyun%26aufirst%3DS.-j.%26aulast%3DLee%26aufirst%3DK.-y.%26aulast%3DOh%26aufirst%3DC.-y.%26aulast%3DHam%26aufirst%3DW.%26atitle%3D-h.%2520Synthesis%2520of%2520%2528%252B%2529-1-Deoxygalactonojirimycin%26jtitle%3DHeterocycles%26date%3D2004%26volume%3D62%26spage%3D333%26epage%3D341%26doi%3D10.3987%2FCOM-03-S%28P%2912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. V.</span></span> <span> </span><span class="NLM_article-title">A General Synthesis of Iminosugars</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">3565</span>– <span class="NLM_lpage">3568</span>, <span class="refDoi"> DOI: 10.1021/jo035763u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo035763u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3565-3568&author=C.+McDonnellauthor=L.+Croninauthor=J.+L.+O%E2%80%99Brienauthor=P.+V.+Murphy&title=A+General+Synthesis+of+Iminosugars&doi=10.1021%2Fjo035763u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68n&amp;dbid=16384&amp;doi=10.1021%2Fjo035763u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo035763u%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DC.%26aulast%3DCronin%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DP.%2BV.%26atitle%3DA%2520General%2520Synthesis%2520of%2520Iminosugars%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3565%26epage%3D3568%26doi%3D10.1021%2Fjo035763u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (+)-Galactostatin and (+)-1-Deoxygalactostatin Utilizing L-Quebrachitol as a Chiral Building Block</span>. <i>J. Chem. Soc., Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1248</span>, <span class="refDoi"> DOI: 10.1039/c39940001247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68o&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1039%2Fc39940001247" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&pages=1247-1248&author=N.+Chidaauthor=T.+Tanikawaauthor=T.+Tobeauthor=S.+Ogawa&title=Synthesis+of+%28%2B%29-Galactostatin+and+%28%2B%29-1-Deoxygalactostatin+Utilizing+L-Quebrachitol+as+a+Chiral+Building+Block&doi=10.1039%2Fc39940001247"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68o&amp;dbid=16384&amp;doi=10.1039%2Fc39940001247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39940001247%26sid%3Dliteratum%253Aachs%26aulast%3DChida%26aufirst%3DN.%26aulast%3DTanikawa%26aufirst%3DT.%26aulast%3DTobe%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520%2528%252B%2529-Galactostatin%2520and%2520%2528%252B%2529-1-Deoxygalactostatin%2520Utilizing%2520L-Quebrachitol%2520as%2520a%2520Chiral%2520Building%2520Block%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1994%26spage%3D1247%26epage%3D1248%26doi%3D10.1039%2Fc39940001247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit68p"><span><span class="NLM_label">(p) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Legler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 5-Amino-5-Deoxy-D-Galactopyranose and 1,5-Dideoxy-1,5-Imino-D-Galactitol, and their Inhibition of Alpha- and Beta-D-Galactosidases</span>. <i>Carbohydr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/S0008-6215(00)90138-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68p&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS0008-6215%2800%2990138-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1986&pages=119-129&author=G.+Leglerauthor=S.+Pohl&title=Synthesis+of+5-Amino-5-Deoxy-D-Galactopyranose+and+1%2C5-Dideoxy-1%2C5-Imino-D-Galactitol%2C+and+their+Inhibition+of+Alpha-+and+Beta-D-Galactosidases&doi=10.1016%2FS0008-6215%2800%2990138-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68p&amp;dbid=16384&amp;doi=10.1016%2FS0008-6215%2800%2990138-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6215%252800%252990138-1%26sid%3Dliteratum%253Aachs%26aulast%3DLegler%26aufirst%3DG.%26aulast%3DPohl%26aufirst%3DS.%26atitle%3DSynthesis%2520of%25205-Amino-5-Deoxy-D-Galactopyranose%2520and%25201%252C5-Dideoxy-1%252C5-Imino-D-Galactitol%252C%2520and%2520their%2520Inhibition%2520of%2520Alpha-%2520and%2520Beta-D-Galactosidases%26jtitle%3DCarbohydr.%2520Res.%26date%3D1986%26volume%3D155%26spage%3D119%26epage%3D129%26doi%3D10.1016%2FS0008-6215%2800%2990138-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Ruiz, E.</span>; <span class="NLM_string-name">Collis, A. J.</span>; <span class="NLM_string-name">Dann, A. S.</span>; <span class="NLM_string-name">Fosberry, A. P.</span>; <span class="NLM_string-name">Ready, S. J.</span>; <span class="NLM_string-name">Vazquez Muniz, M. J.</span></span> <span> </span><span class="NLM_article-title">Fermentative Prodn. of Migalastat</span>. <span class="NLM_patent">WO 2015121488</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=E.+Alvarez-Ruiz&author=A.+J.+Collis&author=A.+S.+Dann&author=A.+P.+Fosberry&author=S.+J.+Ready&author=M.+J.+Vazquez+Muniz&title=Fermentative+Prodn.+of+Migalastat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Ruiz%26aufirst%3DE.%26atitle%3DFermentative%2520Prodn.%2520of%2520Migalastat%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uriel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoyo-Gonzalez, F.</span></span> <span> </span><span class="NLM_article-title">A Short and Efficient Synthesis of 1,5-Dideoxy-1,5-Imino-D-Galactitol (1-Deoxy-D-Galactostatin) and 1,5-Dideoxy-1,5-Imino-L-Altritol (1-Deoxy-L-Altrostatin) from D-Galactose</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>1999</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1055/s-1999-3158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1055%2Fs-1999-3158" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1999&publication_year=1999&pages=593-595&author=C.+Urielauthor=F.+Santoyo-Gonzalez&title=A+Short+and+Efficient+Synthesis+of+1%2C5-Dideoxy-1%2C5-Imino-D-Galactitol+%281-Deoxy-D-Galactostatin%29+and+1%2C5-Dideoxy-1%2C5-Imino-L-Altritol+%281-Deoxy-L-Altrostatin%29+from+D-Galactose&doi=10.1055%2Fs-1999-3158"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1055%2Fs-1999-3158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1999-3158%26sid%3Dliteratum%253Aachs%26aulast%3DUriel%26aufirst%3DC.%26aulast%3DSantoyo-Gonzalez%26aufirst%3DF.%26atitle%3DA%2520Short%2520and%2520Efficient%2520Synthesis%2520of%25201%252C5-Dideoxy-1%252C5-Imino-D-Galactitol%2520%25281-Deoxy-D-Galactostatin%2529%2520and%25201%252C5-Dideoxy-1%252C5-Imino-L-Altritol%2520%25281-Deoxy-L-Altrostatin%2529%2520from%2520D-Galactose%26jtitle%3DSynlett%26date%3D1999%26volume%3D1999%26spage%3D593%26epage%3D595%26doi%3D10.1055%2Fs-1999-3158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit71a"><span><span class="NLM_label">(a) </span> <a href="https://www.boehringer-ingelheim.com/press-release/south-korea-first-approve-next-generation-lung-cancer" class="extLink">https://www.boehringer-ingelheim.com/press-release/south-korea-first-approve-next-generation-lung-cancer</a> (accessed July 18, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+https%3A%2F%2Fwww.boehringer-ingelheim.com%2Fpress-release%2Fsouth-korea-first-approve-next-generation-lung-cancer+%28accessed+July+18%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit71b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1157</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0606-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0606-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27357069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1153-1157&author=E.+S.+Kim&title=Olmutinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0606-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71bR"><div class="casContent"><span class="casTitleNuber">71b</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1157</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co.  Ltd for the treatment of non-small cell lung cancer (NSCLC).  Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.  In Dec. 2015, olmutinib was granted breakthrough therapy designation in NSCLC by the US FDA.  In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-pos. NSCLC.  This article summarizes the milestones in the development of olmutinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY-HbqvpWrrVg90H21EOLACvtfcHk0lg-b3_CWRH56g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP&md5=749828b58c3a4ce11f607c2dcfef6b9c</span></div><a href="/servlet/linkout?suffix=cit71b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0606-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0606-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DOlmutinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1153%26epage%3D1157%26doi%3D10.1007%2Fs40265-016-0606-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit72a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer: Comparative Pharmacokinetics and Drug-Drug Interactions</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.ctrv.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25027951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=917-926&author=S.+Petersauthor=S.+Zimmermannauthor=A.+A.+Adjei&title=Oral+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+for+the+Treatment+of+Non-Small+Cell+Lung+Cancer%3A+Comparative+Pharmacokinetics+and+Drug-Drug+Interactions&doi=10.1016%2Fj.ctrv.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72aR"><div class="casContent"><span class="casTitleNuber">72a</span><div class="casTitle"><span class="NLM_cas:atitle">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions</span></div><div class="casAuthors">Peters, Solange; Zimmermann, Stefan; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of orally active small mol. inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC).  Patients with activating mutations of the EGFR gene show sensitivity to, and clin. benefit from, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls).  First generation reversible ATP-competitive EGFR-TKls, gefitinib and erlotinib, are effective as first, second-line or maintenance therapy.  Despite initial benefit, most patients develop resistance within a year, 50-60% of cases being related to the appearance of a T790M gatekeeper mutation.  Newer, irreversible EGFR-TKls - afatinib and dacomitinib - covalently bind to and inhibit multiple receptors in the ErbB family (EGFR, HER2 and HER4).  These agents have been mainly evaluated for first-line treatment but also in the setting of acquired resistance to first-generation EGFR-TKls.  Afatinib is the first ErbB family blocker approved for patients with NSCLC with activating EGFR mutations; dacomitinib is in late stage clin. development.  Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development.  The EGFR-TKIs differ in their spectrum of target kinases, reversibility of binding to EGFR receptor, pharmacokinetics and potential for drug-drug interactions, as discussed in this review.  For the clinician, these differences are relevant in the setting of polymedicated patients with NSCLC, as well as from the perspective of innovative anticancer drug combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFElQmV4ha7Vg90H21EOLACvtfcHk0lg-b3_CWRH56g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP&md5=31253f81e203aa012a5d87ad29ff6fc3</span></div><a href="/servlet/linkout?suffix=cit72a&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DOral%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Comparative%2520Pharmacokinetics%2520and%2520Drug-Drug%2520Interactions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.ctrv.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit72b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacey, S.</span></span> <span> </span><span class="NLM_article-title">Treatment Approaches for EGFR-Inhibitor-Resistant Patients with Non-Small-Cell Lung Cancer</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">e447</span>– <span class="NLM_lpage">e459</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00246-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2FS1470-2045%2815%2900246-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=26370354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOntLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=e447-e459&author=C.-S.+Tanauthor=D.+Gilliganauthor=S.+Pacey&title=Treatment+Approaches+for+EGFR-Inhibitor-Resistant+Patients+with+Non-Small-Cell+Lung+Cancer&doi=10.1016%2FS1470-2045%2815%2900246-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72bR"><div class="casContent"><span class="casTitleNuber">72b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer</span></div><div class="casAuthors">Tan, Chee-Seng; Gilligan, David; Pacey, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e447-e459</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of patients with advanced EGFR-mutant non-small-cell lung cancer (NSCLC).  At present, first-line treatment with EGFR TKIs (gefitinib, erlotinib, and afatinib) has been approved for patients harbouring exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations.  These agents improve response rates, time to progression, and overall survival.  Unfortunately, patients develop resistance, limiting patient benefit and posing a challenge to oncologists.  Optimum treatment after progression is not clearly defined.  A more detailed understanding of the biol. of EGFR-mutant NSCLC and the mechanisms of resistance to targeted therapy mean that an era of treatment approaches based on rationally developed drugs or therapeutic strategies has begun.  Combination approaches-eg, dual EGFR blockade-to overcome resistance have been trialled and seem to be promising but are potentially limited by toxicity.  Third-generation EGFR-mutant-selective TKIs, such as AZD9291 or rociletininb, which target Thr790Met-mutant tumors, the most common mechanism of EGFR TKI resistance, have entered clin. trials, and exciting, albeit preliminary, efficacy data have been reported.  In this Review, we summarise the scientific literature and evidence on therapy options after EGFR TKI treatment for patients with NSCLC, aiming to provide a guide to oncologists, and consider how to maximise therapeutic advances in outcomes in this rapidly advancing area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_CJqM1DDS3rVg90H21EOLACvtfcHk0lg-b3_CWRH56g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOntLjM&md5=1e04e573a62e12a4abeb88e0c4f8acb2</span></div><a href="/servlet/linkout?suffix=cit72b&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900246-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900246-6%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DC.-S.%26aulast%3DGilligan%26aufirst%3DD.%26aulast%3DPacey%26aufirst%3DS.%26atitle%3DTreatment%2520Approaches%2520for%2520EGFR-Inhibitor-Resistant%2520Patients%2520with%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3De447%26epage%3De459%26doi%3D10.1016%2FS1470-2045%2815%2900246-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">Recent Updates on Third Generation EGFR Inhibitors and Emergence of Fourth Generation EGFR Inhibitors to Combat C797S Resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.ejmech.2017.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28526474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=32-47&author=H.+Patelauthor=R.+Pawaraauthor=A.+Ansariauthor=S.+Surana&title=Recent+Updates+on+Third+Generation+EGFR+Inhibitors+and+Emergence+of+Fourth+Generation+EGFR+Inhibitors+to+Combat+C797S+Resistance&doi=10.1016%2Fj.ejmech.2017.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span></div><div class="casAuthors">Patel, Harun; Pawara, Rahul; Ansari, Azim; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  EGFR T790M mutation leads to resistance to most of clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development, which includes osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  On the other hand recently EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third generation inhibitors.  This review summarizes the third generation inhibitors, synthesis, their mechanism of resistance and latest development on the discovery of a fourth-generation EGFR TKIs and U to Y allosteric strategies to combat the C797S EGFR resistance problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprj-V5hUSHGrVg90H21EOLACvtfcHk0lg-b3_CWRH56g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D&md5=d0ed35bc7deae5ea37a95910df356c1d</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DRecent%2520Updates%2520on%2520Third%2520Generation%2520EGFR%2520Inhibitors%2520and%2520Emergence%2520of%2520Fourth%2520Generation%2520EGFR%2520Inhibitors%2520to%2520Combat%2520C797S%2520Resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D142%26spage%3D32%26epage%3D47%26doi%3D10.1016%2Fj.ejmech.2017.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit74a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cha, M. Y.</span>; <span class="NLM_string-name">Kang, S. J.</span>; <span class="NLM_string-name">Kim, M. R.</span>; <span class="NLM_string-name">Lee, J. Y.</span>; <span class="NLM_string-name">Jeon, J. Y.</span>; <span class="NLM_string-name">Jo, M. G.</span>; <span class="NLM_string-name">Kwak, E. J.</span>; <span class="NLM_string-name">Lee, K. O.</span>; <span class="NLM_string-name">Ha, T. H.</span>; <span class="NLM_string-name">Suh, K. H.</span>; <span class="NLM_string-name">Kim, M. S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Novel Fused Pyrimidine Derivatives for Inhibition of Tyrosine Kinase Activity</span>. <span class="NLM_patent">WO 2011162515</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Y.+Cha&author=S.+J.+Kang&author=M.+R.+Kim&author=J.+Y.+Lee&author=J.+Y.+Jeon&author=M.+G.+Jo&author=E.+J.+Kwak&author=K.+O.+Lee&author=T.+H.+Ha&author=K.+H.+Suh&author=M.+S.+Kim&title=Preparation+of+Novel+Fused+Pyrimidine+Derivatives+for+Inhibition+of+Tyrosine+Kinase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26atitle%3DPreparation%2520of%2520Novel%2520Fused%2520Pyrimidine%2520Derivatives%2520for%2520Inhibition%2520of%2520Tyrosine%2520Kinase%2520Activity%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit74b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baek, J. O.</span>; <span class="NLM_string-name">Jung, J. H.</span>; <span class="NLM_string-name">Kim, H. S.</span>; <span class="NLM_string-name">Ha, T.
H.</span>; <span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Thienopyrimidine Compound and Intermediates Thereof</span>. <span class="NLM_patent">WO 2016108623</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+O.+Baek&author=J.+H.+Jung&author=H.+S.+Kim&author=T.%0AH.+Ha&author=K.+H.+Suh&title=Process+for+Preparation+of+Thienopyrimidine+Compound+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaek%26aufirst%3DJ.%2BO.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Thienopyrimidine%2520Compound%2520and%2520Intermediates%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, W.</span>; <span class="NLM_string-name">Moon, Y.
H.</span>; <span class="NLM_string-name">Ha, T. H.</span>; <span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of Thienopyrimidine Compound and Intermediates Thereof</span>. <span class="NLM_patent">WO 2017074147</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=W.+Jang&author=Y.%0AH.+Moon&author=T.+H.+Ha&author=K.+H.+Suh&title=Method+for+the+Preparation+of+Thienopyrimidine+Compound+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DW.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%2520Thienopyrimidine%2520Compound%2520and%2520Intermediates%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Rucaparib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0716-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-017-0716-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28247266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFGru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=585-592&author=Y.+Y.+Syed&title=Rucaparib%3A+First+Global+Approval&doi=10.1007%2Fs40265-017-0716-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Rucaparib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">585-592</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Rucaparib (Rubraca) is an oral, small mol., poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncol., Inc.  (Boulder, CO, USA) for the treatment of solid tumors.  It has been approved in the USA as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) assocd. advanced ovarian cancer who have been treated with two or more chemotherapies.  A marketing authorization application for rucaparib for the same indication has been submitted to the European Medicines Agency.  Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer.  This article summarizes the milestones in the development of rucaparib leading to this first approval for ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjcxvUxCoC_LVg90H21EOLACvtfcHk0lisihSsdBWH_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFGru7w%253D&md5=3e79c0e50599d5f1916765b506517b18</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0716-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0716-2%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DRucaparib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D585%26epage%3D592%26doi%3D10.1007%2Fs40265-017-0716-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><a href="http://clovisoncology.com/files/rubraca-prescribing-info.pdf" class="extLink">http://clovisoncology.com/files/rubraca-prescribing-info.pdf</a> (accessed July 22, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fclovisoncology.com%2Ffiles%2Frubraca-prescribing-info.pdf+%28accessed+July+22%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Rucaparib and Companion Diagnostics in the PARP Inhibitor Landscape for Recurrent Ovarian Cancer Therapy</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.2217/fon-2016-0002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.2217%2Ffon-2016-0002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27087632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVSqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1439-1456&author=Z.+B.+Jennerauthor=A.+K.+Soodauthor=R.+L.+Coleman&title=Evaluation+of+Rucaparib+and+Companion+Diagnostics+in+the+PARP+Inhibitor+Landscape+for+Recurrent+Ovarian+Cancer+Therapy&doi=10.2217%2Ffon-2016-0002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy</span></div><div class="casAuthors">Jenner, Zachary B.; Sood, Anil K.; Coleman, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1456</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Rucaparib camsylate (CO-338; 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid salt) is a PARP1, 2 and 3 inhibitor.  Phase I studies identified a recommended Phase II dose of 600 mg orally twice daily.  ARIEL2 Part 1 established a tumor genomic profiling test for homologous recombination loss of heterozygosity quantification using a next-generation sequencing companion diagnostic (CDx).  Rucaparib received US FDA Breakthrough Therapy designation for treatment of platinum-sensitive BRCA-mutated advanced ovarian cancer patients who received greater than two lines of platinum-based therapy.  Comparable to rucaparib development, other PARP inhibitors, such as olaparib, niraparib, veliparib and talazoparib, are developing CDx tests for targeted therapy.  PARP inhibitor clin. trials and CDx assays are discussed in this review, as are potential PARP inhibitor combination therapies and likely resistance mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrADXfrLLTKLVg90H21EOLACvtfcHk0lisihSsdBWH_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVSqt7k%253D&md5=1d4258979dbc52465ac599266091bb99</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2217%2Ffon-2016-0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2016-0002%26sid%3Dliteratum%253Aachs%26aulast%3DJenner%26aufirst%3DZ.%2BB.%26aulast%3DSood%26aufirst%3DA.%2BK.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26atitle%3DEvaluation%2520of%2520Rucaparib%2520and%2520Companion%2520Diagnostics%2520in%2520the%2520PARP%2520Inhibitor%2520Landscape%2520for%2520Recurrent%2520Ovarian%2520Cancer%2520Therapy%26jtitle%3DFuture%2520Oncol.%26date%3D2016%26volume%3D12%26spage%3D1439%26epage%3D1456%26doi%3D10.2217%2Ffon-2016-0002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1158%2F1535-7163.MCT-13-0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=24356813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=433-443&author=J.+Muraiauthor=S.-Y.+N.+Huangauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+Jiauthor=S.+Takedaauthor=J.+Morrisauthor=B.+Teicherauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Stereospecific+PARP+Trapping+by+BMN+673+and+Comparison+with+Olaparib+and+Rucaparib&doi=10.1158%2F1535-7163.MCT-13-0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-Yin N.; Renaud, Amelie; Zhang, Yiping; Ji, Jiuping; Takeda, Shunichi; Morris, Joel; Teicher, Beverly; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks.  We recently reported that several PARP inhibitors have an addnl. cytotoxic mechanism by trapping PARP-DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacol. concns.  Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP-DNA trapping.  Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clin. PARP inhibitors, olaparib and rucaparib, using biochem. and cellular assays in genetically modified chicken DT40 and human cancer cell lines.  Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP-DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP-DNA complexes.  The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2.  Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient.  BMN 673 is also approx. 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents Me methane sulfonate (MMS) and temozolomide.  Our study demonstrates that BMN 673 is the most potent clin. PARP inhibitor tested to date with the highest efficiency at trapping PARP-DNA complexes.  Mol Cancer Ther; 13(2); 433-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8p5YTwAneh7Vg90H21EOLACvtfcHk0lhcviztlEQaXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D&md5=513c544d1cb5c2203e7696af76201afd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0803%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.-Y.%2BN.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DStereospecific%2520PARP%2520Trapping%2520by%2520BMN%2520673%2520and%2520Comparison%2520with%2520Olaparib%2520and%2520Rucaparib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D433%26epage%3D443%26doi%3D10.1158%2F1535-7163.MCT-13-0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kern, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalinsky, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. D.</span></span> <span> </span><span class="NLM_article-title">Comparative PARP Enzyme Inhibition of PF-01367338, Olaparib, and MK-4827</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">e13552</span>, <span class="refDoi"> DOI: 10.1200/jco.2011.29.15_suppl.e13552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1200%2Fjco.2011.29.15_suppl.e13552" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=e13552&author=K.+A.+Kernauthor=S.+Zhangauthor=D.+R.+Shalinskyauthor=D.+D.+Wang&title=Comparative+PARP+Enzyme+Inhibition+of+PF-01367338%2C+Olaparib%2C+and+MK-4827&doi=10.1200%2Fjco.2011.29.15_suppl.e13552"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.29.15_suppl.e13552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.29.15_suppl.e13552%26sid%3Dliteratum%253Aachs%26aulast%3DKern%26aufirst%3DK.%2BA.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DD.%2BD.%26atitle%3DComparative%2520PARP%2520Enzyme%2520Inhibition%2520of%2520PF-01367338%252C%2520Olaparib%252C%2520and%2520MK-4827%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3De13552%26doi%3D10.1200%2Fjco.2011.29.15_suppl.e13552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telfer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCrudden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamjoo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. J.</span></span> <span> </span><span class="NLM_article-title">Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6106</span>– <span class="NLM_lpage">6112</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1158%2F1078-0432.CCR-09-0398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=19789326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2lur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6106-6112&author=M.+Aliauthor=B.+A.+Telferauthor=C.+McCruddenauthor=M.+O%E2%80%99Rourkeauthor=H.+D.+Thomasauthor=M.+Kamjooauthor=S.+Kyleauthor=T.+Robsonauthor=C.+Shawauthor=D.+G.+Hirstauthor=N.+J.+Curtinauthor=K.+J.+Williams&title=Vasoactivity+of+AG014699%2C+a+Clinically+Active+Small+Molecule+Inhibitor+of+Poly%28ADP-ribose%29+Polymerase%3A+a+Contributory+Factor+to+Chemopotentiation+In+vivo%3F&doi=10.1158%2F1078-0432.CCR-09-0398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?</span></div><div class="casAuthors">Ali, Majid; Telfer, Brian A.; McCrudden, Cian; O'Rourke, Martin; Thomas, Huw D.; Kamjoo, Marzieh; Kyle, Suzanne; Robson, Tracy; Shaw, Chris; Hirst, David G.; Curtin, Nicola J.; Williams, Kaye J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6106-6112</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP) plays an important role in DNA repair, and PARP inhibitors can enhance the activity of DNA-damaging agents in vitro and in vivo.  AG014699 is a potent PARP inhibitor in phase II clin. development.  However, the range of therapeutics with which AG014699 could interact via a DNA-repair based mechanism is limited.  We aimed to investigate a novel, vascular-based activity of AG014699, underlying in vivo chemosensitization, which could widen its clin. application.  Temozolomide response was analyzed in vitro and in vivo.  Vessel dynamics were monitored using "mismatch" following the administration of perfusion markers and real-time anal. of fluorescently labeled albumin uptake in to tumors established in dorsal window chambers.  Further mechanistic investigations used ex vivo assays of vascular smooth muscle relaxation, gut motility, and myosin light chain kinase (MLCK) inhibition.  AG014699 failed to sensitize SW620 cells to temozolomide in vitro but induced pronounced enhancement in vivo.  AG014699 (1 mg/kg) improved tumor perfusion comparably with the control agents nicotinamide (1 g/kg) and AG14361 (forerunner to AG014699; 10 mg/kg).  AG014699 and AG14361 relaxed preconstricted vascular smooth muscle more potently than the std. agent, hydralazine, with no impact on gut motility.  AG014699 inhibited MLCK at concns. that relaxed isolated arteries, whereas AG14361 had no effect.  Increased vessel perfusion elicited by AG014699 could increase tumor drug accumulation and therapeutic response.  Vasoactive concns. of AG014699 do not cause detrimental side effects to gut motility and may increase the range of therapeutics with which AG014699 could be combined with for clin. benefit. (Clin Cancer Res 2009;15(19):6106-12).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqAJypUhLMRLVg90H21EOLACvtfcHk0lhcviztlEQaXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2lur%252FF&md5=64878c792dc5029396129ff5c6ef32a1</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0398%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DM.%26aulast%3DTelfer%26aufirst%3DB.%2BA.%26aulast%3DMcCrudden%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DKamjoo%26aufirst%3DM.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DRobson%26aufirst%3DT.%26aulast%3DShaw%26aufirst%3DC.%26aulast%3DHirst%26aufirst%3DD.%2BG.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DWilliams%26aufirst%3DK.%2BJ.%26atitle%3DVasoactivity%2520of%2520AG014699%252C%2520a%2520Clinically%2520Active%2520Small%2520Molecule%2520Inhibitor%2520of%2520Poly%2528ADP-ribose%2529%2520Polymerase%253A%2520a%2520Contributory%2520Factor%2520to%2520Chemopotentiation%2520In%2520vivo%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6106%26epage%3D6112%26doi%3D10.1158%2F1078-0432.CCR-09-0398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihnen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">zu Eulenburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolarova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manivong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalukya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginther, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winterhoff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velculescu, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenicke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konecny, G. E.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1002</span>– <span class="NLM_lpage">1015</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1158%2F1535-7163.MCT-12-0813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=23729402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1002-1015&author=M.+Ihnenauthor=C.+zu+Eulenburgauthor=T.+Kolarovaauthor=J.+W.+Qiauthor=K.+Manivongauthor=M.+Chalukyaauthor=J.+Deringauthor=L.+Andersonauthor=C.+Gintherauthor=A.+Meuterauthor=B.+Winterhoffauthor=S.+Jonesauthor=V.+E.+Velculescuauthor=N.+Venkatesanauthor=H.-M.+Rongauthor=S.+Dandekarauthor=N.+Udarauthor=F.+Jaenickeauthor=G.+Losauthor=D.+J.+Slamonauthor=G.+E.+Konecny&title=Therapeutic+Potential+of+the+Poly%28ADP-ribose%29+Polymerase+Inhibitor+Rucaparib+for+the+Treatment+of+Sporadic+Human+Ovarian+Cancer&doi=10.1158%2F1535-7163.MCT-12-0813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer</span></div><div class="casAuthors">Ihnen, Maike; zu Eulenburg, Christine; Kolarova, Teodora; Qi, Jing Wei; Manivong, Kanthinh; Chalukya, Meenal; Dering, Judy; Anderson, Lee; Ginther, Charles; Meuter, Alexandra; Winterhoff, Boris; Jones, Sian; Velculescu, Victor E.; Venkatesan, Natarajan; Rong, Hong-Mei; Dandekar, Sugandha; Udar, Nitin; Jaenicke, Fritz; Los, Gerrit; Slamon, Dennis J.; Konecny, Gottfried E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1002-1015</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer.  We studied the growth inhibitory effects of rucaparib in a panel of 39 ovarian cancer cell lines that were each characterized for mutation and methylation status of BRCA1/2, baseline gene expression signatures, copy no. variations of selected genes, PTEN status, and sensitivity to platinum-based chemotherapy.  To study interactions with chemotherapy, we used multiple drug effect analyses and assessed apoptosis, DNA fragmentation, and γH2AX formation.  Concn.-dependent antiproliferative effects of rucaparib were seen in 26 of 39 (67%) cell lines and were not restricted to cell lines with BRCA1/2 mutations.  Low expression of other genes involved in homologous repair (e.g., BCCIP, BRCC3, ATM, RAD51L1), amplification of AURKA or EMSY, and response to platinum-based chemotherapy was assocd. with sensitivity to rucaparib.  Drug interactions with rucaparib were synergistic for topotecan, synergistic, or additive for carboplatin, doxorubicin or paclitaxel, and additive for gemcitabine.  Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in enhanced apoptosis, DNA fragmentation, and γH2AX formation.  Importantly, rucaparib potentiated chemotherapy independent of its activity as a single agent.  PARP inhibition may be a useful therapeutic strategy for a wider range of ovarian cancers bearing deficiencies in the homologous recombination pathway other than just BRCA1/2 mutations.  These results support further clin. evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe7ZBqJCdQobVg90H21EOLACvtfcHk0lhcviztlEQaXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOltLw%253D&md5=4eaf35f1dd521263a63ee6cb5a8c8ad6</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0813%26sid%3Dliteratum%253Aachs%26aulast%3DIhnen%26aufirst%3DM.%26aulast%3Dzu%2BEulenburg%26aufirst%3DC.%26aulast%3DKolarova%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%2BW.%26aulast%3DManivong%26aufirst%3DK.%26aulast%3DChalukya%26aufirst%3DM.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DMeuter%26aufirst%3DA.%26aulast%3DWinterhoff%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DVenkatesan%26aufirst%3DN.%26aulast%3DRong%26aufirst%3DH.-M.%26aulast%3DDandekar%26aufirst%3DS.%26aulast%3DUdar%26aufirst%3DN.%26aulast%3DJaenicke%26aufirst%3DF.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26atitle%3DTherapeutic%2520Potential%2520of%2520the%2520Poly%2528ADP-ribose%2529%2520Polymerase%2520Inhibitor%2520Rucaparib%2520for%2520the%2520Treatment%2520of%2520Sporadic%2520Human%2520Ovarian%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1002%26epage%3D1015%26doi%3D10.1158%2F1535-7163.MCT-12-0813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span>; <span class="NLM_string-name">Tong, Y.</span>; <span class="NLM_string-name">Jones, D.
R.</span>; <span class="NLM_string-name">Walsh, T.</span>; <span class="NLM_string-name">Danso, M. A.</span>; <span class="NLM_string-name">Ma, C. X.</span>; <span class="NLM_string-name">Silverman, P.</span>; <span class="NLM_string-name">King, M.-C.</span>; <span class="NLM_string-name">Badve, S. S.</span>; <span class="NLM_string-name">Perkins, S. M.</span></span> <span> </span><span class="NLM_article-title">Cisplatin With or Without Rucaparib After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer: Final Efficacy Results of Hoosier Oncology Group BRE09–146</span>.  <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span> <span class="NLM_fpage">1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=1&author=K.+Miller&author=Y.+Tong&author=D.%0AR.+Jones&author=T.+Walsh&author=M.+A.+Danso&author=C.+X.+Ma&author=P.+Silverman&author=M.-C.+King&author=S.+S.+Badve&author=S.+M.+Perkins&title=Cisplatin+With+or+Without+Rucaparib+After+Preoperative+Chemotherapy+in+Patients+with+Triple+Negative+Breast+Cancer%3A+Final+Efficacy+Results+of+Hoosier+Oncology+Group+BRE09%E2%80%93146"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DK.%26atitle%3DCisplatin%2520With%2520or%2520Without%2520Rucaparib%2520After%2520Preoperative%2520Chemotherapy%2520in%2520Patients%2520with%2520Triple%2520Negative%2520Breast%2520Cancer%253A%2520Final%2520Efficacy%2520Results%2520of%2520Hoosier%2520Oncology%2520Group%2520BRE09%25E2%2580%2593146%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span>; <span class="NLM_string-name">Hendifar, A. E.</span>; <span class="NLM_string-name">McWilliams, R. R.</span>; <span class="NLM_string-name">Geva, R.</span>; <span class="NLM_string-name">Epelbaum, R.</span>; <span class="NLM_string-name">Biankin, A.</span>; <span class="NLM_string-name">Vonderheide, R. H.</span>; <span class="NLM_string-name">Wolff, R. A.</span>; <span class="NLM_string-name">Alberts, S. R.</span>; <span class="NLM_string-name">Giordano, H.</span>; <span class="NLM_string-name">Goble, S.</span>; <span class="NLM_string-name">Lin, K.
K.</span>; <span class="NLM_string-name">Shroff, R.
T.</span></span> <span> </span><span class="NLM_article-title">RUCAPANC: An Open-Label, Phase 2 Trial of the PARP Inhibitor Rucaparib in Patients (pts) with Pancreatic Cancer (PC) and a Known Deleterious Germline or Somatic BRCA Mutation</span>.  <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span> <span class="NLM_fpage">1</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1&author=S.+M.+Domchek&author=A.+E.+Hendifar&author=R.+R.+McWilliams&author=R.+Geva&author=R.+Epelbaum&author=A.+Biankin&author=R.+H.+Vonderheide&author=R.+A.+Wolff&author=S.+R.+Alberts&author=H.+Giordano&author=S.+Goble&author=K.%0AK.+Lin&author=R.%0AT.+Shroff&title=RUCAPANC%3A+An+Open-Label%2C+Phase+2+Trial+of+the+PARP+Inhibitor+Rucaparib+in+Patients+%28pts%29+with+Pancreatic+Cancer+%28PC%29+and+a+Known+Deleterious+Germline+or+Somatic+BRCA+Mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26atitle%3DRUCAPANC%253A%2520An%2520Open-Label%252C%2520Phase%25202%2520Trial%2520of%2520the%2520PARP%2520Inhibitor%2520Rucaparib%2520in%2520Patients%2520%2528pts%2529%2520with%2520Pancreatic%2520Cancer%2520%2528PC%2529%2520and%2520a%2520Known%2520Deleterious%2520Germline%2520or%2520Somatic%2520BRCA%2520Mutation%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillmore, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critcher, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fussell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kougoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlinson, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherlock, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, R.</span></span> <span> </span><span class="NLM_article-title">Multkilogram Scale-Up of a Reductive Alkylation Route to a Novel PARP Inhibitor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1897</span>– <span class="NLM_lpage">1904</span>, <span class="refDoi"> DOI: 10.1021/op200238p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op200238p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ohs73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=1897-1904&author=A.+T.+Gillmoreauthor=M.+Badlandauthor=C.+L.+Crookauthor=N.+M.+Castroauthor=D.+J.+Critcherauthor=S.+J.+Fussellauthor=K.+J.+Jonesauthor=M.+C.+Jonesauthor=E.+Kougoulosauthor=J.+S.+Mathewauthor=L.+McMillanauthor=J.+E.+Pearceauthor=F.+L.+Rawlinsonauthor=A.+E.+Sherlockauthor=R.+Walton&title=Multkilogram+Scale-Up+of+a+Reductive+Alkylation+Route+to+a+Novel+PARP+Inhibitor&doi=10.1021%2Fop200238p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Multkilogram Scale-Up of a Reductive Alkylation Route to a Novel PARP Inhibitor</span></div><div class="casAuthors">Gillmore, Adam T.; Badland, Matthew; Crook, Clare L.; Castro, Nieves M.; Critcher, Douglas J.; Fussell, Steven J.; Jones, Katherine J.; Jones, Matthew C.; Kougoulos, Eleftherios; Mathew, Jinu S.; McMillan, Lynne; Pearce, John E.; Rawlinson, Fiona L.; Sherlock, Alexandra E.; Walton, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1897-1904</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel PARP inhibitor 1 is a promising new candidate for treatment of breast and ovarian cancer.  A modified synthetic route to 1 has been developed and demonstrated on 7 kg scale.  In order to scale up the synthesis to multikilogram scale, several synthetic challenges needed to be overcome.  The key issues included significant thermal hazards present in a Leimgruber-Batcho indole synthesis, a low-yielding side-chain installation, a nonrobust Suzuki coupling and hydrogen cyanide generation during a reductive amination.  In addn. to these issues, changing from i.v. to oral delivery required a new salt form and therefore a new crystn. procedure.  This contribution describes development work to solve these issues and scaling up of the new process in the pilot plant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfbJQx6OSuJrVg90H21EOLACvtfcHk0lgI43xsI5nBlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ohs73F&md5=e4810016551595a26f4a6db30302681e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fop200238p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop200238p%26sid%3Dliteratum%253Aachs%26aulast%3DGillmore%26aufirst%3DA.%2BT.%26aulast%3DBadland%26aufirst%3DM.%26aulast%3DCrook%26aufirst%3DC.%2BL.%26aulast%3DCastro%26aufirst%3DN.%2BM.%26aulast%3DCritcher%26aufirst%3DD.%2BJ.%26aulast%3DFussell%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DK.%2BJ.%26aulast%3DJones%26aufirst%3DM.%2BC.%26aulast%3DKougoulos%26aufirst%3DE.%26aulast%3DMathew%26aufirst%3DJ.%2BS.%26aulast%3DMcMillan%26aufirst%3DL.%26aulast%3DPearce%26aufirst%3DJ.%2BE.%26aulast%3DRawlinson%26aufirst%3DF.%2BL.%26aulast%3DSherlock%26aufirst%3DA.%2BE.%26aulast%3DWalton%26aufirst%3DR.%26atitle%3DMultkilogram%2520Scale-Up%2520of%2520a%2520Reductive%2520Alkylation%2520Route%2520to%2520a%2520Novel%2520PARP%2520Inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D1897%26epage%3D1904%26doi%3D10.1021%2Fop200238p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vincentis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">An Efficient Synthesis of Ecopladib</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7871</span>– <span class="NLM_lpage">7876</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2008.06.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1016%2Fj.tet.2008.06.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=7871-7876&author=W.+Liauthor=J.+Liauthor=D.+De+Vincentisauthor=T.+S.+Mansour&title=An+Efficient+Synthesis+of+Ecopladib&doi=10.1016%2Fj.tet.2008.06.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2008.06.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2008.06.045%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDe%2BVincentis%26aufirst%3DD.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DAn%2520Efficient%2520Synthesis%2520of%2520Ecopladib%26jtitle%3DTetrahedron%26date%3D2008%26volume%3D64%26spage%3D7871%26epage%3D7876%26doi%3D10.1016%2Fj.tet.2008.06.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm" class="extLink">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm</a> (accessed July 15, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm495253.htm+%28accessed+July+15%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit88a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Venetoclax: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0596-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0596-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=27260335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVymtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=979-987&author=E.+D.+Deeks&title=Venetoclax%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0596-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88aR"><div class="casContent"><span class="casTitleNuber">88a</span><div class="casTitle"><span class="NLM_cas:atitle">Venetoclax: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">979-987</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Venetoclax (Venclexta) is an oral selective inhibitor of the prosurvival protein BCL-2 and therefore restores the apoptotic ability of malignant cells.  The drug arose from research by Abbott Labs. (now AbbVie) during a collaboration with Genentech and is being co-developed by AbbVie and Genentech/Roche primarily for the treatment of haematol. malignancies.  Venetoclax is approved in the USA for use as monotherapy in patients with chronic lymphocytic leukemia (CLL) with the 17p deletion (as detected by an approved FDA test) who have received at least one prior therapy, and is awaiting approval for similar indications in the EU and Canada.  Venetoclax is also in phase I-III development as combination therapy for CLL, phase I/II development as monotherapy and/or combination therapy for non-Hodgkin lymphomas (including diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma) and acute myeloid leukemia, and phase I development for multiple myeloma, systemic lupus erythematosus and breast cancer.  This article summarizes the milestones in the development of venetoclax leading to this first approval for CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo-_C1vJNwpLVg90H21EOLACvtfcHk0lgI43xsI5nBlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVymtLo%253D&md5=e0f99ba8fb7665bba95ac42626c6aaa3</span></div><a href="/servlet/linkout?suffix=cit88a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0596-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0596-x%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DVenetoclax%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D979%26epage%3D987%26doi%3D10.1007%2Fs40265-016-0596-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit88b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Besbes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirshahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besbes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirshahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billard, C.</span></span> <span> </span><span class="NLM_article-title">New Dimension in Therapeutic Targeting of BCL-2 Family Proteins</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12862</span>– <span class="NLM_lpage">12871</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.18632%2Foncotarget.3868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25970783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2MfjsF2jsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=12862-12871&author=S.+Besbesauthor=M.+Mirshahiauthor=M.+Pocardauthor=C.+Billardauthor=S.+Besbesauthor=M.+Mirshahiauthor=M.+Pocardauthor=C.+Billard&title=New+Dimension+in+Therapeutic+Targeting+of+BCL-2+Family+Proteins&doi=10.18632%2Foncotarget.3868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88bR"><div class="casContent"><span class="casTitleNuber">88b</span><div class="casTitle"><span class="NLM_cas:atitle">New dimension in therapeutic targeting of BCL-2 family proteins</span></div><div class="casAuthors">Besbes Samaher; Mirshahi Massoud; Pocard Marc; Billard Christian; Besbes Samaher; Mirshahi Massoud; Pocard Marc; Billard Christian</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">12862-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Proteins of the BCL-2 family control the mitochondrial pathway of apoptosis.  Targeting these proteins proves to be an attractive strategy for anticancer therapy.  The biological context is based on the fact that BH3-only members of the family are specific antagonists of prosurvival members.  This prompted the identification of "BH3 mimetic" compounds.  These small peptides or organic molecules indeed mimic the BH3 domain of BH3-only proteins: by selectively binding and antagonizing prosurvival proteins, they can induce apoptosis in malignant cells.  Some small-molecule inhibitors of prosurvival proteins have already entered clinical trials in cancer patients and two of them have shown significant therapeutic effects.  The latest developments in the field of targeting BCL-2 family proteins highlight several new antagonists of prosurvival proteins as well as direct activators of proapoptotic proteins.  These compounds open up novel prospects for the development of BH3 mimetic anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRn1i1qso7YZ__I8Jvzw4xCfW6udTcc2eYwgOIHxgRvVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfjsF2jsA%253D%253D&md5=54c3652f33c8cd70a38ef6d0f17ebbff</span></div><a href="/servlet/linkout?suffix=cit88b&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3868%26sid%3Dliteratum%253Aachs%26aulast%3DBesbes%26aufirst%3DS.%26aulast%3DMirshahi%26aufirst%3DM.%26aulast%3DPocard%26aufirst%3DM.%26aulast%3DBillard%26aufirst%3DC.%26aulast%3DBesbes%26aufirst%3DS.%26aulast%3DMirshahi%26aufirst%3DM.%26aulast%3DPocard%26aufirst%3DM.%26aulast%3DBillard%26aufirst%3DC.%26atitle%3DNew%2520Dimension%2520in%2520Therapeutic%2520Targeting%2520of%2520BCL-2%2520Family%2520Proteins%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D12862%26epage%3D12871%26doi%3D10.18632%2Foncotarget.3868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J.</span></span> <span> </span><span class="NLM_article-title">ABT-199 for Chronic Lymphocytic Leukemia</span>. <i>Clin. Adv. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">700</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=25658896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2MrjsVegtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=698-700&author=J.+Seymour&title=ABT-199+for+Chronic+Lymphocytic+Leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-199 for chronic lymphocytic leukemia</span></div><div class="casAuthors">Seymour John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">698-700</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUWQOZeWcSnIIRAdBLKY41fW6udTcc2eYwgOIHxgRvVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrjsVegtQ%253D%253D&md5=9a7e1fec1b8716ea718f8ff6708c5d95</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeymour%26aufirst%3DJ.%26atitle%3DABT-199%2520for%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D12%26spage%3D698%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit90a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, V. S.</span>; <span class="NLM_string-name">Christesen, A. C.</span>; <span class="NLM_string-name">Grieme, T. A.</span>; <span class="NLM_string-name">Ku, Y.-Y.</span>; <span class="NLM_string-name">Mulhern, M. M.</span>; <span class="NLM_string-name">Pu, Y.-M. M.</span></span> <span> </span><span class="NLM_article-title">Processes for the Preparation of an Apoptosis-Inducing Agent</span>. <span class="NLM_patent">US 20140275540</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=V.+S.+Chan&author=A.+C.+Christesen&author=T.+A.+Grieme&author=Y.-Y.+Ku&author=M.+M.+Mulhern&author=Y.-M.+M.+Pu&title=Processes+for+the+Preparation+of+an+Apoptosis-Inducing+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DV.%2BS.%26atitle%3DProcesses%2520for%2520the%2520Preparation%2520of%2520an%2520Apoptosis-Inducing%2520Agent%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit90b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and Venetoclax</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2028</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00374</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWnu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=2028-2042&author=D.+L.+Hughes&title=Patent+Review+of+Manufacturing+Routes+to+Oncology+Drugs%3A+Carfilzomib%2C+Osimertinib%2C+and+Venetoclax&doi=10.1021%2Facs.oprd.6b00374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90bR"><div class="casContent"><span class="casTitleNuber">90b</span><div class="casTitle"><span class="NLM_cas:atitle">Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and Venetoclax</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2028-2042</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Synthetic routes and final forms for three recently approved oncol. drugs are reviewed: carfilzomib (Kyprolis), osimertinib (Tagrisso), and venetoclax (Venclexta).  Several patent applications have been filed for the major synthetic challenge for carfilzomib, installation of the chiral epoxide.  The apparent manufg. route to osimertinib involves seven steps and a longest linear sequence of six steps with a yield of 56%.  The apparent manufg. route to venetoclax is a ten-step convergent synthesis with a seven-step longest linear sequence that proceeds in 52% yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoYYa5DvhU6rVg90H21EOLACvtfcHk0lgX6HGtDzqguw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWnu73J&md5=ab2cfca1cc98e4265693ed68fd96a0ad</span></div><a href="/servlet/linkout?suffix=cit90b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00374%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DPatent%2520Review%2520of%2520Manufacturing%2520Routes%2520to%2520Oncology%2520Drugs%253A%2520Carfilzomib%252C%2520Osimertinib%252C%2520and%2520Venetoclax%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D2028%26epage%3D2042%26doi%3D10.1021%2Facs.oprd.6b00374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catron, N. D.</span>; <span class="NLM_string-name">Chen, S.</span>; <span class="NLM_string-name">Gong, Y.</span>; <span class="NLM_string-name">Zhang, G.
G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Chlorophenyldimethylcyclohexenylmethylpiperazinylnitrotetrahydropyranylmethylaminophenylsulfonylpyrrolopyridinyloxybenzamide Salts and Crystalline Forms for Use as Apoptosis-Inducing Agents</span>. <span class="NLM_patent">WO 2012071336</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+D.+Catron&author=S.+Chen&author=Y.+Gong&author=G.%0AG.+Zhang&title=Preparation+of+Chlorophenyldimethylcyclohexenylmethylpiperazinylnitrotetrahydropyranylmethylaminophenylsulfonylpyrrolopyridinyloxybenzamide+Salts+and+Crystalline+Forms+for+Use+as+Apoptosis-Inducing+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCatron%26aufirst%3DN.%2BD.%26atitle%3DPreparation%2520of%2520Chlorophenyldimethylcyclohexenylmethylpiperazinylnitrotetrahydropyranylmethylaminophenylsulfonylpyrrolopyridinyloxybenzamide%2520Salts%2520and%2520Crystalline%2520Forms%2520for%2520Use%2520as%2520Apoptosis-Inducing%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93a"><span><span class="NLM_label">(a) </span><a href="https://www.shire.com/newsroom/2016/july/9pks5v" class="extLink">https://www.shire.com/newsroom/2016/july/9pks5v</a> (accessed August
12, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.shire.com%2Fnewsroom%2F2016%2Fjuly%2F9pks5v+%28accessed+August%0A12%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit93b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Abidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span> <span> </span><span class="NLM_article-title">Lifitegrast: A Novel Drug for Treatment of Dry Eye Disease</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.195920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit93b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.4103%2F0976-500X.195920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit93b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=28163544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit93b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVChsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=194-198&author=A.+Abidiauthor=P.+Shuklaauthor=A.+Ahmad&title=Lifitegrast%3A+A+Novel+Drug+for+Treatment+of+Dry+Eye+Disease&doi=10.4103%2F0976-500X.195920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93bR"><div class="casContent"><span class="casTitleNuber">92b</span><div class="casTitle"><span class="NLM_cas:atitle">Lifitegrast: a novel drug for treatment of dry eye disease</span></div><div class="casAuthors">Abidi, Afroz; Shukla, Pooja; Ahmad, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">194-198</span>CODEN:
                <span class="NLM_cas:coden">JPPOGN</span>;
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">Dry eye disease (DED) is an inflammatory disorder of ocular surfaces leading to severe disability, esp. in the elderly age group.  The mainstay of therapy includes artificial tears, punctual plugs, topical antiinflammatory agents, and corticosteroids.  In the past few years, only cyclosporine-A emulsions have been added to the existing therapy, but it is discontinued by most patients as it causes burning sensation in the eye.  Hence, progress in new research for a better therapeutic option led to the discovery of lymphocyte function-assocd. antigen intercellular adhesion mol. 1 antagonist, lifitegrast.  It hinders the T-cell activation, release of inflammatory mediators, and consequently inhibits the inflammatory pathways in DED.  It was approved by the US Food and Drug Administration in July 2016 for the treatment of DED.  This review highlights the development process and approval of lifitegrast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGShJCw1byCrVg90H21EOLACvtfcHk0lg6D03WrQnLZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVChsrg%253D&md5=5c2f2e417aa1de1c176b7bca2fe889c6</span></div><a href="/servlet/linkout?suffix=cit93b&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.195920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.195920%26sid%3Dliteratum%253Aachs%26aulast%3DAbidi%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DP.%26aulast%3DAhmad%26aufirst%3DA.%26atitle%3DLifitegrast%253A%2520A%2520Novel%2520Drug%2520for%2520Treatment%2520of%2520Dry%2520Eye%2520Disease%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2016%26volume%3D7%26spage%3D194%26epage%3D198%26doi%3D10.4103%2F0976-500X.195920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit93c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0681-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit93c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1007%2Fs40265-016-0681-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=201-208&author=G.+M.+Keating&title=Lifitegrast+Ophthalmic+Solution+5%25%3A+A+Review+in+Dry+Eye+Disease&doi=10.1007%2Fs40265-016-0681-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93c&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0681-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0681-1%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DLifitegrast%2520Ophthalmic%2520Solution%25205%2525%253A%2520A%2520Review%2520in%2520Dry%2520Eye%2520Disease%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D201%26epage%3D208%26doi%3D10.1007%2Fs40265-016-0681-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, D. M.</span></span> <span> </span><span class="NLM_article-title">Lifitegrast: First LFA-1/ICAM-1 Antagonist for Treatment of Dry Eye Disease</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1358/dot.2016.52.9.2542066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=10.1358%2Fdot.2016.52.9.2542066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A280%3ADC%252BC2sjgtVSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=485-493&author=D.+M.+Paton&title=Lifitegrast%3A+First+LFA-1%2FICAM-1+Antagonist+for+Treatment+of+Dry+Eye+Disease&doi=10.1358%2Fdot.2016.52.9.2542066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease</span></div><div class="casAuthors">Paton D M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">485-493</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Dry eye disease is an extremely common condition affecting millions worldwide.  The underlying pathophysiological mechanism is thought to be localized inflammation of the ocular surface resulting in the localization of T cells at this surface followed by their activation and subsequent liberation of cytokines.  This effect on T cells results from the binding of lymphocyte function-associated antigen-1 (LFA-1) located on T cells to intercellular adhesion molecule 1 (ICAM-1) expressed on inflamed epithelium and endothelium, and on T cells.  Lifitegrast is a T-cell integrin antagonist designed to mimic ICAM-1, thus blocking the interaction of LFA-1 and ICAM-1.  Lifitegrast enters the systemic circulation to a limited extent thus reducing the likelihood of unwanted systemic reactions.  Clinical trials in over 2,500 subjects with dry eye disease have shown that 5.0% lifitegrast given by ocular instillation causes a significant reduction in objective and subjective signs and symptoms of the disease.  These beneficial effects are associated with a relatively low incidence of unwanted effects, almost all local in nature.  In light of these findings, lifitegrast was approved by the Food and Drug Administration (FDA) in 2016 for the treatment of dry eye disease, the first drug with this mechanism of action to be so approved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOIXkJaUrUfax48Rj5GnGofW6udTcc2ebgTTagJDyOqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjgtVSguw%253D%253D&md5=f78738ca410cfac0ffc943d8cabb049a</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.9.2542066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.9.2542066%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DD.%2BM.%26atitle%3DLifitegrast%253A%2520First%2520LFA-1%252FICAM-1%2520Antagonist%2520for%2520Treatment%2520of%2520Dry%2520Eye%2520Disease%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D485%26epage%3D493%26doi%3D10.1358%2Fdot.2016.52.9.2542066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadek, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oslob, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evanchik, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1021/ml2002482</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml2002482" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVGlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=203-206&author=M.+Zhongauthor=T.+R.+Gadekauthor=M.+Buiauthor=W.+Shenauthor=J.+Burnierauthor=K.+J.+Barrauthor=E.+J.+Hananauthor=J.+D.+Oslobauthor=C.+H.+Yuauthor=J.+Zhuauthor=M.+R.+Arkinauthor=M.+J.+Evanchikauthor=W.+M.+Flanaganauthor=U.+Hochauthor=J.+Hydeauthor=S.+Prabhuauthor=J.+A.+Silvermanauthor=J.+Wright&title=Discovery+and+Development+of+Potent+LFA-1%2FICAM-1+Antagonist+SAR+1118+as+an+Ophthalmic+Solution+for+Treating+Dry+Eye&doi=10.1021%2Fml2002482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye</span></div><div class="casAuthors">Zhong, Min; Gadek, Thomas R.; Bui, Minna; Shen, Wang; Burnier, John; Barr, Kenneth J.; Hanan, Emily J.; Oslob, Johan D.; Yu, Chul H.; Zhu, Jiang; Arkin, Michelle R.; Evanchik, Marc J.; Flanagan, W. Mike; Hoch, Ute; Hyde, Jennifer; Prabhu, Saileta; Silverman, Jeffrey A.; Wright, Jasmin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-206</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunol. synapse, and augmentation of T-cell receptor signaling.  The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was obsd. in animal models and patients diagnosed with dry eye.  Therefore, it has been hypothesized that small mol. LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye.  In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic soln. for treating dry eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxdplnevXUtbVg90H21EOLACvtfcHk0lg6D03WrQnLZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVGlsLs%253D&md5=e233d520e901644639e7cf4b235dde5a</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fml2002482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml2002482%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DGadek%26aufirst%3DT.%2BR.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DBurnier%26aufirst%3DJ.%26aulast%3DBarr%26aufirst%3DK.%2BJ.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DOslob%26aufirst%3DJ.%2BD.%26aulast%3DYu%26aufirst%3DC.%2BH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DEvanchik%26aufirst%3DM.%2BJ.%26aulast%3DFlanagan%26aufirst%3DW.%2BM.%26aulast%3DHoch%26aufirst%3DU.%26aulast%3DHyde%26aufirst%3DJ.%26aulast%3DPrabhu%26aufirst%3DS.%26aulast%3DSilverman%26aufirst%3DJ.%2BA.%26aulast%3DWright%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Potent%2520LFA-1%252FICAM-1%2520Antagonist%2520SAR%25201118%2520as%2520an%2520Ophthalmic%2520Solution%2520for%2520Treating%2520Dry%2520Eye%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D203%26epage%3D206%26doi%3D10.1021%2Fml2002482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit95a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnier, J.</span></span> <span> </span><span class="NLM_article-title">Crystalline Pharmaceutical and Methods of Preparation and Use Thereof</span>. <span class="NLM_patent">WO 2011050175A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Burnier&title=Crystalline+Pharmaceutical+and+Methods+of+Preparation+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurnier%26aufirst%3DJ.%26atitle%3DCrystalline%2520Pharmaceutical%2520and%2520Methods%2520of%2520Preparation%2520and%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit95b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnier, J.</span>; <span class="NLM_string-name">Gadek, T.</span>; <span class="NLM_string-name">Naud, F.</span></span> <span> </span><span class="NLM_article-title">Crystalline Pharmaceutical and Methods of Preparation and Use Thereof</span>. <span class="NLM_patent">WO 2009139817A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+Burnier&author=T.+Gadek&author=F.+Naud&title=Crystalline+Pharmaceutical+and+Methods+of+Preparation+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurnier%26aufirst%3DJ.%26atitle%3DCrystalline%2520Pharmaceutical%2520and%2520Methods%2520of%2520Preparation%2520and%2520Use%2520Thereof%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit95c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeller, J. R.</span>; <span class="NLM_string-name">Venkatraman, S.</span>; <span class="NLM_string-name">BROT, E. C. A.</span>; <span class="NLM_string-name">IYER, S.</span>; <span class="NLM_string-name">Hall, M.</span></span> <span> </span><span class="NLM_article-title">LFA-1 Inhibitor and Polymorph Thereof</span>. <span class="NLM_patent">WO 2014018748A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+R.+Zeller&author=S.+Venkatraman&author=E.+C.+A.+BROT&author=S.+IYER&author=M.+Hall&title=LFA-1+Inhibitor+and+Polymorph+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZeller%26aufirst%3DJ.%2BR.%26atitle%3DLFA-1%2520Inhibitor%2520and%2520Polymorph%2520Thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-16%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00260%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00260" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677abc1f8c633c10","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
